
<html lang="en"     class="pb-page"  data-request-id="0275215f-ba61-4bda-a4a6-d80ecbd596c4"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;issue:issue:10.1021/jmcmar.2015.58.issue-22;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.5b00457"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Antibody–Drug Conjugates and Small Molecule–Drug Conjugates: Opportunities and Challenges for the Development of Selective Anticancer Cytotoxic Agents" /></meta><meta name="dc.Creator" content="Giulio  Casi" /></meta><meta name="dc.Creator" content="Dario  Neri" /></meta><meta name="dc.Description" content="Conventional cancer chemotherapy heavily relies on the use of cytotoxic agents, which typically do not preferentially localize at the tumor site and cause toxicity to normal organs, preventing dose..." /></meta><meta name="Description" content="Conventional cancer chemotherapy heavily relies on the use of cytotoxic agents, which typically do not preferentially localize at the tumor site and cause toxicity to normal organs, preventing dose..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 23, 2015" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.5b00457" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2015 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b00457" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.5b00457" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b00457" /></link>
        
    
    

<title>Antibody–Drug Conjugates and Small Molecule–Drug Conjugates: Opportunities and Challenges for the Development of Selective Anticancer Cytotoxic Agents | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5b00457" /></meta><meta property="og:title" content="Antibody–Drug Conjugates and Small Molecule–Drug Conjugates: Opportunities and Challenges for the Development of Selective Anticancer Cytotoxic Agents" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00457/20151119/images/large/jm-2015-004574_0002.jpeg" /></meta><meta property="og:description" content="Conventional cancer chemotherapy heavily relies on the use of cytotoxic agents, which typically do not preferentially localize at the tumor site and cause toxicity to normal organs, preventing dose escalation to therapeutically active regimens. In principle, antibodies and other ligands could be used for the selective pharmacodelivery of cytotoxic agents to the neoplastic mass. For many years, the availability of ligands, capable of selective internalization into tumor cells, has been considered to be an essential requirement for the development of targeted cytotoxics. This assumption, however, has recently been challenged on the basis of therapeutic data obtained with noninternalizing drug conjugates. Moreover, quantitative evaluations of the tumor targeting properties of antibodies and of small organic ligands have provided new insights for the implementation of optimal strategies for the development of targeted cytotoxics. In this article, we highlight opportunities and challenges associated with the clinical and industrial development of antibody–drug conjugates and small molecule–drug conjugates for cancer therapy." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.5b00457"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b00457">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.5b00457&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.5b00457&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.5b00457&amp;href=/doi/10.1021/acs.jmedchem.5b00457" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2015</span><span class="cit-fg-volume">, 58</span><span class="cit-fg-issue">, 22</span><span class="cit-fg-pageRange">, 8751-8761</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/58/22" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.5b00461" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Antibody–Drug Conjugates and Small Molecule–Drug Conjugates: Opportunities and Challenges for the Development of Selective Anticancer Cytotoxic Agents</span></h1><h2 class="article_header-subtitle"><span class="hlFld-SubTitle">Miniperspective</span></h2><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Giulio++Casi">Giulio Casi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"> and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dario++Neri">Dario Neri</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Philochem AG, Libernstrasse 3, CH8112 Otelfingen, Switzerland</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH Zürich, Vladimir-Prelog-Weg 1-5/10, 8093 Zürich, Switzerland</span></div><div class="corresp-info"><strong>*</strong>Phone: +41 44 63 37401. E-mail: <a href="/cdn-cgi/l/email-protection#20444152494f0e4e45524960504841524d410e4554485a0e4348"><span class="__cf_email__" data-cfemail="d5b1b4a7bcbafbbbb0a7bc95a5bdb4a7b8b4fbb0a1bdaffbb6bd">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b00457&amp;href=/doi/10.1021%2Facs.jmedchem.5b00457" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2015</span></span><span class="cit-volume">, 58</span><span class="cit-issue">, 22</span><span class="cit-pageRange">, 8751–8761</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 16, 2015</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>20 March 2015</li><li><span class="item_label"><b>Published</b> online</span>23 July 2015</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 November 2015</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.5b00457" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00457</a></div><div class="article_header-article-copyright"><strong>Copyright © 2015 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8751%26pageCount%3D11%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DGiulio%2BCasi%252C%2BDario%2BNeri%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D58%26issueNum%3D22%26contentID%3Dacs.jmedchem.5b00457%26title%3DAntibody%25E2%2580%2593Drug%2BConjugates%2Band%2BSmall%2BMolecule%25E2%2580%2593Drug%2BConjugates%253A%2BOpportunities%2Band%2BChallenges%2Bfor%2Bthe%2BDevelopment%2Bof%2BSelective%2BAnticancer%2BCytotoxic%2BAgents%26numPages%3D11%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8761%26publicationDate%3DNovember%2B2015">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.5b00457"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">8812</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">94</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.5b00457" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Antibody–Drug Conjugates and Small Molecule–Drug Conjugates: Opportunities and Challenges for the Development of Selective Anticancer Cytotoxic Agents&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Giulio&quot;,&quot;last_name&quot;:&quot;Casi&quot;},{&quot;first_name&quot;:&quot;Dario&quot;,&quot;last_name&quot;:&quot;Neri&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2015&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;23&quot;,&quot;issue&quot;:&quot;22&quot;,&quot;volume&quot;:&quot;58&quot;,&quot;pages&quot;:&quot;8751-8761&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.5b00457&quot;},&quot;abstract&quot;:&quot;Conventional cancer chemotherapy heavily relies on the use of cytotoxic agents, which typically do not preferentially localize at the tumor site and cause toxicity to normal organs, preventing dose escalation to therapeutically active regimens. In principle, antibodies and other ligands could be used for the selective pharmacodelivery of cytotoxic agents to the neoplastic mass. For many years, the availability of ligands, capable of selective internalization into tumor cells, has been considered to be an essential requirement for the development of targeted cytotoxics. This assumption, however, has recently been challenged on the basis of therapeutic data obtained with noninternalizing drug conjugates. Moreover, quantitative evaluations of the tumor targeting properties of antibodies and of small organic ligands have provided new insights for the implementation of optimal strategies for the development of targeted cytotoxics. In this article, we highlight opportunities and challenges associated with the clini&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b00457&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b00457" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b00457&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b00457" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b00457&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b00457" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b00457&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b00457&amp;href=/doi/10.1021/acs.jmedchem.5b00457" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.5b00457" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.5b00457" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.5b00457%26sid%3Dliteratum%253Aachs%26pmid%3D26079148%26genre%3Darticle%26aulast%3DCasi%26date%3D2015%26atitle%3DAntibody%25E2%2580%2593Drug%2BConjugates%2Band%2BSmall%2BMolecule%25E2%2580%2593Drug%2BConjugates%253A%2BOpportunities%2Band%2BChallenges%2Bfor%2Bthe%2BDevelopment%2Bof%2BSelective%2BAnticancer%2BCytotoxic%2BAgents%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D58%26issue%3D22%26spage%3D8751%26epage%3D8761%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291909" title="Immunology">Immunology</a>,</li><li><a href="/action/doSearch?ConceptID=292519" title="Cancer therapy">Cancer therapy</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290975" title="Biopolymers">Biopolymers</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/58/22" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/jmcmar.2015.58.issue-22/20151125/jmcmar.2015.58.issue-22.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00457/20151119/images/medium/jm-2015-004574_0002.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00457/20151119/images/large/jm-2015-004574_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00457&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Conventional cancer chemotherapy heavily relies on the use of cytotoxic agents, which typically do not preferentially localize at the tumor site and cause toxicity to normal organs, preventing dose escalation to therapeutically active regimens. In principle, antibodies and other ligands could be used for the selective pharmacodelivery of cytotoxic agents to the neoplastic mass. For many years, the availability of ligands, capable of selective internalization into tumor cells, has been considered to be an essential requirement for the development of targeted cytotoxics. This assumption, however, has recently been challenged on the basis of therapeutic data obtained with noninternalizing drug conjugates. Moreover, quantitative evaluations of the tumor targeting properties of antibodies and of small organic ligands have provided new insights for the implementation of optimal strategies for the development of targeted cytotoxics. In this article, we highlight opportunities and challenges associated with the clinical and industrial development of antibody–drug conjugates and small molecule–drug conjugates for cancer therapy.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Conventional Anticancer Drugs and the First Series of Antibody–Drug Conjugates</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17022" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17022" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Conventional cancer chemotherapy typically relies on the use of small-molecule drugs (e.g., cytotoxic agents, kinase inhibitors), which inhibit the growth of cells undergoing rapid proliferation (or even kill them), thus offering a potential therapeutic benefit to cancer patients. The combination of highly toxic agents has revolutionized the treatment of many hematological malignancies, some of which are now curable. The induction of cancer cures for disseminated solid tumors by means of cytotoxic agents is more difficult, but some metastatic malignancies (e.g., metastatic testicular cancer)<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> can be eradicated by a combination of chemotherapeutic drugs.</div><div class="NLM_p">Unfortunately, the majority of patients with metastatic solid tumors die from the disease, after chemotherapeutic regimens have failed to induce objective response or when resistance develops.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> One of the most serious limitations of conventional cancer chemotherapy relates to the fact that most small molecule therapeutic agents (e.g., cytotoxic agents) do <i>not</i> preferentially localize at the tumor site. This pharmacokinetic limitation has long been appreciated in mouse models of cancer.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3, 4)</a> Importantly, recent PET studies with radiolabeled drugs in cancer patients have unambiguously shown that cytotoxic agents accumulate in certain healthy organs (e.g., those involved in the excretion process; Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) while failing to efficiently target neoplastic masses in vivo.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5, 6)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00457/20151119/images/medium/jm-2015-004574_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00457/20151119/images/large/jm-2015-004574_0004.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. PET images at multiple time points of a patient with metastatic mesothelioma, injected with <sup>11</sup>C-docetaxel. Drug uptake in the neoplastic lesions is not visible, while accumulation in the liver and in some other normal organ structures can be seen at multiple time points. The arrow to the chest indicates the pleural localization of the mesothelium. Reproduced with permission from  <cite>European Journal of Nuclear Medicine and Molecular Imaging</cite> (<contrib-group>van der Veldt, A. A. M.</contrib-group>; ), Vol. <em>37</em>, pp 1950–1958. Copyright <span class="NLM_year">2010</span>, Springer.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00457/20151119/images/large/jm-2015-004574_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00457&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Monoclonal antibodies have been considered as possible vehicles for the selective in vivo pharmacodelivery of drugs, under the assumption that the exquisite binding specificity of the antibody molecule would facilitate a selective accumulation at the site of disease. The history of the development of antibody–drug conjugates (ADCs) has extensively been reviewed elsewhere<a onclick="showRef(event, 'ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9">(7-9)</a> and will not be repeated here. Nonetheless, a few aspects of antibody-based drug delivery deserve a closer analysis:</div><div class="NLM_p">(i) The real ability of antibody to preferentially localize at the site of disease, which is essential for the implementation of efficient pharmacodelivery strategies in cancer patients, remains largely unexplored in clinical trials. Few monoclonal antibodies have been studied with nuclear medicine procedures and adequate dosimetric analyses in a sufficiently large number of patients.<a onclick="showRef(event, 'ref10 ref11 ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19">(10-19)</a> In those studies, a large variability in tumor uptake, from patient to patient and from lesion to lesion, was observed. Antibodies that display tumor/organ and tumor/blood ratios of >5:1 at 24 h after intravenous injection represent the exception rather than the rule.</div><div class="NLM_p">(ii) The antibody format (scFv, diabody, miniantibody, or small immune proteins (SIP), IgG; Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">02</a>a) greatly impacts pharmacokinetic properties and tumor uptake. A number of independent studies have found that miniantibodies or SIPs may exhibit the best compromise between efficient tumor uptake and a sufficiently rapid clearance from circulation.<a onclick="showRef(event, 'ref20 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref20 ref21 ref22">(20-22)</a> Nonetheless, if maximal antibody accumulation at the tumor site is desired, the IgG format may represent the preferred one, as its long circulation time in blood counterbalances the inherently slow extravasation process of proteins and of antibodies.<a onclick="showRef(event, 'ref21 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref21 ref23 ref24">(21, 23, 24)</a> However, in humans, typically more than 99% of the antibody administered does not reach the tumor.<a onclick="showRef(event, 'ref10 ref11 ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19">(10-19)</a> The persistent high levels of drug–conjugate in blood may be responsible for undesired toxicities as a consequence of both premature and undesired drug release in off-target organs (e.g., endothelium, liver; Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">02</a>b).</div><div class="NLM_p">(iii) A microscopic analysis of antibody localization within the tumor mass exhibits a preferential accumulation on perivascular tumor cells.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> This feature, which may hinder certain pharmacodelivery strategies, most probably results from the inefficient extravasation of antibody molecules and by their trapping by antigen on perivascular tumor cells (the so-called “antigen barrier effect”,<a onclick="showRef(event, 'ref26 ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref26 ref27 ref28">(26-28)</a> Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">02</a>c).</div><div class="NLM_p">(iv) While initially low-potency drugs (e.g., doxorubicin) were used for ADC development programs,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> the field has gradually progressed toward the use of ultrapotent payloads, often capable of killing cells at subnanomolar concentrations. The use of highly cytotoxic drugs is also justified by cost-of-goods considerations, as monoclonal antibodies (in IgG format) have a molecular weight of 150 000 Da, while drugs are typically smaller than 1000 Da. It is probably not economically feasible to administer doses of more than 1 g of antibody–drug conjugate to a patient. Less potent drugs may be used for ADC applications if multivalent (e.g., dendrimeric) linkers are used, leading to high drug/antibody ratios.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00457/20151119/images/medium/jm-2015-004574_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00457/20151119/images/large/jm-2015-004574_0005.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (a) Schematic representation showing domain composition of engineered fragments including scFv (25 kDa), diabody (55 kDa), SIP/minibody (80 kDa), and intact antibodies (150 kDa). (b) Macroscopic distribution of <sup>64</sup>Cu-DOTA-trastuzumab in breast cancer patients (1, 24, and 48 h) following intravenous administration. The majority of injected antibody molecules do not reach their target in vivo: virtually all of them accumulate (at least transiently) in excretory organs (liver for intact antibodies, kidneys for small antibody fragments). This research was originally published in JNM. <contrib-group>Tamura, K.; Kurihara, H.; Yonemori, K.; Tsuda, H.; Suzuki, J.; Kono, Y.; Honda, N.; Kodaira, M.; Yamamoto, H.; Yunokawa, M.; Shimizu, C.; Hasegawa, K.; Kanayama, Y.; Nozaki, S.; Kinoshita, T.; Wada, Y.; Tazawa, S.; Takahashi, K.; Watanabe, Y.; Fujiwara, Y.</contrib-group><sup>64</sup>Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer.  <cite>J. Nucl. Med.</cite> <span class="NLM_year">2013</span>, <em>54</em>, 1869−1875. © by the Society of Nuclear Medicine and Molecular Imaging, Inc. (c) Microscopic images of tumor tissue after trastuzumab–FITC conjugate injection (green). Tumor blood vessels (red) and nuclei (blue) were also stained. The image depicts trapping of trastuzumab in the vicinity of blood vessels. Adapted by permission from  <cite>Cancer Research</cite>, <span class="NLM_year">2007</span>, Vol. <em>67</em>, pp 254–261, <contrib-group>Dennis, M. S.; Jin, H.; Dugger, D.; Yang, R.; McFarland, L.; Ogasawara, A.; Williams, S.; Cole, M. J.; Ross, S.; Schwall, R.</contrib-group>Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> with permission from American Association for Cancer Research.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00457/20151119/images/large/jm-2015-004574_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00457&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Two ADC products are currently available on the market for cancer therapy applications: brentuximab vedotin and trastuzumab emtansine.</div><div class="NLM_p">Brentuximab vedotin is an anti-CD30 antibody, coupled to the MMAE auristatin, by a cleavable linker comprising a valine-citruline moiety and a self-immolating spacer (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">03</a>). The product has been approved for the treatment of last-line Hodgkin lymphoma and anaplastic large cell lymphoma, on the basis of compelling objective responses observed in phase II clinical trials in heavily pretreated patients.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div><div class="NLM_p">In particular, brentuximab vedotin (when dosed at 1.8 mg/kg, every 3 weeks) mediated 75% overall responses in Hodgkin lymphoma patients that had failed autologous stem cell transplant, with 34% of the patients experiencing complete responses that lasted on average 29 months. In the anaplastic large cell lymphoma settings, brentuximab vedotin provided a substantial benefit to patients that failed at least one multiagent chemotherapy regimen, with 87% overall response rates, of which 57% were complete responses, and a progression free survival of 12.6 months. Importantly the treatments were well tolerated, with the most common side effects reported as neutropenia, peripheral sensory neuropathy, fatigue, nausea, fever, and thrombocytopenia. These encouraging data have recently been complemented by the results of a randomized phase III clinical trial in the consolidation setting for Hodgkin lymphoma patients who had received a bone marrow transplant. A new phase III trial that features a combination of brentuximab vedotin and chemotherapy was recently started in younger patients with newly diagnosed Hodgkin lymphoma (NCT-02166463).</div><div class="NLM_p">Trastuzumab emtansine consists of the anti-HER2 trastuzumab antibody, armed with the maytansinoid DM1, equipped with a noncleavable linker (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">03</a>). It has been proposed that the drug may be released after product internalization, upon intracellular proteolytic digestion of the antibody moiety.<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32, 33)</a> However, a certain instability of the ADC in blood has been documented, with maleimide elimination occurring slowly under physiological conditions.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Trastuzumab emtansine has received marketing authorization for the second-line treatment of a subset of patients with metastatic breast cancer. Specifically, it has been approved for the treatment of patients with HER2-positive metastatic breast cancer that has previously been treated with Herceptin and a taxane chemotherapy. Trastuzumab emtansine showed convincing clinical efficacy in a phase III clinical study in 991 patients treated with 3.6 mg/kg of ADC every 3 weeks, in comparison to established chemotherapy with lapatinib and capecitabine. Progression free survival (9.6 months versus 6.4 months) and overall survival (30.9 months versus 25.1 months) were improved in the ADC-treatment arm. Safety was significantly improved compared to chemotherapy, with substantially fewer grade 3/4 adverse events.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> In a recent front-line phase III clinical study in breast cancer patients, however, trastuzumab emtansine was not found to be superior to the corresponding naked trastuzumab antibody, used in combination with either docetaxel or paclitaxel chemotherapy.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00457/20151119/images/medium/jm-2015-004574_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00457/20151119/images/large/jm-2015-004574_0006.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structures of the two antibody–drug conjugate products currently available on the market for cancer therapy: brentuximab vedotin (left) and trastuzumab emtansine (right).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00457/20151119/images/large/jm-2015-004574_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00457&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Trastuzumab emtansine is used in the clinic at 3.6 mg/kg doses, while tumor eradications with the same product have been observed in mice at doses of 15 mg/kg.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Chemically defined anti-Her2 ADCs, with precise control of site and stoichiometry of drug conjugation, displayed improved half-life, efficacy, and safety, relative to conventional heterogeneous ADCs, in rodent xenograft models.<a onclick="showRef(event, 'ref37 ref38 ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref37 ref38 ref39 ref40">(37-40)</a></div><div class="NLM_p">Large clinical experience is available from gemtuzumab ozogamicin, a humanized IgG4 κ CD33 antibody conjugated to the DNA-binder calicheamicin-γ1 via a hydrolysis sensitive hydrazone. Gemtuzumab ozogamicin received accelerated U.S. marketing approval in 2000 for the treatment of patients of 60 years of age and older with CD33<sup>+</sup> AML in first relapse, who were not eligible for standard chemotherapy. Subsequent trials failed to confirm therapeutic benefits at doses of 9 mg/m<sup>2</sup> when GO was used in combination with chemotherapy. These data and the slight increase in deaths in the group receiving the ADC compared to those receiving chemotherapy led to voluntary withdrawal of the drug in 2010 from the market. Interestingly the acid-sensitive hydrazone was required to elicit potent antitumor activity in an antigen independent manner on solid tumors in vivo.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Gemtuzumab ozogamicin is also active in AML patients whose cells apparently do not express CD33.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> The product remains available for compassionate use, and recent studies have showed promising efficacy when the ADC was administered either following a fractionated schedule<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43, 44)</a> or to patients with more favorable prognosis AML during standard induction therapy.<a onclick="showRef(event, 'ref45 ref46 ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref45 ref46 ref47 ref48">(45-48)</a></div><div class="NLM_p">Additionally, many promising ADC products can eradicate tumors in mice at doses that are well tolerated. For example, an anti-CD33 antibody, coupled to a potent DNA alkylating drug of the pyrrolobenzodiazepine family, has recently been shown to eradicate subcutaneously grafted AML chloroma lesions in mice at doses as low as 0.1 mg/kg.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></div><div class="NLM_p last">It remains to be seen, however, how easily these promising preclinical therapeutic observations can be translated to the human situation. For example, if the tumor targeting performance (e.g., tumor uptake) of an ADC is much better in rodents than in patients, the corresponding therapeutic behavior may be different in the two species.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">The Need for Antibody Internalization: Fiction or Reality?</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35435" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35435" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Virtually all small molecule anticancer drugs exert their activity by binding to an <i>intracellular</i> target. For this reason, it has been widely assumed that the use of internalizing pharmacodelivery vehicles may represent an absolute requirement for ADC development. Indeed, it has been claimed that “targeting an ADC to a noninternalizing target antigen with the expectation that extracellulary released drug will diffuse into the target cell is not a recipe for a successful ADC”.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> In principle, the ability to deliver cytotoxic agents only to target cells that express the antigen recognized by the cognate antibody, sparing all other cells in the body, would represent an extremely attractive therapeutic feature. In practice, however, several factors limit the performance of internalizing ADCs, including the moderate accumulation of antibody molecules at the tumor site (typically <0.1% injected dose per gram of tumor in humans)<a onclick="showRef(event, 'ref10 ref11 ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19">(10-19)</a> and the heterogenous antibody distribution within the tumor mass. In addition, while the antibody internalization process can easily be studied in vitro, the same process often remains a “black box” in vivo, as it is difficult to recover and analyze neoplastic masses from patients.</div><div class="NLM_p">Recently, an increasing body of experimental evidence has shown that certain ADCs, based on noninternalizing ligands, can efficiently deliver cytotoxic agents to neoplastic masses.<a onclick="showRef(event, 'ref51 ref52 ref53 ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref51 ref52 ref53 ref54 ref55">(51-55)</a> When suitable linker–payload combinations are used, these targeted cytotoxics can liberate their payload at the tumor site and display a potent anticancer activity in mouse models of cancer.<a onclick="showRef(event, 'ref56 ref57 ref58'); return false;" href="javascript:void(0);" class="ref ref56 ref57 ref58">(56-58)</a> In principle, it should be possible to use antibodies for the efficient delivery and release of drugs in the <i>extracellular</i> tumor space (e.g., through proteolytic cleavage or by reduction of disulfide bonds).<a onclick="showRef(event, 'ref56 ref57 ref58 ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref56 ref57 ref58 ref59 ref60">(56-60)</a> The drugs could then internalize into tumor cells or other cellular targets (e.g., tumor endothelial cells, tumor resident leukocytes), causing localized damage. The therapeutic performance of these ADCs is likely to depend on many factors, including the antibody’s tumor targeting efficiency, the kinetics of drug release, as well as the diffusion properties of the drug payload.</div><div class="NLM_p last">Splice isoforms of fibronectin and of tenascin C are abundantly found in the tumor subendothelial extracellular matrix, making them attractive noninternalizing targets for pharmacodelivery applications.<a onclick="showRef(event, 'ref51 ref52 ref53 ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref51 ref52 ref53 ref54 ref55">(51-55)</a> These antigens are more accessible, abundant, and genetically stable than tumor-associated antigens located on the cell membrane, thus facilitating the development of ADC products with long residence time at the tumor site. The ADCs would release their payload in the extracellular space, facilitating a bystander effect on neighboring tumor cells. As antibody internalization would no longer be needed, biodistribution and imaging data, obtained with noninternalizing antibodies, could be more easily integrated into modeling studies for the prediction of ADC in vivo performance.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Small Ligands and Peptides as Alternatives to Antibodies for Pharmacodelivery Applications</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05065" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05065" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In principle, small organic ligands and peptides could be used as alternatives to antibodies for tumor targeting applications. While high-affinity human monoclonal antibodies can be raised against virtually all protein targets (for example, by panning combinatorial phage display libraries),<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> it is not always possible to isolate small organic or peptidic ligands to proteins of pharmaceutical interest. Nonetheless, a number of small ligands to tumor-associated antigens have been characterized in terms of their tumor targeting properties and for pharmacodelivery applications.<a onclick="showRef(event, 'ref4 ref62'); return false;" href="javascript:void(0);" class="ref ref4 ref62">(4, 62)</a> Some of the most promising compounds in this category are depicted in Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>. They include folate derivatives (binding to the folate receptor, a protein overexpressed in ovarian cancer and in other malignancies),<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> glutamic acid urea derivatives (binding to the prostate specific membrane antigen, a surface marker of prostate cancer cells),<a onclick="showRef(event, 'ref64 ref65 ref66'); return false;" href="javascript:void(0);" class="ref ref64 ref65 ref66">(64-66)</a> somatostatin analogues (particularly indicated for neuroendocrine tumors),<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> and certain aromatic sulfonamides specific to carbonic anhydrase IX (a marker of hypoxia and of renal cell carcinoma).<a onclick="showRef(event, 'ref58 ref68 ref69 ref70 ref71'); return false;" href="javascript:void(0);" class="ref ref58 ref68 ref69 ref70 ref71">(58, 68-71)</a></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00457/20151119/images/medium/jm-2015-004574_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00457/20151119/images/large/jm-2015-004574_0007.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Structures of relevant classes of small molecule tumor targeting moieties. For a more comprehensive list of small molecule–drug conjugates (SMDCs) in preclinical and clinical development, see Low et al. (2015) [ref <a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">62</a>].</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00457/20151119/images/large/jm-2015-004574_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00457&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The opportunity of using small ligands for pharmacodelivery applications has recently been reviewed in detail.<a onclick="showRef(event, 'ref4 ref62'); return false;" href="javascript:void(0);" class="ref ref4 ref62">(4, 62)</a> There is a strong evidence that ligands with a dissociation constant to their target of 10 nM or better may be needed, in order to achieve an efficient tumor targeting performance.<a onclick="showRef(event, 'ref62 ref70'); return false;" href="javascript:void(0);" class="ref ref62 ref70">(62, 70)</a> In some cases, multivalent binding (“avidity”) may compensate for insufficient affinity,<a onclick="showRef(event, 'ref69 ref72 ref73 ref74'); return false;" href="javascript:void(0);" class="ref ref69 ref72 ref73 ref74">(69, 72-74)</a> but almost all products in clinical development feature a single tumor-targeting moiety, coupled to a potent cytotoxic payload.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a></div><div class="NLM_p">Traditionally, the discovery of small ligands to tumor associated antigens has been difficult and has often relied on the synthesis of analogues to naturally occurring ligands. However, progress in DNA-encoded chemical library technologies promises to facilitate the hit discovery process.<a onclick="showRef(event, 'ref4 ref75 ref76 ref77'); return false;" href="javascript:void(0);" class="ref ref4 ref75 ref76 ref77">(4, 75-77)</a> Indeed, the tagging of individual compounds with DNA fragments, serving as amplifiable identification barcodes, in split and pool synthetic strategies, allows the construction and screening of chemical libraries containing millions of molecules. Similarly, the discovery of high-affinity binding cyclic peptides has been greatly facilitated by the construction and selection of very large combinatorial libraries, featuring the incorporation of non-natural amino acids<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> or the cyclization of cysteine-containing peptides with reactive chemical moieties serving as structural scaffolds.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a></div><div class="NLM_p">Folic acid derivatives probably represent the first small molecule ligands, which have successfully been used for the selective pharmacodelivery of cytotoxic drugs and other payloads to the tumor environment.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> The folic acid receptor is present at low levels in most normal tissues, with the exception of kidney, spleen, and lung tissue.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> By contrast, the same target is strongly upregulated in many epithelial cancers, including tumors of the ovary, breast, lung, colon, and kidney.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Vintafolide (also known as EC145)<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> is a conjugate consisting of folic acid as a targeting moiety, connected to desacetylvinblastine as toxic payload through a linker comprising a charged peptide linker and a disulfide bond with a self-immolative spacer for drug release (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). Endocyte developed vintafolide for several indications. Initially the conjugate was studied for the treatment of patients with platinum-resistant ovarian cancer in combination with pegylated lisosomal doxorubicin (PLD) versus PLD alone. The combination extended progression-free survival for approximately 2 months in direct correlation with folate receptor expression.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> Moreover, Endocyte has recently reported promising results of an interim analysis of phase II data, comparing the use of vintafolide plus docetaxel versus docetaxel alone for the treatment of patients with non-small-cell lung cancer. The combination treatment extended progression-free survival by 1.2 months and overall survival by 5.9 months.<a onclick="showRef(event, 'ref62 ref83'); return false;" href="javascript:void(0);" class="ref ref62 ref83">(62, 83)</a> Vintafolide is currently developed in combination with Doxil in a phase III trial for the treatment of platinum-resistant ovarian cancer; the enrollment in this trial was suspended in May 2014 following the recommendation from the data safety monitoring board (DSMB) based on futility. The clinical data are currently being reviewed.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a></div><div class="NLM_p">Endocyte and Bristol-Myers Squibb have also investigated conjugates based on other payloads, such as tubulysins or epothilones, in clinical trials.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a></div><div class="NLM_p">Prostate-specific membrane antigen (PSMA) is an accessible cell-surface bound homodimeric endopeptidase, which can be efficiently targeted using urea-based derivatives of glutamic acid (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). PSMA is usually absent in normal adult tissues, exception made for normal prostate tissue and duodenum.<a onclick="showRef(event, 'ref84 ref85'); return false;" href="javascript:void(0);" class="ref ref84 ref85">(84, 85)</a> In most cases PSMA-selective imaging agents showed high uptake in salivary and lacrimal glands, which may reflect either target expression in those tissues or ligand binding to noncognate proteins.<a onclick="showRef(event, 'ref65 ref86'); return false;" href="javascript:void(0);" class="ref ref65 ref86">(65, 86)</a> By contrast, the antigen is strongly expressed in the majority of localized and metastatic prostate cancer cells.<a onclick="showRef(event, 'ref87 ref88'); return false;" href="javascript:void(0);" class="ref ref87 ref88">(87, 88)</a> PSMA has also been reported to be overexpressed in the neovasculature of many malignancies.<a onclick="showRef(event, 'ref89 ref90'); return false;" href="javascript:void(0);" class="ref ref89 ref90">(89, 90)</a> The tumor-targeting performance of various PSMA ligands has been validated in rodents and in cancer patients, using nuclear medicine procedures.<a onclick="showRef(event, 'ref65 ref86 ref64 ref66'); return false;" href="javascript:void(0);" class="ref ref65 ref86 ref64 ref66">(65, 86, 64, 66)</a></div><div class="NLM_p">Carbonic anhydrase IX (CAIX) represents an additional example of a tumor-associated antigen, which can be targeted both with antibodies and with small organic ligands. Several types of carbonic anhydrases can be found inside (CAI, CAII, CAIII, CAVII, and CAXIII) or on the surface (CAIV, CAIX, CAXII, CAXIV, and CAXV) of cells. Interestingly, CAIX is virtually undetectable in normal adult tissues except for a strong expression in stomach, duodenum, and gall bladder.<a onclick="showRef(event, 'ref68 ref84 ref91'); return false;" href="javascript:void(0);" class="ref ref68 ref84 ref91">(68, 84, 91)</a> By contrast, CAIX is overexpressed in the majority of clear-cell carcinomas, as a result of a von Hippel–Lindau mutation or deletion.<a onclick="showRef(event, 'ref92 ref93'); return false;" href="javascript:void(0);" class="ref ref92 ref93">(92, 93)</a> Additionally, the antigen can be found at sites of hypoxia.<a onclick="showRef(event, 'ref94 ref95'); return false;" href="javascript:void(0);" class="ref ref94 ref95">(94, 95)</a> An ADC product targeting CAIX has been brought to clinical trials by Bayer.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> Certain small aromatic sulfonamides (in particular, acetazolamide; Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>) can be used as delivery vehicles for tumor targeting applications.<a onclick="showRef(event, 'ref69 ref97'); return false;" href="javascript:void(0);" class="ref ref69 ref97">(69, 97)</a> For example, an acetazolamide moiety coupled to a near-infrared fluorophore has been shown to selectively localize to subcutaneously grafted human renal cell carcinomas.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> The improvement of acetazolamide affinity to its target, using DNA-encoded chemical library technology, led to a further increase in tumor uptake (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>).<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00457/20151119/images/medium/jm-2015-004574_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00457/20151119/images/large/jm-2015-004574_0001.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Evaluation of targeting performance of IRDye 750 conjugates in near-infrared fluorescence imaging of balb/c nu/nu mice bearing SK-RC-52 xenografts. An amount of 3 nmol of ligand–IRDye 750 conjugate was injected: untargeted control (a), targeted based on acetazolamide <b>1</b> (b), and targeted based on pharmacophore pair <b>2</b> (c). Chemical structures of <b>1</b> and <b>2</b> are provided in Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>. Reproduced with permission from  <cite>Nature Chemistry</cite> (<contrib-group>Wichert, M.</contrib-group>; ), Vol. <em>7</em>, pp 241–249. Copyright <span class="NLM_year">2015</span>, Nature Publishing Group.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00457/20151119/images/large/jm-2015-004574_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00457&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In our experience, CAIX ligands do not efficiently internalize into cancer cells, but they can be used for the selective delivery of cytotoxic payloads (e.g., DM1, MMAE) to the tumor environment, using disulfide-based or peptide-based cleavable linkers,<a onclick="showRef(event, 'ref58 ref69'); return false;" href="javascript:void(0);" class="ref ref58 ref69">(58, 69)</a> [Pretto, F.; Casi, G. unpublished data] with promising therapeutic results. A direct comparison of tumor targeting experiments based on two high-affinity CAIX antibodies or on acetazolamide derivatives revealed a superiority of the small ligands, in terms of speed of targeting, tumor uptake, and selectivity<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> [N. Krall, F. Pretto, M. Mattarella, D. Neri, manuscript submitted; L. Gualandi, C. Hutchinson, F. Pretto, D. Neri, S. Wulhfard, unpublished data].</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Challenges and Opportunities for the Development of Next-Generation Cytotoxic Agents</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76433" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76433" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">As mentioned previously, the high efficacy of targeted therapies often seen in rodent models of cancer rarely translate to patients in the clinic. Ideally, one would like to characterize the biodistribution properties of therapeutic agents in both settings, thus learning about tumor targeting performance in mouse and in man. A number of companies and investigators have realized the importance of using companion diagnostics for the development of targeted therapeutics. Nuclear medicine procedures based on radiolabeled products equipped with radionuclides suitable for SPECT or PET detection appear to be the methodology of choice for the quantitative characterization of tumor targeting results. This approach is equally valuable for antibody-based therapeutics<a onclick="showRef(event, 'ref10 ref11 ref15 ref18'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref15 ref18">(10, 11, 15, 18)</a> and for small molecule–drug conjugates.<a onclick="showRef(event, 'ref98 ref99'); return false;" href="javascript:void(0);" class="ref ref98 ref99">(98, 99)</a> Unfortunately, logistical challenges (e.g., need to work simultaneously with oncology and nuclear medicine units), regulatory hurdles (e.g., requirement to consider the radiolabeled product as a second investigational medicinal agent, with the need to provide adequate documentation and GMP preparation), and radioprotection considerations have so far limited the routine execution of these important investigations.</div><div class="NLM_p">Nuclear medicine procedures are also ideally suited also for studying the fate of delivery vehicle (e.g., antibody or small organic ligand) and of the therapeutic payload (e.g., cytotoxic drug) in vivo. In a pioneering study, the groups of Guus van Dongen and of Matteo Zanda have recently reported the results of biodistribution studies, featuring the simultaneous labeling of the antibody moiety and of a tubulysin payload with two different radionuclides.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> We anticipate that similar studies, if performed in patients with cancer, could provide a much more detailed understanding of the pharmacodelivery process than what is currently available. Alternatively, the fate of a targeted cytotoxic agent could be studied in vivo if biopsies and suitable analytical methodologies are available.</div><div class="NLM_p">It is becoming increasingly clear that delivery vehicle (e.g., antibody or small ligand), cleavable linker, and payload may all contribute to the anticancer activity of conjugates in vivo. It has become common practice to speak about “linker–payload combinations”, as these chemical moieties both contribute to the success (or failure) of a given therapeutic approach. Cleavable linkers may release the toxic payload directly or indirectly (e.g., after subsequent cleavage of a self-immolative spacer).<a onclick="showRef(event, 'ref101 ref102 ref103'); return false;" href="javascript:void(0);" class="ref ref101 ref102 ref103">(101-103)</a> In some cases, a traceless (i.e., linkerless) coupling of drug to the delivery vehicle is possible.<a onclick="showRef(event, 'ref104 ref105'); return false;" href="javascript:void(0);" class="ref ref104 ref105">(104, 105)</a> Linkers may be cleaved by uncatalyzed hydrolytic processes (which are not likely to differ between mouse and man)<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> or by other procedures (e.g., reduction of disulfide bonds, proteolytic cleavage of peptides) which are greatly influenced by the site of in vivo delivery.<a onclick="showRef(event, 'ref56 ref57 ref58 ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref56 ref57 ref58 ref59 ref60">(56-60)</a> While these “triggered” release processes may provide a highly desirable additional selectivity (e.g., if the trigger is more abundant at the tumor site), clinical translational activities become more challenging, as it is difficult to adequately characterize the drug release process in mouse and man.</div><div class="NLM_p">Various antibody–drug coupling methodologies can be considered, as the antibody moiety contains various structures that can be used for chemical modification (e.g., primary amines, cysteines, oligosaccharidic moieties). Site-specific conjugation strategies are emerging as important features for the development of a successful ADC product,<a onclick="showRef(event, 'ref37 ref39 ref40 ref49 ref104 ref105 ref107'); return false;" href="javascript:void(0);" class="ref ref37 ref39 ref40 ref49 ref104 ref105 ref107">(37, 39, 40, 49, 104, 105, 107)</a> as the corresponding conjugates tend to be more homogeneous and to display improved pharmacokinetic profiles. While site-specific drug coupling strategies were not implemented in first-generation ADC products, these features have always been incorporated in the design of small molecule–drug conjugates (SMDCs), as they are assembled by stepwise chemical synthesis processes.</div><div class="NLM_p last">One of the most puzzling aspects in the field of targeted cytotoxics relates to the choice between antibodies and small ligands as preferred vehicles for pharmacodelivery applications. On one hand, antibodies can be rapidly generated against virtually all targets of interest, including proteins of exquisite selectivity (e.g., virtually undetectable in normal adult tissues). Knowledge about the blood clearance and tissue distribution properties of antibodies is largely predictable and transferable from one antigen to the other. However, the tumor targeting properties of anticancer antibodies are still largely unexplored, both at a macroscopic and at a microscopic level, as discussed in a previous section. In addition, for certain antigens, the tumor targeting process may be slow and/or inefficient. By contrast small organic ligands may target tumors rapidly and efficiently. However, certain “off-target” liabilities are often observed in preclinical and clinical imaging studies with SMDCs. Virtually all small ligands characterized so far show some level of kidney uptake, which may be the consequence of a renal clearance process and precipitation (or binding) in renal structures. In addition, an undesired accumulation in normal organs may be observed, for example, when the cognate antigen is expressed at that site. PSMA ligands efficiently accumulate in salivary parotid glands, while CAIX ligands may localize to stomach (where the antigen is expressed) or lung (where other accessible carbonic anhydrase isoforms can be found). Interestingly, some of these “off-target” accumulation features in normal organs can be minimized by the preadministration of competitors<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> or by the administration of judiciously chosen doses. Intact monoclonal antibodies in IgG format are cleared via the hepatobiliary route. By contrast, small antibody fragments and most SMDC products studied so far are cleared via the renal route. The development of small drug conjugates, which may preferably be eliminated via the liver, remains an attractive but largely unexplored possibility.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Cancer Cures and Combination Strategies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15081" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15081" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">ADCs and SMDCs are able to cure cancer in certain animal models of the disease, which do not respond to conventional cytotoxic agents. However, cancer cures in patients treated with ADC and SMDC products are rare. It is important to investigate the reasons behind the different activity observed in rodent models of cancer and in patients. As mentioned above, a quantitative characterization of the ligand-based tumor targeting process and of drug release mechanisms in mouse and man will be important. Imaging technologies will play a crucial role for a “precision medicine” approach to drug development.</div><div class="NLM_p last">If ADCs and SMDCs fail to cure cancer as single agents, then combination strategies may be recommended. The striking activity observed using brentuximab vedotin and nivolumab as single agents in last-line patients with Hodgkin lymphoma has prompted the clinical investigation of combination strategies. In addition, preclinical studies performed in immunocompetent tumor-bearing mice have shown that the combination of ADCs with antibody–cytokine fusion proteins (immunocytokines) or the development of trifunctional antibody products, which simultaneously carry a cytokine moiety and a cytotoxic payload (immunocytokine–drug conjugates, or IDCs), may lead to very potent in vivo activity.<a onclick="showRef(event, 'ref109 ref110'); return false;" href="javascript:void(0);" class="ref ref109 ref110">(109, 110)</a> The antibody-based pharmacodelivery of cytokines and cytotoxic moieties is particularly attractive because of the orthogonal toxicity profiles of these classes of payloads.</div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">Concluding Remarks</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46005" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46005" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The development of targeted cytotoxics represents an area of pharmaceutical research in constant evolution. The modular nature of ADC and SMDC products facilitate an “engineering” approach to drug discovery, in which a precise knowledge and a suitable modeling of the pharmacodelivery process allow prediction of therapeutic performance.<a onclick="showRef(event, 'ref111 ref112'); return false;" href="javascript:void(0);" class="ref ref111 ref112">(111, 112)</a> In practice, in spite of substantial advances over the past 2 decades, several aspects of ADC and SMDC development remain insufficiently studied and will require dedicated future investigations. A detailed characterization of the tumor targeting process and of the drug release process will continue to be important. Different types of linker–payload combinations may be required for different types of malignancies. However, an empirical choice determined by success (or failure) in exploratory clinical trials will continue to be problematic, both from an economical viewpoint and in consideration of the patients’ legitimate request for efficacious drugs.</div><div class="NLM_p last">Sparing normal organs by the improvement of pharmacokinetic properties or by designing drugs with minimal toxicity to healthy tissue (as a consequence of their intrinsic mechanism of action or of an inactivation process in clearance-associated organs) will probably represent one of the most important challenges for the future. In addition, the marriage of targeted cytotoxics and of immunostimulatory products, which represent two of the most prominent classes of anticancer agents, is likely to bear fruits.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.5b00457" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45545" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45545" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dario Neri</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry and Applied Biosciences, Institute of Pharmaceutical
Sciences, ETH Zürich, Vladimir-Prelog-Weg 1-5/10, 8093 Zürich, Switzerland</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#076366756e68296962756e47776f66756a662962736f7d29646f"><span class="__cf_email__" data-cfemail="6e0a0f1c070140000b1c072e1e060f1c030f400b1a0614400d06">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Giulio Casi</span> - <span class="hlFld-Affiliation affiliation">Philochem
AG, Libernstrasse 3, CH8112 Otelfingen, Switzerland</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): G.C. works at Philochem AG, and D.N. is a cofounder and shareholder of Philogen SpA.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71742" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71742" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Giulio Casi</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00457&amp;id=BIO-d995e996-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Giulio Casi</b> studied chemistry at Florence University (Italy) and ETH Zurich (Switzerland). After postdoctoral research at Roche Penzberg (Germany) in 2009 he returned to Switzerland to work for Philochem AG, where he is currently responsible for the research and development of targeted cytotoxics.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Dario Neri</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00457&amp;id=BIO-d995e1001-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Dario Neri</b> studied chemistry at the Scuola Normale Superiore in Pisa (Italy) and obtained his Ph.D. in Chemistry from the ETH Zürich (Switzerland) in 1992, under the supervision of Prof. Kurt Wüthrich. After postdoctoral research at the MRC Centre in Cambridge, U.K., under the supervision of Sir Gregory Winter, he became Professor at the ETH Zürich in 1996. He is a cofounder of Philogen and Philochem.</p></figure></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i9" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i9"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i10" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i10"> Abbreviations Used</h2><tr><td class="NLM_term">ADC</td><td class="NLM_def"><p class="first last">antibody–drug conjugate</p></td></tr><tr><td class="NLM_term">SMDC</td><td class="NLM_def"><p class="first last">small molecule–drug conjugate</p></td></tr><tr><td class="NLM_term">MMAE</td><td class="NLM_def"><p class="first last">monomethyl auristatin E</p></td></tr><tr><td class="NLM_term">AML</td><td class="NLM_def"><p class="first last">acute myeloid leukemia</p></td></tr><tr><td class="NLM_term">CAIX</td><td class="NLM_def"><p class="first last">carbonic anhydrase IX</p></td></tr><tr><td class="NLM_term">IDC</td><td class="NLM_def"><p class="first last">immunocytokine–drug conjugate</p></td></tr><tr><td class="NLM_term">PSMA</td><td class="NLM_def"><p class="first last">prostate specific membrane protein</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03070" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03070" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 112 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Hanna, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Einhorn, L. H.</span><span> </span><span class="NLM_article-title">Testicular cancer—discoveries and updates</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">371</span><span class="NLM_x">, </span> <span class="NLM_fpage">2005</span><span class="NLM_x">–</span> <span class="NLM_lpage">2016</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1056%2FNEJMra1407550" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=25409373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlslGlug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=2005-2016&author=N.+H.+Hannaauthor=L.+H.+Einhorn&title=Testicular+cancer%E2%80%94discoveries+and+updates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Testicular cancer - discoveries and updates</span></div><div class="casAuthors">Hanna, Nasser H.; Einhorn, Lawrence H.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2005-2016, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  This article discusses the recent discoveries, updates in care, and existing controversies in the treatment of patients with testicular cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomxoCgNGLH0LVg90H21EOLACvtfcHk0lh107uLyShGJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlslGlug%253D%253D&md5=395d0b507a4f9b1003785ff92bc4cfd0</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1407550&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1407550%26sid%3Dliteratum%253Aachs%26aulast%3DHanna%26aufirst%3DN.%2BH.%26aulast%3DEinhorn%26aufirst%3DL.%2BH.%26atitle%3DTesticular%2520cancer%25E2%2580%2594discoveries%2520and%2520updates%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26spage%3D2005%26epage%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Szakacs, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paterson, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwig, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Booth-Genthe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottesman, M. M.</span><span> </span><span class="NLM_article-title">Targeting multidrug resistance in cancer</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">–</span> <span class="NLM_lpage">234</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1038%2Fnrd1984" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=16518375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BD28XhvFOlsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=219-234&author=G.+Szakacsauthor=J.+K.+Patersonauthor=J.+A.+Ludwigauthor=C.+Booth-Gentheauthor=M.+M.+Gottesman&title=Targeting+multidrug+resistance+in+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting multidrug resistance in cancer</span></div><div class="casAuthors">Szakacs, Gergely; Paterson, Jill K.; Ludwig, Joseph A.; Booth-Genthe, Catherine; Gottesman, Michael M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">219-234</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Effective treatment of metastatic cancers usually requires the use of toxic chemotherapy.  In most cases, multiple drugs are used, as resistance to single agents occurs almost universally.  For this reason, elucidation of mechanisms that confer simultaneous resistance to different drugs with different targets and chem. structures - multidrug resistance - has been a major goal of cancer biologists during the past 35 years.  Here, we review the most common of these mechanisms, one that relies on drug efflux from cancer cells mediated by ATP-binding cassette (ABC) transporters.  We describe various approaches to combating multidrug-resistant cancer, including the development of drugs that engage, evade or exploit efflux by ABC transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7LUp3JikHr7Vg90H21EOLACvtfcHk0lh107uLyShGJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhvFOlsr8%253D&md5=67ca376f65aa58a71288167f6815a896</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrd1984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1984%26sid%3Dliteratum%253Aachs%26aulast%3DSzakacs%26aufirst%3DG.%26aulast%3DPaterson%26aufirst%3DJ.%2BK.%26aulast%3DLudwig%26aufirst%3DJ.%2BA.%26aulast%3DBooth-Genthe%26aufirst%3DC.%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26atitle%3DTargeting%2520multidrug%2520resistance%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D219%26epage%3D234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Bosslet, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Straub, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumrich, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czech, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerken, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sperker, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroemer, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gesson, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monneret, C.</span><span> </span><span class="NLM_article-title">Elucidation of the mechanism enabling tumor selective prodrug monotherapy</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">1195</span><span class="NLM_x">–</span> <span class="NLM_lpage">1201</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1998&pages=1195-1201&author=K.+Bossletauthor=R.+Straubauthor=M.+Blumrichauthor=J.+Czechauthor=M.+Gerkenauthor=B.+Sperkerauthor=H.+K.+Kroemerauthor=J.+P.+Gessonauthor=M.+Kochauthor=C.+Monneret&title=Elucidation+of+the+mechanism+enabling+tumor+selective+prodrug+monotherapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBosslet%26aufirst%3DK.%26aulast%3DStraub%26aufirst%3DR.%26aulast%3DBlumrich%26aufirst%3DM.%26aulast%3DCzech%26aufirst%3DJ.%26aulast%3DGerken%26aufirst%3DM.%26aulast%3DSperker%26aufirst%3DB.%26aulast%3DKroemer%26aufirst%3DH.%2BK.%26aulast%3DGesson%26aufirst%3DJ.%2BP.%26aulast%3DKoch%26aufirst%3DM.%26aulast%3DMonneret%26aufirst%3DC.%26atitle%3DElucidation%2520of%2520the%2520mechanism%2520enabling%2520tumor%2520selective%2520prodrug%2520monotherapy%26jtitle%3DCancer%2520Res.%26date%3D1998%26volume%3D58%26spage%3D1195%26epage%3D1201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Krall, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheuermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, D.</span><span> </span><span class="NLM_article-title">Small targeted cytotoxics: Current state and promises from DNA-encoded chemical libraries</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1384</span><span class="NLM_x">–</span> <span class="NLM_lpage">1402</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=1384-1402&author=N.+Krallauthor=J.+Scheuermannauthor=D.+Neri&title=Small+targeted+cytotoxics%3A+Current+state+and+promises+from+DNA-encoded+chemical+libraries"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKrall%26aufirst%3DN.%26aulast%3DScheuermann%26aufirst%3DJ.%26aulast%3DNeri%26aufirst%3DD.%26atitle%3DSmall%2520targeted%2520cytotoxics%253A%2520Current%2520state%2520and%2520promises%2520from%2520DNA-encoded%2520chemical%2520libraries%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26spage%3D1384%26epage%3D1402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">van der Veldt, A. A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendrikse, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smit, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooijer, M. P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rijnders, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerritsen, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Hoeven, J. J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Windhorst, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lammertsma, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubberink, M.</span><span> </span><span class="NLM_article-title">Biodistribution and radiation dosimetry of C-11-labelled docetaxel in cancer patients</span> <span class="citation_source-journal">Eur. J. Nucl. Med. Mol. Imaging</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1950</span><span class="NLM_x">–</span> <span class="NLM_lpage">1958</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1007%2Fs00259-010-1489-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=20508935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A280%3ADC%252BC3cjpsFersA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2010&pages=1950-1958&author=A.+A.+M.+van+der+Veldtauthor=N.+H.+Hendrikseauthor=E.+F.+Smitauthor=M.+P.+J.+Mooijerauthor=A.+Y.+Rijndersauthor=W.+R.+Gerritsenauthor=J.+J.+M.+van+der+Hoevenauthor=A.+D.+Windhorstauthor=A.+A.+Lammertsmaauthor=M.+Lubberink&title=Biodistribution+and+radiation+dosimetry+of+C-11-labelled+docetaxel+in+cancer+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Biodistribution and radiation dosimetry of 11C-labelled docetaxel in cancer patients</span></div><div class="casAuthors">van der Veldt Astrid A M; Hendrikse N Harry; Smit Egbert F; Mooijer Martien P J; Rijnders Anneloes Y; Gerritsen Winald R; van der Hoeven Jacobus J M; Windhorst Albert D; Lammertsma Adriaan A; Lubberink Mark</div><div class="citationInfo"><span class="NLM_cas:title">European journal of nuclear medicine and molecular imaging</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1950-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  Docetaxel is an important chemotherapeutic agent used for the treatment of several cancer types.  As radiolabelled anticancer agents provide a potential means for personalized treatment planning, docetaxel was labelled with the positron emitter (11)C.  Non-invasive measurements of [(11)C]docetaxel uptake in organs and tumours may provide additional information on pharmacokinetics and pharmacodynamics of the drug docetaxel.  The purpose of the present study was to determine the biodistribution and radiation absorbed dose of [(11)C]docetaxel in humans.  METHODS:  Biodistribution of [(11)C]docetaxel was measured in seven patients (five men and two women) with solid tumours using PET/CT.  Venous blood samples were collected to measure activity in blood and plasma.  Regions of interest (ROI) for various source organs were defined on PET (high [(11)C]docetaxel uptake) or CT (low [(11)C]docetaxel uptake).  ROI data were used to generate time-activity curves and to calculate percentage injected dose and residence times.  Radiation absorbed doses were calculated according to the MIRD method using OLINDA/EXM 1.0 software.  RESULTS:  Gall bladder and liver demonstrated high [(11)C]docetaxel uptake, whilst uptake in brain and normal lung was low.  The percentage injected dose at 1 h in the liver was 47 +/- 9%. [(11)C]docetaxel was rapidly cleared from plasma and no radiolabelled metabolites were detected. [(11)C]docetaxel uptake in tumours was moderate and highly variable between tumours.  CONCLUSION:  The effective dose of [(11)C]docetaxel was 4.7 microSv/MBq.  As uptake in normal lung is low, [(11)C]docetaxel may be a promising tracer for tumours in the thoracic region.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQxqGMXy1jiK-R_TJajKxJDfW6udTcc2ea8Is-7Y0LDh7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjpsFersA%253D%253D&md5=cc75d090de603c03f691b9c9a63adb95</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1007%2Fs00259-010-1489-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00259-010-1489-y%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bder%2BVeldt%26aufirst%3DA.%2BA.%2BM.%26aulast%3DHendrikse%26aufirst%3DN.%2BH.%26aulast%3DSmit%26aufirst%3DE.%2BF.%26aulast%3DMooijer%26aufirst%3DM.%2BP.%2BJ.%26aulast%3DRijnders%26aufirst%3DA.%2BY.%26aulast%3DGerritsen%26aufirst%3DW.%2BR.%26aulast%3Dvan%2Bder%2BHoeven%26aufirst%3DJ.%2BJ.%2BM.%26aulast%3DWindhorst%26aufirst%3DA.%2BD.%26aulast%3DLammertsma%26aufirst%3DA.%2BA.%26aulast%3DLubberink%26aufirst%3DM.%26atitle%3DBiodistribution%2520and%2520radiation%2520dosimetry%2520of%2520C-11-labelled%2520docetaxel%2520in%2520cancer%2520patients%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%2520Mol.%2520Imaging%26date%3D2010%26volume%3D37%26spage%3D1950%26epage%3D1958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">van der Veldt, A. A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubberink, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathijssen, R. H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loos, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herder, G. J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greuter, H. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comans, E. F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutten, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eriksson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Windhorst, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendrikse, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Postmus, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smit, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lammertsma, A. A.</span><span> </span><span class="NLM_article-title">Toward prediction of efficacy of chemotherapy: A proof of concept study in lung cancer patients using C-11 docetaxel and positron emission tomography</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">4163</span><span class="NLM_x">–</span> <span class="NLM_lpage">4173</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1158%2F1078-0432.CCR-12-3779" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=23620410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1amt7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=4163-4173&author=A.+A.+M.+van+der+Veldtauthor=M.+Lubberinkauthor=R.+H.+J.+Mathijssenauthor=W.+J.+Loosauthor=G.+J.+M.+Herderauthor=H.+N.+Greuterauthor=E.+F.+I.+Comansauthor=H.+B.+Ruttenauthor=J.+Erikssonauthor=A.+D.+Windhorstauthor=N.+H.+Hendrikseauthor=P.+E.+Postmusauthor=E.+F.+Smitauthor=A.+A.+Lammertsma&title=Toward+prediction+of+efficacy+of+chemotherapy%3A+A+proof+of+concept+study+in+lung+cancer+patients+using+C-11+docetaxel+and+positron+emission+tomography"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [11C]docetaxel and Positron Emission Tomography</span></div><div class="casAuthors">van der Veldt, Astrid A. M.; Lubberink, Mark; Mathijssen, Ron H. J.; Loos, Walter J.; Herder, Gerarda J. M.; Greuter, Henri N.; Comans, Emile F. I.; Rutten, Hugo B.; Eriksson, Jonas; Windhorst, Albert D.; Hendrikse, N. Harry; Postmus, Pieter E.; Smit, Egbert F.; Lammertsma, Adriaan A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4163-4173</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Pharmacokinetics of docetaxel can be measured in vivo using positron emission tomog. (PET) and a microdose of radiolabeled docetaxel ([11C]docetaxel).  The objective of this study was to investigate whether a [11C]docetaxel PET microdosing study could predict tumor uptake of therapeutic doses of docetaxel.  Exptl. Design: Docetaxel-naive lung cancer patients underwent 2 [11C]docetaxel PET scans; one after bolus injection of [11C]docetaxel and another during combined infusion of [11C]docetaxel and a therapeutic dose of docetaxel (75 mg·m-2).  Compartmental and spectral analyses were used to quantify [11C]docetaxel tumor kinetics. [11C]docetaxel PET measurements were used to est. the area under the curve (AUC) of docetaxel in tumors.  Tumor response was evaluated using computed tomog. scans.  Results: Net rates of influx (Ki) of [11C]docetaxel in tumors were comparable during microdosing and therapeutic scans. [11C]docetaxel AUCTumor during the therapeutic scan could be predicted reliably using an impulse response function derived from the microdosing scan together with the plasma curve of [11C]docetaxel during the therapeutic scan.  At 90 min, the accumulated amt. of docetaxel in tumors was less than 1% of the total infused dose of docetaxel. [11C]docetaxel Ki derived from the microdosing scan correlated with AUCTumor of docetaxel (Spearman ρ = 0.715; P = 0.004) during the therapeutic scan and with tumor response to docetaxel therapy (Spearman ρ = -0.800; P = 0.010).  Conclusions: Microdosing data of [11C]docetaxel PET can be used to predict tumor uptake of docetaxel during chemotherapy.  The present study provides a framework for investigating the PET microdosing concept for radiolabeled anticancer drugs in patients.  Clin Cancer Res; 19(15); 4163-73. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruvBXmmZcFRrVg90H21EOLACvtfcHk0lgBWX4Ix55tSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1amt7%252FI&md5=b08e686ab324cef9051f5744e4b155a6</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-3779&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-3779%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bder%2BVeldt%26aufirst%3DA.%2BA.%2BM.%26aulast%3DLubberink%26aufirst%3DM.%26aulast%3DMathijssen%26aufirst%3DR.%2BH.%2BJ.%26aulast%3DLoos%26aufirst%3DW.%2BJ.%26aulast%3DHerder%26aufirst%3DG.%2BJ.%2BM.%26aulast%3DGreuter%26aufirst%3DH.%2BN.%26aulast%3DComans%26aufirst%3DE.%2BF.%2BI.%26aulast%3DRutten%26aufirst%3DH.%2BB.%26aulast%3DEriksson%26aufirst%3DJ.%26aulast%3DWindhorst%26aufirst%3DA.%2BD.%26aulast%3DHendrikse%26aufirst%3DN.%2BH.%26aulast%3DPostmus%26aufirst%3DP.%2BE.%26aulast%3DSmit%26aufirst%3DE.%2BF.%26aulast%3DLammertsma%26aufirst%3DA.%2BA.%26atitle%3DToward%2520prediction%2520of%2520efficacy%2520of%2520chemotherapy%253A%2520A%2520proof%2520of%2520concept%2520study%2520in%2520lung%2520cancer%2520patients%2520using%2520C-11%2520docetaxel%2520and%2520positron%2520emission%2520tomography%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D4163%26epage%3D4173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Chari, R. V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widdison, W. C.</span><span> </span><span class="NLM_article-title">Antibody-drug conjugates: An emerging concept in cancer therapy</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">3796</span><span class="NLM_x">–</span> <span class="NLM_lpage">3827</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1002%2Fanie.201307628" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtVGmsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=3796-3827&author=R.+V.+J.+Chariauthor=M.+L.+Millerauthor=W.+C.+Widdison&title=Antibody-drug+conjugates%3A+An+emerging+concept+in+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy</span></div><div class="casAuthors">Chari, Ravi V. J.; Miller, Michael L.; Widdison, Wayne C.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3796-3827</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Traditional cancer chemotherapy is often accompanied by systemic toxicity to the patient.  Monoclonal antibodies against antigens on cancer cells offer an alternative tumor-selective treatment approach.  However, most monoclonal antibodies are not sufficiently potent to be therapeutically active on their own.  Antibody-drug conjugates (ADCs) use antibodies to deliver a potent cytotoxic compd. selectively to tumor cells, thus improving the therapeutic index of chemotherapeutic agents.  The recent approval of two ADCs, brentuximab vedotin and ado-trastuzumab emtansine, for cancer treatment has spurred tremendous research interest in this field.  This Review touches upon the early efforts in the field, and describes how the lessons learned from the first-generation ADCs have led to improvements in every aspect of this technol., i.e., the antibody, the cytotoxic compd., and the linker connecting them, leading to the current successes.  The design of ADCs currently in clin. development, and results from mechanistic studies and preclin. and clin. evaluation are discussed.  Emerging technologies that seek to further advance this exciting area of research are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4T2rhmji6DLVg90H21EOLACvtfcHk0ljhnTXhr5bmZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtVGmsr0%253D&md5=fbfb2f843f516654ea7c0eb98949604c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1002%2Fanie.201307628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201307628%26sid%3Dliteratum%253Aachs%26aulast%3DChari%26aufirst%3DR.%2BV.%2BJ.%26aulast%3DMiller%26aufirst%3DM.%2BL.%26aulast%3DWiddison%26aufirst%3DW.%2BC.%26atitle%3DAntibody-drug%2520conjugates%253A%2520An%2520emerging%2520concept%2520in%2520cancer%2520therapy%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D3796%26epage%3D3827" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Senter, P. D.</span><span> </span><span class="NLM_article-title">Potent antibody drug conjugates for cancer therapy</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">244</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1016%2Fj.cbpa.2009.03.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=19414278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVWltbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2009&pages=235-244&author=P.+D.+Senter&title=Potent+antibody+drug+conjugates+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Potent antibody drug conjugates for cancer therapy</span></div><div class="casAuthors">Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">235-244</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Significant progress has been made in the past few years in the area of antibody drug conjugates (ADCs) for the selective delivery of cytotoxic drugs to tumors.  Early work in this field incorporated clin. approved drugs and mouse monoclonal antibodies (mAbs), which had modest activities, and were generally immunogenic.  The results of these studies prompted investigation that led to the identity of several key parameters that influenced activity and tolerability.  These included the antigen target, the use of non-immunogenic mAb carriers, the incorporation of highly potent drugs and novel conditionally stable linker technologies, and the specific methods used to attach drugs to mAbs.  As a result of these investigations, new agents with pronounced clin. activities have been developed.  These include SGN-35, an ADC directed against the CD30-pos. malignancies such as Hodgkin's disease and anaplastic large cell lymphoma, and trastuzumab-DM1 which has shown activity in metastatic breast carcinoma.  This review details many of the technol. advancements, and provides examples of promising ADCs that are currently in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqomJSUUPIrcbVg90H21EOLACvtfcHk0ljhnTXhr5bmZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVWltbg%253D&md5=3cf72b412351bae075fab1159c49d8c5</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2009.03.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2009.03.023%26sid%3Dliteratum%253Aachs%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DPotent%2520antibody%2520drug%2520conjugates%2520for%2520cancer%2520therapy%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2009%26volume%3D13%26spage%3D235%26epage%3D244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Gerber, H.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grewal, I. S.</span><span> </span><span class="NLM_article-title">Antibody drug-conjugates targeting the tumor vasculature. Current and future developments</span> <span class="citation_source-journal">MAbs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">247</span><span class="NLM_x">–</span> <span class="NLM_lpage">253</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2009&pages=247-253&author=H.-P.+Gerberauthor=P.+D.+Senterauthor=I.+S.+Grewal&title=Antibody+drug-conjugates+targeting+the+tumor+vasculature.+Current+and+future+developments"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGerber%26aufirst%3DH.-P.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26aulast%3DGrewal%26aufirst%3DI.%2BS.%26atitle%3DAntibody%2520drug-conjugates%2520targeting%2520the%2520tumor%2520vasculature.%2520Current%2520and%2520future%2520developments%26jtitle%3DMAbs%26date%3D2009%26volume%3D1%26spage%3D247%26epage%3D253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Poli, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bianchi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Virotta, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bettini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moretti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trachsel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giovannoni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruno, A.</span><span> </span><span class="NLM_article-title">Radretumab radioimmunotherapy in patients with brain metastasis: A I-124-L19SIP dosimetric PET study</span> <span class="citation_source-journal">Cancer Immunol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">134</span><span class="NLM_x">–</span> <span class="NLM_lpage">143</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1158%2F2326-6066.CIR-13-0007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=24777501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntlWku78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2013&pages=134-143&author=G.+L.+Poliauthor=C.+Bianchiauthor=G.+Virottaauthor=A.+Bettiniauthor=R.+Morettiauthor=E.+Trachselauthor=G.+Eliaauthor=L.+Giovannoniauthor=D.+Neriauthor=A.+Bruno&title=Radretumab+radioimmunotherapy+in+patients+with+brain+metastasis%3A+A+I-124-L19SIP+dosimetric+PET+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Radretumab radioimmunotherapy in patients with brain metastasis: A124I-L19SIP dosimetric PET study</span></div><div class="casAuthors">Poli, Gian Luca; Bianchi, Claudia; Virotta, Giorgio; Bettini, Anna; Moretti, Renzo; Trachsel, Eveline; Elia, Giuliano; Giovannoni, Leonardo; Neri, Dario; Bruno, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">134-143</span>CODEN:
                <span class="NLM_cas:coden">CIRACV</span>;
        ISSN:<span class="NLM_cas:issn">2326-6066</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Radioimmunotherapy (RIT) with 131I-labeled L19SIP (radretumab; a small immunoprotein format antibody directed against the ED-B domain of fibronectin; ∼80 kDa mol. wt.) has been investigated in several clin. trials.  Here, we describe the use of immuno-PET imaging with iodine-124 (124I)-labeled L19SIP to predict doses delivered to tumor lesions and healthy organs by a subsequent radretumab RIT in patients with brain metastases from solid cancer.  Bone marrow doses were evaluated both during the diagnostic phase and posttherapy, measuring activities in blood (germanium detector) and whole body (lanthanum bromide detector).  Expected doses for radretumab administration (4,107 MBq/m2) were calcd. from data obtained after administration of an av. of 167 MBq 124I-L19SIP to 6 patients.  To assess lesion av. doses, the positron emission tomog. (PET) scanner was calibrated for the use of 124I with an International Electrotech. Commission (IEC) Body Phantom and recovery coeffs. were calcd.  The av. dose to bone red marrow was 0.21 Gy/GBq, with high correlation between provisional and actual posttherapy doses.  Although the fraction of injected activity in normal organs was similar in different patients, the antibody uptake in the neoplastic lesions varied by as much as a factor of 60.  Immuno-PET with 124I-labeled L19SIP offers significant advantages over conventional 131I imaging, in particular accuracy of dosimetric results.  Furthermore, the study indicates that antibody uptake can be highly variable even in different lesions of the same patient and that immuno-PET procedures may guide product development with armed antibodies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCCv-YIUn28rVg90H21EOLACvtfcHk0ljhnTXhr5bmZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntlWku78%253D&md5=fad3ed8a38f157a35f3a59b2706f0d86</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F2326-6066.CIR-13-0007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2326-6066.CIR-13-0007%26sid%3Dliteratum%253Aachs%26aulast%3DPoli%26aufirst%3DG.%2BL.%26aulast%3DBianchi%26aufirst%3DC.%26aulast%3DVirotta%26aufirst%3DG.%26aulast%3DBettini%26aufirst%3DA.%26aulast%3DMoretti%26aufirst%3DR.%26aulast%3DTrachsel%26aufirst%3DE.%26aulast%3DElia%26aufirst%3DG.%26aulast%3DGiovannoni%26aufirst%3DL.%26aulast%3DNeri%26aufirst%3DD.%26aulast%3DBruno%26aufirst%3DA.%26atitle%3DRadretumab%2520radioimmunotherapy%2520in%2520patients%2520with%2520brain%2520metastasis%253A%2520A%2520I-124-L19SIP%2520dosimetric%2520PET%2520study%26jtitle%3DCancer%2520Immunol.%2520Res.%26date%3D2013%26volume%3D1%26spage%3D134%26epage%3D143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Erba, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sollini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orciuolo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traino, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paganelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bombardieri, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grana, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giovannoni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menssen, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mariani, G.</span><span> </span><span class="NLM_article-title">Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">922</span><span class="NLM_x">–</span> <span class="NLM_lpage">927</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2012&pages=922-927&author=P.+A.+Erbaauthor=M.+Solliniauthor=E.+Orciuoloauthor=C.+Trainoauthor=M.+Petriniauthor=G.+Paganelliauthor=E.+Bombardieriauthor=C.+Granaauthor=L.+Giovannoniauthor=D.+Neriauthor=H.+D.+Menssenauthor=G.+Mariani&title=Radioimmunotherapy+with+radretumab+in+patients+with+relapsed+hematologic+malignancies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DErba%26aufirst%3DP.%2BA.%26aulast%3DSollini%26aufirst%3DM.%26aulast%3DOrciuolo%26aufirst%3DE.%26aulast%3DTraino%26aufirst%3DC.%26aulast%3DPetrini%26aufirst%3DM.%26aulast%3DPaganelli%26aufirst%3DG.%26aulast%3DBombardieri%26aufirst%3DE.%26aulast%3DGrana%26aufirst%3DC.%26aulast%3DGiovannoni%26aufirst%3DL.%26aulast%3DNeri%26aufirst%3DD.%26aulast%3DMenssen%26aufirst%3DH.%2BD.%26aulast%3DMariani%26aufirst%3DG.%26atitle%3DRadioimmunotherapy%2520with%2520radretumab%2520in%2520patients%2520with%2520relapsed%2520hematologic%2520malignancies%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2012%26volume%3D53%26spage%3D922%26epage%3D927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Stillebroer, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zegers, C. M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boerman, O. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oosterwijk, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulders, P. F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donoghue, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Visser, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyen, W. J. G.</span><span> </span><span class="NLM_article-title">Dosimetric analysis of Lu-177-cG250 radioimmunotherapy in renal cell carcinoma patients: Correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on In-111-cG250 imaging</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">82</span><span class="NLM_x">–</span> <span class="NLM_lpage">89</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2012&pages=82-89&author=A.+B.+Stillebroerauthor=C.+M.+L.+Zegersauthor=O.+C.+Boermanauthor=E.+Oosterwijkauthor=P.+F.+A.+Muldersauthor=J.+A.+O%E2%80%99Donoghueauthor=E.+P.+Visserauthor=W.+J.+G.+Oyen&title=Dosimetric+analysis+of+Lu-177-cG250+radioimmunotherapy+in+renal+cell+carcinoma+patients%3A+Correlation+with+myelotoxicity+and+pretherapeutic+absorbed+dose+predictions+based+on+In-111-cG250+imaging"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStillebroer%26aufirst%3DA.%2BB.%26aulast%3DZegers%26aufirst%3DC.%2BM.%2BL.%26aulast%3DBoerman%26aufirst%3DO.%2BC.%26aulast%3DOosterwijk%26aufirst%3DE.%26aulast%3DMulders%26aufirst%3DP.%2BF.%2BA.%26aulast%3DO%25E2%2580%2599Donoghue%26aufirst%3DJ.%2BA.%26aulast%3DVisser%26aufirst%3DE.%2BP.%26aulast%3DOyen%26aufirst%3DW.%2BJ.%2BG.%26atitle%3DDosimetric%2520analysis%2520of%2520Lu-177-cG250%2520radioimmunotherapy%2520in%2520renal%2520cell%2520carcinoma%2520patients%253A%2520Correlation%2520with%2520myelotoxicity%2520and%2520pretherapeutic%2520absorbed%2520dose%2520predictions%2520based%2520on%2520In-111-cG250%2520imaging%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2012%26volume%3D53%26spage%3D82%26epage%3D89" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Sharkey, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajjar, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeldell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brenner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldenberg, D. M.</span><span> </span><span class="NLM_article-title">A phase I trial combining high-dose Y-90-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">620</span><span class="NLM_x">–</span> <span class="NLM_lpage">633</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2005&pages=620-633&author=R.+M.+Sharkeyauthor=G.+Hajjarauthor=D.+Yeldellauthor=A.+Brennerauthor=J.+Burtonauthor=A.+Rubinauthor=D.+M.+Goldenberg&title=A+phase+I+trial+combining+high-dose+Y-90-labeled+humanized+anti-CEA+monoclonal+antibody+with+doxorubicin+and+peripheral+blood+stem+cell+rescue+in+advanced+medullary+thyroid+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSharkey%26aufirst%3DR.%2BM.%26aulast%3DHajjar%26aufirst%3DG.%26aulast%3DYeldell%26aufirst%3DD.%26aulast%3DBrenner%26aufirst%3DA.%26aulast%3DBurton%26aufirst%3DJ.%26aulast%3DRubin%26aufirst%3DA.%26aulast%3DGoldenberg%26aufirst%3DD.%2BM.%26atitle%3DA%2520phase%2520I%2520trial%2520combining%2520high-dose%2520Y-90-labeled%2520humanized%2520anti-CEA%2520monoclonal%2520antibody%2520with%2520doxorubicin%2520and%2520peripheral%2520blood%2520stem%2520cell%2520rescue%2520in%2520advanced%2520medullary%2520thyroid%2520cancer%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2005%26volume%3D46%26spage%3D620%26epage%3D633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Carrasquillo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandit-Taskar, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donoghue, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humm, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zanzonico, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith-Jones, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Divgi, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pryma, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruan, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kemeny, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaggi, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheinberg, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panageas, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ritter, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jungbluth, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Old, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, S. M.</span><span> </span><span class="NLM_article-title">I-124-huA33 antibody PET of colorectal cancer</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1173</span><span class="NLM_x">–</span> <span class="NLM_lpage">1180</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2011&pages=1173-1180&author=J.+A.+Carrasquilloauthor=N.+Pandit-Taskarauthor=J.+A.+O%E2%80%99Donoghueauthor=J.+L.+Hummauthor=P.+Zanzonicoauthor=P.+M.+Smith-Jonesauthor=C.+R.+Divgiauthor=D.+A.+Prymaauthor=S.+T.+Ruanauthor=N.+E.+Kemenyauthor=Y.+M.+Fongauthor=D.+Wongauthor=J.+S.+Jaggiauthor=D.+A.+Scheinbergauthor=M.+Gonenauthor=K.+S.+Panageasauthor=G.+Ritterauthor=A.+A.+Jungbluthauthor=L.+J.+Oldauthor=S.+M.+Larson&title=I-124-huA33+antibody+PET+of+colorectal+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCarrasquillo%26aufirst%3DJ.%2BA.%26aulast%3DPandit-Taskar%26aufirst%3DN.%26aulast%3DO%25E2%2580%2599Donoghue%26aufirst%3DJ.%2BA.%26aulast%3DHumm%26aufirst%3DJ.%2BL.%26aulast%3DZanzonico%26aufirst%3DP.%26aulast%3DSmith-Jones%26aufirst%3DP.%2BM.%26aulast%3DDivgi%26aufirst%3DC.%2BR.%26aulast%3DPryma%26aufirst%3DD.%2BA.%26aulast%3DRuan%26aufirst%3DS.%2BT.%26aulast%3DKemeny%26aufirst%3DN.%2BE.%26aulast%3DFong%26aufirst%3DY.%2BM.%26aulast%3DWong%26aufirst%3DD.%26aulast%3DJaggi%26aufirst%3DJ.%2BS.%26aulast%3DScheinberg%26aufirst%3DD.%2BA.%26aulast%3DGonen%26aufirst%3DM.%26aulast%3DPanageas%26aufirst%3DK.%2BS.%26aulast%3DRitter%26aufirst%3DG.%26aulast%3DJungbluth%26aufirst%3DA.%2BA.%26aulast%3DOld%26aufirst%3DL.%2BJ.%26aulast%3DLarson%26aufirst%3DS.%2BM.%26atitle%3DI-124-huA33%2520antibody%2520PET%2520of%2520colorectal%2520cancer%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2011%26volume%3D52%26spage%3D1173%26epage%3D1180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Borjesson, P. K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jauw, Y. W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bree, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roos, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castelijns, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leemans, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Dongen, G. A. M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boellaard, R.</span><span> </span><span class="NLM_article-title">Radiation dosimetry of Zr-89-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1828</span><span class="NLM_x">–</span> <span class="NLM_lpage">1836</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.2967%2Fjnumed.109.065862" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=19837762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A280%3ADC%252BD1MjisFWnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2009&pages=1828-1836&author=P.+K.+E.+Borjessonauthor=Y.+W.+S.+Jauwauthor=R.+de+Breeauthor=J.+C.+Roosauthor=J.+A.+Castelijnsauthor=C.+R.+Leemansauthor=G.+A.+M.+S.+van+Dongenauthor=R.+Boellaard&title=Radiation+dosimetry+of+Zr-89-labeled+chimeric+monoclonal+antibody+U36+as+used+for+immuno-PET+in+head+and+neck+cancer+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients</span></div><div class="casAuthors">Borjesson Pontus K E; Jauw Yvonne W S; de Bree Remco; Roos Jan C; Castelijns Jonas A; Leemans C Rene; van Dongen Guus A M S; Boellaard Ronald</div><div class="citationInfo"><span class="NLM_cas:title">Journal of nuclear medicine : official publication, Society of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1828-36</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">UNLABELLED:  Immuno-PET is an appealing concept in the detection of tumors and planning of antibody-based therapy.  For this purpose, the long-lived positron emitter (89)Zr (half-life, 78.4 h) recently became available.  The aim of the present first-in-humans (89)Zr immuno-PET study was to assess safety, biodistribution, radiation dose, and quantification of the (89)Zr-labeled chimeric monoclonal antibody (cmAb) U36 in patients with head and neck squamous cell carcinoma (HNSCC).  In addition, the performance of immuno-PET for detecting lymph node metastases was evaluated, as described previously.  METHODS:  Twenty HNSCC patients, scheduled to undergo surgical tumor resection, received 75 MBq of (89)Zr-cmAb U36 (10 mg).  Immuno-PET scans were acquired at 1, 24, 72, or 144 h after injection.  The biodistribution of the radioimmunoconjugate was evaluated by ex vivo radioactivity measurement in blood and in biopsies from the surgical specimen obtained at 168 h after injection.  Uptake levels and residence times in blood, tumors, and organs of interest were derived from quantitative immuno-PET studies, and absorbed doses were calculated using OLINDA/EXM 1.0.  The red marrow dose was calculated using the residence time for blood.  RESULTS:  (89)Zr-cmAb U36 was well tolerated by all subjects.  PET quantification of blood-pool activity in the left ventricle of the heart showed a good agreement with sampled blood activity (difference equals 0.2% +/- 16.9% [mean +/- SD]) except for heavy-weight patients (>100 kg).  A good agreement was also found for the assessment of mAb uptake in primary tumors (mean deviation, -8.4% +/- 34.5%).  The mean absorbed red marrow dose was 0.07 +/- 0.02 mSv/MBq and 0.09 +/- 0.01 mSv/MBq in men and women, respectively.  The normal organ with the highest absorbed dose was the liver (mean dose, 1.25 +/- 0.27 mSv/MBq in men and 1.35 +/- 0.21 mSv/MBq in women), thereafter followed by kidneys, thyroid, lungs, and spleen.  The mean effective dose was 0.53 +/- 0.03 mSv/MBq in men and 0.66 +/- 0.03 mSv/MBq in women.  Measured excretion via the urinary tract was less than 3% during the first 72 h.  CONCLUSION:  (89)Zr immuno-PET can be safely used to quantitatively assess biodistribution, uptake, organ residence times, and radiation dose, justifying its further clinical exploitation in the detection of tumors and planning of mAb-based therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQu901ddEA7J0NHe_gFldTbfW6udTcc2eZPdCTZYXX1Ybntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MjisFWnsw%253D%253D&md5=730800af4c7381d55b17649402858308</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.109.065862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.109.065862%26sid%3Dliteratum%253Aachs%26aulast%3DBorjesson%26aufirst%3DP.%2BK.%2BE.%26aulast%3DJauw%26aufirst%3DY.%2BW.%2BS.%26aulast%3Dde%2BBree%26aufirst%3DR.%26aulast%3DRoos%26aufirst%3DJ.%2BC.%26aulast%3DCastelijns%26aufirst%3DJ.%2BA.%26aulast%3DLeemans%26aufirst%3DC.%2BR.%26aulast%3Dvan%2BDongen%26aufirst%3DG.%2BA.%2BM.%2BS.%26aulast%3DBoellaard%26aufirst%3DR.%26atitle%3DRadiation%2520dosimetry%2520of%2520Zr-89-labeled%2520chimeric%2520monoclonal%2520antibody%2520U36%2520as%2520used%2520for%2520immuno-PET%2520in%2520head%2520and%2520neck%2520cancer%2520patients%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2009%26volume%3D50%26spage%3D1828%26epage%3D1836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Muselaers, C. H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stillebroer, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desar, I. M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boers-Sonderen, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Herpen, C. M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Weijert, M. C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langenhuijsen, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oosterwijk, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leenders, W. P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boerman, O. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulders, P. F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyen, W. J. G.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitor sorafenib decreases In-111-girentuximab uptake in patients with clear cell renal cell carcinoma</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">242</span><span class="NLM_x">–</span> <span class="NLM_lpage">247</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2014&pages=242-247&author=C.+H.+J.+Muselaersauthor=A.+B.+Stillebroerauthor=I.+M.+E.+Desarauthor=M.+J.+Boers-Sonderenauthor=C.+M.+L.+van+Herpenauthor=M.+C.+A.+de+Weijertauthor=J.+F.+Langenhuijsenauthor=E.+Oosterwijkauthor=W.+P.+J.+Leendersauthor=O.+C.+Boermanauthor=P.+F.+A.+Muldersauthor=W.+J.+G.+Oyen&title=Tyrosine+kinase+inhibitor+sorafenib+decreases+In-111-girentuximab+uptake+in+patients+with+clear+cell+renal+cell+carcinoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMuselaers%26aufirst%3DC.%2BH.%2BJ.%26aulast%3DStillebroer%26aufirst%3DA.%2BB.%26aulast%3DDesar%26aufirst%3DI.%2BM.%2BE.%26aulast%3DBoers-Sonderen%26aufirst%3DM.%2BJ.%26aulast%3Dvan%2BHerpen%26aufirst%3DC.%2BM.%2BL.%26aulast%3Dde%2BWeijert%26aufirst%3DM.%2BC.%2BA.%26aulast%3DLangenhuijsen%26aufirst%3DJ.%2BF.%26aulast%3DOosterwijk%26aufirst%3DE.%26aulast%3DLeenders%26aufirst%3DW.%2BP.%2BJ.%26aulast%3DBoerman%26aufirst%3DO.%2BC.%26aulast%3DMulders%26aufirst%3DP.%2BF.%2BA.%26aulast%3DOyen%26aufirst%3DW.%2BJ.%2BG.%26atitle%3DTyrosine%2520kinase%2520inhibitor%2520sorafenib%2520decreases%2520In-111-girentuximab%2520uptake%2520in%2520patients%2520with%2520clear%2520cell%2520renal%2520cell%2520carcinoma%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2014%26volume%3D55%26spage%3D242%26epage%3D247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Breitz, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjorn, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiden, P. L.</span><span> </span><span class="NLM_article-title">Clinical experience with Tc-99m nofetumomab merpentan (Verluma) radioimmunoscintigraphy</span> <span class="citation_source-journal">Clin. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">615</span><span class="NLM_x">–</span> <span class="NLM_lpage">620</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1097%2F00003072-199709000-00007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=9298295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A280%3ADyaK2svktlCmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1997&pages=615-620&author=H.+B.+Breitzauthor=A.+Tylerauthor=M.+J.+Bjornauthor=T.+Lesleyauthor=P.+L.+Weiden&title=Clinical+experience+with+Tc-99m+nofetumomab+merpentan+%28Verluma%29+radioimmunoscintigraphy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical experience with Tc-99m nofetumomab merpentan (Verluma) radioimmunoscintigraphy</span></div><div class="casAuthors">Breitz H B; Tyler A; Bjorn M J; Lesley T; Weiden P L</div><div class="citationInfo"><span class="NLM_cas:title">Clinical nuclear medicine</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">615-20</span>
        ISSN:<span class="NLM_cas:issn">0363-9762</span>.
    </div><div class="casAbstract">Tc-99m nofetumomab merpentan (Verluma), consisting of a Fab fragment of the pancarcinoma murine antibody NR-LU-10, has been previously evaluated as a diagnostic imaging agent in staging patients with lung cancer.  The authors have taken advantage of the pancarcinoma reactivity of this antibody to select patients with a variety of carcinomas for radioimmunotherapy trials.  These have included gastrointestinal, breast, ovary, pancreas, kidney, cervix, and bladder carcinoma.  This article documents the range of tumor types and locations that can be identified by gamma camera imaging with this radioimmunoconjugate.  Tumor was positively identified in 92% of 107 patients studied.  In 15 patients, the images led to suspicion of previously unknown disease.  The authors conclude that this radioimmunoconjugate is useful in assessing patients with advanced disease.  Additional studies may be warranted to explore further the potential benefit of this diagnostic imaging agent in evaluating the extent of disease in patients with a variety of carcinomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS10S5FU1N0Q02yPDyEFiigfW6udTcc2eYIFgdKGqgjV7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2svktlCmuw%253D%253D&md5=f16b14dfe321799f2b8f44a902c9c8c0</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1097%2F00003072-199709000-00007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00003072-199709000-00007%26sid%3Dliteratum%253Aachs%26aulast%3DBreitz%26aufirst%3DH.%2BB.%26aulast%3DTyler%26aufirst%3DA.%26aulast%3DBjorn%26aufirst%3DM.%2BJ.%26aulast%3DLesley%26aufirst%3DT.%26aulast%3DWeiden%26aufirst%3DP.%2BL.%26atitle%3DClinical%2520experience%2520with%2520Tc-99m%2520nofetumomab%2520merpentan%2520%2528Verluma%2529%2520radioimmunoscintigraphy%26jtitle%3DClin.%2520Nucl.%2520Med.%26date%3D1997%26volume%3D22%26spage%3D615%26epage%3D620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Heuveling, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bree, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vugts, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huisman, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giovannoni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoekstra, O. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leemans, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Dongen, G. A. M. S.</span><span> </span><span class="NLM_article-title">Phase 0 microdosing PET study using the human mini antibody F16SIP in head and neck cancer patients</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">397</span><span class="NLM_x">–</span> <span class="NLM_lpage">401</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2013&pages=397-401&author=D.+A.+Heuvelingauthor=R.+de+Breeauthor=D.+J.+Vugtsauthor=M.+C.+Huismanauthor=L.+Giovannoniauthor=O.+S.+Hoekstraauthor=C.+R.+Leemansauthor=D.+Neriauthor=G.+A.+M.+S.+van+Dongen&title=Phase+0+microdosing+PET+study+using+the+human+mini+antibody+F16SIP+in+head+and+neck+cancer+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHeuveling%26aufirst%3DD.%2BA.%26aulast%3Dde%2BBree%26aufirst%3DR.%26aulast%3DVugts%26aufirst%3DD.%2BJ.%26aulast%3DHuisman%26aufirst%3DM.%2BC.%26aulast%3DGiovannoni%26aufirst%3DL.%26aulast%3DHoekstra%26aufirst%3DO.%2BS.%26aulast%3DLeemans%26aufirst%3DC.%2BR.%26aulast%3DNeri%26aufirst%3DD.%26aulast%3Dvan%2BDongen%26aufirst%3DG.%2BA.%2BM.%2BS.%26atitle%3DPhase%25200%2520microdosing%2520PET%2520study%2520using%2520the%2520human%2520mini%2520antibody%2520F16SIP%2520in%2520head%2520and%2520neck%2520cancer%2520patients%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2013%26volume%3D54%26spage%3D397%26epage%3D401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Ychou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelegrin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faurous, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saccavini, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerreau, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossi, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchegger, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mach, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artus, J. C.</span><span> </span><span class="NLM_article-title">Phase-I/II radio-immunotherapy study with iodine-131-labeled anti-CEA monoclonal antibody F6 F(ab′)2 in patients with non-resectable liver metastases from colorectal cancer</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">615</span><span class="NLM_x">–</span> <span class="NLM_lpage">619</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1002%2F%28SICI%291097-0215%2819980209%2975%3A4%3C615%3A%3AAID-IJC20%3E3.0.CO%3B2-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=9466665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADyaK1cXhtV2lu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=1998&pages=615-619&author=M.+Ychouauthor=A.+Pelegrinauthor=P.+Faurousauthor=B.+Robertauthor=J.+C.+Saccaviniauthor=D.+Guerreauauthor=J.+F.+Rossiauthor=M.+Fabbroauthor=F.+Bucheggerauthor=J.+P.+Machauthor=J.+C.+Artus&title=Phase-I%2FII+radio-immunotherapy+study+with+iodine-131-labeled+anti-CEA+monoclonal+antibody+F6+F%28ab%E2%80%B2%292+in+patients+with+non-resectable+liver+metastases+from+colorectal+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Phase-I/II radioimmunotherapy study with iodine-131-labeled anti-CEA monoclonal antibody F6 F(ab')2 in patients with non-resectable liver metastases from colorectal cancer</span></div><div class="casAuthors">Ychou, Marc; Pelegrin, Andre; Faurous, Patrick; Robert, Bruno; Saccavini, Jean-Claude; Guerreau, Dominique; Rossi, Jean-Francois; Fabbro, Michel; Buchegger, Franz; Mach, Jean-Pierre; Artus, Jean-Claude</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">615-619</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Exptl. studies in nude mice with human colon-carcinoma grafts demonstrated the therapeutic efficiency of F(ab')2 fragments to carcinoembryonic antigen (CEA) labeled with a high dose of 131I.  A phase I/II study was designed to det. the max. tolerated dose of 131I-labeled F(ab')2 fragments (131I-F(ab')2) from anti-CEA monoclonal antibody F6, its limiting organ toxicity and tumor uptake.  Ten patients with non-resectable liver metastases from colorectal cancer (9 detected by CT scan and I by laparotomy) were treated with 131I-F(ab')2, doses ranging from 87 to 300 mCi for the first 5 patients, with a const. 300-mCi dose for the last 5 patients.  For all the patients, autologous bone marrow was harvested and stored before treatment.  Circulating CEA ranged from 2 to 126 ng/mI.  No severe adverse events were obsd. during or immediately following infusion of therapeutic doses.  The 9 patients with radiol. evidence of liver metastases showed uptake of 131I-F(ab')2 in the metastases, as obsd. by single-photon-emission tomog.  The only toxicity was hematol., and no severe aplasia was obsd. when up to 250 mCi was infused.  At the 300-mCi dose, 5 out of 6 patients presented grade-3 or -4 hematol. toxicity, with a nadir for neutrophiles and thrombocytes ranging from 25 to 35 days after infusion.  In these 5 cases, bone marrow was re-infused.  No clin. complications were obsd. during aplasia.  The tumor response could be evaluated in 9 out of 10 patients.  One patient showed a partial response of one small liver metastasis (2 cm in diam.) and a stable evolution of the other metastases, 2 patients had stable disease, and 6 showed tumor progression at the time of evaluation (2 or 3 mo after injection) by CT scan.  A dose of 300 mCi 131I-F(ab')2 from the anti-CEA Mab F6 is well tolerated with bone-marrow rescue, whereas a dose of 200 mCi can be infused without severe bone-marrow toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqK1bOLNatdALVg90H21EOLACvtfcHk0lgyaZYPY--Qxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhtV2lu7o%253D&md5=fe84d6fc7b289cfbd0eae0fb993f0a59</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291097-0215%2819980209%2975%3A4%3C615%3A%3AAID-IJC20%3E3.0.CO%3B2-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291097-0215%252819980209%252975%253A4%253C615%253A%253AAID-IJC20%253E3.0.CO%253B2-6%26sid%3Dliteratum%253Aachs%26aulast%3DYchou%26aufirst%3DM.%26aulast%3DPelegrin%26aufirst%3DA.%26aulast%3DFaurous%26aufirst%3DP.%26aulast%3DRobert%26aufirst%3DB.%26aulast%3DSaccavini%26aufirst%3DJ.%2BC.%26aulast%3DGuerreau%26aufirst%3DD.%26aulast%3DRossi%26aufirst%3DJ.%2BF.%26aulast%3DFabbro%26aufirst%3DM.%26aulast%3DBuchegger%26aufirst%3DF.%26aulast%3DMach%26aufirst%3DJ.%2BP.%26aulast%3DArtus%26aufirst%3DJ.%2BC.%26atitle%3DPhase-I%252FII%2520radio-immunotherapy%2520study%2520with%2520iodine-131-labeled%2520anti-CEA%2520monoclonal%2520antibody%2520F6%2520F%2528ab%25E2%2580%25B2%25292%2520in%2520patients%2520with%2520non-resectable%2520liver%2520metastases%2520from%2520colorectal%2520cancer%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D1998%26volume%3D75%26spage%3D615%26epage%3D619" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Wu, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span> </span><span class="NLM_article-title">Arming antibodies: prospects and challenges for immunoconjugates</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">1137</span><span class="NLM_x">–</span> <span class="NLM_lpage">1146</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1038%2Fnbt1141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=16151407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpvVyrtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=1137-1146&author=A.+M.+Wuauthor=P.+D.+Senter&title=Arming+antibodies%3A+prospects+and+challenges+for+immunoconjugates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Arming antibodies: prospects and challenges for immunoconjugates</span></div><div class="casAuthors">Wu, Anna M.; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1137-1146</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Immunoconjugates-monoclonal antibodies (mAbs) coupled to highly toxic agents, including radioisotopes and toxic drugs (ineffective when administered systemically alone)-are becoming a significant component of anticancer treatments.  By combining the exquisite targeting specificity of mAbs with the enhanced tumor-killing power of toxic effector mols., immunoconjugates permit sensitive discrimination between target and normal tissue, resulting in fewer toxic side effects than most conventional chemotherapeutic drugs.  Two radioimmunoconjugates, ibritumomab tiuxetan (Zevalin) and tositumomab-131I (Bexxar), and one drug conjugate, gemtuzumab ozogamicin (Mylotarg), are now on the market.  For the next generation of immunoconjugates, advances in protein engineering will permit greater control of mAb targeting, clearance and pharmacokinetics, resulting in significantly improved delivery to tumors of radioisotopes and potent anticancer drugs.  Pretargeting strategies, which sep. the two functions of antibody-based localization and delivery or generation of the toxic agent into two steps, also promise to afford superior tumor targeting and therapeutic efficacy.  Several challenges in optimizing immunoconjugates remain, however, including poor intratumoral mAb uptake, normal tissue conjugate exposure and issues surrounding drug potency and conditional release from mAb carriers.  Nonetheless, highly promising results from preclin. models will continue to drive the clin. development of this therapeutic class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQIsb1wtkWs7Vg90H21EOLACvtfcHk0liVQRV59WufHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpvVyrtrk%253D&md5=6c2d10cdcffad09d516386607d2223a9</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnbt1141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1141%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DA.%2BM.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DArming%2520antibodies%253A%2520prospects%2520and%2520challenges%2520for%2520immunoconjugates%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D1137%26epage%3D1146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Borsi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balza, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bestagno, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castellani, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carnemolla, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leprini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sepulveda, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrone, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zardi, L.</span><span> </span><span class="NLM_article-title">Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">75</span><span class="NLM_x">–</span> <span class="NLM_lpage">85</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1002%2Fijc.10662" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=12353237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BD38XnvFCru7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2002&pages=75-85&author=L.+Borsiauthor=E.+Balzaauthor=M.+Bestagnoauthor=P.+Castellaniauthor=B.+Carnemollaauthor=A.+Biroauthor=A.+Lepriniauthor=J.+Sepulvedaauthor=O.+Burroneauthor=D.+Neriauthor=L.+Zardi&title=Selective+targeting+of+tumoral+vasculature%3A+Comparison+of+different+formats+of+an+antibody+%28L19%29+to+the+ED-B+domain+of+fibronectin"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin</span></div><div class="casAuthors">Borsi, Laura; Balza, Enrica; Bestagno, Marco; Castellani, Patrizia; Carnemolla, Barbara; Biro, Attila; Leprini, Alessandra; Sepulveda, Jorge; Burrone, Oscar; Neri, Dario; Zardi, Luciano</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">75-85</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">We recently demonstrated that a human recombinant scFv, L19, reacting with the ED-B domain of fibronectin, a marker of angiogenesis, selectively targets tumoral vasculature in vivo.  Using the variable regions of L19, we constructed and expressed a human "small immunoprotein" (SIP) and a complete human IgG1 and performed biodistribution studies in tumor-bearing mice to compare the blood clearance rate, in vivo stability and performance in tumor targeting of the 3 L19 formats [dimeric scFv (scFv)2, SIP and IgG1].  The accumulation of the different antibody formats in the tumors studied was a consequence of the clearance rate and in vivo stability of the mols.  Using the SIP, the %ID/g in tumors was 2-5 times higher than that of the (scFv)2, reaching a max. 4-6 h after injection.  By contrast, the accumulation of IgGI in tumors constantly rose during the expts.  However, due to its slow clearance, the tumor-blood ratio of the %ID/g after 144 h was only about 3 compared to a ratio of 10 for the (scFv)2 and 70 for the SIP after the same period of time.  The different in vivo behavior of these 3 completely human L19 formats could be exploited for different diagnostic and/or therapeutic purposes, depending on clin. needs and disease.  Furthermore, the fact that ED-B is 100% homologous in human and mouse, which ensures that L19 reacts equally well with the human and the murine antigen, should expedite the transfer of these reagents to clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOGonxkjQSFLVg90H21EOLACvtfcHk0liVQRV59WufHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnvFCru7g%253D&md5=5dab3c4e4245b8cc213769d8eb9d8306</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2Fijc.10662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.10662%26sid%3Dliteratum%253Aachs%26aulast%3DBorsi%26aufirst%3DL.%26aulast%3DBalza%26aufirst%3DE.%26aulast%3DBestagno%26aufirst%3DM.%26aulast%3DCastellani%26aufirst%3DP.%26aulast%3DCarnemolla%26aufirst%3DB.%26aulast%3DBiro%26aufirst%3DA.%26aulast%3DLeprini%26aufirst%3DA.%26aulast%3DSepulveda%26aufirst%3DJ.%26aulast%3DBurrone%26aufirst%3DO.%26aulast%3DNeri%26aufirst%3DD.%26aulast%3DZardi%26aufirst%3DL.%26atitle%3DSelective%2520targeting%2520of%2520tumoral%2520vasculature%253A%2520Comparison%2520of%2520different%2520formats%2520of%2520an%2520antibody%2520%2528L19%2529%2520to%2520the%2520ED-B%2520domain%2520of%2520fibronectin%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2002%26volume%3D102%26spage%3D75%26epage%3D85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Berndorff, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borkowski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sieger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rother, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friebe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilger, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cyr, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinkelborg, L. M.</span><span> </span><span class="NLM_article-title">Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: Identification of the best-suited radioimmunoconjugate</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">7053S</span><span class="NLM_x">–</span> <span class="NLM_lpage">7063S</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=7053S-7063S&author=D.+Berndorffauthor=S.+Borkowskiauthor=S.+Siegerauthor=A.+Rotherauthor=M.+Friebeauthor=F.+Vitiauthor=C.+S.+Hilgerauthor=J.+E.+Cyrauthor=L.+M.+Dinkelborg&title=Radioimmunotherapy+of+solid+tumors+by+targeting+extra+domain+B+fibronectin%3A+Identification+of+the+best-suited+radioimmunoconjugate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBerndorff%26aufirst%3DD.%26aulast%3DBorkowski%26aufirst%3DS.%26aulast%3DSieger%26aufirst%3DS.%26aulast%3DRother%26aufirst%3DA.%26aulast%3DFriebe%26aufirst%3DM.%26aulast%3DViti%26aufirst%3DF.%26aulast%3DHilger%26aufirst%3DC.%2BS.%26aulast%3DCyr%26aufirst%3DJ.%2BE.%26aulast%3DDinkelborg%26aufirst%3DL.%2BM.%26atitle%3DRadioimmunotherapy%2520of%2520solid%2520tumors%2520by%2520targeting%2520extra%2520domain%2520B%2520fibronectin%253A%2520Identification%2520of%2520the%2520best-suited%2520radioimmunoconjugate%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D7053S%26epage%3D7063S" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Moreau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raguin, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vrigneaud, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernhard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tizon, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschetti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duchamp, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunotte, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denat, F.</span><span> </span><span class="NLM_article-title">DOTAGA-trastuzumab. A new antibody conjugate targeting HER2/Neu antigen for diagnostic purposes</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">1181</span><span class="NLM_x">–</span> <span class="NLM_lpage">1188</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc200680x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvVGjtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=1181-1188&author=M.+Moreauauthor=O.+Raguinauthor=J.+M.+Vrigneaudauthor=B.+Collinauthor=C.+Bernhardauthor=X.+Tizonauthor=F.+Boschettiauthor=O.+Duchampauthor=F.+Brunotteauthor=F.+Denat&title=DOTAGA-trastuzumab.+A+new+antibody+conjugate+targeting+HER2%2FNeu+antigen+for+diagnostic+purposes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">DOTAGA-Trastuzumab. A New Antibody Conjugate Targeting HER2/Neu Antigen for Diagnostic Purposes</span></div><div class="casAuthors">Moreau, Mathieu; Raguin, Olivier; Vrigneaud, Jean-Marc; Collin, Bertrand; Bernhard, Claire; Tizon, Xavier; Boschetti, Frederic; Duchamp, Olivier; Brunotte, Francois; Denat, Franck</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1181-1188</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Improved bifunctional chelating agents (BFC) are required for indium-111 radiolabeling of monoclonal antibodies (mAbs) under mild conditions to yield stable, target-specific agents. 2,2,2-(10-(2,6-Dioxotetrahydro-2H-pyran-3-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (DOTAGA-anhydride) was evaluated for mAb conjugation and labeling with indium-111.  The DOTA analog was synthesized and conjugated to trastuzumab which targets the HER2/neu receptor in mild conditions (PBS pH 7.4, 25 C, 30 min) and gave a mean degree of conjugation of 2.6 macrocycle per antibody.  Labeling of this immunoconjugate with indium-111 was performed in 75% yield after 1 h at 37 C, and the proportion of 111In-DOTAGA-trastuzumab reached 97% after purifn.  The affinity of DOTAGA-trastuzumab was 5.5, 0.6 nM as evaluated by in vitro satn. assays using HCC1954 breast cancer cell line.  SPECT/CT imaging and biodistribution studies were performed in mice bearing breast cancer BT-474 xenografts.  BT-474 tumors were clearly visualized on SPECT images at 24, 48, and 72 h postinjection.  The tumor uptake of [111In-DOTAGA]-trastuzumab reached 65%ID/g 72 h postinjection.  These results show that the DOTAGA BFC appears to be a valuable tool for biologics conjugation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxTIrhdIOo9bVg90H21EOLACvtfcHk0lhD-85eDkwL6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvVGjtLk%253D&md5=a2552569ece81de76b49e12f9ee8c393</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fbc200680x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc200680x%26sid%3Dliteratum%253Aachs%26aulast%3DMoreau%26aufirst%3DM.%26aulast%3DRaguin%26aufirst%3DO.%26aulast%3DVrigneaud%26aufirst%3DJ.%2BM.%26aulast%3DCollin%26aufirst%3DB.%26aulast%3DBernhard%26aufirst%3DC.%26aulast%3DTizon%26aufirst%3DX.%26aulast%3DBoschetti%26aufirst%3DF.%26aulast%3DDuchamp%26aufirst%3DO.%26aulast%3DBrunotte%26aufirst%3DF.%26aulast%3DDenat%26aufirst%3DF.%26atitle%3DDOTAGA-trastuzumab.%2520A%2520new%2520antibody%2520conjugate%2520targeting%2520HER2%252FNeu%2520antigen%2520for%2520diagnostic%2520purposes%26jtitle%3DBioconjugate%2520Chem.%26date%3D2012%26volume%3D23%26spage%3D1181%26epage%3D1188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Brouwers, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Eerd, J. E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frielink, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oosterwijk, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyen, W. J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corstens, F. H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boerman, O. C.</span><span> </span><span class="NLM_article-title">Optimization of radioimmunotherapy of renal cell carcinoma: Labeling of monoclonal antibody cG250 with I-131, Y-90, Lu-177, or Re-186</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">327</span><span class="NLM_x">–</span> <span class="NLM_lpage">337</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2004&pages=327-337&author=A.+H.+Brouwersauthor=J.+E.+M.+van+Eerdauthor=C.+Frielinkauthor=E.+Oosterwijkauthor=W.+J.+G.+Oyenauthor=F.+H.+M.+Corstensauthor=O.+C.+Boerman&title=Optimization+of+radioimmunotherapy+of+renal+cell+carcinoma%3A+Labeling+of+monoclonal+antibody+cG250+with+I-131%2C+Y-90%2C+Lu-177%2C+or+Re-186"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrouwers%26aufirst%3DA.%2BH.%26aulast%3Dvan%2BEerd%26aufirst%3DJ.%2BE.%2BM.%26aulast%3DFrielink%26aufirst%3DC.%26aulast%3DOosterwijk%26aufirst%3DE.%26aulast%3DOyen%26aufirst%3DW.%2BJ.%2BG.%26aulast%3DCorstens%26aufirst%3DF.%2BH.%2BM.%26aulast%3DBoerman%26aufirst%3DO.%2BC.%26atitle%3DOptimization%2520of%2520radioimmunotherapy%2520of%2520renal%2520cell%2520carcinoma%253A%2520Labeling%2520of%2520monoclonal%2520antibody%2520cG250%2520with%2520I-131%252C%2520Y-90%252C%2520Lu-177%252C%2520or%2520Re-186%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2004%26volume%3D45%26spage%3D327%26epage%3D337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Dennis, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dugger, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFarland, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogasawara, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwall, R.</span><span> </span><span class="NLM_article-title">Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">254</span><span class="NLM_x">–</span> <span class="NLM_lpage">261</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=254-261&author=M.+S.+Dennisauthor=H.+Jinauthor=D.+Duggerauthor=R.+Yangauthor=L.+McFarlandauthor=A.+Ogasawaraauthor=S.+Williamsauthor=M.+J.+Coleauthor=S.+Rossauthor=R.+Schwall&title=Imaging+tumors+with+an+albumin-binding+Fab%2C+a+novel+tumor-targeting+agent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDennis%26aufirst%3DM.%2BS.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DDugger%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DR.%26aulast%3DMcFarland%26aufirst%3DL.%26aulast%3DOgasawara%26aufirst%3DA.%26aulast%3DWilliams%26aufirst%3DS.%26aulast%3DCole%26aufirst%3DM.%2BJ.%26aulast%3DRoss%26aufirst%3DS.%26aulast%3DSchwall%26aufirst%3DR.%26atitle%3DImaging%2520tumors%2520with%2520an%2520albumin-binding%2520Fab%252C%2520a%2520novel%2520tumor-targeting%2520agent%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D254%26epage%3D261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Saga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neumann, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heya, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinuya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paik, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinstein, J. N.</span><span> </span><span class="NLM_article-title">Targeting cancer micrometastases with monoclonal-antibodies—A binding-site barrier</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">8999</span><span class="NLM_x">–</span> <span class="NLM_lpage">9003</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=1995&pages=8999-9003&author=T.+Sagaauthor=R.+D.+Neumannauthor=T.+Heyaauthor=J.+Satoauthor=S.+Kinuyaauthor=N.+Leauthor=C.+H.+Paikauthor=J.+N.+Weinstein&title=Targeting+cancer+micrometastases+with+monoclonal-antibodies%E2%80%94A+binding-site+barrier"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSaga%26aufirst%3DT.%26aulast%3DNeumann%26aufirst%3DR.%2BD.%26aulast%3DHeya%26aufirst%3DT.%26aulast%3DSato%26aufirst%3DJ.%26aulast%3DKinuya%26aufirst%3DS.%26aulast%3DLe%26aufirst%3DN.%26aulast%3DPaik%26aufirst%3DC.%2BH.%26aulast%3DWeinstein%26aufirst%3DJ.%2BN.%26atitle%3DTargeting%2520cancer%2520micrometastases%2520with%2520monoclonal-antibodies%25E2%2580%2594A%2520binding-site%2520barrier%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1995%26volume%3D92%26spage%3D8999%26epage%3D9003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Adams, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schier, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCall, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmons, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horak, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alpaugh, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marks, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiner, L. M.</span><span> </span><span class="NLM_article-title">High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">4750</span><span class="NLM_x">–</span> <span class="NLM_lpage">4755</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=11406547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BD3MXks1Grtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=4750-4755&author=G.+P.+Adamsauthor=R.+Schierauthor=A.+M.+McCallauthor=H.+H.+Simmonsauthor=E.+M.+Horakauthor=R.+K.+Alpaughauthor=J.+D.+Marksauthor=L.+M.+Weiner&title=High+affinity+restricts+the+localization+and+tumor+penetration+of+single-chain+Fv+antibody+molecules"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules</span></div><div class="casAuthors">Adams, Gregory P.; Schier, Robert; McCall, Adrian M.; Simmons, Heidi H.; Horak, Eva M.; Alpaugh, R. Katherine; Marks, James D.; Weiner, Louis M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4750-4755</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Antitumor monoclonal antibodies must bind to tumor antigens with high affinity to achieve durable tumor retention.  This has spurred efforts to generate high affinity antibodies for use in cancer therapy.  However, it has been hypothesized that very high affinity interactions between antibodies and tumor antigens may impair efficient tumor penetration of the monoclonal antibodies and thus diminish effective in vivo targeting.  Here the authors show that intrinsic affinity properties regulate the quant. delivery of antitumor single-chain Fv (scFv) mols. to solid tumors and the penetration of scFv from the vasculature into tumor masses.  In biodistribution studies examg. a series of radioiodinated scFv mutants with affinities ranging from 10-7-10-11 M, quant. tumor retention did not significantly increase with enhancements in affinity beyond 10-9 M.  Similar distribution patterns were obsd. when the scFv were evaluated in the absence of renal clearance in anephric mice, indicating that the rapid renal clearance of the scFv was not responsible for these observations.  IHC and IF evaluations of tumor sections after the i.v. administration of scFv affinity mutants revealed that the lowest affinity mol. exhibited diffuse tumor staining whereas the highest affinity scFv was primarily retained in the perivascular regions of the tumor.  These results indicate that antibody-based mols. with extremely high affinity have impaired tumor penetration properties that must be considered in the design of antibody-based cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmzJy0rEvErLVg90H21EOLACvtfcHk0lhD-85eDkwL6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXks1Grtbs%253D&md5=ac011358d042f75f21df3d40c626cfc5</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DG.%2BP.%26aulast%3DSchier%26aufirst%3DR.%26aulast%3DMcCall%26aufirst%3DA.%2BM.%26aulast%3DSimmons%26aufirst%3DH.%2BH.%26aulast%3DHorak%26aufirst%3DE.%2BM.%26aulast%3DAlpaugh%26aufirst%3DR.%2BK.%26aulast%3DMarks%26aufirst%3DJ.%2BD.%26aulast%3DWeiner%26aufirst%3DL.%2BM.%26atitle%3DHigh%2520affinity%2520restricts%2520the%2520localization%2520and%2520tumor%2520penetration%2520of%2520single-chain%2520Fv%2520antibody%2520molecules%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D4750%26epage%3D4755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Rudnick, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaller, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein-Szanto, A. J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiner, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marks, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, G. P.</span><span> </span><span class="NLM_article-title">Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">2250</span><span class="NLM_x">–</span> <span class="NLM_lpage">2259</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1158%2F0008-5472.CAN-10-2277" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=21406401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtFWgtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=2250-2259&author=S.+I.+Rudnickauthor=J.+L.+Louauthor=C.+C.+Shallerauthor=Y.+Tangauthor=A.+J.+P.+Klein-Szantoauthor=L.+M.+Weinerauthor=J.+D.+Marksauthor=G.+P.+Adams&title=Influence+of+affinity+and+antigen+internalization+on+the+uptake+and+penetration+of+Anti-HER2+antibodies+in+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Influence of Affinity and Antigen Internalization on the Uptake and Penetration of Anti-HER2 Antibodies in Solid Tumors</span></div><div class="casAuthors">Rudnick, Stephen I.; Lou, Jianlong; Shaller, Calvin C.; Tang, Yong; Klein-Szanto, Andres J. P.; Weiner, Louis M.; Marks, James D.; Adams, Gregory P.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2250-2259</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Antibody drugs are widely used in cancer therapy, but conditions to maximize tumor penetration and efficacy have yet to be fully elucidated.  In this study, we investigated the impact of antibody binding affinity on tumor targeting and penetration with affinity variants that recognize the same epitope.  Specifically, we compared four derivs. of the C6.5 monoclonal antibody (mAb), which recognizes the same HER2 epitope (monovalent KD values ranging from 270 to 0.56 nmol/L).  Moderate affinity was assocd. with the highest tumor accumulation at 24 and 120 h after i.v. injection, whereas high affinity was found to produce the lowest tumor accumulation.  Highest affinity mAbs were confined to the perivascular space of tumors with an av. penetration of 20.4 ± 7.5 μm from tumor blood vessels.  Conversely, lowest affinity mAbs exhibited a broader distribution pattern with an av. penetration of 84.8 ± 12.8 μm.  In vitro internalization assays revealed that antibody internalization and catabolism generally increased with affinity, plateauing once the rate of HER2 internalization exceeded the rate of antibody dissocn.  Effects of internalization and catabolism on tumor targeting were further examd. using antibodies of moderate (C6.5) or high-affinity (trastuzumab), labeled with residualizing (111In-labeled) or nonresidualizing (125I-labeled) radioisotopes.  Significant amts. of antibody of both affinities were degraded by tumors in vivo.  Furthermore, moderate- to high-affinity mAbs targeting the same HER2 epitope with monovalent affinity above 23 nmol/L had equal tumor accumulation of residualizing radiolabel over 120 h.  Results indicated equal tumor exposure, suggesting that mAb penetration and retention in tumors reflected affinity-based differences in tumor catabolism.  Together, these results suggest that high-d., rapidly internalizing antigens subject high-affinity antibodies to greater internalization and degrdn., thereby limiting their penetration of tumors.  In contrast, lower-affinity antibodies penetrate tumors more effectively when rates of antibody-antigen dissocn. are higher than those of antigen internalization.  Together, our findings offer insights into how to optimize the ability of therapeutic antibodies to penetrate tumors.  Cancer Res; 71(6); 2250-9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkntN8xRbgdrVg90H21EOLACvtfcHk0lg6czHQAySjQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtFWgtLg%253D&md5=b14f4516bc938c4b54df8f66b55ef42b</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-2277&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-2277%26sid%3Dliteratum%253Aachs%26aulast%3DRudnick%26aufirst%3DS.%2BI.%26aulast%3DLou%26aufirst%3DJ.%2BL.%26aulast%3DShaller%26aufirst%3DC.%2BC.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DKlein-Szanto%26aufirst%3DA.%2BJ.%2BP.%26aulast%3DWeiner%26aufirst%3DL.%2BM.%26aulast%3DMarks%26aufirst%3DJ.%2BD.%26aulast%3DAdams%26aufirst%3DG.%2BP.%26atitle%3DInfluence%2520of%2520affinity%2520and%2520antigen%2520internalization%2520on%2520the%2520uptake%2520and%2520penetration%2520of%2520Anti-HER2%2520antibodies%2520in%2520solid%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D2250%26epage%3D2259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Trail, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willner, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasch, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henderson, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofstead, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casazza, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Firestone, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hellström, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hellström, K. E.</span><span> </span><span class="NLM_article-title">Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">261</span><span class="NLM_x">, </span> <span class="NLM_fpage">212</span><span class="NLM_x">–</span> <span class="NLM_lpage">215</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1126%2Fscience.8327892" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=8327892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADyaK3sXltlWjtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=261&publication_year=1993&pages=212-215&author=P.+A.+Trailauthor=D.+Willnerauthor=S.+J.+Laschauthor=A.+J.+Hendersonauthor=S.+Hofsteadauthor=A.+M.+Casazzaauthor=R.+A.+Firestoneauthor=I.+Hellstr%C3%B6mauthor=K.+E.+Hellstr%C3%B6m&title=Cure+of+xenografted+human+carcinomas+by+BR96-doxorubicin+immunoconjugates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates</span></div><div class="casAuthors">Trail, P. A.; Willner, D.; Lasch, S. J.; Henderson, A. J.; Hofstead, S.; Casazza, A. M.; Firestone, R. A.; Hellstrom, I.; Hellstrom, K. E.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">261</span>
        (<span class="NLM_cas:issue">5118</span>),
    <span class="NLM_cas:pages">212-15</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">Immunoconjugates (BR96-DOX) were prepd. between chimeric monoclonal antibody BR96 and the anticancer drug doxorubicin.  The monoclonal antibody binds an antigen related to Lewis Y that is abundantly expressed at the surface of cells from many human carcinomas; it has a high degree of tumor selectivity and is internalized after binding.  BR96-DOX induced complete regressions and cures of xenografted human lung, breast, and colon carcinomas growing s.c. in athymic mice and cured 70 percent of mice bearing extensive metastasis of a human lung carcinoma.  Also, BR96-DOX cured 94 percent of athymic rats with s.c. human lung carcinoma, even though the rats, like humans and in contrast to mice, expressed the BR96 target antigen in normal tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkJ15RWFve9rVg90H21EOLACvtfcHk0lg6czHQAySjQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXltlWjtLk%253D&md5=3a366cdac960b3324fd1100c1dc97653</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1126%2Fscience.8327892&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.8327892%26sid%3Dliteratum%253Aachs%26aulast%3DTrail%26aufirst%3DP.%2BA.%26aulast%3DWillner%26aufirst%3DD.%26aulast%3DLasch%26aufirst%3DS.%2BJ.%26aulast%3DHenderson%26aufirst%3DA.%2BJ.%26aulast%3DHofstead%26aufirst%3DS.%26aulast%3DCasazza%26aufirst%3DA.%2BM.%26aulast%3DFirestone%26aufirst%3DR.%2BA.%26aulast%3DHellstr%25C3%25B6m%26aufirst%3DI.%26aulast%3DHellstr%25C3%25B6m%26aufirst%3DK.%2BE.%26atitle%3DCure%2520of%2520xenografted%2520human%2520carcinomas%2520by%2520BR96-doxorubicin%2520immunoconjugates%26jtitle%3DScience%26date%3D1993%26volume%3D261%26spage%3D212%26epage%3D215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Lowinger, T. B.</span><span> </span><span class="NLM_article-title">Applications of biodegradable and biocompatible polyacetal drug conjugates to improve drug delivery</span>.  <span class="citation_source-book">Abstracts of Papers—American Chemical Society</span>; <span class="NLM_publisher-name">American Chemical Society</span>: <span class="NLM_publisher-loc">Washington, DC</span>,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=T.+B.+Lowinger&title=Abstracts+of+Papers%E2%80%94American+Chemical+Society"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DLowinger%26aufirst%3DT.%2BB.%26atitle%3DApplications%2520of%2520biodegradable%2520and%2520biocompatible%2520polyacetal%2520drug%2520conjugates%2520to%2520improve%2520drug%2520delivery%26btitle%3DAbstracts%2520of%2520Papers%25E2%2580%2594American%2520Chemical%2520Society%26pub%3DAmerican%2520Chemical%2520Society%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">de Claro, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGinn, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwitkowski, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bullock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khandelwal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habtemariam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouyang, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saber, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koti, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borrego, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clouse, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akinsanya, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kane, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaminskas, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farrell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pazdur, R.</span><span> </span><span class="NLM_article-title">U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">5845</span><span class="NLM_x">–</span> <span class="NLM_lpage">5849</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1158%2F1078-0432.CCR-12-1803" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=22962441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1GhtrzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=5845-5849&author=R.+A.+de+Claroauthor=K.+McGinnauthor=V.+Kwitkowskiauthor=J.+Bullockauthor=A.+Khandelwalauthor=B.+Habtemariamauthor=Y.+L.+Ouyangauthor=H.+Saberauthor=K.+Leeauthor=K.+Kotiauthor=M.+Rothmannauthor=M.+Shapiroauthor=F.+Borregoauthor=K.+Clouseauthor=X.+H.+Chenauthor=J.+Brownauthor=L.+Akinsanyaauthor=R.+Kaneauthor=E.+Kaminskasauthor=A.+Farrellauthor=R.+Pazdur&title=U.S.+Food+and+Drug+Administration+approval+summary%3A+brentuximab+vedotin+for+the+treatment+of+relapsed+Hodgkin+lymphoma+or+relapsed+systemic+anaplastic+large-cell+lymphoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma</span></div><div class="casAuthors">de Claro, R. Angelo; McGinn, Karen; Kwitkowski, Virginia; Bullock, Julie; Khandelwal, Aakanksha; Habtemariam, Bahru; Ouyang, Yanli; Saber, Haleh; Lee, Kyung; Koti, Kallappa; Rothmann, Mark; Shapiro, Marjorie; Borrego, Francisco; Clouse, Kathleen; Chen, Xiao Hong; Brown, Janice; Akinsanya, Lara; Kane, Robert; Kaminskas, Edvardas; Farrell, Ann; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5845-5849</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The U.S. Food and Drug Administration (FDA) describes the accelerated approval of brentuximab vedotin for patients with relapsed Hodgkin lymphoma and relapsed systemic anaplastic large-cell lymphoma (sALCL).  FDA analyzed the results of two single-arm trials, enrolling 102 patients with Hodgkin lymphoma and 58 patients with sALCL.  Both trials had primary endpoints of objective response rate (ORR) and key secondary endpoints of response duration and complete response (CR) rate.  For patients with Hodgkin lymphoma, ORR was 73% (95% CI, 65-83%); median response duration was 6.7 mo, and CR was 32% (95% CI, 23-42%).  For patients with sALCL, ORR was 86% (95% CI, 77-95%), median response duration was 12.6 mo, and CR was 57% (95% CI, 44-70%).  The most common adverse reactions were neutropenia, peripheral sensory neuropathy, fatigue, nausea, anemia, upper respiratory infection, diarrhea, pyrexia, rash, thrombocytopenia, cough, and vomiting.  FDA granted accelerated approval of brentuximab vedotin for the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplantation (ASCT) or after failure of at least two prior multiagent chemotherapy regimens in patients who are not ASCT candidates, and for the treatment of patients with sALCL after failure of at least one prior multiagent chemotherapy regimen.  Clin Cancer Res; 18(21); 5845-9. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofSyQY_xMc87Vg90H21EOLACvtfcHk0lgfvLLLWxN0mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1GhtrzI&md5=c974edc86d32673b060b912932585c09</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-1803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-1803%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BClaro%26aufirst%3DR.%2BA.%26aulast%3DMcGinn%26aufirst%3DK.%26aulast%3DKwitkowski%26aufirst%3DV.%26aulast%3DBullock%26aufirst%3DJ.%26aulast%3DKhandelwal%26aufirst%3DA.%26aulast%3DHabtemariam%26aufirst%3DB.%26aulast%3DOuyang%26aufirst%3DY.%2BL.%26aulast%3DSaber%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DKoti%26aufirst%3DK.%26aulast%3DRothmann%26aufirst%3DM.%26aulast%3DShapiro%26aufirst%3DM.%26aulast%3DBorrego%26aufirst%3DF.%26aulast%3DClouse%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DX.%2BH.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DAkinsanya%26aufirst%3DL.%26aulast%3DKane%26aufirst%3DR.%26aulast%3DKaminskas%26aufirst%3DE.%26aulast%3DFarrell%26aufirst%3DA.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DU.S.%2520Food%2520and%2520Drug%2520Administration%2520approval%2520summary%253A%2520brentuximab%2520vedotin%2520for%2520the%2520treatment%2520of%2520relapsed%2520Hodgkin%2520lymphoma%2520or%2520relapsed%2520systemic%2520anaplastic%2520large-cell%2520lymphoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D5845%26epage%3D5849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Erickson, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, P. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widdison, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovtun, Y. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldmacher, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blättler, W. A.</span><span> </span><span class="NLM_article-title">Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">4426</span><span class="NLM_x">–</span> <span class="NLM_lpage">4433</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1158%2F0008-5472.CAN-05-4489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=16618769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BD28XjsFSlurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=4426-4433&author=H.+K.+Ericksonauthor=P.+U.+Parkauthor=W.+C.+Widdisonauthor=Y.+V.+Kovtunauthor=L.+M.+Garrettauthor=K.+Hoffmanauthor=R.+J.+Lutzauthor=V.+S.+Goldmacherauthor=W.+A.+Bl%C3%A4ttler&title=Antibody-maytansinoid+conjugates+are+activated+in+targeted+cancer+cells+by+lysosomal+degradation+and+linker-dependent+intracellular+processing"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-Maytansinoid Conjugates Are Activated in Targeted Cancer Cells by Lysosomal Degradation and Linker-Dependent Intracellular Processing</span></div><div class="casAuthors">Erickson, Hans K.; Park, Peter U.; Widdison, Wayne C.; Kovtun, Yelena V.; Garrett, Lisa M.; Hoffman, Karen; Lutz, Robert J.; Goldmacher, Victor S.; Blaettler, Walter A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4426-4433</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Antibody-drug conjugates are targeted anticancer agents consisting of a cytotoxic drug covalently linked to a monoclonal antibody for tumor antigen-specific activity.  Once bound to the target cell-surface antigen, the conjugate must be processed to release an active form of the drug, which can reach its intracellular target.  Here, we used both biol. and biochem. methods to better define this process for antibody-maytansinoid conjugates.  In particular, we examd. the metabolic fate in cells of huC242-maytansinoid conjugates contg. either a disulfide linker (huC242-SPDB-DM4) or a thioether linker (huC242-SMCC-DM1).  Using cell cycle anal. combined with lysosomal inhibitors, we showed that lysosomal processing is required for the activity of antibody-maytansinoid conjugates, irresp. of the linker.  We also identified and characterized the released maytansinoid mols. from these conjugates, and measured their rate of release compared with the kinetics of cell cycle arrest.  Both conjugates are efficiently degraded in lysosomes to yield metabolites consisting of the intact maytansinoid drug and linker attached to lysine.  The lysine adduct is the sole metabolite from the thioether-linked conjugate.  However, the lysine metabolite generated from the disulfide-linked conjugate is reduced and S-methylated to yield the lipophilic and potently cytotoxic metabolite, S-methyl-DM4.  These findings provide insight into the mechanism of action of antibody-maytansinoid conjugates in general, and more specifically, identify a biochem. mechanism that may account for the significantly enhanced antitumor efficacy obsd. with disulfide-linked conjugates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZZDy7Sl_BxrVg90H21EOLACvtfcHk0lgfvLLLWxN0mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjsFSlurs%253D&md5=aaf42c96e596e17a7896a265d5e1d158</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-4489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-4489%26sid%3Dliteratum%253Aachs%26aulast%3DErickson%26aufirst%3DH.%2BK.%26aulast%3DPark%26aufirst%3DP.%2BU.%26aulast%3DWiddison%26aufirst%3DW.%2BC.%26aulast%3DKovtun%26aufirst%3DY.%2BV.%26aulast%3DGarrett%26aufirst%3DL.%2BM.%26aulast%3DHoffman%26aufirst%3DK.%26aulast%3DLutz%26aufirst%3DR.%2BJ.%26aulast%3DGoldmacher%26aufirst%3DV.%2BS.%26aulast%3DBl%25C3%25A4ttler%26aufirst%3DW.%2BA.%26atitle%3DAntibody-maytansinoid%2520conjugates%2520are%2520activated%2520in%2520targeted%2520cancer%2520cells%2520by%2520lysosomal%2520degradation%2520and%2520linker-dependent%2520intracellular%2520processing%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D4426%26epage%3D4433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Kovtun, Y. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Audette, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayo, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maloney, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erickson, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, X. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilhelm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ab, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widdison, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kellogg, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinkas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldmacher, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chari, R. V. J.</span><span> </span><span class="NLM_article-title">Antibody-maytansinoid conjugates designed to bypass multidrug resistance</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">2528</span><span class="NLM_x">–</span> <span class="NLM_lpage">2537</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1158%2F0008-5472.CAN-09-3546" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=20197459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtFygur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=2528-2537&author=Y.+V.+Kovtunauthor=C.+A.+Audetteauthor=M.+F.+Mayoauthor=G.+E.+Jonesauthor=H.+Dohertyauthor=E.+K.+Maloneyauthor=H.+K.+Ericksonauthor=X.+X.+Sunauthor=S.+Wilhelmauthor=O.+Abauthor=K.+C.+Laiauthor=W.+C.+Widdisonauthor=B.+Kelloggauthor=H.+Johnsonauthor=J.+Pinkasauthor=R.+J.+Lutzauthor=R.+Singhauthor=V.+S.+Goldmacherauthor=R.+V.+J.+Chari&title=Antibody-maytansinoid+conjugates+designed+to+bypass+multidrug+resistance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance</span></div><div class="casAuthors">Kovtun, Yelena V.; Audette, Charlene A.; Mayo, Michele F.; Jones, Gregory E.; Doherty, Heather; Maloney, Erin K.; Erickson, Hans K.; Sun, Xiuxia; Wilhelm, Sharon; Ab, Olga; Lai, Katharine C.; Widdison, Wayne C.; Kellogg, Brenda; Johnson, Holly; Pinkas, Jan; Lutz, Robert J.; Singh, Rajeeva; Goldmacher, Victor S.; Chari, Ravi V. J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2528-2537</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Conjugation of cytotoxic compds. to antibodies that bind to cancer-specific antigens makes these drugs selective in killing cancer cells.  However, many of the compds. used in such antibody-drug conjugates (ADC) are substrates for the multidrug transporter MDR1.  To evade the MDR1-mediated resistance, we conjugated the highly cytotoxic maytansinoid DM1 to antibodies via the maleimidyl-based hydrophilic linker PEG4Mal.  Following uptake into target cells, conjugates made with the PEG4Mal linker were processed to a cytotoxic metabolite that was retained by MDR1-expressing cells better than a metabolite of similar conjugates prepd. with the nonpolar linker N-succinimidyl-4-(maleimidomethyl)cyclohexane-1-carboxylate (SMCC).  In accord, PEG4Mal-linked conjugates were more potent in killing MDR1-expressing cells in culture.  In addn., PEG4Mal-linked conjugates were markedly more effective in eradicating MDR1-expressing human xenograft tumors than SMCC-linked conjugates while being tolerated similarly, thus showing an improved therapeutic index.  This study points the way to the development of ADCs that bypass multidrug resistance.  Cancer Res; 70(6); 2528-37.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreA_G5nmeju7Vg90H21EOLACvtfcHk0lgfvLLLWxN0mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtFygur4%253D&md5=17a2600cc85203b3bace74e31d346daa</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-3546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-3546%26sid%3Dliteratum%253Aachs%26aulast%3DKovtun%26aufirst%3DY.%2BV.%26aulast%3DAudette%26aufirst%3DC.%2BA.%26aulast%3DMayo%26aufirst%3DM.%2BF.%26aulast%3DJones%26aufirst%3DG.%2BE.%26aulast%3DDoherty%26aufirst%3DH.%26aulast%3DMaloney%26aufirst%3DE.%2BK.%26aulast%3DErickson%26aufirst%3DH.%2BK.%26aulast%3DSun%26aufirst%3DX.%2BX.%26aulast%3DWilhelm%26aufirst%3DS.%26aulast%3DAb%26aufirst%3DO.%26aulast%3DLai%26aufirst%3DK.%2BC.%26aulast%3DWiddison%26aufirst%3DW.%2BC.%26aulast%3DKellogg%26aufirst%3DB.%26aulast%3DJohnson%26aufirst%3DH.%26aulast%3DPinkas%26aufirst%3DJ.%26aulast%3DLutz%26aufirst%3DR.%2BJ.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DGoldmacher%26aufirst%3DV.%2BS.%26aulast%3DChari%26aufirst%3DR.%2BV.%2BJ.%26atitle%3DAntibody-maytansinoid%2520conjugates%2520designed%2520to%2520bypass%2520multidrug%2520resistance%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D2528%26epage%3D2537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Chudasama, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stark, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrold, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibbitts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girish, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frey, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mager, D. E.</span><span> </span><span class="NLM_article-title">Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">520</span><span class="NLM_x">–</span> <span class="NLM_lpage">527</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1038%2Fclpt.2012.153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=22968044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtl2iurfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2012&pages=520-527&author=V.+L.+Chudasamaauthor=F.+S.+Starkauthor=J.+M.+Harroldauthor=J.+Tibbittsauthor=S.+R.+Girishauthor=M.+Guptaauthor=N.+Freyauthor=D.+E.+Mager&title=Semi-mechanistic+population+pharmacokinetic+model+of+multivalent+trastuzumab+emtansine+in+patients+with+metastatic+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Semi-mechanistic Population Pharmacokinetic Model of Multivalent Trastuzumab Emtansine in Patients with Metastatic Breast Cancer</span></div><div class="casAuthors">Chudasama, V. L.; Schaedeli Stark, F.; Harrold, J. M.; Tibbitts, J.; Girish, S. R.; Gupta, M.; Frey, N.; Mager, D. E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">520-527</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate (ADC) composed of multiple mols. of the antimicrotubule agent DM1 linked to trastuzumab, a humanized anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibody.  Pharmacokinetics data from phase I (n = 52) and phase II (n = 111) studies in HER2-pos. metastatic breast cancer patients show a shorter terminal half-life for T-DM1 than for total trastuzumab (TTmAb).  In this work, we translated prior preclin. modeling in monkeys to develop a semi-mechanistic population pharmacokinetics model to characterize T-DM1 and TTmAb concn. profiles.  A series of transit compartments with the same disposition parameters was used to describe the deconjugation process from higher to lower drug-to-antibody ratios (DARs).  The structure could explain the shorter terminal half-life of T-DM1 relative to TTmab.  The final model integrates prior knowledge of T-DM1 DARs from preclin. studies and could provide a platform for understanding and characterizing the pharmacokinetics of other ADC systems.  Clin. Pharmacol. & Therapeutics (2012); 92 4, 520-527. doi:10.1038/clpt.2012.153.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsh_7mNP3TbrVg90H21EOLACvtfcHk0lgnFgf_GY8sJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtl2iurfP&md5=1d04057bdead10453770c704e5ed28f4</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2012.153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2012.153%26sid%3Dliteratum%253Aachs%26aulast%3DChudasama%26aufirst%3DV.%2BL.%26aulast%3DStark%26aufirst%3DF.%2BS.%26aulast%3DHarrold%26aufirst%3DJ.%2BM.%26aulast%3DTibbitts%26aufirst%3DJ.%26aulast%3DGirish%26aufirst%3DS.%2BR.%26aulast%3DGupta%26aufirst%3DM.%26aulast%3DFrey%26aufirst%3DN.%26aulast%3DMager%26aufirst%3DD.%2BE.%26atitle%3DSemi-mechanistic%2520population%2520pharmacokinetic%2520model%2520of%2520multivalent%2520trastuzumab%2520emtansine%2520in%2520patients%2520with%2520metastatic%2520breast%2520cancer%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2012%26volume%3D92%26spage%3D520%26epage%3D527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Peddi, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurvitz, S. A.</span><span> </span><span class="NLM_article-title">Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer</span> <span class="citation_source-journal">Future Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">319</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.2217%2Ffon.13.7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=23469968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjs1ektrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=319-326&author=P.+F.+Peddiauthor=S.+A.+Hurvitz&title=Trastuzumab+emtansine%3A+the+first+targeted+chemotherapy+for+treatment+of+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer</span></div><div class="casAuthors">Peddi, Parvin F.; Hurvitz, Sara A.</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">319-326</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Trastuzumab emtansine (T-DM1) is a novel antibody-drug conjugate, comprised of a potent cytotoxic drug connected via a stable linker to the anti-HER2 antibody, trastuzumab, thereby primarily targeting chemotherapy delivery to cells overexpressing the HER2 receptor.  A Phase II randomized trial of T-DM1 in the front-line metastatic breast cancer setting revealed promising activity and improved safety compared with std. chemotherapy plus trastuzumab.  Subsequently, a Phase III trial in patients with trastuzumab-pretreated metastatic breast cancer showed T-DM1 to be assocd. with prolonged progression-free and overall survival compared with lapatinib plus capecitabine.  T-DM1 represents a major shift in the treatment of patients with breast cancer as it replaces traditional nontargeted chemotherapy with a smart' medication that directs the cytotoxic therapy to cancer cells by using a known biomarker.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHjKcoGj06urVg90H21EOLACvtfcHk0lgnFgf_GY8sJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjs1ektrY%253D&md5=00757349fb840db6f78d4418981d362c</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.2217%2Ffon.13.7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.13.7%26sid%3Dliteratum%253Aachs%26aulast%3DPeddi%26aufirst%3DP.%2BF.%26aulast%3DHurvitz%26aufirst%3DS.%2BA.%26atitle%3DTrastuzumab%2520emtansine%253A%2520the%2520first%2520targeted%2520chemotherapy%2520for%2520treatment%2520of%2520breast%2520cancer%26jtitle%3DFuture%2520Oncol.%26date%3D2013%26volume%3D9%26spage%3D319%26epage%3D326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Phillips, G. D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dugger, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crocker, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mai, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blattler, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chari, R. V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, W. L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeppen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwall, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenkare-Mitra, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span> </span><span class="NLM_article-title">Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">9280</span><span class="NLM_x">–</span> <span class="NLM_lpage">9290</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1158%2F0008-5472.CAN-08-1776" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=19010901" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=9280-9290&author=G.+D.+L.+Phillipsauthor=G.+Liauthor=D.+L.+Duggerauthor=L.+M.+Crockerauthor=K.+L.+Parsonsauthor=E.+Maiauthor=W.+A.+Blattlerauthor=J.+M.+Lambertauthor=R.+V.+J.+Chariauthor=R.+J.+Lutzauthor=W.+L.+T.+Wongauthor=F.+S.+Jacobsonauthor=H.+Koeppenauthor=R.+H.+Schwallauthor=S.+R.+Kenkare-Mitraauthor=S.+D.+Spencerauthor=M.+X.+Sliwkowski&title=Targeting+HER2-positive+breast+cancer+with+trastuzumab-DM1%2C+an+antibody-cytotoxic+drug+conjugate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-1776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-1776%26sid%3Dliteratum%253Aachs%26aulast%3DPhillips%26aufirst%3DG.%2BD.%2BL.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DDugger%26aufirst%3DD.%2BL.%26aulast%3DCrocker%26aufirst%3DL.%2BM.%26aulast%3DParsons%26aufirst%3DK.%2BL.%26aulast%3DMai%26aufirst%3DE.%26aulast%3DBlattler%26aufirst%3DW.%2BA.%26aulast%3DLambert%26aufirst%3DJ.%2BM.%26aulast%3DChari%26aufirst%3DR.%2BV.%2BJ.%26aulast%3DLutz%26aufirst%3DR.%2BJ.%26aulast%3DWong%26aufirst%3DW.%2BL.%2BT.%26aulast%3DJacobson%26aufirst%3DF.%2BS.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DSchwall%26aufirst%3DR.%2BH.%26aulast%3DKenkare-Mitra%26aufirst%3DS.%2BR.%26aulast%3DSpencer%26aufirst%3DS.%2BD.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DTargeting%2520HER2-positive%2520breast%2520cancer%2520with%2520trastuzumab-DM1%252C%2520an%2520antibody-cytotoxic%2520drug%2520conjugate%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D9280%26epage%3D9290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Tian, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manibusan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phuong, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hehli, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeGuzman, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ensari, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinkstaff, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biroc, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiJoseph, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dougher, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dushin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tchistiakova, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feyfant, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerber, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sapra, P.</span><span> </span><span class="NLM_article-title">A general approach to site-specific antibody drug conjugates</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">1766</span><span class="NLM_x">–</span> <span class="NLM_lpage">1771</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1073%2Fpnas.1321237111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=24443552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFyjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=1766-1771&author=F.+Tianauthor=Y.+C.+Luauthor=A.+Manibusanauthor=A.+Sellersauthor=H.+Tranauthor=Y.+Sunauthor=T.+Phuongauthor=R.+Barnettauthor=B.+Hehliauthor=F.+Songauthor=M.+J.+DeGuzmanauthor=S.+Ensariauthor=J.+K.+Pinkstaffauthor=L.+M.+Sullivanauthor=S.+L.+Birocauthor=H.+Choauthor=P.+G.+Schultzauthor=J.+DiJosephauthor=M.+Dougherauthor=D.+S.+Maauthor=R.+Dushinauthor=M.+Lealauthor=L.+Tchistiakovaauthor=E.+Feyfantauthor=H.+P.+Gerberauthor=P.+Sapra&title=A+general+approach+to+site-specific+antibody+drug+conjugates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">A general approach to site-specific antibody drug conjugates</span></div><div class="casAuthors">Tian, Feng; Lu, Yingchun; Manibusan, Anthony; Sellers, Aaron; Tran, Hon; Sun, Ying; Phuong, Trung; Barnett, Richard; Hehli, Brad; Song, Frank; De Guzman, Michael J.; Ensari, Semsi; Pinkstaff, Jason K.; Sullivan, Lorraine M.; Biroc, Sandra L.; Cho, Ho; Schultz, Peter G.; Di Joseph, John; Dougher, Maureen; Ma, Dangshe; Dushin, Russell; Leal, Mauricio; Tchistiakova, Lioudmila; Feyfant, Eric; Gerber, Hans-Peter; Sapra, Puja</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1766-1771</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Using an expanded genetic code, antibodies with site-specifically incorporated nonnative amino acids were produced in stable cell lines derived from a CHO cell line with titers over 1 g/L.  Using anti-5T4 and anti-Her2 antibodies as model systems, site-specific antibody drug conjugates (NDCs) were produced, via oxime bond formation between ketones on the side chain of the incorporated nonnative amino acid and hydroxylamine functionalized monomethyl auristatin D with either protease-cleavable or noncleavable linkers.  When noncleavable linkers were used, these conjugates were highly stable and displayed improved in vitro efficacy as well as in vivo efficacy and pharmacokinetic stability in rodent models relative to conventional antibody drug conjugates conjugated through either engineered surface-exposed or reduced interchain disulfide bond cysteine residues.  The advantages of the oxime-bonded, site-specific NDCs were even more apparent when low-antigen-expressing (2+) target cell lines were used in the comparative studies.  NDCs generated with protease-cleavable linkers demonstrated that the site of conjugation had a significant impact on the stability of these rationally designed prodrug linkers.  In a single-dose rat toxicol. study, a site-specific anti-Her2 NDC was well tolerated at dose levels up to 90 mg/kg.  These expts. support the notion that chem. defined antibody conjugates can be synthesized in com. relevant yields and can lead to antibody drug conjugates with improved properties relative to the heterogeneous conjugates formed by nonspecific chem. modification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSiiFYqUipo7Vg90H21EOLACvtfcHk0lgnFgf_GY8sJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFyjs7g%253D&md5=293401bcfaa0d74ce03daca26e9ad18e</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1321237111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1321237111%26sid%3Dliteratum%253Aachs%26aulast%3DTian%26aufirst%3DF.%26aulast%3DLu%26aufirst%3DY.%2BC.%26aulast%3DManibusan%26aufirst%3DA.%26aulast%3DSellers%26aufirst%3DA.%26aulast%3DTran%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DPhuong%26aufirst%3DT.%26aulast%3DBarnett%26aufirst%3DR.%26aulast%3DHehli%26aufirst%3DB.%26aulast%3DSong%26aufirst%3DF.%26aulast%3DDeGuzman%26aufirst%3DM.%2BJ.%26aulast%3DEnsari%26aufirst%3DS.%26aulast%3DPinkstaff%26aufirst%3DJ.%2BK.%26aulast%3DSullivan%26aufirst%3DL.%2BM.%26aulast%3DBiroc%26aufirst%3DS.%2BL.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DDiJoseph%26aufirst%3DJ.%26aulast%3DDougher%26aufirst%3DM.%26aulast%3DMa%26aufirst%3DD.%2BS.%26aulast%3DDushin%26aufirst%3DR.%26aulast%3DLeal%26aufirst%3DM.%26aulast%3DTchistiakova%26aufirst%3DL.%26aulast%3DFeyfant%26aufirst%3DE.%26aulast%3DGerber%26aufirst%3DH.%2BP.%26aulast%3DSapra%26aufirst%3DP.%26atitle%3DA%2520general%2520approach%2520to%2520site-specific%2520antibody%2520drug%2520conjugates%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2014%26volume%3D111%26spage%3D1766%26epage%3D1771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Shen, B.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raab, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhakta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenrick, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons-Reponte, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tien, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, S.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mai, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibbitts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baudys, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saadi, O. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scales, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hass, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trung, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solis, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuji, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flagella, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khawlil, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebens, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandlen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaur, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheller, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polakis, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Junutula, J. R.</span><span> </span><span class="NLM_article-title">Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">184</span><span class="NLM_x">–</span> <span class="NLM_lpage">189</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1038%2Fnbt.2108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=22267010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVGqtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=184-189&author=B.-Q.+Shenauthor=K.+Xuauthor=L.+Liuauthor=H.+Raabauthor=S.+Bhaktaauthor=M.+Kenrickauthor=K.+L.+Parsons-Reponteauthor=J.+Tienauthor=S.-F.+Yuauthor=E.+Maiauthor=D.+Liauthor=J.+Tibbittsauthor=J.+Baudysauthor=O.+M.+Saadiauthor=S.+J.+Scalesauthor=P.+J.+McDonaldauthor=P.+E.+Hassauthor=C.+Eigenbrotauthor=N.+Trungauthor=W.+A.+Solisauthor=R.+N.+Fujiauthor=K.+M.+Flagellaauthor=D.+Patelauthor=S.+D.+Spencerauthor=L.+A.+Khawlilauthor=A.+Ebensauthor=W.+L.+Wongauthor=R.+Vandlenauthor=S.+Kaurauthor=M.+X.+Sliwkowskiauthor=R.+H.+Schellerauthor=P.+Polakisauthor=J.+R.+Junutula&title=Conjugation+site+modulates+the+in+vivo+stability+and+therapeutic+activity+of+antibody-drug+conjugates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates</span></div><div class="casAuthors">Shen, Ben-Quan; Xu, Keyang; Liu, Luna; Raab, Helga; Bhakta, Sunil; Kenrick, Margaret; Parsons-Reponte, Kathryn L.; Tien, Janet; Yu, Shang-Fan; Mai, Elaine; Li, Dongwei; Tibbitts, Jay; Baudys, Jakub; Saad, Ola M.; Scales, Suzie J.; McDonald, Paul J.; Hass, Philip E.; Eigenbrot, Charles; Nguyen, Trung; Solis, Willy A.; Fuji, Reina N.; Flagella, Kelly M.; Patel, Darshana; Spencer, Susan D.; Khawli, Leslie A.; Ebens, Allen; Wong, Wai Lee; Vandlen, Richard; Kaur, Surinder; Sliwkowski, Mark X.; Scheller, Richard H.; Polakis, Paul; Junutula, Jagath R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">184-189</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The reactive thiol in cysteine is used for coupling maleimide linkers in the generation of antibody conjugates.  To assess the impact of the conjugation site, we engineered cysteines into a therapeutic HER2/neu antibody at three sites differing in solvent accessibility and local charge.  The highly solvent-accessible site rapidly lost conjugated thiol-reactive linkers in plasma owing to maleimide exchange with reactive thiols in albumin, free cysteine or glutathione.  In contrast, a partially accessible site with a pos. charged environment promoted hydrolysis of the succinimide ring in the linker, thereby preventing this exchange reaction.  The site with partial solvent-accessibility and neutral charge displayed both properties.  In a mouse mammary tumor model, the stability and therapeutic activity of the antibody conjugate were affected pos. by succinimide ring hydrolysis and neg. by maleimide exchange with thiol-reactive constituents in plasma.  Thus, the chem. and structural dynamics of the conjugation site can influence antibody conjugate performance by modulating the stability of the antibody-linker interface.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkINkMwQTMFrVg90H21EOLACvtfcHk0lgF2gpN4ShTRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVGqtLg%253D&md5=c647fc5bdfe93dfdabb15ca40934837f</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2108%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DB.-Q.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DRaab%26aufirst%3DH.%26aulast%3DBhakta%26aufirst%3DS.%26aulast%3DKenrick%26aufirst%3DM.%26aulast%3DParsons-Reponte%26aufirst%3DK.%2BL.%26aulast%3DTien%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DS.-F.%26aulast%3DMai%26aufirst%3DE.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DTibbitts%26aufirst%3DJ.%26aulast%3DBaudys%26aufirst%3DJ.%26aulast%3DSaadi%26aufirst%3DO.%2BM.%26aulast%3DScales%26aufirst%3DS.%2BJ.%26aulast%3DMcDonald%26aufirst%3DP.%2BJ.%26aulast%3DHass%26aufirst%3DP.%2BE.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DTrung%26aufirst%3DN.%26aulast%3DSolis%26aufirst%3DW.%2BA.%26aulast%3DFuji%26aufirst%3DR.%2BN.%26aulast%3DFlagella%26aufirst%3DK.%2BM.%26aulast%3DPatel%26aufirst%3DD.%26aulast%3DSpencer%26aufirst%3DS.%2BD.%26aulast%3DKhawlil%26aufirst%3DL.%2BA.%26aulast%3DEbens%26aufirst%3DA.%26aulast%3DWong%26aufirst%3DW.%2BL.%26aulast%3DVandlen%26aufirst%3DR.%26aulast%3DKaur%26aufirst%3DS.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DScheller%26aufirst%3DR.%2BH.%26aulast%3DPolakis%26aufirst%3DP.%26aulast%3DJunutula%26aufirst%3DJ.%2BR.%26atitle%3DConjugation%2520site%2520modulates%2520the%2520in%2520vivo%2520stability%2520and%2520therapeutic%2520activity%2520of%2520antibody-drug%2520conjugates%26jtitle%3DNat.%2520Biotechnol.%26date%3D2012%26volume%3D30%26spage%3D184%26epage%3D189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Junutula, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flagella, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ha, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raab, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhakta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dugger, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mai, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, G. D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiraragi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuji, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibbitts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandlen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheller, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polakis, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span> </span><span class="NLM_article-title">Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">4769</span><span class="NLM_x">–</span> <span class="NLM_lpage">4778</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1158%2F1078-0432.CCR-10-0987" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=20805300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1aktbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=4769-4778&author=J.+R.+Junutulaauthor=K.+M.+Flagellaauthor=R.+A.+Grahamauthor=K.+L.+Parsonsauthor=E.+Haauthor=H.+Raabauthor=S.+Bhaktaauthor=T.+Nguyenauthor=D.+L.+Duggerauthor=G.+M.+Liauthor=E.+Maiauthor=G.+D.+L.+Phillipsauthor=H.+Hiraragiauthor=R.+N.+Fujiauthor=J.+Tibbittsauthor=R.+Vandlenauthor=S.+D.+Spencerauthor=R.+H.+Schellerauthor=P.+Polakisauthor=M.+X.+Sliwkowski&title=Engineered+thio-trastuzumab-DM1+conjugate+with+an+improved+therapeutic+index+to+target+human+epidermal+growth+factor+receptor+2-positive+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer</span></div><div class="casAuthors">Junutula, Jagath R.; Flagella, Kelly M.; Graham, Richard A.; Parsons, Kathryn L.; Ha, Edward; Raab, Helga; Bhakta, Sunil; Nguyen, Trung; Dugger, Debra L.; Li, Guangmin; Mai, Elaine; Lewis Phillips, Gail D.; Hiraragi, Hajime; Fuji, Reina N.; Tibbitts, Jay; Vandlen, Richard; Spencer, Susan D.; Scheller, Richard H.; Polakis, Paul; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4769-4778</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Antibody drug conjugates (ADCs) combine the ideal properties of both antibodies and cytotoxic drugs by targeting potent drugs to the antigen-expressing tumor cells, thereby enhancing their antitumor activity.  Successful ADC development for a given target antigen depends on optimization of antibody selection, linker stability, cytotoxic drug potency, and mode of linker-drug conjugation to the antibody.  Here, we systematically examd. the in vitro potency as well as in vivo preclin. efficacy and safety profiles of a heterogeneous prepn. of conventional trastuzumab-mcc-DM1 (TMAb-mcc-DM1) ADC with that of a homogeneous engineered thio-trastuzumab-mpeo-DM1 (thioTMAb-mpeo-DM1) conjugate.  To generate thioTMAb-mpeo-DM1, one drug maytansinoid 1 (DM1) mol. was conjugated to an engineered cysteine residue at Ala114 (Kabat numbering) on each trastuzumab-heavy chain, resulting in two DM1 mols. per antibody.  ThioTMAb-mpeo-DM1 retained similar in vitro anti-cell proliferation activity and human epidermal growth factor receptor 2 (HER2) binding properties to that of the conventional ADC.  Furthermore, it showed improved efficacy over the conventional ADC at DM1-equiv doses (μg/m2) and retained efficacy at equiv. antibody doses (mg/kg).  An improved safety profile of >2-fold was obsd. in a short-term target-independent rat safety study.  In cynomolgus monkey safety studies, thioTMAb-mpeo-DM1 was tolerated at higher antibody doses (up to 48 mg/kg or 6000 μg DM1/m2) compared with the conventional ADC that had dose-limiting toxicity at 30 mg/kg (6000 μg DM1/m2).  The engineered thioTMAb-mpeo-DM1 with broadened therapeutic index represents a promising antibody drug conjugate for future clin. development of HER2-pos. targeted breast cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowkqzAMGHmA7Vg90H21EOLACvtfcHk0lhIOOmGj5F0Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1aktbjK&md5=888bda7f06d1ed864111b607dae5f969</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-0987&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-0987%26sid%3Dliteratum%253Aachs%26aulast%3DJunutula%26aufirst%3DJ.%2BR.%26aulast%3DFlagella%26aufirst%3DK.%2BM.%26aulast%3DGraham%26aufirst%3DR.%2BA.%26aulast%3DParsons%26aufirst%3DK.%2BL.%26aulast%3DHa%26aufirst%3DE.%26aulast%3DRaab%26aufirst%3DH.%26aulast%3DBhakta%26aufirst%3DS.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DDugger%26aufirst%3DD.%2BL.%26aulast%3DLi%26aufirst%3DG.%2BM.%26aulast%3DMai%26aufirst%3DE.%26aulast%3DPhillips%26aufirst%3DG.%2BD.%2BL.%26aulast%3DHiraragi%26aufirst%3DH.%26aulast%3DFuji%26aufirst%3DR.%2BN.%26aulast%3DTibbitts%26aufirst%3DJ.%26aulast%3DVandlen%26aufirst%3DR.%26aulast%3DSpencer%26aufirst%3DS.%2BD.%26aulast%3DScheller%26aufirst%3DR.%2BH.%26aulast%3DPolakis%26aufirst%3DP.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DEngineered%2520thio-trastuzumab-DM1%2520conjugate%2520with%2520an%2520improved%2520therapeutic%2520index%2520to%2520target%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202-positive%2520breast%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26spage%3D4769%26epage%3D4778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Junutula, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raab, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhakta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leipold, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weir, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simpson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dennis, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, Y. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duenas, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorrell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katta, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDorman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flagella, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venook, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowman, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandlen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheller, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polakis, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallet, W.</span><span> </span><span class="NLM_article-title">Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">925</span><span class="NLM_x">–</span> <span class="NLM_lpage">932</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1038%2Fnbt.1480" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=18641636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1Wmu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=925-932&author=J.+R.+Junutulaauthor=H.+Raabauthor=S.+Clarkauthor=S.+Bhaktaauthor=D.+D.+Leipoldauthor=S.+Weirauthor=Y.+Chenauthor=M.+Simpsonauthor=S.+P.+Tsaiauthor=M.+S.+Dennisauthor=Y.+Luauthor=Y.+G.+Mengauthor=C.+Ngauthor=J.+Yangauthor=C.+C.+Leeauthor=E.+Duenasauthor=J.+Gorrellauthor=V.+Kattaauthor=A.+Kimauthor=K.+McDormanauthor=K.+Flagellaauthor=R.+Venookauthor=S.+Rossauthor=S.+D.+Spencerauthor=W.+L.+Wongauthor=H.+B.+Lowmanauthor=R.+Vandlenauthor=M.+X.+Sliwkowskiauthor=R.+H.+Schellerauthor=P.+Polakisauthor=W.+Mallet&title=Site-specific+conjugation+of+a+cytotoxic+drug+to+an+antibody+improves+the+therapeutic+index"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index</span></div><div class="casAuthors">Junutula, Jagath R.; Raab, Helga; Clark, Suzanna; Bhakta, Sunil; Leipold, Douglas D.; Weir, Sylvia; Chen, Yvonne; Simpson, Michelle; Tsai, Siao Ping; Dennis, Mark S.; Lu, Yanmei; Meng, Y. Gloria; Ng, Carl; Yang, Jihong; Lee, Chien C.; Duenas, Eileen; Gorrell, Jeffrey; Katta, Viswanatham; Kim, Amy; McDorman, Kevin; Flagella, Kelly; Venook, Rayna; Ross, Sarajane; Spencer, Susan D.; Wong, Wai Lee; Lowman, Henry B.; Vandlen, Richard; Sliwkowski, Mark X.; Scheller, Richard H.; Polakis, Paul; Mallet, William</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">925-932</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Antibody-drug conjugates enhance the antitumor effects of antibodies and reduce adverse systemic effects of potent cytotoxic drugs.  However, conventional drug conjugation strategies yield heterogeneous conjugates with relatively narrow therapeutic index (max. tolerated dose/curative dose).  Using leads from the authors' previously described phage display-based method to predict suitable conjugation sites, the authors engineered cysteine substitutions at positions on light and heavy chains that provide reactive thiol groups and do not perturb Ig folding and assembly, or alter antigen binding.  When conjugated to monomethyl auristatin E, an antibody against the ovarian cancer antigen MUC16 is as efficacious as a conventional conjugate in mouse xenograft models.  Moreover, it is tolerated at higher doses in rats and cynomolgus monkeys than the same conjugate prepd. by conventional approaches.  The favorable in vivo properties of the near-homogeneous compn. of this conjugate suggest that this strategy offers a general approach to retaining the antitumor efficacy of antibody-drug conjugates, while minimizing their systemic toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4HIiPBABzRLVg90H21EOLACvtfcHk0lhIOOmGj5F0Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1Wmu7s%253D&md5=d55f59594fb6349d0337dfed2783e83c</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1480&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1480%26sid%3Dliteratum%253Aachs%26aulast%3DJunutula%26aufirst%3DJ.%2BR.%26aulast%3DRaab%26aufirst%3DH.%26aulast%3DClark%26aufirst%3DS.%26aulast%3DBhakta%26aufirst%3DS.%26aulast%3DLeipold%26aufirst%3DD.%2BD.%26aulast%3DWeir%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DSimpson%26aufirst%3DM.%26aulast%3DTsai%26aufirst%3DS.%2BP.%26aulast%3DDennis%26aufirst%3DM.%2BS.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DMeng%26aufirst%3DY.%2BG.%26aulast%3DNg%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DDuenas%26aufirst%3DE.%26aulast%3DGorrell%26aufirst%3DJ.%26aulast%3DKatta%26aufirst%3DV.%26aulast%3DKim%26aufirst%3DA.%26aulast%3DMcDorman%26aufirst%3DK.%26aulast%3DFlagella%26aufirst%3DK.%26aulast%3DVenook%26aufirst%3DR.%26aulast%3DRoss%26aufirst%3DS.%26aulast%3DSpencer%26aufirst%3DS.%2BD.%26aulast%3DWong%26aufirst%3DW.%2BL.%26aulast%3DLowman%26aufirst%3DH.%2BB.%26aulast%3DVandlen%26aufirst%3DR.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DScheller%26aufirst%3DR.%2BH.%26aulast%3DPolakis%26aufirst%3DP.%26aulast%3DMallet%26aufirst%3DW.%26atitle%3DSite-specific%2520conjugation%2520of%2520a%2520cytotoxic%2520drug%2520to%2520an%2520antibody%2520improves%2520the%2520therapeutic%2520index%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D925%26epage%3D932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Boghaert, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khandke, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sridharan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armellino, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dougher, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiJoseph, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamann, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sridharan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damle, N. K.</span><span> </span><span class="NLM_article-title">Tumoricidal effect of calicheamicin immuno-conjugates using a passive targeting strategy</span> <span class="citation_source-journal">Int. J. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">675</span><span class="NLM_x">–</span> <span class="NLM_lpage">684</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=16465373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BD28XitFWitro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2006&pages=675-684&author=E.+R.+Boghaertauthor=K.+Khandkeauthor=L.+Sridharanauthor=D.+Armellinoauthor=M.+Dougherauthor=J.+F.+DiJosephauthor=A.+Kunzauthor=P.+R.+Hamannauthor=A.+Sridharanauthor=S.+Jonesauthor=C.+Discafaniauthor=N.+K.+Damle&title=Tumoricidal+effect+of+calicheamicin+immuno-conjugates+using+a+passive+targeting+strategy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Tumoricidal effect of calicheamicin immuno-conjugates using a passive targeting strategy</span></div><div class="casAuthors">Boghaert, Erwin R.; Khandke, Kiran; Sridharan, Latha; Armellino, Douglas; Dougher, Maureen; DiJoseph, John F.; Kunz, Arthur; Hamann, Philip R.; Sridharan, Ashwin; Jones, Stanley; Discafani, Carolyn; Damle, Nitin K.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">675-684</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1019-6439</span>.
    
            (<span class="NLM_cas:orgname">International Journal of Oncology</span>)
        </div><div class="casAbstract">Calicheamicin is a potent chemotherapeutic with a low therapeutic index that requires targeting to tumor cells for its use in the clinic.  To treat acute myeloid leukemia, calicheamicin has been conjugated to an antibody that recognizes CD33 (gemtuzumab ozogamicin).  The application range of this 'active' targeting strategy is limited since it depends on specific antigen expression by tumor cells.  This limitation could be reduced by using an antigen-independent 'passive targeting' strategy for calicheamicin.  'Passive targeting' relies on the dysfunctional vasculature of a neoplastic tumor that allows enhanced retention of macromols.  We studied the efficacy of calicheamicin conjugated to various carrier mols.: i.e. Ig, albumin or PEGylated Fc fragments.  In nude mice, a conjugate of anti-CD33 and calicheamicin accumulates in human tumor xenografts in the absence of detectable amts. of targeting antigen.  Passive targeting provided sufficient accumulation of this conjugate to inhibit tumor growth of 10 different CD33-neg. xenograft models.  This efficacy depended on the use of an acid-labile linker between antibody and calicheamicin.  Substitution of Ig as a carrier with either albumin or PEGylated Fc reduced or eliminated the efficacy of the conjugate.  The results showed that using 'non-specific' Ig for passive targeting of calicheamicin might be an effective mode of cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8fLdjEgE99rVg90H21EOLACvtfcHk0lhIOOmGj5F0Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XitFWitro%253D&md5=0641078e0bc35ea2cee475421ca63795</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoghaert%26aufirst%3DE.%2BR.%26aulast%3DKhandke%26aufirst%3DK.%26aulast%3DSridharan%26aufirst%3DL.%26aulast%3DArmellino%26aufirst%3DD.%26aulast%3DDougher%26aufirst%3DM.%26aulast%3DDiJoseph%26aufirst%3DJ.%2BF.%26aulast%3DKunz%26aufirst%3DA.%26aulast%3DHamann%26aufirst%3DP.%2BR.%26aulast%3DSridharan%26aufirst%3DA.%26aulast%3DJones%26aufirst%3DS.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DDamle%26aufirst%3DN.%2BK.%26atitle%3DTumoricidal%2520effect%2520of%2520calicheamicin%2520immuno-conjugates%2520using%2520a%2520passive%2520targeting%2520strategy%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2006%26volume%3D28%26spage%3D675%26epage%3D684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Jedema, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barge, R. M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Velden, V. H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nijmeijer, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Dongen, J. J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willemze, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falkenburg, J. H. F.</span><span> </span><span class="NLM_article-title">Internalization and cell cycle-dependent killing of leukemic cells by gemtuzumab ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">316</span><span class="NLM_x">–</span> <span class="NLM_lpage">325</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2004&pages=316-325&author=I.+Jedemaauthor=R.+M.+Y.+Bargeauthor=V.+H.+J.+van+der+Veldenauthor=B.+A.+Nijmeijerauthor=J.+J.+M.+van+Dongenauthor=R.+Willemzeauthor=J.+H.+F.+Falkenburg&title=Internalization+and+cell+cycle-dependent+killing+of+leukemic+cells+by+gemtuzumab+ozogamicin%3A+rationale+for+efficacy+in+CD33-negative+malignancies+with+endocytic+capacity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJedema%26aufirst%3DI.%26aulast%3DBarge%26aufirst%3DR.%2BM.%2BY.%26aulast%3Dvan%2Bder%2BVelden%26aufirst%3DV.%2BH.%2BJ.%26aulast%3DNijmeijer%26aufirst%3DB.%2BA.%26aulast%3Dvan%2BDongen%26aufirst%3DJ.%2BJ.%2BM.%26aulast%3DWillemze%26aufirst%3DR.%26aulast%3DFalkenburg%26aufirst%3DJ.%2BH.%2BF.%26atitle%3DInternalization%2520and%2520cell%2520cycle-dependent%2520killing%2520of%2520leukemic%2520cells%2520by%2520gemtuzumab%2520ozogamicin%253A%2520rationale%2520for%2520efficacy%2520in%2520CD33-negative%2520malignancies%2520with%2520endocytic%2520capacity%26jtitle%3DLeukemia%26date%3D2004%26volume%3D18%26spage%3D316%26epage%3D325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Farhat, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reman, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raffoux, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berthon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pautas, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kammoun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chantepie, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rousselot, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chevret, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dombret, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castaigne, S.</span><span> </span><span class="NLM_article-title">Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: A phase 1/2 study of the acute leukemia French association</span> <span class="citation_source-journal">Am. J. Hematol</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">62</span><span class="NLM_x">–</span> <span class="NLM_lpage">65</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1002%2Fajh.22201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=22072535" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1egs77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2012&pages=62-65&author=H.+Farhatauthor=O.+Remanauthor=E.+Raffouxauthor=C.+Berthonauthor=C.+Pautasauthor=L.+Kammounauthor=S.+Chantepieauthor=C.+Gardinauthor=P.+Rousselotauthor=S.+Chevretauthor=H.+Dombretauthor=S.+Castaigne&title=Fractionated+doses+of+gemtuzumab+ozogamicin+with+escalated+doses+of+daunorubicin+and+cytarabine+as+first+acute+myeloid+leukemia+salvage+in+patients+aged+50-70-year+old%3A+A+phase+1%2F2+study+of+the+acute+leukemia+French+association"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: A phase 1/2 study of the acute leukemia French association</span></div><div class="casAuthors">Farhat, Hassan; Reman, Oumedaly; Raffoux, Emmanuel; Berthon, Celine; Pautas, Cecile; Kammoun, Leila; Chantepie, Sylvain; Gardin, Claude; Rousselot, Philippe; Chevret, Sylvie; Dombret, Herve; Castaigne, Sylvie</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Hematology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">62-65</span>CODEN:
                <span class="NLM_cas:coden">AJHEDD</span>;
        ISSN:<span class="NLM_cas:issn">0361-8609</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">This Phase 1/2 study aimed to det. optimal doses of daunorubicin (DNR; mg/m2) and cytarabine (mg/m2) to be combined with fractionated doses of gemtuzumab ozogamicin (GO, Mylotarg; 3 mg/m2 on day 1, 4, and 7) satisfying safety requirements.  Three dose levels of DNR/AraC were investigated namely (45, 100), (60, 100), and (60, 200).  Patients included were acute myeloid leukemia in first relapse, aged 50-70 years.  Hematol. recovery was 31 days for neutrophil and 32 days for platelet counts.  A documented infectious episode > Grade 2 occurred in 11/20 patients (55%).  None of the 20 patients had signs of veno-occlusive disease.  Overall, eleven patients reached complete remission (CR), two CR with incomplete platelets recovery.  The results showed that combination of fractionated GO doses with DNR at 60 mg/m2/d for 3 days and cytarabine at 200 mg/m2/d for 7 days is tolerable and could be further investigated in the front-line therapy.  Am. J. Hematol., 2012. © 2011 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkWuEf9jmMhbVg90H21EOLACvtfcHk0lh6oq2tCM0O2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1egs77O&md5=c4979646949d3b5309590549b99c91e6</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1002%2Fajh.22201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fajh.22201%26sid%3Dliteratum%253Aachs%26aulast%3DFarhat%26aufirst%3DH.%26aulast%3DReman%26aufirst%3DO.%26aulast%3DRaffoux%26aufirst%3DE.%26aulast%3DBerthon%26aufirst%3DC.%26aulast%3DPautas%26aufirst%3DC.%26aulast%3DKammoun%26aufirst%3DL.%26aulast%3DChantepie%26aufirst%3DS.%26aulast%3DGardin%26aufirst%3DC.%26aulast%3DRousselot%26aufirst%3DP.%26aulast%3DChevret%26aufirst%3DS.%26aulast%3DDombret%26aufirst%3DH.%26aulast%3DCastaigne%26aufirst%3DS.%26atitle%3DFractionated%2520doses%2520of%2520gemtuzumab%2520ozogamicin%2520with%2520escalated%2520doses%2520of%2520daunorubicin%2520and%2520cytarabine%2520as%2520first%2520acute%2520myeloid%2520leukemia%2520salvage%2520in%2520patients%2520aged%252050-70-year%2520old%253A%2520A%2520phase%25201%252F2%2520study%2520of%2520the%2520acute%2520leukemia%2520French%2520association%26jtitle%3DAm.%2520J.%2520Hematol%26date%3D2012%26volume%3D87%26spage%3D62%26epage%3D65" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Taksin, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Legrand, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raffoux, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Revel, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Contentin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouabdallah, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pautas, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turlure, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reman, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varet, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Botton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pousset, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farhat, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chevret, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dombret, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castaigne, S.</span><span> </span><span class="NLM_article-title">High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">66</span><span class="NLM_x">–</span> <span class="NLM_lpage">71</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=66-71&author=A.+L.+Taksinauthor=O.+Legrandauthor=E.+Raffouxauthor=T.+de+Revelauthor=X.+Thomasauthor=N.+Contentinauthor=R.+Bouabdallahauthor=C.+Pautasauthor=P.+Turlureauthor=O.+Remanauthor=C.+Gardinauthor=B.+Varetauthor=S.+de+Bottonauthor=F.+Poussetauthor=H.+Farhatauthor=S.+Chevretauthor=H.+Dombretauthor=S.+Castaigne&title=High+efficacy+and+safety+profile+of+fractionated+doses+of+Mylotarg+as+induction+therapy+in+patients+with+relapsed+acute+myeloblastic+leukemia%3A+a+prospective+study+of+the+alfa+group"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTaksin%26aufirst%3DA.%2BL.%26aulast%3DLegrand%26aufirst%3DO.%26aulast%3DRaffoux%26aufirst%3DE.%26aulast%3Dde%2BRevel%26aufirst%3DT.%26aulast%3DThomas%26aufirst%3DX.%26aulast%3DContentin%26aufirst%3DN.%26aulast%3DBouabdallah%26aufirst%3DR.%26aulast%3DPautas%26aufirst%3DC.%26aulast%3DTurlure%26aufirst%3DP.%26aulast%3DReman%26aufirst%3DO.%26aulast%3DGardin%26aufirst%3DC.%26aulast%3DVaret%26aufirst%3DB.%26aulast%3Dde%2BBotton%26aufirst%3DS.%26aulast%3DPousset%26aufirst%3DF.%26aulast%3DFarhat%26aufirst%3DH.%26aulast%3DChevret%26aufirst%3DS.%26aulast%3DDombret%26aufirst%3DH.%26aulast%3DCastaigne%26aufirst%3DS.%26atitle%3DHigh%2520efficacy%2520and%2520safety%2520profile%2520of%2520fractionated%2520doses%2520of%2520Mylotarg%2520as%2520induction%2520therapy%2520in%2520patients%2520with%2520relapsed%2520acute%2520myeloblastic%2520leukemia%253A%2520a%2520prospective%2520study%2520of%2520the%2520alfa%2520group%26jtitle%3DLeukemia%26date%3D2007%26volume%3D21%26spage%3D66%26epage%3D71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Burnett, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hills, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milligan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kjeldsen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, J. A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstone, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wheatley, K.</span><span> </span><span class="NLM_article-title">Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: Results of the MRC AML15 trial</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">369</span><span class="NLM_x">–</span> <span class="NLM_lpage">377</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1200%2FJCO.2010.31.4310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=21172891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivFWmsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=369-377&author=A.+K.+Burnettauthor=R.+K.+Hillsauthor=D.+Milliganauthor=L.+Kjeldsenauthor=J.+Kellauthor=N.+H.+Russellauthor=J.+A.+L.+Yinauthor=A.+Hunterauthor=A.+H.+Goldstoneauthor=K.+Wheatley&title=Identification+of+patients+with+acute+myeloblastic+leukemia+who+benefit+from+the+addition+of+gemtuzumab+ozogamicin%3A+Results+of+the+MRC+AML15+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial</span></div><div class="casAuthors">Burnett, Alan K.; Hills, Robert K.; Milligan, Donald; Kjeldsen, Lars; Kell, Jonathan; Russell, Nigel H.; Yin, John A. L.; Hunter, Ann; Goldstone, Anthony H.; Wheatley, Keith</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">369-377</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Antibody-directed chemotherapy for acute myeloid leukemia (AML) may permit more treatment to be administered without escalating toxicity.  Gemtuzumab ozogamicin (GO) is an immunoconjugate between CD33 and calicheamicin that is internalized when binding to the epitope.  We previously established that it is feasible to combine GO with conventional chemotherapy.  We now report a large randomized trial testing the addn. of GO to induction and/or consolidation chemotherapy in untreated younger patients.  Patients and Methods In this open-label trial, 1,113 patients, predominantly younger than age 60 years, were randomly assigned to receive a single dose of GO (3 mg/m2) on day 1 of induction course 1 with one of the following three induction schedules: daunorubicin and cytarabine; cytarabine, daunorubicin, and etoposide; or fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin.  In remission, 948 patients were randomly assigned to GO in course 3 in combination with amsacrine, cytarabine, and etoposide or high-dose cytarabine.  The primary end points were response rate and survival.  Results The addn. of GO was well tolerated with no significant increase in toxicity.  There was no overall difference in response or survival in either induction of consolidation.  However, a predefined anal. by cytogenetics showed highly significant interaction with induction GO (P = .001), with significant survival benefit for patients with favorable cytogenetics, no benefit for patients with poor-risk disease, and a trend for benefit in intermediate-risk patients.  An internally validated prognostic index identified approx. 70% of patients with a predicted benefit of 10% in 5-yr survival.  Conclusion A substantial proportion of younger patients with AML have improved survival with the addn. of GO to induction chemotherapy with little addnl. toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreGPpBKujaYLVg90H21EOLACvtfcHk0lh6oq2tCM0O2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivFWmsrY%253D&md5=908d4ab8c1a9d3ad27fdc397708034d2</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1200%2FJCO.2010.31.4310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2010.31.4310%26sid%3Dliteratum%253Aachs%26aulast%3DBurnett%26aufirst%3DA.%2BK.%26aulast%3DHills%26aufirst%3DR.%2BK.%26aulast%3DMilligan%26aufirst%3DD.%26aulast%3DKjeldsen%26aufirst%3DL.%26aulast%3DKell%26aufirst%3DJ.%26aulast%3DRussell%26aufirst%3DN.%2BH.%26aulast%3DYin%26aufirst%3DJ.%2BA.%2BL.%26aulast%3DHunter%26aufirst%3DA.%26aulast%3DGoldstone%26aufirst%3DA.%2BH.%26aulast%3DWheatley%26aufirst%3DK.%26atitle%3DIdentification%2520of%2520patients%2520with%2520acute%2520myeloblastic%2520leukemia%2520who%2520benefit%2520from%2520the%2520addition%2520of%2520gemtuzumab%2520ozogamicin%253A%2520Results%2520of%2520the%2520MRC%2520AML15%2520trial%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3D369%26epage%3D377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Burnett, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hills, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freeman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kjeldsen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Craddock, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dufva, I. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wheatley, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milligan, D.</span><span> </span><span class="NLM_article-title">Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">3924</span><span class="NLM_x">–</span> <span class="NLM_lpage">3931</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1200%2FJCO.2012.42.2964" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=22851554" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvValtbfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=3924-3931&author=A.+K.+Burnettauthor=N.+H.+Russellauthor=R.+K.+Hillsauthor=J.+Kellauthor=S.+Freemanauthor=L.+Kjeldsenauthor=A.+E.+Hunterauthor=J.+Yinauthor=C.+F.+Craddockauthor=I.+H.+Dufvaauthor=K.+Wheatleyauthor=D.+Milligan&title=Addition+of+gemtuzumab+ozogamicin+to+induction+chemotherapy+improves+survival+in+older+patients+with+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia</span></div><div class="casAuthors">Burnett, Alan K.; Russell, Nigel H.; Hills, Robert K.; Kell, Jonathan; Freeman, Sylvie; Kjeldsen, Lars; Hunter, Ann E.; Yin, John; Craddock, Charles F.; Dufva, Inge Hoegh; Wheatley, Keith; Milligan, Donald</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">3924-3931</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose There has been little survival improvement in older patients with acute myeloid leukemia (AML) in the last two decades.  Improving induction treatment may improve the rate and quality of remission and consequently survival.  In our previous trial, in younger patients, we showed improved survival for the majority of patients when adding gemtuzumab ozogamicin (GO) to induction chemotherapy.  Patients and Methods Untreated patients with AML or high-risk myelodysplastic syndrome (median age, 67 years; range, 51 to 84 years) were randomly assigned to receive induction chemotherapy with either daunorubicin/ara-C or daunorubicin/clofarabine, with (n = 559) or without (n = 556) GO 3 mg/m2 on day 1 of course one of therapy.  The primary end point was overall survival (OS).  Results The overall response rate was 69% (complete remission [CR], 60%; CR with incomplete recovery [CRi], 9%), with no difference between GO (70%) and no GO (68%) arms.  There was no difference in 30- or 60-day mortality and no major increase in toxicity with GO.  With median follow-up of 30 mo (range, 5.5 to 54.6 mo), 3-yr cumulative incidence of relapse was significantly lower with GO (68% v76%; hazard ratio [HR], 0.78; 95% Cl, 0.66 to 0.93; P = .007), and 3-yr survival was significantly better (25% v20%; HR, 0.87; 95% Cl. 0.76 to 1.00; P = .05).  The benefit was apparent across subgroups.  There was no interaction with other treatment interventions.  A meta-anal. of 2,228 patients in two United Kingdom National Cancer Research Institute trials showed significant improvements in relapse (HR, 0.82; 95% Cl, 0.72 to 0.93; P = .002) and OS (HR, 0.88; 95% Cl, 0.79 to 0.98; P = .02).  Conclusion. Adding GO (3 mg/m2) to induction chemotherapy reduces relapse risk and improves survival with little increase in toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqokpkqhoUJ7bVg90H21EOLACvtfcHk0li8l5i8iHajug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvValtbfM&md5=98d118c9fa65d6d0168c7162997c6681</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.42.2964&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.42.2964%26sid%3Dliteratum%253Aachs%26aulast%3DBurnett%26aufirst%3DA.%2BK.%26aulast%3DRussell%26aufirst%3DN.%2BH.%26aulast%3DHills%26aufirst%3DR.%2BK.%26aulast%3DKell%26aufirst%3DJ.%26aulast%3DFreeman%26aufirst%3DS.%26aulast%3DKjeldsen%26aufirst%3DL.%26aulast%3DHunter%26aufirst%3DA.%2BE.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DCraddock%26aufirst%3DC.%2BF.%26aulast%3DDufva%26aufirst%3DI.%2BH.%26aulast%3DWheatley%26aufirst%3DK.%26aulast%3DMilligan%26aufirst%3DD.%26atitle%3DAddition%2520of%2520gemtuzumab%2520ozogamicin%2520to%2520induction%2520chemotherapy%2520improves%2520survival%2520in%2520older%2520patients%2520with%2520acute%2520myeloid%2520leukemia%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D3924%26epage%3D3931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Castaigne, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pautas, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terre, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raffoux, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bordessoule, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bastie, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Legrand, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turlure, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reman, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Revel, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gastaud, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Gunzburg, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Contentin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henry, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marolleau, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aljijakli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rousselot, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenaux, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preudhomme, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chevret, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dombret, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acute Leukemia French Association</span><span> </span><span class="NLM_article-title">Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">379</span><span class="NLM_x">, </span> <span class="NLM_fpage">1508</span><span class="NLM_x">–</span> <span class="NLM_lpage">1516</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2012&pages=1508-1516&author=S.+Castaigneauthor=C.+Pautasauthor=C.+Terreauthor=E.+Raffouxauthor=D.+Bordessouleauthor=J.+N.+Bastieauthor=O.+Legrandauthor=X.+Thomasauthor=P.+Turlureauthor=O.+Remanauthor=T.+de+Revelauthor=L.+Gastaudauthor=N.+de+Gunzburgauthor=N.+Contentinauthor=E.+Henryauthor=J.+P.+Marolleauauthor=A.+Aljijakliauthor=P.+Rousselotauthor=P.+Fenauxauthor=C.+Preudhommeauthor=S.+Chevretauthor=H.+Dombretauthor=Acute+Leukemia+French+Association&title=Effect+of+gemtuzumab+ozogamicin+on+survival+of+adult+patients+with+de-novo+acute+myeloid+leukaemia+%28ALFA-0701%29%3A+a+randomised%2C+open-label%2C+phase+3+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCastaigne%26aufirst%3DS.%26aulast%3DPautas%26aufirst%3DC.%26aulast%3DTerre%26aufirst%3DC.%26aulast%3DRaffoux%26aufirst%3DE.%26aulast%3DBordessoule%26aufirst%3DD.%26aulast%3DBastie%26aufirst%3DJ.%2BN.%26aulast%3DLegrand%26aufirst%3DO.%26aulast%3DThomas%26aufirst%3DX.%26aulast%3DTurlure%26aufirst%3DP.%26aulast%3DReman%26aufirst%3DO.%26aulast%3Dde%2BRevel%26aufirst%3DT.%26aulast%3DGastaud%26aufirst%3DL.%26aulast%3Dde%2BGunzburg%26aufirst%3DN.%26aulast%3DContentin%26aufirst%3DN.%26aulast%3DHenry%26aufirst%3DE.%26aulast%3DMarolleau%26aufirst%3DJ.%2BP.%26aulast%3DAljijakli%26aufirst%3DA.%26aulast%3DRousselot%26aufirst%3DP.%26aulast%3DFenaux%26aufirst%3DP.%26aulast%3DPreudhomme%26aufirst%3DC.%26aulast%3DChevret%26aufirst%3DS.%26aulast%3DDombret%26aufirst%3DH.%26aulast%3D%26atitle%3DEffect%2520of%2520gemtuzumab%2520ozogamicin%2520on%2520survival%2520of%2520adult%2520patients%2520with%2520de-novo%2520acute%2520myeloid%2520leukaemia%2520%2528ALFA-0701%2529%253A%2520a%2520randomised%252C%2520open-label%252C%2520phase%25203%2520study%26jtitle%3DLancet%26date%3D2012%26volume%3D379%26spage%3D1508%26epage%3D1516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Delaunay, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Recher, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pigneux, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witz, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vey, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanchet, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefebvre, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luquet, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guillerme, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volteau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gyan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lioure, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jourdan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouscary, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guieze, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Randriamalala, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uribe, M. E. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreyfus, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacombe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bene, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cahn, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harousseau, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ifrah, N.</span><span> </span><span class="NLM_article-title">Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation. Results of the GOELAMS AML 2006 IR study</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x">, </span> <span class="NLM_fpage">37</span><span class="NLM_x">–</span> <span class="NLM_lpage">38</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2011&pages=37-38&author=J.+Delaunayauthor=C.+Recherauthor=A.+Pigneuxauthor=F.+Witzauthor=N.+Veyauthor=O.+Blanchetauthor=P.+Lefebvreauthor=I.+Luquetauthor=I.+Guillermeauthor=C.+Volteauauthor=E.+Gyanauthor=B.+Lioureauthor=E.+Jourdanauthor=D.+Bouscaryauthor=R.+Guiezeauthor=E.+Randriamalalaauthor=M.+E.+O.+Uribeauthor=F.+Dreyfusauthor=C.+Lacombeauthor=M.+C.+Beneauthor=J.+Y.+Cahnauthor=J.+L.+Harousseauauthor=N.+Ifrah&title=Addition+of+gemtuzumab+ozogamycin+to+chemotherapy+improves+event-free+survival+but+not+overall+survival+of+AML+patients+with+intermediate+cytogenetics+not+eligible+for+allogeneic+transplantation.+Results+of+the+GOELAMS+AML+2006+IR+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDelaunay%26aufirst%3DJ.%26aulast%3DRecher%26aufirst%3DC.%26aulast%3DPigneux%26aufirst%3DA.%26aulast%3DWitz%26aufirst%3DF.%26aulast%3DVey%26aufirst%3DN.%26aulast%3DBlanchet%26aufirst%3DO.%26aulast%3DLefebvre%26aufirst%3DP.%26aulast%3DLuquet%26aufirst%3DI.%26aulast%3DGuillerme%26aufirst%3DI.%26aulast%3DVolteau%26aufirst%3DC.%26aulast%3DGyan%26aufirst%3DE.%26aulast%3DLioure%26aufirst%3DB.%26aulast%3DJourdan%26aufirst%3DE.%26aulast%3DBouscary%26aufirst%3DD.%26aulast%3DGuieze%26aufirst%3DR.%26aulast%3DRandriamalala%26aufirst%3DE.%26aulast%3DUribe%26aufirst%3DM.%2BE.%2BO.%26aulast%3DDreyfus%26aufirst%3DF.%26aulast%3DLacombe%26aufirst%3DC.%26aulast%3DBene%26aufirst%3DM.%2BC.%26aulast%3DCahn%26aufirst%3DJ.%2BY.%26aulast%3DHarousseau%26aufirst%3DJ.%2BL.%26aulast%3DIfrah%26aufirst%3DN.%26atitle%3DAddition%2520of%2520gemtuzumab%2520ozogamycin%2520to%2520chemotherapy%2520improves%2520event-free%2520survival%2520but%2520not%2520overall%2520survival%2520of%2520AML%2520patients%2520with%2520intermediate%2520cytogenetics%2520not%2520eligible%2520for%2520allogeneic%2520transplantation.%2520Results%2520of%2520the%2520GOELAMS%2520AML%25202006%2520IR%2520study%26jtitle%3DBlood%26date%3D2011%26volume%3D118%26spage%3D37%26epage%3D38" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Sutherland, M. S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffrey, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kostner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sussman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyon, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrington, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klussman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westendorf, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernstein, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benjamin, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drachman, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McEarchern, J. A.</span><span> </span><span class="NLM_article-title">SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">1455</span><span class="NLM_x">–</span> <span class="NLM_lpage">1463</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2013&pages=1455-1463&author=M.+S.+K.+Sutherlandauthor=R.+B.+Walterauthor=S.+C.+Jeffreyauthor=P.+J.+Burkeauthor=C.+P.+Yuauthor=H.+Kostnerauthor=I.+Stoneauthor=M.+C.+Ryanauthor=D.+Sussmanauthor=R.+P.+Lyonauthor=W.+P.+Zengauthor=K.+H.+Harringtonauthor=K.+Klussmanauthor=L.+Westendorfauthor=D.+Meyerauthor=I.+D.+Bernsteinauthor=P.+D.+Senterauthor=D.+R.+Benjaminauthor=J.+G.+Drachmanauthor=J.+A.+McEarchern&title=SGN-CD33A%3A+a+novel+CD33-targeting+antibody-drug+conjugate+using+a+pyrrolobenzodiazepine+dimer+is+active+in+models+of+drug-resistant+AML"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSutherland%26aufirst%3DM.%2BS.%2BK.%26aulast%3DWalter%26aufirst%3DR.%2BB.%26aulast%3DJeffrey%26aufirst%3DS.%2BC.%26aulast%3DBurke%26aufirst%3DP.%2BJ.%26aulast%3DYu%26aufirst%3DC.%2BP.%26aulast%3DKostner%26aufirst%3DH.%26aulast%3DStone%26aufirst%3DI.%26aulast%3DRyan%26aufirst%3DM.%2BC.%26aulast%3DSussman%26aufirst%3DD.%26aulast%3DLyon%26aufirst%3DR.%2BP.%26aulast%3DZeng%26aufirst%3DW.%2BP.%26aulast%3DHarrington%26aufirst%3DK.%2BH.%26aulast%3DKlussman%26aufirst%3DK.%26aulast%3DWestendorf%26aufirst%3DL.%26aulast%3DMeyer%26aufirst%3DD.%26aulast%3DBernstein%26aufirst%3DI.%2BD.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26aulast%3DBenjamin%26aufirst%3DD.%2BR.%26aulast%3DDrachman%26aufirst%3DJ.%2BG.%26aulast%3DMcEarchern%26aufirst%3DJ.%2BA.%26atitle%3DSGN-CD33A%253A%2520a%2520novel%2520CD33-targeting%2520antibody-drug%2520conjugate%2520using%2520a%2520pyrrolobenzodiazepine%2520dimer%2520is%2520active%2520in%2520models%2520of%2520drug-resistant%2520AML%26jtitle%3DBlood%26date%3D2013%26volume%3D122%26spage%3D1455%26epage%3D1463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Bander, N. H.</span><span> </span><span class="NLM_article-title">Antibody–drug conjugate target selection: critical factors</span>. In  <span class="citation_source-book">Methods in Molecular Biology: Antibody–Drug Conjugates</span>; <span class="NLM_contrib-group">Ducry, L.</span>, Ed.; <span class="NLM_publisher-name">Humana Press</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">1045</span>, pp  <span class="NLM_fpage">29</span><span class="NLM_x">–</span> <span class="NLM_lpage">40</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1007%2F978-1-62703-541-5_2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&pages=29-40&author=N.+H.+Banderauthor=L.+Ducry&title=Methods+in+Molecular+Biology%3A+Antibody%E2%80%93Drug+Conjugates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1007%2F978-1-62703-541-5_2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-62703-541-5_2%26sid%3Dliteratum%253Aachs%26aulast%3DBander%26aufirst%3DN.%2BH.%26atitle%3DAntibody%25E2%2580%2593drug%2520conjugate%2520target%2520selection%253A%2520critical%2520factors%26btitle%3DMethods%2520in%2520Molecular%2520Biology%253A%2520Antibody%25E2%2580%2593Drug%2520Conjugates%26aulast%3DDucry%26aufirst%3DL.%26pub%3DHumana%2520Press%26date%3D2013%26volume%3D1045%26spage%3D29%26epage%3D40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Tarli, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balza, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borsi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castellani, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berndorff, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinkelborg, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zardi, L.</span><span> </span><span class="NLM_article-title">A high-affinity human antibody that targets tumoral blood vessels</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">192</span><span class="NLM_x">–</span> <span class="NLM_lpage">198</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1999&pages=192-198&author=L.+Tarliauthor=E.+Balzaauthor=F.+Vitiauthor=L.+Borsiauthor=P.+Castellaniauthor=D.+Berndorffauthor=L.+Dinkelborgauthor=D.+Neriauthor=L.+Zardi&title=A+high-affinity+human+antibody+that+targets+tumoral+blood+vessels"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTarli%26aufirst%3DL.%26aulast%3DBalza%26aufirst%3DE.%26aulast%3DViti%26aufirst%3DF.%26aulast%3DBorsi%26aufirst%3DL.%26aulast%3DCastellani%26aufirst%3DP.%26aulast%3DBerndorff%26aufirst%3DD.%26aulast%3DDinkelborg%26aufirst%3DL.%26aulast%3DNeri%26aufirst%3DD.%26aulast%3DZardi%26aufirst%3DL.%26atitle%3DA%2520high-affinity%2520human%2520antibody%2520that%2520targets%2520tumoral%2520blood%2520vessels%26jtitle%3DBlood%26date%3D1999%26volume%3D94%26spage%3D192%26epage%3D198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Viti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarli, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giovannoni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zardi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, D.</span><span> </span><span class="NLM_article-title">Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">347</span><span class="NLM_x">–</span> <span class="NLM_lpage">352</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1999&pages=347-352&author=F.+Vitiauthor=L.+Tarliauthor=L.+Giovannoniauthor=L.+Zardiauthor=D.+Neri&title=Increased+binding+affinity+and+valence+of+recombinant+antibody+fragments+lead+to+improved+targeting+of+tumoral+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DViti%26aufirst%3DF.%26aulast%3DTarli%26aufirst%3DL.%26aulast%3DGiovannoni%26aufirst%3DL.%26aulast%3DZardi%26aufirst%3DL.%26aulast%3DNeri%26aufirst%3DD.%26atitle%3DIncreased%2520binding%2520affinity%2520and%2520valence%2520of%2520recombinant%2520antibody%2520fragments%2520lead%2520to%2520improved%2520targeting%2520of%2520tumoral%2520angiogenesis%26jtitle%3DCancer%2520Res.%26date%3D1999%26volume%3D59%26spage%3D347%26epage%3D352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Pini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santucci, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carnemolla, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zardi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, D.</span><span> </span><span class="NLM_article-title">Design and use of a phage display library—Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">273</span><span class="NLM_x">, </span> <span class="NLM_fpage">21769</span><span class="NLM_x">–</span> <span class="NLM_lpage">21776</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1998&pages=21769-21776&author=A.+Piniauthor=F.+Vitiauthor=A.+Santucciauthor=B.+Carnemollaauthor=L.+Zardiauthor=P.+Neriauthor=D.+Neri&title=Design+and+use+of+a+phage+display+library%E2%80%94Human+antibodies+with+subnanomolar+affinity+against+a+marker+of+angiogenesis+eluted+from+a+two-dimensional+gel"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPini%26aufirst%3DA.%26aulast%3DViti%26aufirst%3DF.%26aulast%3DSantucci%26aufirst%3DA.%26aulast%3DCarnemolla%26aufirst%3DB.%26aulast%3DZardi%26aufirst%3DL.%26aulast%3DNeri%26aufirst%3DP.%26aulast%3DNeri%26aufirst%3DD.%26atitle%3DDesign%2520and%2520use%2520of%2520a%2520phage%2520display%2520library%25E2%2580%2594Human%2520antibodies%2520with%2520subnanomolar%2520affinity%2520against%2520a%2520marker%2520of%2520angiogenesis%2520eluted%2520from%2520a%2520two-dimensional%2520gel%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1998%26volume%3D273%26spage%3D21769%26epage%3D21776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Villa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trachsel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaspar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schliemann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sommavilla, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rybak, J.-N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rösli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borsi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, D.</span><span> </span><span class="NLM_article-title">A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">2405</span><span class="NLM_x">–</span> <span class="NLM_lpage">2413</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1002%2Fijc.23408" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=18271006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltlaitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2008&pages=2405-2413&author=A.+Villaauthor=E.+Trachselauthor=M.+Kasparauthor=C.+Schliemannauthor=R.+Sommavillaauthor=J.-N.+Rybakauthor=C.+R%C3%B6sliauthor=L.+Borsiauthor=D.+Neri&title=A+high-affinity+human+monoclonal+antibody+specific+to+the+alternatively+spliced+EDA+domain+of+fibronectin+efficiently+targets+tumor+neo-vasculature+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo</span></div><div class="casAuthors">Villa, Alessandra; Trachsel, Eveline; Kaspar, Manuela; Schliemann, Christoph; Sommavilla, Roberto; Rybak, Jascha-N.; Rosli, Christoph; Borsi, Laura; Neri, Dario</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2405-2413</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The alternatively spliced extra-domain B of fibronectin is one of the best characterized markers of tumor angiogenesis.  Similarly, the extra-domain A (EDA), which can also be inserted in the fibronectin transcript by a mechanism of alternative splicing, has been shown to preferentially accumulate around new blood vessels in certain tumors, but this antigen has not been investigated so far as a target for antibody-based biomol. intervention.  We here describe the generation of 3 human monoclonal antibodies (named F8, B7 and D5), which recognize the same epitope of EDA, but which differ in terms of their dissocn. const. to the human antigen (KD = 3.1, 16 and 17 nM, measured for monomeric prepns. of the F8, B7 and D5 antibodies, resp., in recombinant scFv format).  When the 3 antibody fragments were cloned and expressed with a 5 amino acid linker, the 3 resulting homodimeric antibody prepns. displayed comparable tumor: organ ratios in quant. biodistribution studies, performed in immunocompetent 129SvEv mice, bearing s.c. syngeneic F9 murine tumors.  The percent injected dose per g (%ID/g) values in tumors 24 h after i.v. injection were 9.3, 10.2 and 13 for F8, B7 and D5, resp.  The F8 antibody may serve as useful building block for the development of antibody-based targeted anti-cancer therapeutics.  Preclin. and clin. investigations are facilitated by the fact that F8 recognizes the human and mouse antigen with comparable affinity, and by the observation that EDA over-expression is detectable not only in solid tumors, but also in hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCDNzvnkQ667Vg90H21EOLACvtfcHk0lgFX6VgeSJK3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltlaitbs%253D&md5=0e5b83f216d9f14026542d56f9c47697</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1002%2Fijc.23408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.23408%26sid%3Dliteratum%253Aachs%26aulast%3DVilla%26aufirst%3DA.%26aulast%3DTrachsel%26aufirst%3DE.%26aulast%3DKaspar%26aufirst%3DM.%26aulast%3DSchliemann%26aufirst%3DC.%26aulast%3DSommavilla%26aufirst%3DR.%26aulast%3DRybak%26aufirst%3DJ.-N.%26aulast%3DR%25C3%25B6sli%26aufirst%3DC.%26aulast%3DBorsi%26aufirst%3DL.%26aulast%3DNeri%26aufirst%3DD.%26atitle%3DA%2520high-affinity%2520human%2520monoclonal%2520antibody%2520specific%2520to%2520the%2520alternatively%2520spliced%2520EDA%2520domain%2520of%2520fibronectin%2520efficiently%2520targets%2520tumor%2520neo-vasculature%2520in%2520vivo%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2008%26volume%3D122%26spage%3D2405%26epage%3D2413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Neri, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bicknell, R.</span><span> </span><span class="NLM_article-title">Tumour vascular targeting</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">436</span><span class="NLM_x">–</span> <span class="NLM_lpage">446</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1038%2Fnrc1627" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=15928674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1Gmsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=436-446&author=D.+Neriauthor=R.+Bicknell&title=Tumour+vascular+targeting"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor vascular targeting</span></div><div class="casAuthors">Neri, Dario; Bicknell, Roy</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">436-446</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  It is now accepted that the growth of solid tumors is dependent on their capacity to acquire a blood supply, and much effort has been directed towards the development of agents (known as anti-angiogenics) that disrupt this process.  More recently, it has become apparent that targeted destruction of the established tumor vasculature is another avenue for exciting therapeutic opportunities.  In this article, we present evidence that vascular targeting is an effective antitumor strategy in animal models, describe strategies for identifying putative tumor vascular targets and discuss future prospects for vascular targeting in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHDz-gycOPj7Vg90H21EOLACvtfcHk0lgZG0_iW61d1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1Gmsrw%253D&md5=42e0398a709c0158a4dee3437b2b765e</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Fnrc1627&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1627%26sid%3Dliteratum%253Aachs%26aulast%3DNeri%26aufirst%3DD.%26aulast%3DBicknell%26aufirst%3DR.%26atitle%3DTumour%2520vascular%2520targeting%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D436%26epage%3D446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Perrino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steiner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krall, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernardes, G. J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pretto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, D.</span><span> </span><span class="NLM_article-title">Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">2569</span><span class="NLM_x">–</span> <span class="NLM_lpage">2578</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=2569-2578&author=E.+Perrinoauthor=M.+Steinerauthor=N.+Krallauthor=G.+J.+L.+Bernardesauthor=F.+Prettoauthor=G.+Casiauthor=D.+Neri&title=Curative+properties+of+noninternalizing+antibody-drug+conjugates+based+on+maytansinoids"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPerrino%26aufirst%3DE.%26aulast%3DSteiner%26aufirst%3DM.%26aulast%3DKrall%26aufirst%3DN.%26aulast%3DBernardes%26aufirst%3DG.%2BJ.%2BL.%26aulast%3DPretto%26aufirst%3DF.%26aulast%3DCasi%26aufirst%3DG.%26aulast%3DNeri%26aufirst%3DD.%26atitle%3DCurative%2520properties%2520of%2520noninternalizing%2520antibody-drug%2520conjugates%2520based%2520on%2520maytansinoids%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D2569%26epage%3D2578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Bernardes, G. J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trüssel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwager, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheuermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, D.</span><span> </span><span class="NLM_article-title">A traceless vascular-targeting antibody-drug conjugate for cancer therapy</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">941</span><span class="NLM_x">–</span> <span class="NLM_lpage">944</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=941-944&author=G.+J.+L.+Bernardesauthor=G.+Casiauthor=I.+Hartmannauthor=S.+Tr%C3%BCsselauthor=K.+Schwagerauthor=J.+Scheuermannauthor=D.+Neri&title=A+traceless+vascular-targeting+antibody-drug+conjugate+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBernardes%26aufirst%3DG.%2BJ.%2BL.%26aulast%3DCasi%26aufirst%3DG.%26aulast%3DHartmann%26aufirst%3DI.%26aulast%3DTr%25C3%25BCssel%26aufirst%3DS.%26aulast%3DSchwager%26aufirst%3DK.%26aulast%3DScheuermann%26aufirst%3DJ.%26aulast%3DNeri%26aufirst%3DD.%26atitle%3DA%2520traceless%2520vascular-targeting%2520antibody-drug%2520conjugate%2520for%2520cancer%2520therapy%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2012%26volume%3D51%26spage%3D941%26epage%3D944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Krall, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pretto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decurtins, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernardes, G. J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Supuran, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, D.</span><span> </span><span class="NLM_article-title">A small-molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">4231</span><span class="NLM_x">–</span> <span class="NLM_lpage">4235</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1002%2Fanie.201310709" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=24623670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkt1Slu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=4231-4235&author=N.+Krallauthor=F.+Prettoauthor=W.+Decurtinsauthor=G.+J.+L.+Bernardesauthor=C.+T.+Supuranauthor=D.+Neri&title=A+small-molecule+drug+conjugate+for+the+treatment+of+carbonic+anhydrase+IX+expressing+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">A small-molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors</span></div><div class="casAuthors">Krall, Nikolaus; Pretto, Francesca; Decurtins, Willy; Bernardes, Goncalo J. L.; Supuran, Claudiu T.; Neri, Dario</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4231-4235</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Antibody-drug conjugates are a very promising class of new anticancer agents, but the use of small-mol. ligands for the targeted delivery of cytotoxic drugs into solid tumors is less well established.  Here, we describe the first small-mol. drug conjugates for the treatment of carbonic anhydrase IX expressing solid tumors.  Using ligand-dye conjugates we demonstrate that such mols. can preferentially accumulate inside antigen-pos. lesions, have fast targeting kinetics and good tumor-penetrating properties, and are easily accessible by total synthesis.  A disulfide-linked drug conjugate with the maytansinoid DM1 as the cytotoxic payload and a deriv. of acetazolamide as the targeting ligand exhibited a potent antitumor effect in SKRC52 renal cell carcinoma in vivo.  It was furthermore superior to sunitinib and sorafenib, both small-mol. std.-of-care drugs for the treatment of kidney cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAXXWLN4ez_LVg90H21EOLACvtfcHk0lgZG0_iW61d1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkt1Slu7s%253D&md5=77086a5a6f22815497b62470a7a09c6d</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1002%2Fanie.201310709&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201310709%26sid%3Dliteratum%253Aachs%26aulast%3DKrall%26aufirst%3DN.%26aulast%3DPretto%26aufirst%3DF.%26aulast%3DDecurtins%26aufirst%3DW.%26aulast%3DBernardes%26aufirst%3DG.%2BJ.%2BL.%26aulast%3DSupuran%26aufirst%3DC.%2BT.%26aulast%3DNeri%26aufirst%3DD.%26atitle%3DA%2520small-molecule%2520drug%2520conjugate%2520for%2520the%2520treatment%2520of%2520carbonic%2520anhydrase%2520IX%2520expressing%2520tumors%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D4231%26epage%3D4235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Rothberg, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wojtkowiak, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ben-Nun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bogyo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blum, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattingly, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillies, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sloane, B. F.</span><span> </span><span class="NLM_article-title">Acid-mediated tumor proteolysis: Contribution of cysteine cathepsins</span> <span class="citation_source-journal">Neoplasia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1111</span><span class="NLM_x">–</span> <span class="NLM_lpage">1123</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=1111-1123&author=J.+M.+Rothbergauthor=K.+M.+Baileyauthor=J.+W.+Wojtkowiakauthor=Y.+Ben-Nunauthor=M.+Bogyoauthor=E.+Weberauthor=K.+Moinauthor=G.+Blumauthor=R.+R.+Mattinglyauthor=R.+J.+Gilliesauthor=B.+F.+Sloane&title=Acid-mediated+tumor+proteolysis%3A+Contribution+of+cysteine+cathepsins"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRothberg%26aufirst%3DJ.%2BM.%26aulast%3DBailey%26aufirst%3DK.%2BM.%26aulast%3DWojtkowiak%26aufirst%3DJ.%2BW.%26aulast%3DBen-Nun%26aufirst%3DY.%26aulast%3DBogyo%26aufirst%3DM.%26aulast%3DWeber%26aufirst%3DE.%26aulast%3DMoin%26aufirst%3DK.%26aulast%3DBlum%26aufirst%3DG.%26aulast%3DMattingly%26aufirst%3DR.%2BR.%26aulast%3DGillies%26aufirst%3DR.%2BJ.%26aulast%3DSloane%26aufirst%3DB.%2BF.%26atitle%3DAcid-mediated%2520tumor%2520proteolysis%253A%2520Contribution%2520of%2520cysteine%2520cathepsins%26jtitle%3DNeoplasia%26date%3D2013%26volume%3D15%26spage%3D1111%26epage%3D1123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Fuhrmann, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauthier, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leroux, J. C.</span><span> </span><span class="NLM_article-title">Targeting of injectable drug nanocrystals</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1762</span><span class="NLM_x">–</span> <span class="NLM_lpage">1771</span></span><div class="citationLinks">[<a href="/doi/10.1021/mp5001247" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmvF2nu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=1762-1771&author=K.+Fuhrmannauthor=M.+A.+Gauthierauthor=J.+C.+Leroux&title=Targeting+of+injectable+drug+nanocrystals"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting of Injectable Drug Nanocrystals</span></div><div class="casAuthors">Fuhrmann, Kathrin; Gauthier, Marc A.; Leroux, Jean-Christophe</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1762-1771</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  "Nano" drug delivery carriers are established technologies for improving the therapeutic index of chemotherapeutic drugs and overcoming formulation challenges of poorly water-sol. compds.  Two important remaining challenges, however, are the need to formulate drugs on a case-by-case basis (due to the specific chem. of each drug) and the difficulty assocd. with transporting large amts. of drug specifically to the site of the tumor (in part because of moderate to poor drug loadings).  One of the most valuable "nano" opportunities in this field is to address these challenges by creating nanocarriers composed of the drug itself, in the form of so-called nanocrystals.  However, "nano" creates both opportunities and challenges for targeted drug delivery, which are critically discussed in both in vitro and in vivo settings in this contribution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmwlOcCH7PX7Vg90H21EOLACvtfcHk0lj1p-oab-7vVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmvF2nu7s%253D&md5=88322a39eada4523e770667fd8a50c40</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Fmp5001247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp5001247%26sid%3Dliteratum%253Aachs%26aulast%3DFuhrmann%26aufirst%3DK.%26aulast%3DGauthier%26aufirst%3DM.%2BA.%26aulast%3DLeroux%26aufirst%3DJ.%2BC.%26atitle%3DTargeting%2520of%2520injectable%2520drug%2520nanocrystals%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2014%26volume%3D11%26spage%3D1762%26epage%3D1771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Winter, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoogenboom, H. R.</span><span> </span><span class="NLM_article-title">Making antibodies by phage display technology</span> <span class="citation_source-journal">Annu. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">433</span><span class="NLM_x">–</span> <span class="NLM_lpage">455</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1146%2Fannurev.iy.12.040194.002245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=8011287" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADyaK2cXivFKju7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1994&pages=433-455&author=G.+Winterauthor=A.+D.+Griffithsauthor=R.+E.+Hawkinsauthor=H.+R.+Hoogenboom&title=Making+antibodies+by+phage+display+technology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Making antibodies by phage display technology</span></div><div class="casAuthors">Winter, Greg; Griffiths, Andrew D.; Hawkins, Robert E.; Hoogenboom, Hennie R.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Immunology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">433-55</span>CODEN:
                <span class="NLM_cas:coden">ARIMDU</span>;
        ISSN:<span class="NLM_cas:issn">0732-0582</span>.
    </div><div class="casAbstract">Antibody fragments of predetd. binding specificity have recently been constructed from repertoires of antibody V genes, bypassing hybridoma technol. and even immunization.  The V gene repertoires are harvested from populations of lymphocytes, or assembled in vitro, and cloned for display of assocd. heavy and light chain variable domains on the surface of filamentous bacteriophage.  Rare phage are selected from the repertoire by binding to antigen; sol. antibody fragments are expressed from infected bacteria; and the affinity of binding of selected antibodies is improved by mutation.  The process mimics immune selection, and antibodies with many different binding specificities have been isolated from the same phage repertoire.  Thus, human antibody fragments have been isolated with specificities against both foreign and self antigens, including haptens, carbohydrates, secreted and cell surface proteins, viral coat proteins, and intracellular antigens from the lumen of the endoplasmic reticulum and the nucleus.  Such antibodies have potential as reagents for research and in therapy.  A review with 112 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocC4KWhSvU6bVg90H21EOLACvtfcHk0lj1p-oab-7vVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXivFKju7g%253D&md5=5fa4f90f05fac0b475cee59772fcd992</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1146%2Fannurev.iy.12.040194.002245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.iy.12.040194.002245%26sid%3Dliteratum%253Aachs%26aulast%3DWinter%26aufirst%3DG.%26aulast%3DGriffiths%26aufirst%3DA.%2BD.%26aulast%3DHawkins%26aufirst%3DR.%2BE.%26aulast%3DHoogenboom%26aufirst%3DH.%2BR.%26atitle%3DMaking%2520antibodies%2520by%2520phage%2520display%2520technology%26jtitle%3DAnnu.%2520Rev.%2520Immunol.%26date%3D1994%26volume%3D12%26spage%3D433%26epage%3D455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Srinivasarao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galliford, C. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Low, P. S.</span><span> </span><span class="NLM_article-title">Principles in the design of ligand-targeted cancer therapeutics and imaging agents</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">203</span><span class="NLM_x">–</span> <span class="NLM_lpage">219</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1038%2Fnrd4519" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=25698644" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtVylsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=203-219&author=M.+Srinivasaraoauthor=C.+V.+Gallifordauthor=P.+S.+Low&title=Principles+in+the+design+of+ligand-targeted+cancer+therapeutics+and+imaging+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Principles in the design of ligand-targeted cancer therapeutics and imaging agents</span></div><div class="casAuthors">Srinivasarao, Madduri; Galliford, Chris V.; Low, Philip S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">203-219</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Most cancer drugs are designed to interfere with one or more events in cell proliferation or survival.  As healthy cells may also need to proliferate and avoid apoptosis, anticancer agents can be toxic to such cells.  To minimize these toxicities, strategies have been developed wherein the therapeutic agent is targeted to tumor cells through conjugation to a tumor-cell-specific small-mol. ligand, thereby reducing delivery to normal cells and the assocd. collateral toxicity.  This Review describes the major principles in the design of ligand-targeted drugs and provides an overview of ligand-drug conjugates and ligand-imaging-agent conjugates that are currently in development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSVpXZcVlh_bVg90H21EOLACvtfcHk0lj1p-oab-7vVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtVylsb4%253D&md5=71e2e7ad51f7f55415ccddb9ed1ea3db</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1038%2Fnrd4519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4519%26sid%3Dliteratum%253Aachs%26aulast%3DSrinivasarao%26aufirst%3DM.%26aulast%3DGalliford%26aufirst%3DC.%2BV.%26aulast%3DLow%26aufirst%3DP.%2BS.%26atitle%3DPrinciples%2520in%2520the%2520design%2520of%2520ligand-targeted%2520cancer%2520therapeutics%2520and%2520imaging%2520agents%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D203%26epage%3D219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Low, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henne, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doorneweerd, D. D.</span><span> </span><span class="NLM_article-title">Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases</span> <span class="citation_source-journal">Acc. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">120</span><span class="NLM_x">–</span> <span class="NLM_lpage">129</span></span><div class="citationLinks">[<a href="/doi/10.1021/ar7000815" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BD2sXot1Gltbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2008&pages=120-129&author=P.+S.+Lowauthor=W.+A.+Henneauthor=D.+D.+Doorneweerd&title=Discovery+and+development+of+folic-acid-based+receptor+targeting+for+imaging+and+therapy+of+cancer+and+inflammatory+diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Folic-Acid-Based Receptor Targeting for Imaging and Therapy of Cancer and Inflammatory Diseases</span></div><div class="casAuthors">Low, Philip S.; Henne, Walter A.; Doorneweerd, Derek D.</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">120-129</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The field of folic-acid-targeted drug delivery has grown rapidly over the past decade, with several applications currently in human clin. trials.  Owing to the small size of the vitamin, its high affinity for the folate receptor (Kd = 10-10 M), the limited distribution of its receptor in normal tissues (primarily in kidney proximal tubules), the overexpression of its receptor in pathol. cells (upregulated in cancer cells and activated macrophages/monocytes), and its ease of conjugation to imaging and therapeutic agents, the use of folate as a targeting ligand for selective delivery of attached mols. to tumor tissues and sites of inflammation has attracted considerable interest.  This account reviews the discovery of folic acid as a targeting ligand and its current use in the selective targeting of drugs to malignant masses and sites of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpM5t9sRmCOBbVg90H21EOLACvtfcHk0lj1p-oab-7vVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXot1Gltbk%253D&md5=20620eb124d19634b10c27a48ed46849</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Far7000815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far7000815%26sid%3Dliteratum%253Aachs%26aulast%3DLow%26aufirst%3DP.%2BS.%26aulast%3DHenne%26aufirst%3DW.%2BA.%26aulast%3DDoorneweerd%26aufirst%3DD.%2BD.%26atitle%3DDiscovery%2520and%2520development%2520of%2520folic-acid-based%2520receptor%2520targeting%2520for%2520imaging%2520and%2520therapy%2520of%2520cancer%2520and%2520inflammatory%2520diseases%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2008%26volume%3D41%26spage%3D120%26epage%3D129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Hillier, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maresca, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Femia, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marquis, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foss, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmerman, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckelman, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pomper, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joyal, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babich, J. W.</span><span> </span><span class="NLM_article-title">Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">6932</span><span class="NLM_x">–</span> <span class="NLM_lpage">6940</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1158%2F0008-5472.CAN-09-1682" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=19706750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVOmtLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=6932-6940&author=S.+M.+Hillierauthor=K.+P.+Marescaauthor=F.+J.+Femiaauthor=J.+C.+Marquisauthor=C.+A.+Fossauthor=N.+Nguyenauthor=C.+N.+Zimmermanauthor=J.+A.+Barrettauthor=W.+C.+Eckelmanauthor=M.+G.+Pomperauthor=J.+L.+Joyalauthor=J.+W.+Babich&title=Preclinical+evaluation+of+novel+glutamate-urea-lysine+analogues+that+target+prostate-specific+membrane+antigen+as+molecular+imaging+pharmaceuticals+for+prostate+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical Evaluation of Novel Glutamate-Urea-Lysine Analogues That Target Prostate-Specific Membrane Antigen as Molecular Imaging Pharmaceuticals for Prostate Cancer</span></div><div class="casAuthors">Hillier, Shawn M.; Maresca, Kevin P.; Femia, Frank J.; Marquis, John C.; Foss, Catherine A.; Nguyen, Nghi; Zimmerman, Craig N.; Barrett, John A.; Eckelman, William C.; Pomper, Martin G.; Joyal, John L.; Babich, John W.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6932-6940</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Prostate-specific membrane antigen (PSMA) is expressed in normal human prostate epithelium and is highly up-regulated in prostate cancer.  We previously reported a series of novel small mol. inhibitors targeting PSMA.  Two compds., MIP-1072, (S)-2-(3-((S)-1-carboxy-5-(4-iodobenzylamino)pentyl)ureido)pentanedioic acid, and MIP-1095, (S)-2-(3-((S)-1-carboxy-5-(3-(4-iodophenyl)ureido)pentyl)ureido)pentanedioic acid, were selected for further evaluation.  MIP-1072 and MIP-1095 potently inhibited the glutamate carboxypeptidase activity of PSMA (Ki = 4.6 ± 1.6 nM and 0.24 ± 0.14 nM, resp.) and, when radiolabeled with 123I, exhibited high affinity for PSMA on human prostate cancer LNCaP cells (Kd = 3.8 ± 1.3 nM and 0.81 ± 0.39 nM, resp.).  The assocn. of [123I]MIP-1072 and [123I]MIP-1095 with PSMA was specific; there was no binding to human prostate cancer PC3 cells, which lack PSMA, and binding was abolished by coincubation with a structurally unrelated NAALADase inhibitor, 2-(phosphonomethyl)pentanedioic acid (PMPA).  [123I]MIP-1072 and [123I]MIP-1095 internalized into LNCaP cells at 37°C.  Tissue distribution studies in mice showed 17.3 ± 6.3% (at 1 h) and 34.3 ± 12.7% (at 4 h) injected dose per g of LNCaP xenograft tissue, for [123I]MIP-1072 and [123I]MIP-1095, resp.  [123I]MIP-1095 exhibited greater tumor uptake but slower washout from blood and nontarget tissues compared with [123I]MIP-1072.  Specific binding to PSMA in vivo was shown by competition with PMPA in LNCaP xenografts, and the absence of uptake in PC3 xenografts.  The uptake of [123I]MIP-1072 and [123I]MIP-1095 in tumor-bearing mice was corroborated by single-photon emission computed tomog./computed tomog. (SPECT/CT) imaging.  PSMA-specific radiopharmaceuticals should provide a novel mol. targeting option for the detection and staging of prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmETFDEvmsZLVg90H21EOLACvtfcHk0ljgGVcrisAe6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVOmtLzE&md5=f222208c3c3fbcaa376306c49c9ec80b</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-1682&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-1682%26sid%3Dliteratum%253Aachs%26aulast%3DHillier%26aufirst%3DS.%2BM.%26aulast%3DMaresca%26aufirst%3DK.%2BP.%26aulast%3DFemia%26aufirst%3DF.%2BJ.%26aulast%3DMarquis%26aufirst%3DJ.%2BC.%26aulast%3DFoss%26aufirst%3DC.%2BA.%26aulast%3DNguyen%26aufirst%3DN.%26aulast%3DZimmerman%26aufirst%3DC.%2BN.%26aulast%3DBarrett%26aufirst%3DJ.%2BA.%26aulast%3DEckelman%26aufirst%3DW.%2BC.%26aulast%3DPomper%26aufirst%3DM.%2BG.%26aulast%3DJoyal%26aufirst%3DJ.%2BL.%26aulast%3DBabich%26aufirst%3DJ.%2BW.%26atitle%3DPreclinical%2520evaluation%2520of%2520novel%2520glutamate-urea-lysine%2520analogues%2520that%2520target%2520prostate-specific%2520membrane%2520antigen%2520as%2520molecular%2520imaging%2520pharmaceuticals%2520for%2520prostate%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D6932%26epage%3D6940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Vallabhajosula, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nikolopoulou, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babich, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborne, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tagawa, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipai, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solnes, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maresca, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armor, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joyal, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crummet, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stubbs, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, S. J.</span><span> </span><span class="NLM_article-title">Tc-99m-labeled small-molecule inhibitors of prostate-specific membrane antigen: Pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1791</span><span class="NLM_x">–</span> <span class="NLM_lpage">1798</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2014&pages=1791-1798&author=S.+Vallabhajosulaauthor=A.+Nikolopoulouauthor=J.+W.+Babichauthor=J.+R.+Osborneauthor=S.+T.+Tagawaauthor=I.+Lipaiauthor=L.+Solnesauthor=K.+P.+Marescaauthor=T.+Armorauthor=J.+L.+Joyalauthor=R.+Crummetauthor=J.+B.+Stubbsauthor=S.+J.+Goldsmith&title=Tc-99m-labeled+small-molecule+inhibitors+of+prostate-specific+membrane+antigen%3A+Pharmacokinetics+and+biodistribution+studies+in+healthy+subjects+and+patients+with+metastatic+prostate+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVallabhajosula%26aufirst%3DS.%26aulast%3DNikolopoulou%26aufirst%3DA.%26aulast%3DBabich%26aufirst%3DJ.%2BW.%26aulast%3DOsborne%26aufirst%3DJ.%2BR.%26aulast%3DTagawa%26aufirst%3DS.%2BT.%26aulast%3DLipai%26aufirst%3DI.%26aulast%3DSolnes%26aufirst%3DL.%26aulast%3DMaresca%26aufirst%3DK.%2BP.%26aulast%3DArmor%26aufirst%3DT.%26aulast%3DJoyal%26aufirst%3DJ.%2BL.%26aulast%3DCrummet%26aufirst%3DR.%26aulast%3DStubbs%26aufirst%3DJ.%2BB.%26aulast%3DGoldsmith%26aufirst%3DS.%2BJ.%26atitle%3DTc-99m-labeled%2520small-molecule%2520inhibitors%2520of%2520prostate-specific%2520membrane%2520antigen%253A%2520Pharmacokinetics%2520and%2520biodistribution%2520studies%2520in%2520healthy%2520subjects%2520and%2520patients%2520with%2520metastatic%2520prostate%2520cancer%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2014%26volume%3D55%26spage%3D1791%26epage%3D1798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">Hillier, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maresca, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merkin, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marquis, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmerman, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckelman, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joyal, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babich, J. W.</span><span> </span><span class="NLM_article-title">Tc-99m-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1369</span><span class="NLM_x">–</span> <span class="NLM_lpage">1376</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2013&pages=1369-1376&author=S.+M.+Hillierauthor=K.+P.+Marescaauthor=G.+Luauthor=R.+D.+Merkinauthor=J.+C.+Marquisauthor=C.+N.+Zimmermanauthor=W.+C.+Eckelmanauthor=J.+L.+Joyalauthor=J.+W.+Babich&title=Tc-99m-labeled+small-molecule+inhibitors+of+prostate-specific+membrane+antigen+for+molecular+imaging+of+prostate+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHillier%26aufirst%3DS.%2BM.%26aulast%3DMaresca%26aufirst%3DK.%2BP.%26aulast%3DLu%26aufirst%3DG.%26aulast%3DMerkin%26aufirst%3DR.%2BD.%26aulast%3DMarquis%26aufirst%3DJ.%2BC.%26aulast%3DZimmerman%26aufirst%3DC.%2BN.%26aulast%3DEckelman%26aufirst%3DW.%2BC.%26aulast%3DJoyal%26aufirst%3DJ.%2BL.%26aulast%3DBabich%26aufirst%3DJ.%2BW.%26atitle%3DTc-99m-labeled%2520small-molecule%2520inhibitors%2520of%2520prostate-specific%2520membrane%2520antigen%2520for%2520molecular%2520imaging%2520of%2520prostate%2520cancer%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2013%26volume%3D54%26spage%3D1369%26epage%3D1376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Ginj, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waser, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cescato, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wild, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erchegyi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivier, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maecke, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reubi, J. C.</span><span> </span><span class="NLM_article-title">Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">16436</span><span class="NLM_x">–</span> <span class="NLM_lpage">16441</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1073%2Fpnas.0607761103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=17056720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1WmsLjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=16436-16441&author=M.+Ginjauthor=H.+Zhangauthor=B.+Waserauthor=R.+Cescatoauthor=D.+Wildauthor=X.+Wangauthor=J.+Erchegyiauthor=J.+Rivierauthor=H.+R.+Maeckeauthor=J.+C.+Reubi&title=Radiolabeled+somatostatin+receptor+antagonists+are+preferable+to+agonists+for+in+vivo+peptide+receptor+targeting+of+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors</span></div><div class="casAuthors">Ginj, Mihaela; Zhang, Hanwen; Waser, Beatrice; Cescato, Renzo; Wild, Damian; Wang, Xuejuan; Erchegyi, Judit; Rivier, Jean; Macke, Helmut R.; Reubi, Jean Claude</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">16436-16441</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Targeting neuroendocrine tumors expressing somatostatin receptor subtypes (sst) with radiolabeled somatostatin agonists is an established diagnostic and therapeutic approach in oncol.  While agonists readily internalize into tumor cells, permitting accumulation of radioactivity, radiolabeled antagonists do not, and they have not been considered for tumor targeting.  The macrocyclic chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) was coupled to two potent somatostatin receptor-selective peptide antagonists [NH2-CO-c(DCys-Phe-Tyr-DAgl8(Me,2-naphthoyl)-Lys-Thr-Phe-Cys)-OH (sst3-ODN-8) and a sst2-selective antagonist (sst2-ANT)], for labeling with 111/natIn.  111Ln-DOTA-sst3-ODN-8 and 111/natIn-DOTA-[4-NO2-Phe-c(DCys-Tyr-DTrp-Lys-Thr-Cys)-DTyr-NH2] (111/natIn-DOTA-sst2-ANT) showed high sst3- and sst2-binding affinity, resp.  They did not trigger sst3 or sst2 internalization but prevented agonist-stimulated internalization.  111In-DOTA-sst3-ODN-8 and 111In-DOTA-sst2-ANT were injected i.v. into mice bearing sst3- and sst2-expressing tumors, and their biodistribution was monitored.  In the sst3-expressing tumors, strong accumulation of 111In-DOTA-sst3-ODN-8 was obsd., peaking at 1 h with 60% injected radioactivity per g of tissue and remaining at a high level for >72 h.  Excess of sst3-ODN-8 blocked uptake.  As a control, the potent agonist 111In-DOTA-[1-Nal3]-octreotide, with strong sst3-binding and internalization properties showed a much lower and shorter-lasting uptake in sst3-expressing tumors.  Similarly, 111In-DOTA-sst2-ANT was injected into mice bearing sst2-expressing tumors.  Tumor uptake was considerably higher than with the highly potent sst2-selective agonist 111In-diethylenetriaminepentaacetic acid-[Tyr3,Thr8]-octreotide (111In-DTPA-TATE).  Scatchard plots showed that antagonists labeled many more sites than agonists.  Somatostatin antagonist radiotracers therefore are preferable over agonists for the in vivo targeting of sst3- or sst2-expressing tumors.  Antagonist radioligands for other peptide receptors need to be evaluated in nuclear oncol. as a result of this paradigm shift.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQVLwhowXQV7Vg90H21EOLACvtfcHk0ljgGVcrisAe6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1WmsLjJ&md5=7cc5c4608ed7591a096b9514863bbdea</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0607761103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0607761103%26sid%3Dliteratum%253Aachs%26aulast%3DGinj%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWaser%26aufirst%3DB.%26aulast%3DCescato%26aufirst%3DR.%26aulast%3DWild%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DErchegyi%26aufirst%3DJ.%26aulast%3DRivier%26aufirst%3DJ.%26aulast%3DMaecke%26aufirst%3DH.%2BR.%26aulast%3DReubi%26aufirst%3DJ.%2BC.%26atitle%3DRadiolabeled%2520somatostatin%2520receptor%2520antagonists%2520are%2520preferable%2520to%2520agonists%2520for%2520in%2520vivo%2520peptide%2520receptor%2520targeting%2520of%2520tumors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2006%26volume%3D103%26spage%3D16436%26epage%3D16441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group">Neri, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Supuran, C. T.</span><span> </span><span class="NLM_article-title">Interfering with pH regulation in tumours as a therapeutic strategy</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">767</span><span class="NLM_x">–</span> <span class="NLM_lpage">777</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1038%2Fnrd3554" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=21921921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFOlsL7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=767-777&author=D.+Neriauthor=C.+T.+Supuran&title=Interfering+with+pH+regulation+in+tumours+as+a+therapeutic+strategy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Interfering with pH regulation in tumours as a therapeutic strategy</span></div><div class="casAuthors">Neri, Dario; Supuran, Claudiu T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">767-777</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The high metabolic rate of tumors often leads to acidosis and hypoxia in poorly perfused regions.  Tumor cells have thus evolved the ability to function in a more acidic environment than normal cells.  Key pH regulators in tumor cells include: isoforms 2, 9 and 12 of carbonic anhydrase, isoforms of anion exchangers, Na+/HCO3- co-transporters, Na+/H+ exchangers, monocarboxylate transporters and the vacuolar ATPase.  Both small mols. and antibodies targeting these pH regulators are currently at various stages of clin. development.  These antitumor mechanisms are not exploited by the classical cancer drugs and therefore represent a new anticancer drug discovery strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrl7enRfSHzprVg90H21EOLACvtfcHk0ljg0O2yFjmqpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFOlsL7L&md5=7a1e1b7badcf7d2e26bd70da2bfe0925</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1038%2Fnrd3554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3554%26sid%3Dliteratum%253Aachs%26aulast%3DNeri%26aufirst%3DD.%26aulast%3DSupuran%26aufirst%3DC.%2BT.%26atitle%3DInterfering%2520with%2520pH%2520regulation%2520in%2520tumours%2520as%2520a%2520therapeutic%2520strategy%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D767%26epage%3D777" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group">Krall, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pretto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, D.</span><span> </span><span class="NLM_article-title">A bivalent small molecule-drug conjugate directed against carbonic anhydrase IX can elicit complete tumour regression in mice</span> <span class="citation_source-journal">Chem. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">3640</span><span class="NLM_x">–</span> <span class="NLM_lpage">3644</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1039%2FC4SC00685B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFSgs7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=3640-3644&author=N.+Krallauthor=F.+Prettoauthor=D.+Neri&title=A+bivalent+small+molecule-drug+conjugate+directed+against+carbonic+anhydrase+IX+can+elicit+complete+tumour+regression+in+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">A bivalent small molecule-drug conjugate directed against carbonic anhydrase IX can elicit complete tumour regression in mice</span></div><div class="casAuthors">Krall, N.; Pretto, F.; Neri, D.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3640-3644</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">There is a pressing need for the development of innovative chem. drug delivery strategies in oncol., since conventional chemotherapeutic agents typically do not localize to solid tumors in vivo.  It is widely accepted that bivalent antibody formats accumulate in tumors more strongly than monovalent ones and that they should thus be preferred for antibody-based drug delivery approaches.  For small mol.-drug conjugates this is less clear.  Here, the authors show that a bivalent ligand against the tumor marker carbonic anhydrase IX leads to an improved tumor-targeting performance compared with the corresponding monovalent counterpart in the SKRC52 model of constitutively CAIX-pos. renal cell carcinoma.  A bivalent disulfide-linked small drug conjugate with the potent cytotoxic maytansinoid DM1 as the payload can mediate complete eradication of the same tumors, which are resistant to std.-of-care therapeutics, in a proportion of treated mice.  In the A375 melanoma model, which preferentially expresses CAIX at sites distant to blood vessels, no measurable tumor accumulation could be obsd.  The authors' results suggest that the use of bivalent small mol. ligand-drug conjugates against CAIX may represent an attractive chem. strategy for the treatment of constitutively CAIX-pos. kidney cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZslzjAAno7rVg90H21EOLACvtfcHk0ljg0O2yFjmqpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFSgs7fL&md5=87c92eed915589fd3c8c9f4bfebdb5e0</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1039%2FC4SC00685B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4SC00685B%26sid%3Dliteratum%253Aachs%26aulast%3DKrall%26aufirst%3DN.%26aulast%3DPretto%26aufirst%3DF.%26aulast%3DNeri%26aufirst%3DD.%26atitle%3DA%2520bivalent%2520small%2520molecule-drug%2520conjugate%2520directed%2520against%2520carbonic%2520anhydrase%2520IX%2520can%2520elicit%2520complete%2520tumour%2520regression%2520in%2520mice%26jtitle%3DChem.%2520Sci.%26date%3D2014%26volume%3D5%26spage%3D3640%26epage%3D3644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group">Wichert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krall, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decurtins, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franzini, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pretto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheuermann, J.</span><span> </span><span class="NLM_article-title">Dual-display of small molecules enables the discovery of ligand pairs and facilitates affinity maturation</span> <span class="citation_source-journal">Nat. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">241</span><span class="NLM_x">–</span> <span class="NLM_lpage">249</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1038%2Fnchem.2158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=25698334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFSgtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=241-249&author=M.+Wichertauthor=N.+Krallauthor=W.+Decurtinsauthor=R.+M.+Franziniauthor=F.+Prettoauthor=P.+Schneiderauthor=D.+Neriauthor=J.+Scheuermann&title=Dual-display+of+small+molecules+enables+the+discovery+of+ligand+pairs+and+facilitates+affinity+maturation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-display of small molecules enables the discovery of ligand pairs and facilitates affinity maturation</span></div><div class="casAuthors">Wichert, Moreno; Krall, Nikolaus; Decurtins, Willy; Franzini, Raphael M.; Pretto, Francesca; Schneider, Petra; Neri, Dario; Scheuermann, Jorg</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">241-249</span>CODEN:
                <span class="NLM_cas:coden">NCAHBB</span>;
        ISSN:<span class="NLM_cas:issn">1755-4330</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In contrast to std. fragment-based drug discovery approaches, dual-display DNA-encoded chem. libraries have the potential to identify fragment pairs that bind simultaneously and benefit from the chelate effect.  However, the technol. has been limited by the difficulty in unambiguously decoding the ligand pairs from large combinatorial libraries.  Here we report a strategy that overcomes this limitation and enables the efficient identification of ligand pairs that bind to a target protein.  Small org. mols. were conjugated to the 5' and 3' ends of complementary DNA strands that contain a unique identifying code.  DNA hybridization followed by an inter-strand code-transfer created a stable dual-display DNA-encoded chem. library of 111,100 members.  Using this approach we report the discovery of a low micromolar binder to alpha-1-acid glycoprotein and the affinity maturation of a ligand to carbonic anhydrase IX, an established marker of renal cell carcinoma.  The newly discovered subnanomolar carbonic anhydrase IX binder dramatically improved tumor targeting performance in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUqxl8F6d-3LVg90H21EOLACvtfcHk0ljg0O2yFjmqpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFSgtr4%253D&md5=760dcbd3bb22f0f2affa980b3df3286b</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1038%2Fnchem.2158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchem.2158%26sid%3Dliteratum%253Aachs%26aulast%3DWichert%26aufirst%3DM.%26aulast%3DKrall%26aufirst%3DN.%26aulast%3DDecurtins%26aufirst%3DW.%26aulast%3DFranzini%26aufirst%3DR.%2BM.%26aulast%3DPretto%26aufirst%3DF.%26aulast%3DSchneider%26aufirst%3DP.%26aulast%3DNeri%26aufirst%3DD.%26aulast%3DScheuermann%26aufirst%3DJ.%26atitle%3DDual-display%2520of%2520small%2520molecules%2520enables%2520the%2520discovery%2520of%2520ligand%2520pairs%2520and%2520facilitates%2520affinity%2520maturation%26jtitle%3DNat.%2520Chem.%26date%3D2015%26volume%3D7%26spage%3D241%26epage%3D249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group">Doss, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolb, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mocharla, V. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alpaugh, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D. Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J. Q.</span><span> </span><span class="NLM_article-title">Biodistribution and radiation dosimetry of the carbonic anhydrase IX imaging agent [(18) F]VM4-037 determined from PET/CT scans in healthy volunteers</span> <span class="citation_source-journal">Mol. Imaging Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">739</span><span class="NLM_x">–</span> <span class="NLM_lpage">746</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1007%2Fs11307-014-0730-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=24696183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A280%3ADC%252BC2cngtVSnuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2014&pages=739-746&author=M.+Dossauthor=H.+C.+Kolbauthor=J.+C.+Walshauthor=V.+P.+Mocharlaauthor=Z.+H.+Zhuauthor=M.+Hakaauthor=R.+K.+Alpaughauthor=D.+Y.+T.+Chenauthor=J.+Q.+Yu&title=Biodistribution+and+radiation+dosimetry+of+the+carbonic+anhydrase+IX+imaging+agent+%5B%2818%29+F%5DVM4-037+determined+from+PET%2FCT+scans+in+healthy+volunteers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Biodistribution and radiation dosimetry of the carbonic anhydrase IX imaging agent [(18) F]VM4-037 determined from PET/CT scans in healthy volunteers</span></div><div class="casAuthors">Doss Mohan; Kolb Hartmuth C; Walsh Joseph C; Mocharla Vani P; Zhu Zhihong; Haka Michael; Alpaugh R Katherine; Chen David Y T; Yu Jian Q</div><div class="citationInfo"><span class="NLM_cas:title">Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">739-46</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  [(18) F]VM4-037 has been developed as a positron emission tomography (PET) imaging marker to detect carbonic anhydrase IX (CA-IX) overexpression and is being investigated for use as a surrogate marker for tissue hypoxia.  The purpose of this study was to determine the biodistribution and estimate the radiation dose from [(18) F]VM4-037 using whole-body PET/CT scans in healthy human volunteers.  PROCEDURES:  Successive whole-body PET/CT scans were performed after intravenous injection of [(18) F]VM4-037 in four healthy humans.  The radiotracer uptakes in different organs were determined from the analysis of the PET scans.  Human radiation doses were estimated using OLINDA/EXM software.  RESULTS:  High uptake of [(18) F]VM4-037 was observed in the liver and kidneys, with little clearance of activity during the study period, with mean standardized uptake values of ~35 in liver and ~22 in kidneys at ~1 h after injection.  The estimated effective dose was 28 ± 1 μSv/MBq and the absorbed doses for the kidneys and liver were 273 ± 31 and 240 ± 68 μGy/MBq, respectively, for the adult male phantom.  Hence, the effective dose would be 10 ± 0.5 mSv for the anticipated injected activity of 370 MBq, and the kidney and liver doses would be 101 ± 11 and 89 ± 25 mGy, respectively.  CONCLUSIONS:  [(18) F]VM4-037 displayed very high uptake in the liver and kidneys with little clearance of activity during the study period, resulting in these organs receiving the highest radiation doses among all bodily organs.  Though the effective dose and the organ doses are within the limits considered as safe, the enhanced uptake of [(18) F]VM4-037 in the kidneys and liver will make the compound unsuitable for imaging overexpression of CA-IX in those two organs.  However, the tracer may be suitable for imaging overexpression of CA-IX in lesions in other regions of the body such as in the lungs or head and neck region.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQn4Ys9iwIVwSEJCPKhJPuqfW6udTcc2eZiYdXu3axoFbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cngtVSnuw%253D%253D&md5=f7a58fc6b3cbdc1ae4658d91f4dbfdbd</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1007%2Fs11307-014-0730-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11307-014-0730-7%26sid%3Dliteratum%253Aachs%26aulast%3DDoss%26aufirst%3DM.%26aulast%3DKolb%26aufirst%3DH.%2BC.%26aulast%3DWalsh%26aufirst%3DJ.%2BC.%26aulast%3DMocharla%26aufirst%3DV.%2BP.%26aulast%3DZhu%26aufirst%3DZ.%2BH.%26aulast%3DHaka%26aufirst%3DM.%26aulast%3DAlpaugh%26aufirst%3DR.%2BK.%26aulast%3DChen%26aufirst%3DD.%2BY.%2BT.%26aulast%3DYu%26aufirst%3DJ.%2BQ.%26atitle%3DBiodistribution%2520and%2520radiation%2520dosimetry%2520of%2520the%2520carbonic%2520anhydrase%2520IX%2520imaging%2520agent%2520%255B%252818%2529%2520F%255DVM4-037%2520determined%2520from%2520PET%252FCT%2520scans%2520in%2520healthy%2520volunteers%26jtitle%3DMol.%2520Imaging%2520Biol.%26date%3D2014%26volume%3D16%26spage%3D739%26epage%3D746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group">Lepenies, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sonkaria, S.</span><span> </span><span class="NLM_article-title">Targeting C-type lectin receptors with multivalent carbohydrate ligands</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">1271</span><span class="NLM_x">–</span> <span class="NLM_lpage">1281</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=1271-1281&author=B.+Lepeniesauthor=J.+Leeauthor=S.+Sonkaria&title=Targeting+C-type+lectin+receptors+with+multivalent+carbohydrate+ligands"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLepenies%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DSonkaria%26aufirst%3DS.%26atitle%3DTargeting%2520C-type%2520lectin%2520receptors%2520with%2520multivalent%2520carbohydrate%2520ligands%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2013%26volume%3D65%26spage%3D1271%26epage%3D1281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group">Chittasupho, C.</span><span> </span><span class="NLM_article-title">Multivalent ligand: design principle for targeted therapeutic delivery approach</span> <span class="citation_source-journal">Ther. Delivery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1171</span><span class="NLM_x">–</span> <span class="NLM_lpage">1187</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.4155%2Ftde.12.99" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=23116010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFCrurbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=1171-1187&author=C.+Chittasupho&title=Multivalent+ligand%3A+design+principle+for+targeted+therapeutic+delivery+approach"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Multivalent ligand: design principle for targeted therapeutic delivery approach</span></div><div class="casAuthors">Chittasupho, Chuda</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Delivery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1171-1187</span>CODEN:
                <span class="NLM_cas:coden">TDHEA7</span>;
        ISSN:<span class="NLM_cas:issn">2041-5990</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Multivalent interactions of biol. mols. play an important role in many biochem. events.  A multivalent ligand comprises of multiple copies of ligands conjugated to scaffolds, allowing the simultaneous binding of multivalent ligands to multiple binding sites or receptors.  Many research groups have successfully designed and synthesized multivalent ligands to increase the binding affinity, avidity and specificity of the ligand to the receptor.  A multimeric ligand is a promising option for the specific treatment of diseases.  In this review, the factors affecting multivalent interactions, including the size and shape of the ligand, geometry and an arrangement of ligands on the scaffold, linker length, thermodn., and kinetics of the interactions are discussed.  Examples of the multivalent ligand applications for therapeutic delivery are also summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWWDU1KszkuLVg90H21EOLACvtfcHk0ljDGBoPv3OpYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFCrurbJ&md5=0b30d1d1675cfb7bbdc38dfbf7168b7e</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.4155%2Ftde.12.99&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ftde.12.99%26sid%3Dliteratum%253Aachs%26aulast%3DChittasupho%26aufirst%3DC.%26atitle%3DMultivalent%2520ligand%253A%2520design%2520principle%2520for%2520targeted%2520therapeutic%2520delivery%2520approach%26jtitle%3DTher.%2520Delivery%26date%3D2012%26volume%3D3%26spage%3D1171%26epage%3D1187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group">Guillemard, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nedev, H. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berezov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murali, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saragovi, H. U.</span><span> </span><span class="NLM_article-title">HER2-mediated internalization of a targeted prodrug cytotoxic conjugate is dependent on the valency of the targeting ligand</span> <span class="citation_source-journal">DNA Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">350</span><span class="NLM_x">–</span> <span class="NLM_lpage">358</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2005&pages=350-358&author=V.+Guillemardauthor=H.+N.+Nedevauthor=A.+Berezovauthor=R.+Muraliauthor=H.+U.+Saragovi&title=HER2-mediated+internalization+of+a+targeted+prodrug+cytotoxic+conjugate+is+dependent+on+the+valency+of+the+targeting+ligand"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGuillemard%26aufirst%3DV.%26aulast%3DNedev%26aufirst%3DH.%2BN.%26aulast%3DBerezov%26aufirst%3DA.%26aulast%3DMurali%26aufirst%3DR.%26aulast%3DSaragovi%26aufirst%3DH.%2BU.%26atitle%3DHER2-mediated%2520internalization%2520of%2520a%2520targeted%2520prodrug%2520cytotoxic%2520conjugate%2520is%2520dependent%2520on%2520the%2520valency%2520of%2520the%2520targeting%2520ligand%26jtitle%3DDNA%2520Cell%2520Biol.%26date%3D2005%26volume%3D24%26spage%3D350%26epage%3D358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group">Daguer, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zambaldo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciobanu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morieux, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barluenga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winssinger, N.</span><span> </span><span class="NLM_article-title">DNA display of fragment pairs as a tool for the discovery of novel biologically active small molecules</span> <span class="citation_source-journal">Chem. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">739</span><span class="NLM_x">–</span> <span class="NLM_lpage">744</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1039%2FC4SC01654H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=30154995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFyhu73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=739-744&author=J.+P.+Daguerauthor=C.+Zambaldoauthor=M.+Ciobanuauthor=P.+Morieuxauthor=S.+Barluengaauthor=N.+Winssinger&title=DNA+display+of+fragment+pairs+as+a+tool+for+the+discovery+of+novel+biologically+active+small+molecules"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">DNA display of fragment pairs as a tool for the discovery of novel biologically active small molecules</span></div><div class="casAuthors">Daguer, J.-P.; Zambaldo, C.; Ciobanu, M.; Morieux, P.; Barluenga, S.; Winssinger, N.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">739-744</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Fragment-based lead discovery has proven to be a powerful method in the drug discovery process.  The combinatorial output that is accessible by combining fragments is very attractive; however, identifying fragment pairs that bind synergistically and linking them productively can be challenging.  Several technologies have now been established to prep. and screen nucleic acid-encoded libraries (ssDNA, dsDNA, PNA), and it has been shown that pairs of mols. combined by hybridization can bind synergistically to a target.  Herein we apply this concept to combinatorially pair two libraries of small mol. fragments, use the fittest fragments supplemented with closely related analogs to build a focused library covalently linking the fragments with different spacers, and apply this strategy to the discovery of a potent ligand for Hsp70.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhgZK31sH7tLVg90H21EOLACvtfcHk0ljDGBoPv3OpYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFyhu73I&md5=98216526b528a7fb92d3d5759f215bb3</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1039%2FC4SC01654H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4SC01654H%26sid%3Dliteratum%253Aachs%26aulast%3DDaguer%26aufirst%3DJ.%2BP.%26aulast%3DZambaldo%26aufirst%3DC.%26aulast%3DCiobanu%26aufirst%3DM.%26aulast%3DMorieux%26aufirst%3DP.%26aulast%3DBarluenga%26aufirst%3DS.%26aulast%3DWinssinger%26aufirst%3DN.%26atitle%3DDNA%2520display%2520of%2520fragment%2520pairs%2520as%2520a%2520tool%2520for%2520the%2520discovery%2520of%2520novel%2520biologically%2520active%2520small%2520molecules%26jtitle%3DChem.%2520Sci.%26date%3D2015%26volume%3D6%26spage%3D739%26epage%3D744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group">Franzini, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheuermann, J.</span><span> </span><span class="NLM_article-title">DNA-encoded chemical libraries: Advancing beyond conventional small-molecule libraries</span> <span class="citation_source-journal">Acc. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1247</span><span class="NLM_x">–</span> <span class="NLM_lpage">1255</span></span><div class="citationLinks">[<a href="/doi/10.1021/ar400284t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltF2ls7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2014&pages=1247-1255&author=R.+M.+Franziniauthor=D.+Neriauthor=J.+Scheuermann&title=DNA-encoded+chemical+libraries%3A+Advancing+beyond+conventional+small-molecule+libraries"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">DNA-Encoded Chemical Libraries: Advancing beyond Conventional Small-Molecule Libraries</span></div><div class="casAuthors">Franzini, Raphael M.; Neri, Dario; Scheuermann, Jorg</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1247-1255</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  DNA-encoded chem. libraries (DECLs) represent a promising tool in drug discovery.  DECL technol. allows the synthesis and screening of chem. libraries of unprecedented size at moderate costs.  In analogy to phage-display technol., where large antibody libraries are displayed on the surface of filamentous phage and are genetically encoded in the phage genome, DECLs feature the display of individual small org. chem. moieties on DNA fragments serving as amplifiable identification barcodes.  The DNA-tag facilitates the synthesis and allows the simultaneous screening of very large sets of compds. (up to billions of mols.), because the hit compds. can easily be identified and quantified by PCR-amplification of the DNA-barcode followed by high-throughput DNA sequencing.  Several approaches have been used to generate DECLs, differing both in the methods used for library encoding and for the combinatorial assembly of chem. moieties.  For example, DECLs can be used for fragment-based drug discovery, displaying a single mol. on DNA or two chem. moieties at the extremities of complementary DNA strands.  DECLs can vary substantially in the chem. structures and the library size.  While ultralarge libraries contg. billions of compds. have been reported contg. four or more sets of building blocks, also smaller libraries have been shown to be efficient for ligand discovery.  In general, it has been found that the overall library size is a poor predictor for library performance and that the no. and diversity of the building blocks are rather important indicators.  Smaller libraries consisting of two to three sets of building blocks better fulfill the criteria of drug-likeness and often have higher quality.  In this Account, we present advances in the DECL field from proof-of-principle studies to practical applications for drug discovery, both in industry and in academia.  DECL technol. can yield specific binders to a variety of target proteins and is likely to become a std. tool for pharmaceutical hit discovery, lead expansion, and Chem. Biol. research.  The introduction of new methodologies for library encoding and for compd. synthesis in the presence of DNA is an exciting research field and will crucially contribute to the performance and the propagation of the technol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcaCmssNgPLLVg90H21EOLACvtfcHk0lgxBEX2GmohUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltF2ls7g%253D&md5=c37bd1625b668e869fcc26d5ef0a017a</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Far400284t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far400284t%26sid%3Dliteratum%253Aachs%26aulast%3DFranzini%26aufirst%3DR.%2BM.%26aulast%3DNeri%26aufirst%3DD.%26aulast%3DScheuermann%26aufirst%3DJ.%26atitle%3DDNA-encoded%2520chemical%2520libraries%253A%2520Advancing%2520beyond%2520conventional%2520small-molecule%2520libraries%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2014%26volume%3D47%26spage%3D1247%26epage%3D1255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group">Chan, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGregor, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D. R.</span><span> </span><span class="NLM_article-title">Novel selection methods for DNA-encoded chemical libraries</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">26C</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">61</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1016%2Fj.cbpa.2015.02.010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26C&publication_year=2015&pages=55-61&author=A.+I.+Chanauthor=L.+M.+McGregorauthor=D.+R.+Liu&title=Novel+selection+methods+for+DNA-encoded+chemical+libraries"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2015.02.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2015.02.010%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DA.%2BI.%26aulast%3DMcGregor%26aufirst%3DL.%2BM.%26aulast%3DLiu%26aufirst%3DD.%2BR.%26atitle%3DNovel%2520selection%2520methods%2520for%2520DNA-encoded%2520chemical%2520libraries%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2015%26volume%3D26C%26spage%3D55%26epage%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group">Morioka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loik, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hipolito, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suga, H.</span><span> </span><span class="NLM_article-title">Selection-based discovery of macrocyclic peptides for the next generation therapeutics</span> <span class="citation_source-journal">Curr. Opin Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">26C</span><span class="NLM_x">, </span> <span class="NLM_fpage">34</span><span class="NLM_x">–</span> <span class="NLM_lpage">41</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1016%2Fj.cbpa.2015.01.023" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26C&publication_year=2015&pages=34-41&author=T.+Moriokaauthor=N.+D.+Loikauthor=C.+J.+Hipolitoauthor=Y.+Gotoauthor=H.+Suga&title=Selection-based+discovery+of+macrocyclic+peptides+for+the+next+generation+therapeutics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2015.01.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2015.01.023%26sid%3Dliteratum%253Aachs%26aulast%3DMorioka%26aufirst%3DT.%26aulast%3DLoik%26aufirst%3DN.%2BD.%26aulast%3DHipolito%26aufirst%3DC.%2BJ.%26aulast%3DGoto%26aufirst%3DY.%26aulast%3DSuga%26aufirst%3DH.%26atitle%3DSelection-based%2520discovery%2520of%2520macrocyclic%2520peptides%2520for%2520the%2520next%2520generation%2520therapeutics%26jtitle%3DCurr.%2520Opin%2520Chem.%2520Biol.%26date%3D2015%26volume%3D26C%26spage%3D34%26epage%3D41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group">Heinis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutherford, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freund, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winter, G.</span><span> </span><span class="NLM_article-title">Phage-encoded combinatorial chemical libraries based on bicyclic peptides</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">502</span><span class="NLM_x">–</span> <span class="NLM_lpage">507</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1038%2Fnchembio.184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=19483697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BD1MXms1altbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=502-507&author=C.+Heinisauthor=T.+Rutherfordauthor=S.+Freundauthor=G.+Winter&title=Phage-encoded+combinatorial+chemical+libraries+based+on+bicyclic+peptides"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Phage-encoded combinatorial chemical libraries based on bicyclic peptides</span></div><div class="casAuthors">Heinis, Christian; Rutherford, Trevor; Freund, Stephan; Winter, Greg</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">502-507</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here we describe a phage strategy for the selection of ligands based on bicyclic or linear peptides attached covalently to an org. core.  We designed peptide repertoires with three reactive cysteine residues, each spaced apart by several random amino acid residues, and we fused the repertoires to the phage gene-3-protein.  Conjugation with tris-(bromomethyl)benzene via the reactive cysteines generated repertoires of peptide conjugates with two peptide loops anchored to a mesitylene core.  Iterative affinity selections yielded several enzyme inhibitors; after further mutagenesis and selection, we were able to chem. synthesize a lead inhibitor (PK15; Ki = 1.5 nM) specific to human plasma kallikrein that efficiently interrupted the intrinsic coagulation pathway in human plasma tested ex vivo.  This approach offers a powerful means of generating and selecting bicyclic macrocycles (or if cleaved, linear derivs. thereof) as ligands poised at the interface of small-mol. drugs and biologics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZhJRZyldisLVg90H21EOLACvtfcHk0lgxBEX2GmohUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXms1altbs%253D&md5=0634460f77b185fbcf85309c6dbf93e3</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.184%26sid%3Dliteratum%253Aachs%26aulast%3DHeinis%26aufirst%3DC.%26aulast%3DRutherford%26aufirst%3DT.%26aulast%3DFreund%26aufirst%3DS.%26aulast%3DWinter%26aufirst%3DG.%26atitle%3DPhage-encoded%2520combinatorial%2520chemical%2520libraries%2520based%2520on%2520bicyclic%2520peptides%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2009%26volume%3D5%26spage%3D502%26epage%3D507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group">Parker, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turk, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westrick, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Low, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leamon, C. P.</span><span> </span><span class="NLM_article-title">Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">338</span><span class="NLM_x">, </span> <span class="NLM_fpage">284</span><span class="NLM_x">–</span> <span class="NLM_lpage">293</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1016%2Fj.ab.2004.12.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=15745749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitVaqur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=2005&pages=284-293&author=N.+Parkerauthor=M.+J.+Turkauthor=E.+Westrickauthor=J.+D.+Lewisauthor=P.+S.+Lowauthor=C.+P.+Leamon&title=Folate+receptor+expression+in+carcinomas+and+normal+tissues+determined+by+a+quantitative+radioligand+binding+assay"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay</span></div><div class="casAuthors">Parker, Nikki; Turk, Mary Jo; Westrick, Elaine; Lewis, Jeffrey D.; Low, Philip S.; Leamon, Christopher P.</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">284-293</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The folate receptor (FR) is a valuable therapeutic target that is highly expressed on a variety of cancers.  The current development of folate-targeted cancer therapies has created the need for quantitating functional FRs in clin. specimens.  In this article, we report on the creation of a highly sensitive radioactive binding method for quant. measuring FR expression in frozen tissue homogenates.  Expression was pos. in approx. 89% of human ovarian carcinomas but was negligible in both mucinous ovarian carcinomas and normal ovary.  Expression was also significant in carcinomas of the kidney, endometrium, lung, breast, bladder, and pancreas.  Normal tissues from humans and six different lab. species were also analyzed; surprisingly, some interspecies variability in FR expression (esp. in kidney, spleen, and lung tissue) was found.  Interestingly, normal human lung tissue displayed high expression levels, whereas expression in normal lung of the other species was negligible.  However, considering that folate-drug conjugates fail to accumulate in the lungs of patients, the consequence of this finding was not considered to be of clin. concern.  Overall, this new methodol. is reliable for detg. functional FR expression levels in tissues, and it could possibly be a useful clin. test to det. patient candidacy for FR-targeted therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwtgdifJwHuLVg90H21EOLACvtfcHk0lgxBEX2GmohUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitVaqur0%253D&md5=cec9651fddccd602d715a27ab93f288c</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.ab.2004.12.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ab.2004.12.026%26sid%3Dliteratum%253Aachs%26aulast%3DParker%26aufirst%3DN.%26aulast%3DTurk%26aufirst%3DM.%2BJ.%26aulast%3DWestrick%26aufirst%3DE.%26aulast%3DLewis%26aufirst%3DJ.%2BD.%26aulast%3DLow%26aufirst%3DP.%2BS.%26aulast%3DLeamon%26aufirst%3DC.%2BP.%26atitle%3DFolate%2520receptor%2520expression%2520in%2520carcinomas%2520and%2520normal%2520tissues%2520determined%2520by%2520a%2520quantitative%2520radioligand%2520binding%2520assay%26jtitle%3DAnal.%2520Biochem.%26date%3D2005%26volume%3D338%26spage%3D284%26epage%3D293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group">Morris, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joyrich, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naumann, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurer, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strauss, H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uszler, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Symanowski, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harb, W. A.</span><span> </span><span class="NLM_article-title">Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (Tc-99m-etarfolatide)</span> <span class="citation_source-journal">Ann. Oncol</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">852</span><span class="NLM_x">–</span> <span class="NLM_lpage">858</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1093%2Fannonc%2Fmdu024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=24667717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A280%3ADC%252BC2crnt1ymsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=852-858&author=R.+T.+Morrisauthor=R.+N.+Joyrichauthor=R.+W.+Naumannauthor=N.+P.+Shahauthor=A.+H.+Maurerauthor=H.+W.+Straussauthor=J.+M.+Uszlerauthor=J.+T.+Symanowskiauthor=P.+R.+Ellisauthor=W.+A.+Harb&title=Phase+II+study+of+treatment+of+advanced+ovarian+cancer+with+folate-receptor-targeted+therapeutic+%28vintafolide%29+and+companion+SPECT-based+imaging+agent+%28Tc-99m-etarfolatide%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide)</span></div><div class="casAuthors">Morris R T; Joyrich R N; Naumann R W; Symanowski J T; Shah N P; Maurer A H; Strauss H W; Uszler J M; Ellis P R; Harb W A</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">852-858</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  This report examines (99m)Tc-etarfolatide imaging to identify the presence of folate receptor (FR) on tumors of women with recurrent/refractory ovarian or endometrial cancer and correlates expression with response to FR-targeted therapy (vintafolide).  PATIENTS AND METHODS:  In this phase II, single-arm, multicenter study, patients with advanced ovarian cancer were imaged with (99m)Tc-etarfolatide before vintafolide treatment.  Up to 10 target lesions (TLs) were selected based on Response Evaluation Criteria In Solid Tumors criteria using computed tomography scans.  Single-photon emission computed tomography images of TLs were assessed for (99m)Tc-etarfolatide uptake as either FR positive or negative.  Patients were categorized by percentage of TLs positive and grouped as FR(100%), FR(10%-90%), and FR(0%).  Lesion and patient response were correlated with etarfolatide uptake.  RESULTS:  Forty-nine patients were enrolled; 43 were available for analysis.  One hundred thirty-nine lesions were (99m)Tc-etarfolatide evaluable: 110 FR positive and 29 FR negative.  Lesion disease control rate (DCR = stable or response) was observed in 56.4% of FR-positive lesions versus 20.7% of FR-negative lesions (P < 0.001).  Patient DCR was 57%, 36%, and 33% in FR(100%), FR(10%-90%), and FR(0%) patients, respectively.  Median overall survival was 14.6, 9.6, and 3.0 months in FR(100%), FR(10%-90%), and FR(0%) patients, respectively.  CONCLUSIONS:  Overall response to FR-targeted therapy and DCR correlate with FR positivity demonstrated by (99m)Tc-etarfolatide imaging.  CLINICAL TRIAL NUMBER:  NCT00507741.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTm3hC1BFRecGPgL4LrC-0VfW6udTcc2eYe1RKnzvZtBrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2crnt1ymsw%253D%253D&md5=69bfa70dba6ad5b1da9e763e12e795fc</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdu024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdu024%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DR.%2BT.%26aulast%3DJoyrich%26aufirst%3DR.%2BN.%26aulast%3DNaumann%26aufirst%3DR.%2BW.%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DMaurer%26aufirst%3DA.%2BH.%26aulast%3DStrauss%26aufirst%3DH.%2BW.%26aulast%3DUszler%26aufirst%3DJ.%2BM.%26aulast%3DSymanowski%26aufirst%3DJ.%2BT.%26aulast%3DEllis%26aufirst%3DP.%2BR.%26aulast%3DHarb%26aufirst%3DW.%2BA.%26atitle%3DPhase%2520II%2520study%2520of%2520treatment%2520of%2520advanced%2520ovarian%2520cancer%2520with%2520folate-receptor-targeted%2520therapeutic%2520%2528vintafolide%2529%2520and%2520companion%2520SPECT-based%2520imaging%2520agent%2520%2528Tc-99m-etarfolatide%2529%26jtitle%3DAnn.%2520Oncol%26date%3D2014%26volume%3D25%26spage%3D852%26epage%3D858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group">Naumann, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burger, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sausville, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kutarska, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghamande, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabrail, N. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depasquale, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nowara, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gersh, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teneriello, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harb, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konstantinopoulos, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penson, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Symanowski, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovejoy, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leamon, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgenstern, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messmann, R. A.</span><span> </span><span class="NLM_article-title">PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">4400</span><span class="NLM_x">–</span> <span class="NLM_lpage">4406</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1200%2FJCO.2013.49.7685" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=24127448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjt1Shtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=4400-4406&author=R.+W.+Naumannauthor=R.+L.+Colemanauthor=R.+A.+Burgerauthor=E.+A.+Sausvilleauthor=E.+Kutarskaauthor=S.+A.+Ghamandeauthor=N.+Y.+Gabrailauthor=S.+E.+Depasqualeauthor=E.+Nowaraauthor=L.+Gilbertauthor=R.+H.+Gershauthor=M.+G.+Tenerielloauthor=W.+A.+Harbauthor=P.+A.+Konstantinopoulosauthor=R.+T.+Pensonauthor=J.+T.+Symanowskiauthor=C.+D.+Lovejoyauthor=C.+P.+Leamonauthor=D.+E.+Morgensternauthor=R.+A.+Messmann&title=PRECEDENT%3A+a+randomized+phase+II+trial+comparing+vintafolide+%28EC145%29+and+pegylated+liposomal+doxorubicin+%28PLD%29+in+combination+versus+PLD+alone+in+patients+with+platinum-resistant+ovarian+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer</span></div><div class="casAuthors">Naumann, R. Wendel; Coleman, Robert L.; Burger, Robert A.; Sausville, Edward A.; Kutarska, Elzbieta; Ghamande, Sharad A.; Gabrail, Nashat Y.; DePasquale, Stephen E.; Nowara, Elzbieta; Gilbert, Lucy; Gersh, Robert H.; Teneriello, Michael G.; Harb, Wael A.; Konstantinopoulos, Panagiotis A.; Penson, Richard T.; Symanowski, James T.; Lovejoy, Chandra D.; Leanon, Christopher P.; Morgenstern, David E.; Messmann, Richar A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">4400-4406</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Vintafolide (EC145) is a folic acid-desacetylvinblastine conjugate that binds to the folate receptor (FR), which is expressed on the majority of epithelial ovarian cancers.  This randomized phase II trial evaluated vintafolide combined with pegylated liposomal doxorubicin (PLD) compared with PLD alone.  The utility of an FR-targeted imaging agent, 99mTc-etarfolatide (EC20), in selecting patients likely to benefit from vintafolide was also examd.  Patients and Methods Women with recurrent platinum-resistant ovarian cancer who had undergone ≤ two prior cytotoxic regimens were randomly assigned at a 2:1 ratio to PLD (50 mg/m2 i.v. [IV] once every 28 days) with or without vintafolide (2.5 mg IV three times per wk during weeks 1 and 3).  Etarfolatide scanning was optional.  The primary objective was to compare progression-free survival (PFS) between the groups.  Results The intent-to-treat population comprised 149 patients.  Median PFS was 5.0 and 2.7 mo for the vintafolide plus PLD and PLD-alone arms, resp. (hazard ratio [HR], 0.63; 95% CI, 0.41 to 0.96; P = .031).  The greatest benefit was obsd. in patients with 100% of lesions pos. for FR, with median PFS of 5.5 compared with 1.5 mo for PLD alone (HR, 0.38; 95% CI, 0.17 to 0.85; P = .013).  The group of patients with FR-pos. disease (10% to 90%) experienced some PFS improvement (HR, 0.873), whereas patients with disease that did not express FR experienced no PFS benefit (HR, 1.806).  Conclusion Vintafolide plus PLD is the first combination to demonstrate an improvement over std. therapy in a randomized trial of patients with platinum-resistant ovarian cancer.  Etarfolatide can identify patients likely to benefit from vintafolide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjeCxk34QG_LVg90H21EOLACvtfcHk0lg3sIWk-23C6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjt1Shtrc%253D&md5=6f242890f38c502872b4bf7b49241f28</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1200%2FJCO.2013.49.7685&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2013.49.7685%26sid%3Dliteratum%253Aachs%26aulast%3DNaumann%26aufirst%3DR.%2BW.%26aulast%3DColeman%26aufirst%3DR.%2BL.%26aulast%3DBurger%26aufirst%3DR.%2BA.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26aulast%3DKutarska%26aufirst%3DE.%26aulast%3DGhamande%26aufirst%3DS.%2BA.%26aulast%3DGabrail%26aufirst%3DN.%2BY.%26aulast%3DDepasquale%26aufirst%3DS.%2BE.%26aulast%3DNowara%26aufirst%3DE.%26aulast%3DGilbert%26aufirst%3DL.%26aulast%3DGersh%26aufirst%3DR.%2BH.%26aulast%3DTeneriello%26aufirst%3DM.%2BG.%26aulast%3DHarb%26aufirst%3DW.%2BA.%26aulast%3DKonstantinopoulos%26aufirst%3DP.%2BA.%26aulast%3DPenson%26aufirst%3DR.%2BT.%26aulast%3DSymanowski%26aufirst%3DJ.%2BT.%26aulast%3DLovejoy%26aufirst%3DC.%2BD.%26aulast%3DLeamon%26aufirst%3DC.%2BP.%26aulast%3DMorgenstern%26aufirst%3DD.%2BE.%26aulast%3DMessmann%26aufirst%3DR.%2BA.%26atitle%3DPRECEDENT%253A%2520a%2520randomized%2520phase%2520II%2520trial%2520comparing%2520vintafolide%2520%2528EC145%2529%2520and%2520pegylated%2520liposomal%2520doxorubicin%2520%2528PLD%2529%2520in%2520combination%2520versus%2520PLD%2520alone%2520in%2520patients%2520with%2520platinum-resistant%2520ovarian%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D4400%26epage%3D4406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group">LoRusso, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edelman, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bever, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forman, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilat, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heath, E. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malburg, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leamon, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messmann, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sausville, E. A.</span><span> </span><span class="NLM_article-title">Phase I study of folate conjugate EC145 (vintafolide) in patients with refractory solid tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">4011</span><span class="NLM_x">–</span> <span class="NLM_lpage">4016</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1200%2FJCO.2011.41.4946" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=23032618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A280%3ADC%252BC3s%252FitFCrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=4011-4016&author=P.+M.+LoRussoauthor=M.+J.+Edelmanauthor=S.+L.+Beverauthor=K.+M.+Formanauthor=M.+Pilatauthor=M.+F.+Quinnauthor=J.+Liauthor=E.+I.+Heathauthor=L.+M.+Malburgauthor=P.+J.+Kleinauthor=C.+P.+Leamonauthor=R.+A.+Messmannauthor=E.+A.+Sausville&title=Phase+I+study+of+folate+conjugate+EC145+%28vintafolide%29+in+patients+with+refractory+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors</span></div><div class="casAuthors">Lorusso Patricia M; Edelman Martin J; Bever Susan L; Forman Karen M; Pilat Maryjo; Quinn Mary F; Li Jing; Heath Elisabeth I; Malburg Lisa M; Klein Patrick J; Leamon Christopher P; Messmann Richard A; Sausville Edward A</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">4011-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  EC145 (vintafolide), a conjugate of folic acid and the vinca alkaloid desacetylvinblastine hydrazide (DAVLBH), is a ligand for the folate receptor (FR), with activity against FR-positive tumor xenografts in vivo.  This phase I study determined the maximum-tolerated dose (MTD) of EC145 administered as a bolus intravenous injection or 1-hour infusion in patients with refractory solid tumors.  PATIENTS AND METHODS:  EC145 was administered as a bolus injection or 1-hour infusion on days 1, 3, and 5 and days 15, 17, and 19 of each 28-day cycle with dose escalation in cohorts of three to six patients until the MTD was identified.  Plasma pharmacokinetics were determined on days 1 and 3 of the first cycle.  RESULTS:  The MTD of EC145 was 2.5 mg when administered as either a bolus injection or 1-hour infusion.  Constipation was the dose-limiting toxicity with both routes.  Constipation, nausea, fatigue, and vomiting were the most commonly reported adverse events.  One partial response to therapy was observed in a patient with metastatic ovarian cancer.  CONCLUSION:  EC145 administered by bolus injection or as a 1-hour infusion at a dose of 2.5 mg on days 1, 3, and 5 and days 15, 17, and 19 of a 28-day cycle has an acceptable safety profile in patients with advanced cancer.  On the basis of these findings, phase II studies of EC145 have been initiated in patients with advanced epithelial ovarian cancer and non-small-cell lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTgjStBWJ3DPJQHPYJuLg8TfW6udTcc2ebMtIKRPmgGqrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s%252FitFCrsA%253D%253D&md5=cfbc76346785033ebb51e7cf4494cd68</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.41.4946&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.41.4946%26sid%3Dliteratum%253Aachs%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26aulast%3DEdelman%26aufirst%3DM.%2BJ.%26aulast%3DBever%26aufirst%3DS.%2BL.%26aulast%3DForman%26aufirst%3DK.%2BM.%26aulast%3DPilat%26aufirst%3DM.%26aulast%3DQuinn%26aufirst%3DM.%2BF.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DHeath%26aufirst%3DE.%2BI.%26aulast%3DMalburg%26aufirst%3DL.%2BM.%26aulast%3DKlein%26aufirst%3DP.%2BJ.%26aulast%3DLeamon%26aufirst%3DC.%2BP.%26aulast%3DMessmann%26aufirst%3DR.%2BA.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26atitle%3DPhase%2520I%2520study%2520of%2520folate%2520conjugate%2520EC145%2520%2528vintafolide%2529%2520in%2520patients%2520with%2520refractory%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D4011%26epage%3D4016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group">Uhlen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fagerberg, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallstrom, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindskog, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oksvold, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mardinoglu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sivertsson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kampf, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sjostedt, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asplund, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edlund, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szigyarto, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Odeberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Djureinovic, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takanen, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hober, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alm, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edqvist, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berling, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tegel, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulder, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rockberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwenk, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamsten, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Feilitzen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forsberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Persson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johansson, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwahlen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Heijne, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ponten, F.</span><span> </span><span class="NLM_article-title">Proteomics. Tissue-based map of the human proteome</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">347</span><span class="NLM_x">, </span> <span class="NLM_fpage">394</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2015&pages=394&author=M.+Uhlenauthor=L.+Fagerbergauthor=B.+M.+Hallstromauthor=C.+Lindskogauthor=P.+Oksvoldauthor=A.+Mardinogluauthor=A.+Sivertssonauthor=C.+Kampfauthor=E.+Sjostedtauthor=A.+Asplundauthor=I.+Olssonauthor=K.+Edlundauthor=E.+Lundbergauthor=S.+Navaniauthor=C.+A.+Szigyartoauthor=J.+Odebergauthor=D.+Djureinovicauthor=J.+O.+Takanenauthor=S.+Hoberauthor=T.+Almauthor=P.+H.+Edqvistauthor=H.+Berlingauthor=H.+Tegelauthor=J.+Mulderauthor=J.+Rockbergauthor=P.+Nilssonauthor=J.+M.+Schwenkauthor=M.+Hamstenauthor=K.+von+Feilitzenauthor=M.+Forsbergauthor=L.+Perssonauthor=F.+Johanssonauthor=M.+Zwahlenauthor=G.+von+Heijneauthor=J.+Nielsenauthor=F.+Ponten&title=Proteomics.+Tissue-based+map+of+the+human+proteome"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DUhlen%26aufirst%3DM.%26aulast%3DFagerberg%26aufirst%3DL.%26aulast%3DHallstrom%26aufirst%3DB.%2BM.%26aulast%3DLindskog%26aufirst%3DC.%26aulast%3DOksvold%26aufirst%3DP.%26aulast%3DMardinoglu%26aufirst%3DA.%26aulast%3DSivertsson%26aufirst%3DA.%26aulast%3DKampf%26aufirst%3DC.%26aulast%3DSjostedt%26aufirst%3DE.%26aulast%3DAsplund%26aufirst%3DA.%26aulast%3DOlsson%26aufirst%3DI.%26aulast%3DEdlund%26aufirst%3DK.%26aulast%3DLundberg%26aufirst%3DE.%26aulast%3DNavani%26aufirst%3DS.%26aulast%3DSzigyarto%26aufirst%3DC.%2BA.%26aulast%3DOdeberg%26aufirst%3DJ.%26aulast%3DDjureinovic%26aufirst%3DD.%26aulast%3DTakanen%26aufirst%3DJ.%2BO.%26aulast%3DHober%26aufirst%3DS.%26aulast%3DAlm%26aufirst%3DT.%26aulast%3DEdqvist%26aufirst%3DP.%2BH.%26aulast%3DBerling%26aufirst%3DH.%26aulast%3DTegel%26aufirst%3DH.%26aulast%3DMulder%26aufirst%3DJ.%26aulast%3DRockberg%26aufirst%3DJ.%26aulast%3DNilsson%26aufirst%3DP.%26aulast%3DSchwenk%26aufirst%3DJ.%2BM.%26aulast%3DHamsten%26aufirst%3DM.%26aulast%3Dvon%2BFeilitzen%26aufirst%3DK.%26aulast%3DForsberg%26aufirst%3DM.%26aulast%3DPersson%26aufirst%3DL.%26aulast%3DJohansson%26aufirst%3DF.%26aulast%3DZwahlen%26aufirst%3DM.%26aulast%3Dvon%2BHeijne%26aufirst%3DG.%26aulast%3DNielsen%26aufirst%3DJ.%26aulast%3DPonten%26aufirst%3DF.%26atitle%3DProteomics.%2520Tissue-based%2520map%2520of%2520the%2520human%2520proteome%26jtitle%3DScience%26date%3D2015%26volume%3D347%26spage%3D394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group">Uhlen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oksvold, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fagerberg, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonasson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forsberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwahlen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kampf, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wester, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hober, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wernerus, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjorling, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ponten, F.</span><span> </span><span class="NLM_article-title">Towards a knowledge-based human protein atlas</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">1248</span><span class="NLM_x">–</span> <span class="NLM_lpage">1250</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1038%2Fnbt1210-1248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=21139605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFals7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=1248-1250&author=M.+Uhlenauthor=P.+Oksvoldauthor=L.+Fagerbergauthor=E.+Lundbergauthor=K.+Jonassonauthor=M.+Forsbergauthor=M.+Zwahlenauthor=C.+Kampfauthor=K.+Westerauthor=S.+Hoberauthor=H.+Wernerusauthor=L.+Bjorlingauthor=F.+Ponten&title=Towards+a+knowledge-based+human+protein+atlas"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Towards a knowledge-based Human Protein Atlas</span></div><div class="casAuthors">Uhlen, Mathias; Oksvold, Per; Fagerberg, Linn; Lundberg, Emma; Jonasson, Kalle; Forsberg, Mattias; Zwahlen, Martin; Kampf, Caroline; Wester, Kenneth; Hober, Sophia; Wernerus, Henrik; Bjoerling, Lisa; Ponten, Fredrik</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1248-1250</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrBEKpb82v_rVg90H21EOLACvtfcHk0liQXd9I_wNFcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFals7nO&md5=2d71435d159298360fa71b2c5f71b7d7</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1038%2Fnbt1210-1248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1210-1248%26sid%3Dliteratum%253Aachs%26aulast%3DUhlen%26aufirst%3DM.%26aulast%3DOksvold%26aufirst%3DP.%26aulast%3DFagerberg%26aufirst%3DL.%26aulast%3DLundberg%26aufirst%3DE.%26aulast%3DJonasson%26aufirst%3DK.%26aulast%3DForsberg%26aufirst%3DM.%26aulast%3DZwahlen%26aufirst%3DM.%26aulast%3DKampf%26aufirst%3DC.%26aulast%3DWester%26aufirst%3DK.%26aulast%3DHober%26aufirst%3DS.%26aulast%3DWernerus%26aufirst%3DH.%26aulast%3DBjorling%26aufirst%3DL.%26aulast%3DPonten%26aufirst%3DF.%26atitle%3DTowards%2520a%2520knowledge-based%2520human%2520protein%2520atlas%26jtitle%3DNat.%2520Biotechnol.%26date%3D2010%26volume%3D28%26spage%3D1248%26epage%3D1250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group">Zechmann, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Afshar-Oromieh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armor, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stubbs, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hadaschik, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joyal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kopka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debus, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babich, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haberkorn, U.</span><span> </span><span class="NLM_article-title">Radiation dosimetry and first therapy results with a I-124/I-131-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy</span> <span class="citation_source-journal">Eur. J. Nucl. Med. Mol. Imaging</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">1280</span><span class="NLM_x">–</span> <span class="NLM_lpage">1292</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1007%2Fs00259-014-2713-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=24577951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpvFGltrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2014&pages=1280-1292&author=C.+M.+Zechmannauthor=A.+Afshar-Oromiehauthor=T.+Armorauthor=J.+B.+Stubbsauthor=W.+Mierauthor=B.+Hadaschikauthor=J.+Joyalauthor=K.+Kopkaauthor=J.+Debusauthor=J.+W.+Babichauthor=U.+Haberkorn&title=Radiation+dosimetry+and+first+therapy+results+with+a+I-124%2FI-131-labeled+small+molecule+%28MIP-1095%29+targeting+PSMA+for+prostate+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy</span></div><div class="casAuthors">Zechmann, Christian M.; Afshar-Oromieh, Ali; Armor, Tom; Stubbs, James B.; Mier, Walter; Hadaschik, Boris; Joyal, John; Kopka, Klaus; Debus, Juergen; Babich, John W.; Haberkorn, Uwe</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Nuclear Medicine and Molecular Imaging</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1280-1292</span>CODEN:
                <span class="NLM_cas:coden">EJNMA6</span>;
        ISSN:<span class="NLM_cas:issn">1619-7070</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Introduction: Since the prostate-specific membrane antigen (PSMA) is frequently over-expressed in prostate cancer (PCa) several PSMA-targeting mols. are under development to detect and treat metastatic castration resistant prostate cancer (mCRPC).  We investigated the tissue kinetics of a small mol. inhibitor of PSMA ((S)-2-(3-((S)-1-carboxy-5-(3-(4-[124I]iodophenyl)ureido)pentyl)ureido)pentanedioicacid;MIP-1095) using PET/CT to est. radiation dosimetry for the potential therapeutic use of 131I-MIP-1095 in men with mCRPC.  We also report preliminary safety and efficacy of the first 28 consecutive patients treated under a compassionate-use protocol with a single cycle of 131I-MIP-1095.  Methods: Sixteen patients with known prostate cancer underwent PET/CT imaging after i.v. administration of 124I-MIP-1095 (mean activity: 67.4 MBq).  Each patient was scanned using PET/CT up to five times at 1, 4, 24, 48 and 72 h post injection.  Vols. of interest were defined for tumor lesions and normal organs at each time point followed by dose calcns. using the OLINDA/EXM software.  Twenty-eight men with mCRPC were treated with a single cycle of 131I-MIP-1095 (mean activity: 4.8 GBq, range 2 to 7.2 GBq) and followed for safety and efficacy.  Baseline and follow up examns. included a complete blood count, liver and kidney function tests, and measurement of serum PSA.  Results: I-124-MIP-1095 PET/CT images showed excellent tumor uptake and moderate uptake in liver, proximal intestine and within a few hours post-injection also in the kidneys.  High uptake values were obsd. only in salivary and lacrimal glands.  Dosimetry ests. for I-131-MIP-1095 revealed that the highest absorbed doses were delivered to the salivary glands (3.8 mSv/MBq), liver (1.7 mSv/MBq) and kidneys (1.4 mSv/MBq).  The absorbed dose calcd. for the red marrow was 0.37 mSv/MBq.  PSA values decreased by >50 % in 60.7 % of the men treated.  Of men with bone pain, 84.6 % showed complete or moderate redn. in pain.  Hematol. toxicities were mild.  Of men treated, 25 % had a transient slight to moderate dry mouth.  No adverse effects on renal function were obsd.  Conclusion: Based on the biodistribution and dose calcns. of the PSMA-targeted small mol. 124I-MIP-1095 therapy with the authentic analog 131I-MIP-1095 enables a targeted tumor therapy with unprecedented doses delivered to the tumor lesions.  Involved lymph node and bone metastases were exposed to estd. absorbed doses upwards of 300 Gy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoglz6WiJ4cwrVg90H21EOLACvtfcHk0ljmTVl8cOcYEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpvFGltrs%253D&md5=ceeddb0e8e38069a9f683302334d0529</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1007%2Fs00259-014-2713-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00259-014-2713-y%26sid%3Dliteratum%253Aachs%26aulast%3DZechmann%26aufirst%3DC.%2BM.%26aulast%3DAfshar-Oromieh%26aufirst%3DA.%26aulast%3DArmor%26aufirst%3DT.%26aulast%3DStubbs%26aufirst%3DJ.%2BB.%26aulast%3DMier%26aufirst%3DW.%26aulast%3DHadaschik%26aufirst%3DB.%26aulast%3DJoyal%26aufirst%3DJ.%26aulast%3DKopka%26aufirst%3DK.%26aulast%3DDebus%26aufirst%3DJ.%26aulast%3DBabich%26aufirst%3DJ.%2BW.%26aulast%3DHaberkorn%26aufirst%3DU.%26atitle%3DRadiation%2520dosimetry%2520and%2520first%2520therapy%2520results%2520with%2520a%2520I-124%252FI-131-labeled%2520small%2520molecule%2520%2528MIP-1095%2529%2520targeting%2520PSMA%2520for%2520prostate%2520cancer%2520therapy%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%2520Mol.%2520Imaging%26date%3D2014%26volume%3D41%26spage%3D1280%26epage%3D1292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group">Silver, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicer, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fair, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heston, W. D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">CordonCardo, C.</span><span> </span><span class="NLM_article-title">Prostate-specific membrane antigen expression in normal and malignant human tissues</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">81</span><span class="NLM_x">–</span> <span class="NLM_lpage">85</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=9815541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A280%3ADyaK1M%252FjsFamtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1997&pages=81-85&author=D.+A.+Silverauthor=I.+Pellicerauthor=W.+R.+Fairauthor=W.+D.+W.+Hestonauthor=C.+CordonCardo&title=Prostate-specific+membrane+antigen+expression+in+normal+and+malignant+human+tissues"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Prostate-specific membrane antigen expression in normal and malignant human tissues</span></div><div class="casAuthors">Silver D A; Pellicer I; Fair W R; Heston W D; Cordon-Cardo C</div><div class="citationInfo"><span class="NLM_cas:title">Clinical cancer research : an official journal of the American Association for Cancer Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">81-5</span>
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    </div><div class="casAbstract">Prostate-specific membrane antigen is a type II membrane protein with folate hydrolase activity produced by prostatic epithelium.  The expression of this molecule has also been documented in extraprostatic tissues, including small bowel and brain.  In the present study, an extensive immunohistochemical analysis was performed on a panel of well-characterized normal and malignant human tissues to further define the pattern of prostate-specific membrane antigen (PSMA) expression.  Detectable PSMA levels were identified in prostatic epithelium, duodenal mucosa, and a subset of proximal renal tubules.  A subpopulation of neuroendocrine cells in the colonic crypts also exhibited PSMA immunoreactivity.  All other normal tissues, including cerebral cortex and cerebellum, had undetectable levels of PSMA.  Thirty-three of 35 primary prostate adenocarcinomas and 7 of 8 lymph node metastases displayed tumor cell PSMA immunostaining.  Eight of 18 prostate tumors metastatic to bone expressed PSMA.  All of the other nonprostatic primary tumors studied had undetectable PSMA levels.  However, intense staining was observed in endothelial cells of capillary vessels in peritumoral and endotumoral areas of certain malignancies, including 8 of 17 renal cell carcinomas, 7 of 13 transitional cell carcinomas, and 3 of 19 colon carcinomas.  Extraprostatic PSMA expression appears to be highly restricted.  Nevertheless, its diverse anatomical distribution implies a broader functional significance than previously suspected.  The decrease in PSMA immunoreactivity noted in advanced prostate cancer suggests that expression of this molecule may be linked to the degree of tumor differentiation.  The neoexpression of PSMA in endothelial cells of capillary beds in certain tumors may be related to tumor angiogenesis and suggests a potential mechanism for specific targeting of tumor neovasculature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQa3hRIf6mlYUcLvDNbOD4DfW6udTcc2eameQwbRVHg8bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M%252FjsFamtA%253D%253D&md5=06fb3a1b21fc371a5e42843ed558e5eb</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSilver%26aufirst%3DD.%2BA.%26aulast%3DPellicer%26aufirst%3DI.%26aulast%3DFair%26aufirst%3DW.%2BR.%26aulast%3DHeston%26aufirst%3DW.%2BD.%2BW.%26aulast%3DCordonCardo%26aufirst%3DC.%26atitle%3DProstate-specific%2520membrane%2520antigen%2520expression%2520in%2520normal%2520and%2520malignant%2520human%2520tissues%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D1997%26volume%3D3%26spage%3D81%26epage%3D85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group">Israeli, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fair, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heston, W. D. W.</span><span> </span><span class="NLM_article-title">Molecular-cloning of a complementary-DNA encoding a prostate-specific membrane antigen</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">227</span><span class="NLM_x">–</span> <span class="NLM_lpage">230</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1993&pages=227-230&author=R.+S.+Israeliauthor=C.+T.+Powellauthor=W.+R.+Fairauthor=W.+D.+W.+Heston&title=Molecular-cloning+of+a+complementary-DNA+encoding+a+prostate-specific+membrane+antigen"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIsraeli%26aufirst%3DR.%2BS.%26aulast%3DPowell%26aufirst%3DC.%2BT.%26aulast%3DFair%26aufirst%3DW.%2BR.%26aulast%3DHeston%26aufirst%3DW.%2BD.%2BW.%26atitle%3DMolecular-cloning%2520of%2520a%2520complementary-DNA%2520encoding%2520a%2520prostate-specific%2520membrane%2520antigen%26jtitle%3DCancer%2520Res.%26date%3D1993%26volume%3D53%26spage%3D227%26epage%3D230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group">Chang, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuter, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heston, W. D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bander, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grauer, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaudin, P. B.</span><span> </span><span class="NLM_article-title">Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">3192</span><span class="NLM_x">–</span> <span class="NLM_lpage">3198</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10397265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADyaK1MXksVCqtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1999&pages=3192-3198&author=S.+S.+Changauthor=V.+E.+Reuterauthor=W.+D.+W.+Hestonauthor=N.+H.+Banderauthor=L.+S.+Grauerauthor=P.+B.+Gaudin&title=Five+different+anti-prostate-specific+membrane+antigen+%28PSMA%29+antibodies+confirm+PSMA+expression+in+tumor-associated+neovasculature"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature</span></div><div class="casAuthors">Chang, Sam S.; Reuter, Victor E.; Heston, W. D. W.; Bander, Neil H.; Grauer, Lana S.; Gaudin, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3192-3198</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">AACR Subscription Office</span>)
        </div><div class="casAbstract">Prostate-specific membrane antigen (PSMA) is a type II integral membrane glycoprotein that was initially characterized by the monoclonal antibody (mAb) 7E11.  PSMA is highly expressed in prostate secretory-acinar epithelium and prostate cancer as well as in several extraprostatic tissues.  Recent evidence suggests that PSMA is also expressed in tumor-assocd. neovasculature.  We examd. the immunohistochem. characteristics of 7E11 and those of four recently developed anti-PSMA mAbs (J591, J415, and Hybritech PEQ226.5 and PM2J004.5), each of which binds a distinct epitope of PSMA.  Using the streptavidin-biotin method, we evaluated these mAbs in viable prostate cancer cell lines and various fresh-frozen benign and malignant tissue specimens.  In the latter, we compared the localization of the anti-PSMA mAbs to that of the anti-endothelial cell mAb CD34.  With rare exceptions, all five anti-PSMA mAbs reacted strongly with the neovasculature of a wide spectrum of malignant neoplasms: conventional (clear cell) renal carcinoma (11 of 11 cases), transitional cell carcinoma of the urinary bladder (6 of 6 cases), testicular embryonal carcinoma (1 of 1 case), colonic adenocarcinoma (5 of 5 cases), neuroendocrine carcinoma (5 of 5 cases), glioblastoma multiforme (1 of 1 cases), malignant melanoma (5 of 5 cases), pancreatic duct carcinoma (4 of 4 cases), non-small cell lung carcinoma (5 of 5 cases), soft tissue sarcoma (5 of 6 cases), breast carcinoma (5 of 6 cases), and prostatic adenocarcinoma (2 of 12 cases).  Localization of the anti-PSMA mAbs to tumor-assocd. neovasculature was confirmed by CD34 immunohistochem. in sequential tissue sections.  Normal vascular endothelium in non-cancer-bearing tissue was consistently PSMA neg.  The anti-PSMA mAbs reacted with the neoplastic cells of prostatic adenocarcinoma (12 of 12 cases) but not with the neoplastic cells of any other tumor type, including those of benign and malignant vascular tumors (0 of 3 hemangiomas, 0 of 1 hemangioendothelioma, and 0 of 1 angiosarcoma).  The mAbs to the extracellular PSMA domain (J591, J415, and Hybritech PEQ226.5) bound viable prostate cancer cells (LNCaP and PC3-PIP), whereas the mAbs to the intracellular domain (7E11 and Hybritech PM2J004.5) did not.  All five anti-PSMA mAbs reacted with fresh-frozen benign prostate secretory-acinar epithelium (28 of 28 cases), duodenal columnar (brush border) epithelium (11 of 11 cases), proximal renal tubular epithelium (5 of 5 cases), colonic ganglion cells (1 of 12 cases), and benign breast epithelium (8 of 8 cases).  A subset of skeletal muscle cells was pos. with 7E11 (7 of 7 cases) and neg. with the other four anti-PSMA mAbs.  PSMA was consistently expressed in the neovasculature of a wide variety of malignant neoplasms and may be an effective target for mAb-based antineovasculature therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaiAU2o4bdlrVg90H21EOLACvtfcHk0ljmTVl8cOcYEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXksVCqtbs%253D&md5=9da67909245aeb912538d4d5ec571472</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DS.%2BS.%26aulast%3DReuter%26aufirst%3DV.%2BE.%26aulast%3DHeston%26aufirst%3DW.%2BD.%2BW.%26aulast%3DBander%26aufirst%3DN.%2BH.%26aulast%3DGrauer%26aufirst%3DL.%2BS.%26aulast%3DGaudin%26aufirst%3DP.%2BB.%26atitle%3DFive%2520different%2520anti-prostate-specific%2520membrane%2520antigen%2520%2528PSMA%2529%2520antibodies%2520confirm%2520PSMA%2520expression%2520in%2520tumor-associated%2520neovasculature%26jtitle%3DCancer%2520Res.%26date%3D1999%26volume%3D59%26spage%3D3192%26epage%3D3198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajasekaran, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navarro, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knudsen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bander, N. H.</span><span> </span><span class="NLM_article-title">Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">3629</span><span class="NLM_x">–</span> <span class="NLM_lpage">3634</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=9288760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADyaK2sXlvFensbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1997&pages=3629-3634&author=H.+Liuauthor=P.+Moyauthor=S.+Kimauthor=Y.+Xiaauthor=A.+Rajasekaranauthor=V.+Navarroauthor=B.+Knudsenauthor=N.+H.+Bander&title=Monoclonal+antibodies+to+the+extracellular+domain+of+prostate-specific+membrane+antigen+also+react+with+tumor+vascular+endothelium"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium</span></div><div class="casAuthors">Liu, He; Moy, Peggy; Kim, Sae; Xia, Yan; Rajasekaran, Ayyappan; Navarro, Vincent; Knudsen, Beatrice; Bander, Neil H.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3629-3634</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Prostate-specific membrane antigen (PSMA), initially defined by monoclonal antibody (mAb) 7E11, is a now well-characterized type 2 integral membrane glycoprotein expressed in a highly restricted manner by prostate epithelial cells.  7E11 has been shown to bind an intracellular epitope of PSMA that, in viable cells, is not available for binding.  Herein, the authors report the initial characterization of the first 4 reported IgG mAbs that bind the external domain of PSMA.  Competitive binding studies indicate these antibodies define 2 distinct, noncompeting epitopes on the extracellular domain of PSMA.  In contrast to 7E11, these mAbs bind to viable LNCaP cells in vitro.  In addn., they show strong immunohistochem. reactivity to tissue sections of prostate epithelia, including prostate cancer.  These mAbs were also strongly reactive with vascular endothelium within a wide variety of carcinomas (including lung, colon, breast, and others) but not with normal vascular endothelium.  These antibodies should prove useful for in vivo targeting to prostate cancer, as well as to the vascular compartment of a wide variety of carcinomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnfwsJ-92adbVg90H21EOLACvtfcHk0lhXzKx35PCJgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXlvFensbo%253D&md5=35bfbebbbca72a6d5ef3667d84a772c3</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DMoy%26aufirst%3DP.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DXia%26aufirst%3DY.%26aulast%3DRajasekaran%26aufirst%3DA.%26aulast%3DNavarro%26aufirst%3DV.%26aulast%3DKnudsen%26aufirst%3DB.%26aulast%3DBander%26aufirst%3DN.%2BH.%26atitle%3DMonoclonal%2520antibodies%2520to%2520the%2520extracellular%2520domain%2520of%2520prostate-specific%2520membrane%2520antigen%2520also%2520react%2520with%2520tumor%2520vascular%2520endothelium%26jtitle%3DCancer%2520Res.%26date%3D1997%26volume%3D57%26spage%3D3629%26epage%3D3634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group">De Simone, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alterio, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Supuran, C. T.</span><span> </span><span class="NLM_article-title">Exploiting the hydrophobic and hydrophilic binding sites for designing carbonic anhydrase inhibitors</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">793</span><span class="NLM_x">–</span> <span class="NLM_lpage">810</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1517%2F17460441.2013.795145" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=23627619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpslCnsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=793-810&author=G.+De+Simoneauthor=V.+Alterioauthor=C.+T.+Supuran&title=Exploiting+the+hydrophobic+and+hydrophilic+binding+sites+for+designing+carbonic+anhydrase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Exploiting the hydrophobic and hydrophilic binding sites for designing carbonic anhydrase inhibitors</span></div><div class="casAuthors">De Simone, Giuseppina; Alterio, Vincenzo; Supuran, Claudiu T.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">793-810</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Carbonic anhydrases (CAs, EC 4.2.1.1) exist as five genetically distinct families (α, β, γ, δ and ζ) in organisms all over the phylogenetic tree.  Due to the ubiquity of such enzymes, the selective inhibition and polypharmacol. of inhibitors is an important aspect of all drug design campaigns.  There are several classes of CA inhibitors (CAIs): i) metal ion binders (sulfonamides and their isosteres [sulfamates/sulfamides], dithiocarbamates, mercaptans and hydroxamates); ii) compds. anchoring to the zinc-coordinated water mol./hydroxide ion (phenols, carboxylates, polyamines, esters and sulfocoumarins) and iii) coumarins and related compds. which apparently bind even further away from the metal ion.  Areas covered: The authors rationalize the drug design strategies of inhibitors belonging to the first two classes, based on recent X-ray crystallog. data.  More precisely, this is achieved by analyzing how the hydrophobic and hydrophilic halves of the enzyme active site interact with inhibitors.  This task has been eased by the recent report of β-CA-like enzymes possessing carbon disulfide and carbonyl sulfide hydrolase activities, resp., allowing the authors to propose a general approach of structure-based drug design of CAIs.  Expert opinion: Although amazing progress has been made in the structure-based drug design of CAIs, this field is still in progress, with many constantly emerging new findings.  Indeed, several new such enzymes were discovered and characterized recently and novel chemotypes were explored for finding compds. with a better inhibition profile.  It is anticipated that this will continue to be one of the main frontiers in the search of pharmacol. relevant enzyme inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolHwWEtsN36rVg90H21EOLACvtfcHk0lhXzKx35PCJgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpslCnsb0%253D&md5=a17278d030023ae0a92e1efd33531e93</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1517%2F17460441.2013.795145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2013.795145%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSimone%26aufirst%3DG.%26aulast%3DAlterio%26aufirst%3DV.%26aulast%3DSupuran%26aufirst%3DC.%2BT.%26atitle%3DExploiting%2520the%2520hydrophobic%2520and%2520hydrophilic%2520binding%2520sites%2520for%2520designing%2520carbonic%2520anhydrase%2520inhibitors%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2013%26volume%3D8%26spage%3D793%26epage%3D810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group">Thiry, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dogne, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masereel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Supuran, C. T.</span><span> </span><span class="NLM_article-title">Targeting tumor-associated carbonic anhydrase IX in cancer therapy</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">566</span><span class="NLM_x">–</span> <span class="NLM_lpage">573</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2006&pages=566-573&author=A.+Thiryauthor=J.+M.+Dogneauthor=B.+Masereelauthor=C.+T.+Supuran&title=Targeting+tumor-associated+carbonic+anhydrase+IX+in+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DThiry%26aufirst%3DA.%26aulast%3DDogne%26aufirst%3DJ.%2BM.%26aulast%3DMasereel%26aufirst%3DB.%26aulast%3DSupuran%26aufirst%3DC.%2BT.%26atitle%3DTargeting%2520tumor-associated%2520carbonic%2520anhydrase%2520IX%2520in%2520cancer%2520therapy%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2006%26volume%3D27%26spage%3D566%26epage%3D573" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group">Bui, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seligson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pantuck, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorey, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horvath, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leibovich, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chopra, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanbridge, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerman, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palotie, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Figlin, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belldegrun, A. S.</span><span> </span><span class="NLM_article-title">Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">802</span><span class="NLM_x">–</span> <span class="NLM_lpage">811</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=12576453" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtVKksbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=802-811&author=M.+H.+Buiauthor=D.+Seligsonauthor=K.+R.+Hanauthor=A.+J.+Pantuckauthor=F.+J.+Doreyauthor=Y.+Huangauthor=S.+Horvathauthor=B.+C.+Leibovichauthor=S.+Chopraauthor=S.+Y.+Liaoauthor=E.+Stanbridgeauthor=M.+I.+Lermanauthor=A.+Palotieauthor=R.+A.+Figlinauthor=A.+S.+Belldegrun&title=Carbonic+anhydrase+IX+is+an+independent+predictor+of+survival+in+advanced+renal+clear+cell+carcinoma%3A+implications+for+prognosis+and+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: Implications for prognosis and therapy</span></div><div class="casAuthors">Bui, Matthew H. T.; Seligson, David; Han, Ken-ryu; Pantuck, Allan J.; Dorey, Frederick J.; Huang, Yunda; Horvath, Steve; Leibovich, Bradley C.; Chopra, Shefali; Liao, Shu-Yuan; Stanbridge, Eric; Lerman, Michael I.; Palotie, Aarno; Figlin, Robert A.; Belldegrun, Arie S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">802-811</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Metastatic renal cell carcinoma (RCC) has a poor prognosis and an unpredictable course.  To date, there are no mol. markers which can reliably predict RCC outcome.  We investigated whether a novel kidney cancer marker, carbonic anhydrase IX (CAIX), is assocd. with progression and survival.  Immunohistochem. anal. using a CAIX monoclonal antibody was performed on tissue microarrays constructed from paraffin-embedded specimens from patients (N = 321) treated by nephrectomy for clear cell RCC.  CAIX staining was correlated with response to treatment, clin. factors, pathol. features, and survival.  CAIX staining was present in 94% of clear cell RCCs.  Survival tree anal. detd. that a cutoff of 85% CAIX staining provided the most accurate prediction of survival.  Low CAIX (≤85%) staining was an independent poor prognostic factor for survival for patients with metastatic RCC, with a hazard ratio of 3.10 (P < 0.001).  CAIX significantly substratified patients with metastatic disease when analyzed by T stage, Fuhrman grade, nodal involvement, and performance status.  For patients with nonmetastatic RCC and at high risk for progression, low CAIX predicted a worse outcome similar to patients with metastatic disease.  Overall expression of CAIX decreased with development of metastasis; as demonstrated by the lower CAIX staining levels in metastatic lesions relative to matched primary tumor specimens.  On the basis of our data, CAIX is the most significant mol. marker described in kidney cancer to date.  Decreased CAIX levels are independently assocd. with poor survival in advanced RCC.  CAIX reflects significant changes in tumor biol., which should be used to predict clin. outcome and identify high-risk patients in need for adjuvant immunotherapy and CAIX-targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn0CJC-APRsrVg90H21EOLACvtfcHk0ljFKDpEOkIhOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtVKksbg%253D&md5=f112d99528227748821a97213fdf45ea</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBui%26aufirst%3DM.%2BH.%26aulast%3DSeligson%26aufirst%3DD.%26aulast%3DHan%26aufirst%3DK.%2BR.%26aulast%3DPantuck%26aufirst%3DA.%2BJ.%26aulast%3DDorey%26aufirst%3DF.%2BJ.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DHorvath%26aufirst%3DS.%26aulast%3DLeibovich%26aufirst%3DB.%2BC.%26aulast%3DChopra%26aufirst%3DS.%26aulast%3DLiao%26aufirst%3DS.%2BY.%26aulast%3DStanbridge%26aufirst%3DE.%26aulast%3DLerman%26aufirst%3DM.%2BI.%26aulast%3DPalotie%26aufirst%3DA.%26aulast%3DFiglin%26aufirst%3DR.%2BA.%26aulast%3DBelldegrun%26aufirst%3DA.%2BS.%26atitle%3DCarbonic%2520anhydrase%2520IX%2520is%2520an%2520independent%2520predictor%2520of%2520survival%2520in%2520advanced%2520renal%2520clear%2520cell%2520carcinoma%253A%2520implications%2520for%2520prognosis%2520and%2520therapy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2003%26volume%3D9%26spage%3D802%26epage%3D811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group">Svastova, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hulikova, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rafajova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zat’ovicova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibadulinova, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cecchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scozzafava, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Supuran, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pastorek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pastorekova, S.</span><span> </span><span class="NLM_article-title">Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH</span> <span class="citation_source-journal">FEBS Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">577</span><span class="NLM_x">, </span> <span class="NLM_fpage">439</span><span class="NLM_x">–</span> <span class="NLM_lpage">445</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=577&publication_year=2004&pages=439-445&author=E.+Svastovaauthor=A.+Hulikovaauthor=M.+Rafajovaauthor=M.+Zat%E2%80%99ovicovaauthor=A.+Gibadulinovaauthor=A.+Casiniauthor=A.+Cecchiauthor=A.+Scozzafavaauthor=C.+T.+Supuranauthor=J.+Pastorekauthor=S.+Pastorekova&title=Hypoxia+activates+the+capacity+of+tumor-associated+carbonic+anhydrase+IX+to+acidify+extracellular+pH"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSvastova%26aufirst%3DE.%26aulast%3DHulikova%26aufirst%3DA.%26aulast%3DRafajova%26aufirst%3DM.%26aulast%3DZat%25E2%2580%2599ovicova%26aufirst%3DM.%26aulast%3DGibadulinova%26aufirst%3DA.%26aulast%3DCasini%26aufirst%3DA.%26aulast%3DCecchi%26aufirst%3DA.%26aulast%3DScozzafava%26aufirst%3DA.%26aulast%3DSupuran%26aufirst%3DC.%2BT.%26aulast%3DPastorek%26aufirst%3DJ.%26aulast%3DPastorekova%26aufirst%3DS.%26atitle%3DHypoxia%2520activates%2520the%2520capacity%2520of%2520tumor-associated%2520carbonic%2520anhydrase%2520IX%2520to%2520acidify%2520extracellular%2520pH%26jtitle%3DFEBS%2520Lett.%26date%3D2004%26volume%3D577%26spage%3D439%26epage%3D445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group">Scheurer, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rybak, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elia, G.</span><span> </span><span class="NLM_article-title">Modulation of gene expression by hypoxia in human umbilical cord vein endothelial cells: A transcriptomic and proteomic study</span> <span class="citation_source-journal">Proteomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1737</span><span class="NLM_x">–</span> <span class="NLM_lpage">1760</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=1737-1760&author=S.+B.+Scheurerauthor=J.+N.+Rybakauthor=C.+Rosliauthor=D.+Neriauthor=G.+Elia&title=Modulation+of+gene+expression+by+hypoxia+in+human+umbilical+cord+vein+endothelial+cells%3A+A+transcriptomic+and+proteomic+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DScheurer%26aufirst%3DS.%2BB.%26aulast%3DRybak%26aufirst%3DJ.%2BN.%26aulast%3DRosli%26aufirst%3DC.%26aulast%3DNeri%26aufirst%3DD.%26aulast%3DElia%26aufirst%3DG.%26atitle%3DModulation%2520of%2520gene%2520expression%2520by%2520hypoxia%2520in%2520human%2520umbilical%2520cord%2520vein%2520endothelial%2520cells%253A%2520A%2520transcriptomic%2520and%2520proteomic%2520study%26jtitle%3DProteomics%26date%3D2004%26volume%3D4%26spage%3D1737%26epage%3D1760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group">Petrul, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schatz, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kopitz, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adnane, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCabe, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trail, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ha, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voznesensky, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranges, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamburini, P. P.</span><span> </span><span class="NLM_article-title">Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9</span> <span class="citation_source-journal">Mol. Cancer. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">340</span><span class="NLM_x">–</span> <span class="NLM_lpage">349</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1158%2F1535-7163.MCT-11-0523" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=22147747" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFWltbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=340-349&author=H.+M.+Petrulauthor=C.+A.+Schatzauthor=C.+C.+Kopitzauthor=L.+Adnaneauthor=T.+J.+McCabeauthor=P.+Trailauthor=S.+Haauthor=Y.+S.+Changauthor=A.+Voznesenskyauthor=G.+Rangesauthor=P.+P.+Tamburini&title=Therapeutic+mechanism+and+efficacy+of+the+antibody-drug+conjugate+BAY+79-4620+targeting+human+carbonic+anhydrase+9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Mechanism and Efficacy of the Antibody-Drug Conjugate BAY 79-4620 Targeting Human Carbonic Anhydrase 9</span></div><div class="casAuthors">Petrul, Heike M.; Schatz, Christoph A.; Kopitz, Charlotte C.; Adnane, Lila; McCabe, Timothy J.; Trail, Pamela; Ha, Sha; Chang, Yong S.; Voznesensky, Andrei; Ranges, Gerald; Tamburini, Paul P.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">340-349</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Carbonic anhydrase IX (CAIX) is a cell surface glycoprotein that is expressed in many different tumors and yet restricted in normal tissues to the gastrointestinal tract.  It is upregulated by hypoxia and correlates with tumor grade and poor survival in several tumor indications.  Monoclonal antibodies (mAb) with single digit nanomolar binding affinity for CAIX were derived by panning with the recombinant ectodomain of CAIX against the MorphoSys HUCAL Gold library of human Fabs.  Highest affinity Fabs were converted to full-length IgGs and subjected to further characterization based upon their avidity and selectivity for CAIX, their capacity to undergo internalization in CAIX-expressing cell lines, and their selective localization to CAIX-pos. human xenografted tumors when administered to mice as fluorescent conjugates.  Through this selection process, the 3ee9 mAb was identified, which upon conjugation to monomethyl auristatin E through a self-immolative enzyme-cleavable linker yielded the potent and selective CAIX antibody-drug conjugate CAIX-ADC (BAY 79-4620).  In preclin. human xenograft models in mice representing several tumor indications, BAY 79-4620 showed potent antitumor efficacy and in some models showed partial and complete tumor shrinkage even following a single dose.  The mechanism of action was shown by histol. to involve the sequelae of events typical of antitubulin agents.  Efficacy in murine preclin. models correlated semiquant., with CAIX expression levels as detd. by immunohistochem. and ELISA.  These preclin. data collectively support the development of BAY 79-4620 for the treatment of cancer patients with CAIX overexpressing tumors.  Mol Cancer Ther; 11(2); 340-9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzBKmx-bIGLrVg90H21EOLACvtfcHk0ljFKDpEOkIhOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFWltbg%253D&md5=93d29b1c4b8b23cb39a8efd6e8490322</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0523%26sid%3Dliteratum%253Aachs%26aulast%3DPetrul%26aufirst%3DH.%2BM.%26aulast%3DSchatz%26aufirst%3DC.%2BA.%26aulast%3DKopitz%26aufirst%3DC.%2BC.%26aulast%3DAdnane%26aufirst%3DL.%26aulast%3DMcCabe%26aufirst%3DT.%2BJ.%26aulast%3DTrail%26aufirst%3DP.%26aulast%3DHa%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DY.%2BS.%26aulast%3DVoznesensky%26aufirst%3DA.%26aulast%3DRanges%26aufirst%3DG.%26aulast%3DTamburini%26aufirst%3DP.%2BP.%26atitle%3DTherapeutic%2520mechanism%2520and%2520efficacy%2520of%2520the%2520antibody-drug%2520conjugate%2520BAY%252079-4620%2520targeting%2520human%2520carbonic%2520anhydrase%25209%26jtitle%3DMol.%2520Cancer.%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D340%26epage%3D349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group">Dubois, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lieuwes, N. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maresca, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thiry, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Supuran, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scozzafava, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wouters, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambin, P.</span><span> </span><span class="NLM_article-title">Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model</span> <span class="citation_source-journal">Radiother. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">423</span><span class="NLM_x">–</span> <span class="NLM_lpage">428</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1016%2Fj.radonc.2009.06.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=19616332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFajtL%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2009&pages=423-428&author=L.+Duboisauthor=N.+G.+Lieuwesauthor=A.+Marescaauthor=A.+Thiryauthor=C.+T.+Supuranauthor=A.+Scozzafavaauthor=B.+G.+Woutersauthor=P.+Lambin&title=Imaging+of+CA+IX+with+fluorescent+labelled+sulfonamides+distinguishes+hypoxic+and+%28re%29-oxygenated+cells+in+a+xenograft+tumour+model"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model</span></div><div class="casAuthors">Dubois, Ludwig; Lieuwes, Natasja G.; Maresca, Alfonso; Thiry, Anne; Supuran, Claudiu T.; Scozzafava, Andrea; Wouters, Bradly G.; Lambin, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">Radiotherapy and Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">423-428</span>CODEN:
                <span class="NLM_cas:coden">RAONDT</span>;
        ISSN:<span class="NLM_cas:issn">0167-8140</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Background and purpose: Carbonic anhydrase (CA) IX is suggested to be an endogenous marker of hypoxia.  Fluorescent sulfonamides with a high affinity for CA IX (CAI) have been developed and shown to bind to cells only when CA IX protein was expressed and while cells were hypoxic.  The aim of this study was to investigate the in vivo CAI binding properties in a xenograft tumor model using fluorescent imaging.  Materials and methods: NMRI-nu mice s.c. transplanted with HT-29 colorectal tumors were treated with 7% oxygen or with nicotinamide and carbogen and were compared with control animals.  CAI accumulation was monitored by non-invasive fluorescent imaging.  Results: Specific CAI accumulation could be obsd. in delineated tumor areas as compared with a non-sulfonamide analog (P < 0.01).  Administration of nicotinamide and carbogen, decreasing acute and chronic hypoxia, resp., prevented CAI accumulation (P < 0.05).  When treated with 7% oxygen breathing, a 3-fold higher CAI accumulation (P < 0.01) was obsd.  Furthermore, the bound CAI fraction was rapidly reduced upon tumor reoxygenation (P < 0.01).  Conclusions: Our in vivo imaging results confirm previous in vitro data demonstrating that CAI binding and retention require exposure to hypoxia.  Fluorescent labeled sulfonamides provide a powerful tool to visualize hypoxia response.  An important step is made towards clin. applicability, indicating the potential of patient selection for CA IX-directed therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqflu9ig3U107Vg90H21EOLACvtfcHk0liATty3cq5e4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFajtL%252FE&md5=281fab357f99b53bd768aa4c2c77eadd</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2Fj.radonc.2009.06.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.radonc.2009.06.019%26sid%3Dliteratum%253Aachs%26aulast%3DDubois%26aufirst%3DL.%26aulast%3DLieuwes%26aufirst%3DN.%2BG.%26aulast%3DMaresca%26aufirst%3DA.%26aulast%3DThiry%26aufirst%3DA.%26aulast%3DSupuran%26aufirst%3DC.%2BT.%26aulast%3DScozzafava%26aufirst%3DA.%26aulast%3DWouters%26aufirst%3DB.%2BG.%26aulast%3DLambin%26aufirst%3DP.%26atitle%3DImaging%2520of%2520CA%2520IX%2520with%2520fluorescent%2520labelled%2520sulfonamides%2520distinguishes%2520hypoxic%2520and%2520%2528re%2529-oxygenated%2520cells%2520in%2520a%2520xenograft%2520tumour%2520model%26jtitle%3DRadiother.%2520Oncol.%26date%3D2009%26volume%3D92%26spage%3D423%26epage%3D428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group">Maurer, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elsinga, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyen, W. J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, W. A.</span><span> </span><span class="NLM_article-title">Imaging the folate receptor on cancer cells with Tc-99m-etarfolatide: Properties, clinical use, and future potential of folate receptor imaging</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">701</span><span class="NLM_x">–</span> <span class="NLM_lpage">704</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2014&pages=701-704&author=A.+H.+Maurerauthor=P.+Elsingaauthor=S.+Fantiauthor=B.+Nguyenauthor=W.+J.+G.+Oyenauthor=W.+A.+Weber&title=Imaging+the+folate+receptor+on+cancer+cells+with+Tc-99m-etarfolatide%3A+Properties%2C+clinical+use%2C+and+future+potential+of+folate+receptor+imaging"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMaurer%26aufirst%3DA.%2BH.%26aulast%3DElsinga%26aufirst%3DP.%26aulast%3DFanti%26aufirst%3DS.%26aulast%3DNguyen%26aufirst%3DB.%26aulast%3DOyen%26aufirst%3DW.%2BJ.%2BG.%26aulast%3DWeber%26aufirst%3DW.%2BA.%26atitle%3DImaging%2520the%2520folate%2520receptor%2520on%2520cancer%2520cells%2520with%2520Tc-99m-etarfolatide%253A%2520Properties%252C%2520clinical%2520use%252C%2520and%2520future%2520potential%2520of%2520folate%2520receptor%2520imaging%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2014%26volume%3D55%26spage%3D701%26epage%3D704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group">Kularatne, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santhapuram, H. K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Low, P. S.</span><span> </span><span class="NLM_article-title">Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">780</span><span class="NLM_x">–</span> <span class="NLM_lpage">789</span></span><div class="citationLinks">[<a href="/doi/10.1021/mp900069d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsF2hsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2009&pages=780-789&author=S.+A.+Kularatneauthor=K.+Wangauthor=H.+K.+R.+Santhapuramauthor=P.+S.+Low&title=Prostate-specific+membrane+antigen+targeted+imaging+and+therapy+of+prostate+cancer+using+a+PSMA+inhibitor+as+a+homing+ligand"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand</span></div><div class="casAuthors">Kularatne, Sumith A.; Wang, Kevin; Santhapuram, Hari-Krishna R.; Low, Philip S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">780-789</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Prostate cancer (PCa) is a major cause of mortality and morbidity in Western society today.  Current methods for detecting PCa are limited, leaving most early malignancies undiagnosed and sites of metastasis in advanced disease undetected.  Major deficiencies also exist in the treatment of PCa, esp. metastatic disease.  In an effort to improve both detection and therapy of PCa, we have developed a PSMA-targeted ligand that delivers attached imaging and therapeutic agents selectively to PCa cells without targeting normal cells.  The PSMA-targeted radioimaging agent (DUPA-99mTc) was found to bind PSMA-pos. human PCa cells (LNCaP cell line) with nanomolar affinity (KD = 14 nM).  Imaging and biodistribution studies revealed that DUPA-99mTc localizes primarily to LNCaP cell tumor xenografts in nu/nu mice (% injected dose/g = 11.3 at 4 h postinjection; tumor-to-muscle ratio = 75:1).  Two PSMA-targeted optical imaging agents (DUPA-FITC and DUPA-rhodamine B) were also shown to efficiently label PCa cells and to internalize and traffic to intracellular endosomes.  A PSMA-targeted chemotherapeutic agent (DUPA-TubH) was demonstrated to kill PSMA-pos. LNCaP cells in culture (IC50 = 3 nM) and to eliminate established tumor xenografts in nu/nu mice with no detectable wt. loss.  Blockade of tumor targeting upon administration of excess PSMA inhibitor (PMPA) and the absence of targeting to PSMA-neg. tumors confirmed the specificity of each of the above targeted reagents for PSMA.  Tandem use of the imaging and therapeutic agents targeted to the same receptor could allow detection, staging, monitoring, and treatment of PCa with improved accuracy and efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoF7vaoehkEsrVg90H21EOLACvtfcHk0liATty3cq5e4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsF2hsrw%253D&md5=2fba93274e7f4c4ff0910e2edef9e189</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1021%2Fmp900069d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp900069d%26sid%3Dliteratum%253Aachs%26aulast%3DKularatne%26aufirst%3DS.%2BA.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DSanthapuram%26aufirst%3DH.%2BK.%2BR.%26aulast%3DLow%26aufirst%3DP.%2BS.%26atitle%3DProstate-specific%2520membrane%2520antigen%2520targeted%2520imaging%2520and%2520therapy%2520of%2520prostate%2520cancer%2520using%2520a%2520PSMA%2520inhibitor%2520as%2520a%2520homing%2520ligand%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2009%26volume%3D6%26spage%3D780%26epage%3D789" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group">Cohen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vugts, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Visser, G. W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stigter-Van Walsum, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolijn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spiga, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lazzari, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shankar, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zanda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Dongen, G. A. M. S.</span><span> </span><span class="NLM_article-title">Development of novel ADCs: Conjugation of tubulysin analogues to trastuzumab monitored by dual radiolabeling</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">5700</span><span class="NLM_x">–</span> <span class="NLM_lpage">5710</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=5700-5710&author=R.+Cohenauthor=D.+J.+Vugtsauthor=G.+W.+M.+Visserauthor=M.+Stigter-Van+Walsumauthor=M.+Bolijnauthor=M.+Spigaauthor=P.+Lazzariauthor=E.+Shankarauthor=M.+Saniauthor=M.+Zandaauthor=G.+A.+M.+S.+Van+Dongen&title=Development+of+novel+ADCs%3A+Conjugation+of+tubulysin+analogues+to+trastuzumab+monitored+by+dual+radiolabeling"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DR.%26aulast%3DVugts%26aufirst%3DD.%2BJ.%26aulast%3DVisser%26aufirst%3DG.%2BW.%2BM.%26aulast%3DStigter-Van%2BWalsum%26aufirst%3DM.%26aulast%3DBolijn%26aufirst%3DM.%26aulast%3DSpiga%26aufirst%3DM.%26aulast%3DLazzari%26aufirst%3DP.%26aulast%3DShankar%26aufirst%3DE.%26aulast%3DSani%26aufirst%3DM.%26aulast%3DZanda%26aufirst%3DM.%26aulast%3DVan%2BDongen%26aufirst%3DG.%2BA.%2BM.%2BS.%26atitle%3DDevelopment%2520of%2520novel%2520ADCs%253A%2520Conjugation%2520of%2520tubulysin%2520analogues%2520to%2520trastuzumab%2520monitored%2520by%2520dual%2520radiolabeling%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D5700%26epage%3D5710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group">Erez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Segal, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satchi-Fainaro, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shabat, D.</span><span> </span><span class="NLM_article-title">Enhanced cytotoxicity of a polymer-drug conjugate with triple payload of paclitaxel</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">4327</span><span class="NLM_x">–</span> <span class="NLM_lpage">4335</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1016%2Fj.bmc.2009.05.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=19482477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnt1Gru78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=4327-4335&author=R.+Erezauthor=E.+Segalauthor=K.+Millerauthor=R.+Satchi-Fainaroauthor=D.+Shabat&title=Enhanced+cytotoxicity+of+a+polymer-drug+conjugate+with+triple+payload+of+paclitaxel"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced cytotoxicity of a polymer-drug conjugate with triple payload of paclitaxel</span></div><div class="casAuthors">Erez, Rotem; Segal, Ehud; Miller, Keren; Satchi-Fainaro, Ronit; Shabat, Doron</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4327-4335</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The development of targeting approaches to selectively release chemotherapeutic drugs into malignant tissue is a major challenge in anticancer therapy.  We have synthesized an N-(2-hydroxypropyl)-methacrylamide (HPMA) copolymer-drug conjugate with an AB3 self-immolative dendritic linker.  HPMA copolymers are known to accumulate selectively in tumors.  The water-sol. polymer-drug conjugate was designed to release a triple payload of the hydrophobic drug paclitaxel as a result of cleavage by the endogenous enzyme cathepsin B. The polymer-drug conjugate exhibited enhanced cytotoxicity on murine prostate adenocarcinoma (TRAMP C2) cells in comparison to a classic monomeric drug-polymer conjugate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTGwHdZDyk2bVg90H21EOLACvtfcHk0lirlUmksojBtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnt1Gru78%253D&md5=80c0b9b2c90d9bd6cbbbd2810263b77c</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2009.05.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2009.05.028%26sid%3Dliteratum%253Aachs%26aulast%3DErez%26aufirst%3DR.%26aulast%3DSegal%26aufirst%3DE.%26aulast%3DMiller%26aufirst%3DK.%26aulast%3DSatchi-Fainaro%26aufirst%3DR.%26aulast%3DShabat%26aufirst%3DD.%26atitle%3DEnhanced%2520cytotoxicity%2520of%2520a%2520polymer-drug%2520conjugate%2520with%2520triple%2520payload%2520of%2520paclitaxel%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2009%26volume%3D17%26spage%3D4327%26epage%3D4335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group">Ojima, I.</span><span> </span><span class="NLM_article-title">Guided molecular missiles for tumor-targeting chemotherapy-case studies using the second-generation taxolds as warheads</span> <span class="citation_source-journal">Acc. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">108</span><span class="NLM_x">–</span> <span class="NLM_lpage">119</span></span><div class="citationLinks">[<a href="/doi/10.1021/ar700093f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2008&pages=108-119&author=I.+Ojima&title=Guided+molecular+missiles+for+tumor-targeting+chemotherapy-case+studies+using+the+second-generation+taxolds+as+warheads"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1021%2Far700093f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far700093f%26sid%3Dliteratum%253Aachs%26aulast%3DOjima%26aufirst%3DI.%26atitle%3DGuided%2520molecular%2520missiles%2520for%2520tumor-targeting%2520chemotherapy-case%2520studies%2520using%2520the%2520second-generation%2520taxolds%2520as%2520warheads%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2008%26volume%3D41%26spage%3D108%26epage%3D119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group">Weinstain, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Segal, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satchi-Fainaro, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shabat, D.</span><span> </span><span class="NLM_article-title">Real-time monitoring of drug release</span> <span class="citation_source-journal">Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">553</span><span class="NLM_x">–</span> <span class="NLM_lpage">555</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1039%2FB919329D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=20062859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisFWqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2010&pages=553-555&author=R.+Weinstainauthor=E.+Segalauthor=R.+Satchi-Fainaroauthor=D.+Shabat&title=Real-time+monitoring+of+drug+release"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Real-time monitoring of drug release</span></div><div class="casAuthors">Weinstain, Roy; Segal, Ehud; Satchi-Fainaro, Ronit; Shabat, Doron</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">553-555</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A new prodrug system, assembled using a distinctive coumarin linker, was demonstrated to report real-time activation and drug release in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriuAN_vhaJSrVg90H21EOLACvtfcHk0lirlUmksojBtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisFWqug%253D%253D&md5=a6e8dc9cd68a8b5fdfc6a03a446b6513</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1039%2FB919329D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FB919329D%26sid%3Dliteratum%253Aachs%26aulast%3DWeinstain%26aufirst%3DR.%26aulast%3DSegal%26aufirst%3DE.%26aulast%3DSatchi-Fainaro%26aufirst%3DR.%26aulast%3DShabat%26aufirst%3DD.%26atitle%3DReal-time%2520monitoring%2520of%2520drug%2520release%26jtitle%3DChem.%2520Commun.%26date%3D2010%26volume%3D46%26spage%3D553%26epage%3D555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group">Bernardes, G. J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steiner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casi, G.</span><span> </span><span class="NLM_article-title">Site-specific chemical modification of antibody fragments using traceless cleavable linkers</span> <span class="citation_source-journal">Nat. Protoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">2079</span><span class="NLM_x">–</span> <span class="NLM_lpage">2089</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=2079-2089&author=G.+J.+L.+Bernardesauthor=M.+Steinerauthor=I.+Hartmannauthor=D.+Neriauthor=G.+Casi&title=Site-specific+chemical+modification+of+antibody+fragments+using+traceless+cleavable+linkers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBernardes%26aufirst%3DG.%2BJ.%2BL.%26aulast%3DSteiner%26aufirst%3DM.%26aulast%3DHartmann%26aufirst%3DI.%26aulast%3DNeri%26aufirst%3DD.%26aulast%3DCasi%26aufirst%3DG.%26atitle%3DSite-specific%2520chemical%2520modification%2520of%2520antibody%2520fragments%2520using%2520traceless%2520cleavable%2520linkers%26jtitle%3DNat.%2520Protoc.%26date%3D2013%26volume%3D8%26spage%3D2079%26epage%3D2089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group">Casi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huguenin-Dezot, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuberbühler, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheuermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, D.</span><span> </span><span class="NLM_article-title">Site-specific traceless coupling of potent cytotoxic drugs to recombinant antibodies for pharmacodelivery</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">134</span><span class="NLM_x">, </span> <span class="NLM_fpage">5887</span><span class="NLM_x">–</span> <span class="NLM_lpage">5892</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja211589m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2012&pages=5887-5892&author=G.+Casiauthor=N.+Huguenin-Dezotauthor=K.+Zuberb%C3%BChlerauthor=J.+Scheuermannauthor=D.+Neri&title=Site-specific+traceless+coupling+of+potent+cytotoxic+drugs+to+recombinant+antibodies+for+pharmacodelivery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1021%2Fja211589m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja211589m%26sid%3Dliteratum%253Aachs%26aulast%3DCasi%26aufirst%3DG.%26aulast%3DHuguenin-Dezot%26aufirst%3DN.%26aulast%3DZuberb%25C3%25BChler%26aufirst%3DK.%26aulast%3DScheuermann%26aufirst%3DJ.%26aulast%3DNeri%26aufirst%3DD.%26atitle%3DSite-specific%2520traceless%2520coupling%2520of%2520potent%2520cytotoxic%2520drugs%2520to%2520recombinant%2520antibodies%2520for%2520pharmacodelivery%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2012%26volume%3D134%26spage%3D5887%26epage%3D5892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group">Santi, D. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reid, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashley, G. W.</span><span> </span><span class="NLM_article-title">Predictable and tunable half-life extension of therapeutic agents by controlled chemical release from macromolecular conjugates</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">6211</span><span class="NLM_x">–</span> <span class="NLM_lpage">6216</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1073%2Fpnas.1117147109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=22474378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmt12murc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=6211-6216&author=D.+V.+Santiauthor=E.+L.+Schneiderauthor=R.+Reidauthor=L.+Robinsonauthor=G.+W.+Ashley&title=Predictable+and+tunable+half-life+extension+of+therapeutic+agents+by+controlled+chemical+release+from+macromolecular+conjugates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Predictable and tunable half-life extension of therapeutic agents by controlled chemical release from macromolecular conjugates</span></div><div class="casAuthors">Santi, Daniel V.; Schneider, Eric L.; Reid, Ralph; Robinson, Louise; Ashley, Gary W.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6211-6216, S6211/1-S6211/9</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Conjugation to macromol. carriers is a proven strategy for improving the pharmacokinetics of drugs, with many stable polyethylene glycol conjugates having reached the market.  Stable conjugates suffer several limitations: loss of drug potency due to conjugation, confining the drug to the extracellular space, and the requirement for a circulating conjugate.  Current research is directed toward overcoming such limitations through releasable conjugates in which the drug is covalently linked to the carrier through a cleavable linker.  Satisfactory linkers that provide predictable cleavage rates tunable over a wide time range that are useful for both circulating and noncirculating conjugates are not yet available.  The authors describe such conjugation linkers on the basis of a nonenzymic β-elimination reaction with preprogrammed, highly tunable cleavage rates.  A set of modular linkers is described that bears a succinimidyl carbonate group for attachment to an amine-contg. drug or prodrug, an azido group for conjugation to the carrier, and a tunable modulator that controls the rate of β-eliminative cleavage.  The linkers provide predictable, tunable release rates of ligands from macromol. conjugates both in vitro and in vivo, with half-lives spanning from a range of hours to >1 y at physiol. pH.  A circulating PEG conjugate achieved a 56-fold half-life extension of the 39-aa peptide exenatide in rats, and a noncirculating s.c. hydrogel conjugate achieved a 150-fold extension.  Using slow-cleaving linkers, the latter may provide a generic format for once-a-month dosage forms of potent drugs.  The releasable linkers provide addnl. benefits that include lowering Cmax and pharmacokinetic coordination of drug combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZxfMMxiRWb7Vg90H21EOLACvtfcHk0li6AQgp14X3tQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmt12murc%253D&md5=78dbf59f2e209ee4e119aa0d2462f64c</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1117147109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1117147109%26sid%3Dliteratum%253Aachs%26aulast%3DSanti%26aufirst%3DD.%2BV.%26aulast%3DSchneider%26aufirst%3DE.%2BL.%26aulast%3DReid%26aufirst%3DR.%26aulast%3DRobinson%26aufirst%3DL.%26aulast%3DAshley%26aufirst%3DG.%2BW.%26atitle%3DPredictable%2520and%2520tunable%2520half-life%2520extension%2520of%2520therapeutic%2520agents%2520by%2520controlled%2520chemical%2520release%2520from%2520macromolecular%2520conjugates%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2012%26volume%3D109%26spage%3D6211%26epage%3D6216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group">Strop, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorywalska, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaria, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dushin, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farias, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casas, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abdiche, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandrasekaran, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samain, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rickert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krimm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dilley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaparro-Riggers, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filzen, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pons, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shelton, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajpal, A.</span><span> </span><span class="NLM_article-title">Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">167</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1016%2Fj.chembiol.2013.01.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=23438745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtFWht74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=161-167&author=P.+Stropauthor=S.+H.+Liuauthor=M.+Dorywalskaauthor=K.+Delariaauthor=R.+G.+Dushinauthor=T.+T.+Tranauthor=W.+H.+Hoauthor=S.+Fariasauthor=M.+G.+Casasauthor=Y.+Abdicheauthor=D.+Zhouauthor=R.+Chandrasekaranauthor=C.+Samainauthor=C.+Looauthor=A.+Rossiauthor=M.+Rickertauthor=S.+Krimmauthor=T.+Wongauthor=S.+M.+Chinauthor=J.+Yuauthor=J.+Dilleyauthor=J.+Chaparro-Riggersauthor=G.+F.+Filzenauthor=C.+J.+O%E2%80%99Donnellauthor=F.+Wangauthor=J.+S.+Myersauthor=J.+Ponsauthor=D.+L.+Sheltonauthor=A.+Rajpal&title=Location+matters%3A+site+of+conjugation+modulates+stability+and+pharmacokinetics+of+antibody+drug+conjugates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Location Matters: Site of Conjugation Modulates Stability and Pharmacokinetics of Antibody Drug Conjugates</span></div><div class="casAuthors">Strop, Pavel; Liu, Shu-Hui; Dorywalska, Magdalena; Delaria, Kathy; Dushin, Russell G.; Tran, Thomas-Toan; Ho, Wei-Hsien; Farias, Santiago; Casas, Meritxell Galindo; Abdiche, Yasmina; Zhou, Dahui; Chandrasekaran, Ramalakshmi; Samain, Caroline; Loo, Carole; Rossi, Andrea; Rickert, Mathias; Krimm, Stellanie; Wong, Teresa; Chin, Sherman Michael; Yu, Jessica; Dilley, Jeanette; Chaparro-Riggers, Javier; Filzen, Gary F.; O'Donnell, Christopher J.; Wang, Fang; Myers, Jeremy S.; Pons, Jaume; Shelton, David L.; Rajpal, Arvind</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">161-167</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Antibody drug conjugates (ADCs) are a therapeutic class offering promise for cancer therapy.  The attachment of cytotoxic drugs to antibodies can result in an effective therapy with better safety potential than nontargeted cytotoxics.  To understand the role of conjugation site, we developed an enzymic method for site-specific antibody drug conjugation using microbial transglutaminase.  This allowed us to attach diverse compds. at multiple positions and investigate how the site influences stability, toxicity, and efficacy.  We show that the conjugation site has significant impact on ADC stability and pharmacokinetics in a species-dependent manner.  These differences can be directly attributed to the position of the linkage rather than the chem. instability, as was obsd. with a maleimide linkage.  With this method, it is possible to produce homogeneous ADCs and tune their properties to maximize the therapeutic window.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIo4ZEVMFX2LVg90H21EOLACvtfcHk0li6AQgp14X3tQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtFWht74%253D&md5=0b419848b5fd4dfa4863a29de0555cf4</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2013.01.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2013.01.010%26sid%3Dliteratum%253Aachs%26aulast%3DStrop%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DS.%2BH.%26aulast%3DDorywalska%26aufirst%3DM.%26aulast%3DDelaria%26aufirst%3DK.%26aulast%3DDushin%26aufirst%3DR.%2BG.%26aulast%3DTran%26aufirst%3DT.%2BT.%26aulast%3DHo%26aufirst%3DW.%2BH.%26aulast%3DFarias%26aufirst%3DS.%26aulast%3DCasas%26aufirst%3DM.%2BG.%26aulast%3DAbdiche%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DChandrasekaran%26aufirst%3DR.%26aulast%3DSamain%26aufirst%3DC.%26aulast%3DLoo%26aufirst%3DC.%26aulast%3DRossi%26aufirst%3DA.%26aulast%3DRickert%26aufirst%3DM.%26aulast%3DKrimm%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DT.%26aulast%3DChin%26aufirst%3DS.%2BM.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DDilley%26aufirst%3DJ.%26aulast%3DChaparro-Riggers%26aufirst%3DJ.%26aulast%3DFilzen%26aufirst%3DG.%2BF.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DMyers%26aufirst%3DJ.%2BS.%26aulast%3DPons%26aufirst%3DJ.%26aulast%3DShelton%26aufirst%3DD.%2BL.%26aulast%3DRajpal%26aufirst%3DA.%26atitle%3DLocation%2520matters%253A%2520site%2520of%2520conjugation%2520modulates%2520stability%2520and%2520pharmacokinetics%2520of%2520antibody%2520drug%2520conjugates%26jtitle%3DChem.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D161%26epage%3D167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group">Muller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schibli, R.</span><span> </span><span class="NLM_article-title">Prospects in folate receptor-targeted radionuclide therapy</span> <span class="citation_source-journal">Front. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">249</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.3389%2Ffonc.2013.00249" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=24069581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFOrsb%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=249&author=C.+Mullerauthor=R.+Schibli&title=Prospects+in+folate+receptor-targeted+radionuclide+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="#"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=&md5=9874b665cc7a056b8e2f928dd3112440</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2013.00249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2013.00249%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DC.%26aulast%3DSchibli%26aufirst%3DR.%26atitle%3DProspects%2520in%2520folate%2520receptor-targeted%2520radionuclide%2520therapy%26jtitle%3DFront.%2520Oncol.%26date%3D2013%26volume%3D3%26spage%3D249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group">Gutbrodt, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, D.</span><span> </span><span class="NLM_article-title">Antibody-based delivery of IL2 and cytotoxics eradicates tumors in immunocompetent mice</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1772</span><span class="NLM_x">–</span> <span class="NLM_lpage">1776</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1158%2F1535-7163.MCT-14-0105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=24759429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFSmsbfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=1772-1776&author=K.+L.+Gutbrodtauthor=G.+Casiauthor=D.+Neri&title=Antibody-based+delivery+of+IL2+and+cytotoxics+eradicates+tumors+in+immunocompetent+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-Based Delivery of IL2 and Cytotoxics Eradicates Tumors in Immunocompetent Mice</span></div><div class="casAuthors">Gutbrodt, Katrin L.; Casi, Giulio; Neri, Dario</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1772-1776</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Antibody-drug conjugates are increasingly being used for cancer therapy, but little is known about their ability to promote anticancer immunity, which may lead to long-lasting remissions.  We investigated the therapeutic effect of antibody-based pharmacodelivery of cemadotin, a cytotoxic drug, and IL2, a strong proinflammatory cytokine.  Using the F8 antibody, which selectively localizes to the tumor neovasculature, combination treatment led to tumor eradication, in a process dependent on CD8+ T cells and natural killer cells in the C1498 syngeneic mouse model of acute myelogenous leukemia.  The clin. combination of antibody-drug conjugates and antibody-cytokine proteins should be facilitated by their orthogonal toxicity profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYKqzwv7dNPbVg90H21EOLACvtfcHk0lg6_t056lK05Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFSmsbfF&md5=e2eceece6e4067596cee2d56aeee028d</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0105%26sid%3Dliteratum%253Aachs%26aulast%3DGutbrodt%26aufirst%3DK.%2BL.%26aulast%3DCasi%26aufirst%3DG.%26aulast%3DNeri%26aufirst%3DD.%26atitle%3DAntibody-based%2520delivery%2520of%2520IL2%2520and%2520cytotoxics%2520eradicates%2520tumors%2520in%2520immunocompetent%2520mice%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D1772%26epage%3D1776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group">List, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, D.</span><span> </span><span class="NLM_article-title">A chemically defined trifunctional antibody–cytokine–drug conjugate with potent antitumor activity</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2641</span><span class="NLM_x">–</span> <span class="NLM_lpage">2652</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1158%2F1535-7163.MCT-14-0599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=25205656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGju7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=2641-2652&author=T.+Listauthor=G.+Casiauthor=D.+Neri&title=A+chemically+defined+trifunctional+antibody%E2%80%93cytokine%E2%80%93drug+conjugate+with+potent+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">A Chemically Defined Trifunctional Antibody-Cytokine-Drug Conjugate with Potent Antitumor Activity</span></div><div class="casAuthors">List, Thomas; Casi, Giulio; Neri, Dario</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2641-2652</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The combination of immunostimulatory agents with cytotoxic drugs is emerging as a promising approach for potentially curative tumor therapy, but advances in this field are hindered by the requirement of testing individual combination partners as single agents in dedicated clin. studies, often with suboptimal efficacy.  Here, we describe for the first time a novel multipayload class of targeted drugs, the immunocytokine-drug conjugates (IDC), which combine a tumor-homing antibody, a cytotoxic drug, and a proinflammatory cytokine in the same mol. entity.  In particular, the IL2 cytokine and the disulfide-linked maytansinoid DM1 microtubular inhibitor could be coupled to the F8 antibody, directed against the alternatively spliced EDA domain of fibronectin, in a site-specific manner, yielding a chem. defined product with selective tumor-homing performance and potent anticancer activity in vivo, as tested in two different immunocompetent mouse models.  Mol Cancer Ther; 13(11); 2641-52. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYZvMHK0YJXLVg90H21EOLACvtfcHk0lg6_t056lK05Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGju7jN&md5=7659283abd808fe2115d06dfe6ca3c28</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0599%26sid%3Dliteratum%253Aachs%26aulast%3DList%26aufirst%3DT.%26aulast%3DCasi%26aufirst%3DG.%26aulast%3DNeri%26aufirst%3DD.%26atitle%3DA%2520chemically%2520defined%2520trifunctional%2520antibody%25E2%2580%2593cytokine%25E2%2580%2593drug%2520conjugate%2520with%2520potent%2520antitumor%2520activity%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D2641%26epage%3D2652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group">Wittrup, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thurber, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhoden, J. J.</span><span> </span><span class="NLM_article-title">Practical theoretic guidance for the design of tumor-targeting agents</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">503</span><span class="NLM_x">, </span> <span class="NLM_fpage">255</span><span class="NLM_x">–</span> <span class="NLM_lpage">268</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1016%2FB978-0-12-396962-0.00010-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=22230572" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC38Xkt1CjsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=503&publication_year=2012&pages=255-268&author=K.+D.+Wittrupauthor=G.+M.+Thurberauthor=M.+M.+Schmidtauthor=J.+J.+Rhoden&title=Practical+theoretic+guidance+for+the+design+of+tumor-targeting+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Practical theoretic guidance for the design of tumor-targeting agents</span></div><div class="casAuthors">Wittrup, K. Dane; Thurber, Greg M.; Schmidt, Michael M.; Rhoden, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">503</span>
        (<span class="NLM_cas:issue">Protein Engineering for Therapeutics, Part B</span>),
    <span class="NLM_cas:pages">255-268</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Theor. analyses of targeting agent pharmacokinetics provides specific guidance with respect to desirable design objectives such as agent size, affinity, and target antigen.  These analyses suggest that IgG-sized macromol. constructs exhibit the most favorable balance between systemic clearance and vascular extravasation, resulting in maximal tumor uptake.  Quant. predictions of the effects of dose and binding affinity on tumor uptake and penetration are also provided.  The single bolus dose required for satn. of xenografted tumors in mice can be predicted from knowledge of antigen expression level and metabolic half-life.  The role of high binding affinity in tumor uptake can be summarized as: essential for small peptides, less important for antibodies, and negligible for nanoparticles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsTAqo0Zxr9LVg90H21EOLACvtfcHk0lg6_t056lK05Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xkt1CjsLg%253D&md5=7ae4e26c99bb6b7246c8c2fe417410be</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-396962-0.00010-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-396962-0.00010-0%26sid%3Dliteratum%253Aachs%26aulast%3DWittrup%26aufirst%3DK.%2BD.%26aulast%3DThurber%26aufirst%3DG.%2BM.%26aulast%3DSchmidt%26aufirst%3DM.%2BM.%26aulast%3DRhoden%26aufirst%3DJ.%2BJ.%26atitle%3DPractical%2520theoretic%2520guidance%2520for%2520the%2520design%2520of%2520tumor-targeting%2520agents%26jtitle%3DMethods%2520Enzymol.%26date%3D2012%26volume%3D503%26spage%3D255%26epage%3D268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group">Tzeng, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwan, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Opel, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navaratna, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittrup, K. D.</span><span> </span><span class="NLM_article-title">Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">3320</span><span class="NLM_x">–</span> <span class="NLM_lpage">3325</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=3320-3325&author=A.+Tzengauthor=B.+H.+Kwanauthor=C.+F.+Opelauthor=T.+Navaratnaauthor=K.+D.+Wittrup&title=Antigen+specificity+can+be+irrelevant+to+immunocytokine+efficacy+and+biodistribution"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTzeng%26aufirst%3DA.%26aulast%3DKwan%26aufirst%3DB.%2BH.%26aulast%3DOpel%26aufirst%3DC.%2BF.%26aulast%3DNavaratna%26aufirst%3DT.%26aulast%3DWittrup%26aufirst%3DK.%2BD.%26atitle%3DAntigen%2520specificity%2520can%2520be%2520irrelevant%2520to%2520immunocytokine%2520efficacy%2520and%2520biodistribution%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2015%26volume%3D112%26spage%3D3320%26epage%3D3325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 94 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Martin Porubský, Soňa Gurská, Jarmila Stanková, Marián Hajdúch, Petr Džubák, <span class="NLM_string-name hlFld-ContribAuthor">Jan Hlaváč</span>. </span><span class="cited-content_cbyCitation_article-title">AminoBODIPY Conjugates for Targeted Drug Delivery Systems and Real-Time Monitoring of Drug Release. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2021,</strong> <em>18 </em>
                                    (6)
                                     , 2385-2396. <a href="https://doi.org/10.1021/acs.molpharmaceut.1c00219" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.1c00219</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.1c00219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.1c00219%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DAminoBODIPY%252BConjugates%252Bfor%252BTargeted%252BDrug%252BDelivery%252BSystems%252Band%252BReal-Time%252BMonitoring%252Bof%252BDrug%252BRelease%26aulast%3DPorubsk%25C3%25BD%26aufirst%3DMartin%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D18032021%26date%3D23042021%26date%3D22042021%26date%3D07052021%26volume%3D18%26issue%3D6%26spage%3D2385%26epage%3D2396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Marta Serafini, Sarah Cargnin, Alberto Massarotti, Gian Cesare Tron, Tracey Pirali, <span class="NLM_string-name hlFld-ContribAuthor">Armando A. Genazzani</span>. </span><span class="cited-content_cbyCitation_article-title">What’s in a Name? Drug Nomenclature and Medicinal Chemistry Trends using INN Publications. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (8)
                                     , 4410-4429. <a href="https://doi.org/10.1021/acs.jmedchem.1c00181" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00181</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00181%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DWhat%2525E2%252580%252599s%252Bin%252Ba%252BName%25253F%252BDrug%252BNomenclature%252Band%252BMedicinal%252BChemistry%252BTrends%252Busing%252BINN%252BPublications%26aulast%3DSerafini%26aufirst%3DMarta%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D01022021%26date%3D13042021%26volume%3D64%26issue%3D8%26spage%3D4410%26epage%3D4429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Agne Janoniene, <span class="NLM_string-name hlFld-ContribAuthor">Vilma Petrikaite</span>. </span><span class="cited-content_cbyCitation_article-title">In Search of Advanced Tumor Diagnostics and Treatment: Achievements and Perspectives of Carbonic Anhydrase IX Targeted Delivery. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2020,</strong> <em>17 </em>
                                    (6)
                                     , 1800-1815. <a href="https://doi.org/10.1021/acs.molpharmaceut.0c00180" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.0c00180</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.0c00180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.0c00180%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DIn%252BSearch%252Bof%252BAdvanced%252BTumor%252BDiagnostics%252Band%252BTreatment%25253A%252BAchievements%252Band%252BPerspectives%252Bof%252BCarbonic%252BAnhydrase%252BIX%252BTargeted%252BDelivery%26aulast%3DJanoniene%26aufirst%3DAgne%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D18022020%26date%3D06052020%26date%3D05052020%26date%3D20052020%26date%3D06052020%26volume%3D17%26issue%3D6%26spage%3D1800%26epage%3D1815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xuelin Xia, Xiaoyuan Yang, Ping Huang, <span class="NLM_string-name hlFld-ContribAuthor">Deyue Yan</span>. </span><span class="cited-content_cbyCitation_article-title">ROS-Responsive Nanoparticles Formed from RGD–Epothilone B Conjugate for Targeted Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">ACS Applied Materials & Interfaces</span><span> <strong>2020,</strong> <em>12 </em>
                                    (16)
                                     , 18301-18308. <a href="https://doi.org/10.1021/acsami.0c00650" title="DOI URL">https://doi.org/10.1021/acsami.0c00650</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsami.0c00650&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsami.0c00650%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Applied%2520Materials%2520%2526%2520Interfaces%26atitle%3DROS-Responsive%252BNanoparticles%252BFormed%252Bfrom%252BRGD%2525E2%252580%252593Epothilone%252BB%252BConjugate%252Bfor%252BTargeted%252BCancer%252BTherapy%26aulast%3DXia%26aufirst%3DXuelin%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D12012020%26date%3D03042020%26date%3D13042020%26date%3D03042020%26volume%3D12%26issue%3D16%26spage%3D18301%26epage%3D18308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Maria-Jesus Blanco, <span class="NLM_string-name hlFld-ContribAuthor">Kevin M. Gardinier</span>. </span><span class="cited-content_cbyCitation_article-title">New Chemical Modalities and Strategic Thinking in Early Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (3)
                                     , 228-231. <a href="https://doi.org/10.1021/acsmedchemlett.9b00582" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00582</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00582%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DNew%252BChemical%252BModalities%252Band%252BStrategic%252BThinking%252Bin%252BEarly%252BDrug%252BDiscovery%26aulast%3DBlanco%26aufirst%3DMaria-Jesus%26date%3D2020%26date%3D2020%26date%3D14012020%26volume%3D11%26issue%3D3%26spage%3D228%26epage%3D231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Syed Muhammad Usama, G. Kate Park, Shinsuke Nomura, Yoonji Baek, Hak Soo Choi, <span class="NLM_string-name hlFld-ContribAuthor">Kevin Burgess</span>. </span><span class="cited-content_cbyCitation_article-title">Role of Albumin in Accumulation and Persistence of Tumor-Seeking Cyanine Dyes. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2020,</strong> <em>31 </em>
                                    (2)
                                     , 248-259. <a href="https://doi.org/10.1021/acs.bioconjchem.9b00771" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.9b00771</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.9b00771&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.9b00771%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DRole%252Bof%252BAlbumin%252Bin%252BAccumulation%252Band%252BPersistence%252Bof%252BTumor-Seeking%252BCyanine%252BDyes%26aulast%3DUsama%26aufirst%3DSyed%2BMuhammad%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D13112019%26date%3D06122019%26date%3D07012020%26volume%3D31%26issue%3D2%26spage%3D248%26epage%3D259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Suzie J. Scales, Siao Ping Tsai, Neelie Zacharias, Josefa dela Cruz-Chuh, Gordy Bullen, Erick Velasquez, Julie Chang, Elise Bruguera, Katherine R. Kozak, <span class="NLM_string-name hlFld-ContribAuthor">Jack Sadowsky</span>. </span><span class="cited-content_cbyCitation_article-title">Development of a Cysteine-Conjugatable Disulfide FRET Probe: Influence of Charge on Linker Cleavage and Payload Trafficking for an Anti-HER2 Antibody Conjugate. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2019,</strong> <em>30 </em>
                                    (12)
                                     , 3046-3056. <a href="https://doi.org/10.1021/acs.bioconjchem.9b00678" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.9b00678</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.9b00678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.9b00678%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DDevelopment%252Bof%252Ba%252BCysteine-Conjugatable%252BDisulfide%252BFRET%252BProbe%25253A%252BInfluence%252Bof%252BCharge%252Bon%252BLinker%252BCleavage%252Band%252BPayload%252BTrafficking%252Bfor%252Ban%252BAnti-HER2%252BAntibody%252BConjugate%26aulast%3DScales%26aufirst%3DSuzie%2BJ.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D07102019%26date%3D07112019%26date%3D03122019%26date%3D14112019%26volume%3D30%26issue%3D12%26spage%3D3046%26epage%3D3056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Gaochan Wu, Tong Zhao, Dongwei Kang, Jian Zhang, Yuning Song, Vigneshwaran Namasivayam, Jacob Kongsted, Christophe Pannecouque, Erik De Clercq, Vasanthanathan Poongavanam, Xinyong Liu, <span class="NLM_string-name hlFld-ContribAuthor">Peng Zhan</span>. </span><span class="cited-content_cbyCitation_article-title">Overview of Recent Strategic Advances in Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (21)
                                     , 9375-9414. <a href="https://doi.org/10.1021/acs.jmedchem.9b00359" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00359</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00359%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DOverview%252Bof%252BRecent%252BStrategic%252BAdvances%252Bin%252BMedicinal%252BChemistry%26aulast%3DWu%26aufirst%3DGaochan%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D26022019%26date%3D28052019%26date%3D03052019%26volume%3D62%26issue%3D21%26spage%3D9375%26epage%3D9414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Lucia Feni, Sara Parente, Clémence Robert, Silvia Gazzola, Daniela Arosio, Umberto Piarulli, <span class="NLM_string-name hlFld-ContribAuthor">Ines Neundorf</span>. </span><span class="cited-content_cbyCitation_article-title">Kiss and Run: Promoting Effective and Targeted Cellular Uptake of a Drug Delivery Vehicle Composed of an Integrin-Targeting Diketopiperazine Peptidomimetic and a Cell-Penetrating Peptide. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2019,</strong> <em>30 </em>
                                    (7)
                                     , 2011-2022. <a href="https://doi.org/10.1021/acs.bioconjchem.9b00292" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.9b00292</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.9b00292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.9b00292%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DKiss%252Band%252BRun%25253A%252BPromoting%252BEffective%252Band%252BTargeted%252BCellular%252BUptake%252Bof%252Ba%252BDrug%252BDelivery%252BVehicle%252BComposed%252Bof%252Ban%252BIntegrin-Targeting%252BDiketopiperazine%252BPeptidomimetic%252Band%252Ba%252BCell-Penetrating%252BPeptide%26aulast%3DFeni%26aufirst%3DLucia%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D22042019%26date%3D24052019%26date%3D19062019%26date%3D03062019%26volume%3D30%26issue%3D7%26spage%3D2011%26epage%3D2022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Myagmarsuren Sengee, J. Johannes Eksteen, Silje Lillemark Nergård, Terje Vasskog, <span class="NLM_string-name hlFld-ContribAuthor">Leiv K. Sydnes</span>. </span><span class="cited-content_cbyCitation_article-title">Preparation and Assessment of Self-Immolative Linkers for Therapeutic Bioconjugates with Amino- and Hydroxyl-Containing Cargoes. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2019,</strong> <em>30 </em>
                                    (5)
                                     , 1489-1499. <a href="https://doi.org/10.1021/acs.bioconjchem.9b00214" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.9b00214</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.9b00214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.9b00214%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DPreparation%252Band%252BAssessment%252Bof%252BSelf-Immolative%252BLinkers%252Bfor%252BTherapeutic%252BBioconjugates%252Bwith%252BAmino-%252Band%252BHydroxyl-Containing%252BCargoes%26aulast%3DSengee%26aufirst%3DMyagmarsuren%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D22032019%26date%3D27042019%26date%3D03052019%26date%3D29042019%26volume%3D30%26issue%3D5%26spage%3D1489%26epage%3D1499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Syed Muhammad Usama, Chen-Ming Lin, <span class="NLM_string-name hlFld-ContribAuthor">Kevin Burgess</span>. </span><span class="cited-content_cbyCitation_article-title">On the Mechanisms of Uptake of Tumor-Seeking Cyanine Dyes. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2018,</strong> <em>29 </em>
                                    (11)
                                     , 3886-3895. <a href="https://doi.org/10.1021/acs.bioconjchem.8b00708" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.8b00708</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.8b00708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.8b00708%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DOn%252Bthe%252BMechanisms%252Bof%252BUptake%252Bof%252BTumor-Seeking%252BCyanine%252BDyes%26aulast%3DUsama%26aufirst%3DSyed%2BMuhammad%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D05102018%26date%3D24102018%26volume%3D29%26issue%3D11%26spage%3D3886%26epage%3D3895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Soňa  Krajčovičová</span>, <span class="hlFld-ContribAuthor ">Tomáš  Gucký</span>, <span class="hlFld-ContribAuthor ">Denisa  Hendrychová</span>, <span class="hlFld-ContribAuthor ">Vladimír  Kryštof</span>, and <span class="hlFld-ContribAuthor ">Miroslav  Soural</span>  . </span><span class="cited-content_cbyCitation_article-title">A Stepwise Approach for the Synthesis of Folic Acid Conjugates with Protein Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2017,</strong> <em>82 </em>
                                    (24)
                                     , 13530-13541. <a href="https://doi.org/10.1021/acs.joc.7b02650" title="DOI URL">https://doi.org/10.1021/acs.joc.7b02650</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.7b02650&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.7b02650%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DA%252BStepwise%252BApproach%252Bfor%252Bthe%252BSynthesis%252Bof%252BFolic%252BAcid%252BConjugates%252Bwith%252BProtein%252BKinase%252BInhibitors%26aulast%3DKraj%25C4%258Dovi%25C4%258Dov%25C3%25A1%26aufirst%3DSo%25C5%2588a%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D18102017%26date%3D05122017%26date%3D15122017%26date%3D24112017%26volume%3D82%26issue%3D24%26spage%3D13530%26epage%3D13541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Madduri  Srinivasarao</span> and <span class="hlFld-ContribAuthor ">Philip S.  Low</span>  . </span><span class="cited-content_cbyCitation_article-title">Ligand-Targeted Drug Delivery. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2017,</strong> <em>117 </em>
                                    (19)
                                     , 12133-12164. <a href="https://doi.org/10.1021/acs.chemrev.7b00013" title="DOI URL">https://doi.org/10.1021/acs.chemrev.7b00013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.7b00013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.7b00013%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DLigand-Targeted%252BDrug%252BDelivery%26aulast%3DSrinivasarao%26aufirst%3DMadduri%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D07012017%26date%3D12092017%26date%3D11102017%26volume%3D117%26issue%3D19%26spage%3D12133%26epage%3D12164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jack D.  Sadowsky</span>, <span class="hlFld-ContribAuthor ">Thomas H.  Pillow</span>, <span class="hlFld-ContribAuthor ">Jinhua  Chen</span>, <span class="hlFld-ContribAuthor ">Fang  Fan</span>, <span class="hlFld-ContribAuthor ">Changrong  He</span>, <span class="hlFld-ContribAuthor ">Yanli  Wang</span>, <span class="hlFld-ContribAuthor ">Gang  Yan</span>, <span class="hlFld-ContribAuthor ">Hui  Yao</span>, <span class="hlFld-ContribAuthor ">Zijin  Xu</span>, <span class="hlFld-ContribAuthor ">Shanique  Martin</span>, <span class="hlFld-ContribAuthor ">Donglu  Zhang</span>, <span class="hlFld-ContribAuthor ">Phillip  Chu</span>, <span class="hlFld-ContribAuthor ">Josefa  dela Cruz-Chuh</span>, <span class="hlFld-ContribAuthor ">Aimee  O’Donohue</span>, <span class="hlFld-ContribAuthor ">Guangmin  Li</span>, <span class="hlFld-ContribAuthor ">Geoffrey  Del Rosario</span>, <span class="hlFld-ContribAuthor ">Jintang  He</span>, <span class="hlFld-ContribAuthor ">Luna  Liu</span>, <span class="hlFld-ContribAuthor ">Carl  Ng</span>, <span class="hlFld-ContribAuthor ">Dian  Su</span>, <span class="hlFld-ContribAuthor ">Gail D.  Lewis Phillips</span>, <span class="hlFld-ContribAuthor ">Katherine R.  Kozak</span>, <span class="hlFld-ContribAuthor ">Shang-Fan  Yu</span>, <span class="hlFld-ContribAuthor ">Keyang  Xu</span>, <span class="hlFld-ContribAuthor ">Douglas  Leipold</span>, and <span class="hlFld-ContribAuthor ">John  Wai</span>  . </span><span class="cited-content_cbyCitation_article-title">Development of Efficient Chemistry to Generate Site-Specific Disulfide-Linked Protein– and Peptide–Payload Conjugates: Application to THIOMAB Antibody–Drug Conjugates. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2017,</strong> <em>28 </em>
                                    (8)
                                     , 2086-2098. <a href="https://doi.org/10.1021/acs.bioconjchem.7b00258" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.7b00258</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.7b00258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.7b00258%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DDevelopment%252Bof%252BEfficient%252BChemistry%252Bto%252BGenerate%252BSite-Specific%252BDisulfide-Linked%252BProtein%2525E2%252580%252593%252Band%252BPeptide%2525E2%252580%252593Payload%252BConjugates%25253A%252BApplication%252Bto%252BTHIOMAB%252BAntibody%2525E2%252580%252593Drug%252BConjugates%26aulast%3DSadowsky%26aufirst%3DJack%2BD.%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D05052017%26date%3D16062017%26date%3D13072017%26date%3D16082017%26date%3D21062017%26volume%3D28%26issue%3D8%26spage%3D2086%26epage%3D2098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu-Wei  Liu</span>, <span class="hlFld-ContribAuthor ">Kak-Shan  Shia</span>, <span class="hlFld-ContribAuthor ">Chien-Huang  Wu</span>, <span class="hlFld-ContribAuthor ">Kuan-Liang  Liu</span>, <span class="hlFld-ContribAuthor ">Yu-Cheng  Yeh</span>, <span class="hlFld-ContribAuthor ">Chen-Fu  Lo</span>, <span class="hlFld-ContribAuthor ">Chiung-Tong  Chen</span>, <span class="hlFld-ContribAuthor ">Yun-Yu  Chen</span>, <span class="hlFld-ContribAuthor ">Teng-Kuang  Yeh</span>, <span class="hlFld-ContribAuthor ">Wei-Han  Chen</span>, <span class="hlFld-ContribAuthor ">Jiing-Jyh  Jan</span>, <span class="hlFld-ContribAuthor ">Yu-Chen  Huang</span>, <span class="hlFld-ContribAuthor ">Chen-Lung  Huang</span>, <span class="hlFld-ContribAuthor ">Ming-Yu  Fang</span>, <span class="hlFld-ContribAuthor ">Brian D.  Gray</span>, <span class="hlFld-ContribAuthor ">Koon Y.  Pak</span>, <span class="hlFld-ContribAuthor ">Tsu-An  Hsu</span>, <span class="hlFld-ContribAuthor ">Kuan-Hsun  Huang</span>, and <span class="hlFld-ContribAuthor ">Lun K.  Tsou</span>  . </span><span class="cited-content_cbyCitation_article-title">Targeting Tumor Associated Phosphatidylserine with New Zinc Dipicolylamine-Based Drug Conjugates. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2017,</strong> <em>28 </em>
                                    (7)
                                     , 1878-1892. <a href="https://doi.org/10.1021/acs.bioconjchem.7b00225" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.7b00225</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.7b00225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.7b00225%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DTargeting%252BTumor%252BAssociated%252BPhosphatidylserine%252Bwith%252BNew%252BZinc%252BDipicolylamine-Based%252BDrug%252BConjugates%26aulast%3DLiu%26aufirst%3DYu-Wei%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D20042017%26date%3D01062017%26date%3D19062017%26date%3D19072017%26date%3D05062017%26volume%3D28%26issue%3D7%26spage%3D1878%26epage%3D1892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David Y.  Jackson</span>  . </span><span class="cited-content_cbyCitation_article-title">Processes for Constructing Homogeneous Antibody Drug Conjugates. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2016,</strong> <em>20 </em>
                                    (5)
                                     , 852-866. <a href="https://doi.org/10.1021/acs.oprd.6b00067" title="DOI URL">https://doi.org/10.1021/acs.oprd.6b00067</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.6b00067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.6b00067%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DProcesses%252Bfor%252BConstructing%252BHomogeneous%252BAntibody%252BDrug%252BConjugates%26aulast%3DJackson%26aufirst%3DDavid%2BY.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D04032016%26date%3D04052016%26date%3D20052016%26date%3D14042016%26volume%3D20%26issue%3D5%26spage%3D852%26epage%3D866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elena  Rosini</span>, <span class="hlFld-ContribAuthor ">Noemi Antonella  Volpi</span>, <span class="hlFld-ContribAuthor ">Barbara  Ziffels</span>, <span class="hlFld-ContribAuthor ">Annalisa  Grimaldi</span>, <span class="hlFld-ContribAuthor ">Silvia  Sacchi</span>, <span class="hlFld-ContribAuthor ">Dario  Neri</span>, <span class="hlFld-ContribAuthor ">Loredano  Pollegioni</span>. </span><span class="cited-content_cbyCitation_article-title">An antibody-based enzymatic therapy for cancer treatment: The selective localization of D-amino acid oxidase to EDA fibronectin. </span><span class="cited-content_cbyCitation_journal-name">Nanomedicine: Nanotechnology, Biology and Medicine</span><span> <strong>2021,</strong> <em>36 </em>, 102424. <a href="https://doi.org/10.1016/j.nano.2021.102424" title="DOI URL">https://doi.org/10.1016/j.nano.2021.102424</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.nano.2021.102424&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.nano.2021.102424%26sid%3Dliteratum%253Aachs%26jtitle%3DNanomedicine%253A%2520Nanotechnology%252C%2520Biology%2520and%2520Medicine%26atitle%3DAn%252Bantibody-based%252Benzymatic%252Btherapy%252Bfor%252Bcancer%252Btreatment%25253A%252BThe%252Bselective%252Blocalization%252Bof%252BD-amino%252Bacid%252Boxidase%252Bto%252BEDA%252Bfibronectin%26aulast%3DRosini%26aufirst%3DElena%26date%3D2021%26volume%3D36%26spage%3D102424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wen‐Qian  Li</span>, <span class="hlFld-ContribAuthor ">Han‐Fei  Guo</span>, <span class="hlFld-ContribAuthor ">Ling‐Yu  Li</span>, <span class="hlFld-ContribAuthor ">Yong‐Fei  Zhang</span>, <span class="hlFld-ContribAuthor ">Jiu‐Wei  Cui</span>. </span><span class="cited-content_cbyCitation_article-title">The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively. </span><span class="cited-content_cbyCitation_journal-name">Cancer Medicine</span><span> <strong>2021,</strong> <em>10 </em>
                                    (14)
                                     , 4677-4696. <a href="https://doi.org/10.1002/cam4.4052" title="DOI URL">https://doi.org/10.1002/cam4.4052</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cam4.4052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcam4.4052%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Medicine%26atitle%3DThe%252Bpromising%252Brole%252Bof%252Bantibody%252Bdrug%252Bconjugate%252Bin%252Bcancer%252Btherapy%25253A%252BCombining%252Btargeting%252Bability%252Bwith%252Bcytotoxicity%252Beffectively%26aulast%3DLi%26aufirst%3DWen%25E2%2580%2590Qian%26date%3D2021%26date%3D2021%26volume%3D10%26issue%3D14%26spage%3D4677%26epage%3D4696" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joshua E.  Reuss</span>, <span class="hlFld-ContribAuthor ">Laura  Gosa</span>, <span class="hlFld-ContribAuthor ">Stephen V.  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody Drug Conjugates in Lung Cancer: state of the current therapeutic landscape and future developments. </span><span class="cited-content_cbyCitation_journal-name">Clinical Lung Cancer</span><span> <strong>2021,</strong> <em>70 </em><a href="https://doi.org/10.1016/j.cllc.2021.07.011" title="DOI URL">https://doi.org/10.1016/j.cllc.2021.07.011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cllc.2021.07.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cllc.2021.07.011%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Lung%2520Cancer%26atitle%3DAntibody%252BDrug%252BConjugates%252Bin%252BLung%252BCancer%25253A%252Bstate%252Bof%252Bthe%252Bcurrent%252Btherapeutic%252Blandscape%252Band%252Bfuture%252Bdevelopments%26aulast%3DReuss%26aufirst%3DJoshua%2BE.%26date%3D2021%26volume%3D70" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Martine K.  Notabi</span>, <span class="hlFld-ContribAuthor ">Eva C.  Arnspang</span>, <span class="hlFld-ContribAuthor ">Morten Ø.  Andersen</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody conjugated lipid nanoparticles as a targeted drug delivery system for hydrophobic pharmaceuticals. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Pharmaceutical Sciences</span><span> <strong>2021,</strong> <em>161 </em>, 105777. <a href="https://doi.org/10.1016/j.ejps.2021.105777" title="DOI URL">https://doi.org/10.1016/j.ejps.2021.105777</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejps.2021.105777&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejps.2021.105777%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Pharmaceutical%2520Sciences%26atitle%3DAntibody%252Bconjugated%252Blipid%252Bnanoparticles%252Bas%252Ba%252Btargeted%252Bdrug%252Bdelivery%252Bsystem%252Bfor%252Bhydrophobic%252Bpharmaceuticals%26aulast%3DNotabi%26aufirst%3DMartine%2BK.%26date%3D2021%26volume%3D161%26spage%3D105777" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joshua Z.  Drago</span>, <span class="hlFld-ContribAuthor ">Shanu  Modi</span>, <span class="hlFld-ContribAuthor ">Sarat  Chandarlapaty</span>. </span><span class="cited-content_cbyCitation_article-title">Unlocking the potential of antibody–drug conjugates for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Clinical Oncology</span><span> <strong>2021,</strong> <em>18 </em>
                                    (6)
                                     , 327-344. <a href="https://doi.org/10.1038/s41571-021-00470-8" title="DOI URL">https://doi.org/10.1038/s41571-021-00470-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41571-021-00470-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41571-021-00470-8%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Clinical%2520Oncology%26atitle%3DUnlocking%252Bthe%252Bpotential%252Bof%252Bantibody%2525E2%252580%252593drug%252Bconjugates%252Bfor%252Bcancer%252Btherapy%26aulast%3DDrago%26aufirst%3DJoshua%2BZ.%26date%3D2021%26date%3D2021%26volume%3D18%26issue%3D6%26spage%3D327%26epage%3D344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lucia  Battistini</span>, <span class="hlFld-ContribAuthor ">Kelly  Bugatti</span>, <span class="hlFld-ContribAuthor ">Andrea  Sartori</span>, <span class="hlFld-ContribAuthor ">Claudio  Curti</span>, <span class="hlFld-ContribAuthor ">Franca  Zanardi</span>. </span><span class="cited-content_cbyCitation_article-title">RGD Peptide‐Drug Conjugates as Effective Dual Targeting Platforms: Recent Advances. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>2021 </em>
                                    (17)
                                     , 2506-2528. <a href="https://doi.org/10.1002/ejoc.202100240" title="DOI URL">https://doi.org/10.1002/ejoc.202100240</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.202100240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.202100240%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DRGD%252BPeptide%2525E2%252580%252590Drug%252BConjugates%252Bas%252BEffective%252BDual%252BTargeting%252BPlatforms%25253A%252BRecent%252BAdvances%26aulast%3DBattistini%26aufirst%3DLucia%26date%3D2021%26date%3D2021%26volume%3D2021%26issue%3D17%26spage%3D2506%26epage%3D2528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mengisteab  Gebrezgiabher</span>, <span class="hlFld-ContribAuthor ">Waleed A.  Zalloum</span>, <span class="hlFld-ContribAuthor ">David J.  Clarke</span>, <span class="hlFld-ContribAuthor ">Steven M.  Miles</span>, <span class="hlFld-ContribAuthor ">Antonina A.  Fedorova</span>, <span class="hlFld-ContribAuthor ">Marina A.  Zenkova</span>, <span class="hlFld-ContribAuthor ">Elena V.  Bichenkova</span>. </span><span class="cited-content_cbyCitation_article-title">RNA knockdown by synthetic peptidyl-oligonucleotide ribonucleases: behavior of recognition and cleavage elements under physiological conditions. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2021,</strong> <em>39 </em>
                                    (7)
                                     , 2555-2574. <a href="https://doi.org/10.1080/07391102.2020.1751711" title="DOI URL">https://doi.org/10.1080/07391102.2020.1751711</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2020.1751711&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2020.1751711%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DRNA%252Bknockdown%252Bby%252Bsynthetic%252Bpeptidyl-oligonucleotide%252Bribonucleases%25253A%252Bbehavior%252Bof%252Brecognition%252Band%252Bcleavage%252Belements%252Bunder%252Bphysiological%252Bconditions%26aulast%3DGebrezgiabher%26aufirst%3DMengisteab%26date%3D2021%26date%3D2020%26volume%3D39%26issue%3D7%26spage%3D2555%26epage%3D2574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tarun Kumar  Patel</span>, <span class="hlFld-ContribAuthor ">Nilanjan  Adhikari</span>, <span class="hlFld-ContribAuthor ">Sk. Abdul  Amin</span>, <span class="hlFld-ContribAuthor ">Swati  Biswas</span>, <span class="hlFld-ContribAuthor ">Tarun  Jha</span>, <span class="hlFld-ContribAuthor ">Balaram  Ghosh</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecule drug conjugates (SMDCs): an emerging strategy for anticancer drug design and discovery. </span><span class="cited-content_cbyCitation_journal-name">New Journal of Chemistry</span><span> <strong>2021,</strong> <em>45 </em>
                                    (12)
                                     , 5291-5321. <a href="https://doi.org/10.1039/D0NJ04134C" title="DOI URL">https://doi.org/10.1039/D0NJ04134C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0NJ04134C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0NJ04134C%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520Journal%2520of%2520Chemistry%26atitle%3DSmall%252Bmolecule%252Bdrug%252Bconjugates%252B%252528SMDCs%252529%25253A%252Ban%252Bemerging%252Bstrategy%252Bfor%252Banticancer%252Bdrug%252Bdesign%252Band%252Bdiscovery%26aulast%3DPatel%26aufirst%3DTarun%2BKumar%26date%3D2021%26date%3D2021%26volume%3D45%26issue%3D12%26spage%3D5291%26epage%3D5321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zoë  Jukes</span>, <span class="hlFld-ContribAuthor ">Goreti Ribeiro  Morais</span>, <span class="hlFld-ContribAuthor ">Paul M.  Loadman</span>, <span class="hlFld-ContribAuthor ">Klaus  Pors</span>. </span><span class="cited-content_cbyCitation_article-title">How can the potential of the duocarmycins be unlocked for cancer therapy?. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2021,</strong> <em>26 </em>
                                    (2)
                                     , 577-584. <a href="https://doi.org/10.1016/j.drudis.2020.11.020" title="DOI URL">https://doi.org/10.1016/j.drudis.2020.11.020</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2020.11.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2020.11.020%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DHow%252Bcan%252Bthe%252Bpotential%252Bof%252Bthe%252Bduocarmycins%252Bbe%252Bunlocked%252Bfor%252Bcancer%252Btherapy%25253F%26aulast%3DJukes%26aufirst%3DZo%25C3%25AB%26date%3D2021%26volume%3D26%26issue%3D2%26spage%3D577%26epage%3D584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yun-Yu  Chen</span>, <span class="hlFld-ContribAuthor ">Chen-Fu  Lo</span>, <span class="hlFld-ContribAuthor ">Tai-Yu  Chiu</span>, <span class="hlFld-ContribAuthor ">Chia-Yu  Hsu</span>, <span class="hlFld-ContribAuthor ">Teng-Kuang  Yeh</span>, <span class="hlFld-ContribAuthor ">Ching-Ping  Chen</span>, <span class="hlFld-ContribAuthor ">Chen-Lung  Huang</span>, <span class="hlFld-ContribAuthor ">Chung-Yu  Huang</span>, <span class="hlFld-ContribAuthor ">Min-Hsien  Wang</span>, <span class="hlFld-ContribAuthor ">Yu-Chen  Huang</span>, <span class="hlFld-ContribAuthor ">Hsuan-Hui  Ho</span>, <span class="hlFld-ContribAuthor ">Yu-Sheng  Chao</span>, <span class="hlFld-ContribAuthor ">Joe C.  Shih</span>, <span class="hlFld-ContribAuthor ">Lun K.  Tsou</span>, <span class="hlFld-ContribAuthor ">Chiung-Tong  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">BPRDP056, a novel small molecule drug conjugate specifically targeting phosphatidylserine for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Translational Oncology</span><span> <strong>2021,</strong> <em>14 </em>
                                    (1)
                                     , 100897. <a href="https://doi.org/10.1016/j.tranon.2020.100897" title="DOI URL">https://doi.org/10.1016/j.tranon.2020.100897</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tranon.2020.100897&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tranon.2020.100897%26sid%3Dliteratum%253Aachs%26jtitle%3DTranslational%2520Oncology%26atitle%3DBPRDP056%25252C%252Ba%252Bnovel%252Bsmall%252Bmolecule%252Bdrug%252Bconjugate%252Bspecifically%252Btargeting%252Bphosphatidylserine%252Bfor%252Bcancer%252Btherapy%26aulast%3DChen%26aufirst%3DYun-Yu%26date%3D2021%26volume%3D14%26issue%3D1%26spage%3D100897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yaroslav  Staroseletz</span>, <span class="hlFld-ContribAuthor ">Bahareh  Amirloo</span>, <span class="hlFld-ContribAuthor ">Aled  Williams</span>, <span class="hlFld-ContribAuthor ">Alexander  Lomzov</span>, <span class="hlFld-ContribAuthor ">Kepa K  Burusco</span>, <span class="hlFld-ContribAuthor ">David J  Clarke</span>, <span class="hlFld-ContribAuthor ">Tom  Brown</span>, <span class="hlFld-ContribAuthor ">Marina A  Zenkova</span>, <span class="hlFld-ContribAuthor ">Elena V  Bichenkova</span>. </span><span class="cited-content_cbyCitation_article-title">Strict conformational demands of RNA cleavage in bulge-loops created by peptidyl-oligonucleotide conjugates. </span><span class="cited-content_cbyCitation_journal-name">Nucleic Acids Research</span><span> <strong>2020,</strong> <em>48 </em>
                                    (19)
                                     , 10662-10679. <a href="https://doi.org/10.1093/nar/gkaa780" title="DOI URL">https://doi.org/10.1093/nar/gkaa780</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/nar/gkaa780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fnar%2Fgkaa780%26sid%3Dliteratum%253Aachs%26jtitle%3DNucleic%2520Acids%2520Research%26atitle%3DStrict%252Bconformational%252Bdemands%252Bof%252BRNA%252Bcleavage%252Bin%252Bbulge-loops%252Bcreated%252Bby%252Bpeptidyl-oligonucleotide%252Bconjugates%26aulast%3DStaroseletz%26aufirst%3DYaroslav%26date%3D2020%26date%3D2020%26volume%3D48%26issue%3D19%26spage%3D10662%26epage%3D10679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicolas  Joubert</span>, <span class="hlFld-ContribAuthor ">Alain  Beck</span>, <span class="hlFld-ContribAuthor ">Charles  Dumontet</span>, <span class="hlFld-ContribAuthor ">Caroline  Denevault-Sabourin</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody–Drug Conjugates: The Last Decade. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceuticals</span><span> <strong>2020,</strong> <em>13 </em>
                                    (9)
                                     , 245. <a href="https://doi.org/10.3390/ph13090245" title="DOI URL">https://doi.org/10.3390/ph13090245</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ph13090245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fph13090245%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceuticals%26atitle%3DAntibody%2525E2%252580%252593Drug%252BConjugates%25253A%252BThe%252BLast%252BDecade%26aulast%3DJoubert%26aufirst%3DNicolas%26date%3D2020%26date%3D2020%26volume%3D13%26issue%3D9%26spage%3D245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mikhail A.  Grin</span>, <span class="hlFld-ContribAuthor ">Nikita V.  Suvorov</span>, <span class="hlFld-ContribAuthor ">Andrey F.  Mironov</span>. </span><span class="cited-content_cbyCitation_article-title">Natural chlorins as a promising platform for creating targeted theranostics in oncology. </span><span class="cited-content_cbyCitation_journal-name">Mendeleev Communications</span><span> <strong>2020,</strong> <em>30 </em>
                                    (4)
                                     , 406-418. <a href="https://doi.org/10.1016/j.mencom.2020.07.003" title="DOI URL">https://doi.org/10.1016/j.mencom.2020.07.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.mencom.2020.07.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.mencom.2020.07.003%26sid%3Dliteratum%253Aachs%26jtitle%3DMendeleev%2520Communications%26atitle%3DNatural%252Bchlorins%252Bas%252Ba%252Bpromising%252Bplatform%252Bfor%252Bcreating%252Btargeted%252Btheranostics%252Bin%252Boncology%26aulast%3DGrin%26aufirst%3DMikhail%2BA.%26date%3D2020%26volume%3D30%26issue%3D4%26spage%3D406%26epage%3D418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arianna  Pina</span>, <span class="hlFld-ContribAuthor ">Malika  Kadri</span>, <span class="hlFld-ContribAuthor ">Daniela  Arosio</span>, <span class="hlFld-ContribAuthor ">Alberto  Dal Corso</span>, <span class="hlFld-ContribAuthor ">Jean‐Luc  Coll</span>, <span class="hlFld-ContribAuthor ">Cesare  Gennari</span>, <span class="hlFld-ContribAuthor ">Didier  Boturyn</span>. </span><span class="cited-content_cbyCitation_article-title">Multimeric Presentation of RGD Peptidomimetics Enhances Integrin Binding and Tumor Cell Uptake. </span><span class="cited-content_cbyCitation_journal-name">Chemistry – A European Journal</span><span> <strong>2020,</strong> <em>26 </em>
                                    (33)
                                     , 7492-7496. <a href="https://doi.org/10.1002/chem.202001115" title="DOI URL">https://doi.org/10.1002/chem.202001115</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.202001115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.202001115%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%25E2%2580%2593%2520A%2520European%2520Journal%26atitle%3DMultimeric%252BPresentation%252Bof%252BRGD%252BPeptidomimetics%252BEnhances%252BIntegrin%252BBinding%252Band%252BTumor%252BCell%252BUptake%26aulast%3DPina%26aufirst%3DArianna%26date%3D2020%26date%3D2020%26volume%3D26%26issue%3D33%26spage%3D7492%26epage%3D7496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dinglin  Zhang</span>, <span class="hlFld-ContribAuthor ">Jianxiang  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Surface engineering of nanomaterials with phospholipid-polyethylene glycol-derived functional conjugates for molecular imaging and targeted therapy. </span><span class="cited-content_cbyCitation_journal-name">Biomaterials</span><span> <strong>2020,</strong> <em>230 </em>, 119646. <a href="https://doi.org/10.1016/j.biomaterials.2019.119646" title="DOI URL">https://doi.org/10.1016/j.biomaterials.2019.119646</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.biomaterials.2019.119646&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.biomaterials.2019.119646%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomaterials%26atitle%3DSurface%252Bengineering%252Bof%252Bnanomaterials%252Bwith%252Bphospholipid-polyethylene%252Bglycol-derived%252Bfunctional%252Bconjugates%252Bfor%252Bmolecular%252Bimaging%252Band%252Btargeted%252Btherapy%26aulast%3DZhang%26aufirst%3DDinglin%26date%3D2020%26volume%3D230%26spage%3D119646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Navid  Rabiee</span>, <span class="hlFld-ContribAuthor ">Mohammad Tavakkoli  Yaraki</span>, <span class="hlFld-ContribAuthor ">Soha Mokhtari  Garakani</span>, <span class="hlFld-ContribAuthor ">Shima Mokhtari  Garakani</span>, <span class="hlFld-ContribAuthor ">Sepideh  Ahmadi</span>, <span class="hlFld-ContribAuthor ">Aseman  Lajevardi</span>, <span class="hlFld-ContribAuthor ">Mojtaba  Bagherzadeh</span>, <span class="hlFld-ContribAuthor ">Mohammad  Rabiee</span>, <span class="hlFld-ContribAuthor ">Lobat  Tayebi</span>, <span class="hlFld-ContribAuthor ">Mohammadreza  Tahriri</span>, <span class="hlFld-ContribAuthor ">Michael R.  Hamblin</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in porphyrin-based nanocomposites for effective targeted imaging and therapy. </span><span class="cited-content_cbyCitation_journal-name">Biomaterials</span><span> <strong>2020,</strong> <em>232 </em>, 119707. <a href="https://doi.org/10.1016/j.biomaterials.2019.119707" title="DOI URL">https://doi.org/10.1016/j.biomaterials.2019.119707</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.biomaterials.2019.119707&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.biomaterials.2019.119707%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomaterials%26atitle%3DRecent%252Badvances%252Bin%252Bporphyrin-based%252Bnanocomposites%252Bfor%252Beffective%252Btargeted%252Bimaging%252Band%252Btherapy%26aulast%3DRabiee%26aufirst%3DNavid%26date%3D2020%26volume%3D232%26spage%3D119707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marcos  Fernández</span>, <span class="hlFld-ContribAuthor ">André  Shamsabadi</span>, <span class="hlFld-ContribAuthor ">Vijay  Chudasama</span>. </span><span class="cited-content_cbyCitation_article-title">Fine-tuning thio-pyridazinediones as SMDC scaffolds (with intracellular thiol release
              via
              a novel self-immolative linker). </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2020,</strong> <em>56 </em>
                                    (7)
                                     , 1125-1128. <a href="https://doi.org/10.1039/C9CC08744C" title="DOI URL">https://doi.org/10.1039/C9CC08744C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9CC08744C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9CC08744C%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DFine-tuning%252Bthio-pyridazinediones%252Bas%252BSMDC%252Bscaffolds%252B%252528with%252Bintracellular%252Bthiol%252Brelease%252Bvia%252Ba%252Bnovel%252Bself-immolative%252Blinker%252529%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DMarcos%26date%3D2020%26date%3D2020%26volume%3D56%26issue%3D7%26spage%3D1125%26epage%3D1128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nooshafarin  Amani</span>, <span class="hlFld-ContribAuthor ">Farid Abedin  Dorkoosh</span>, <span class="hlFld-ContribAuthor ">Hamid  Mobedi</span>. </span><span class="cited-content_cbyCitation_article-title">ADCs, as Novel Revolutionary Weapons for Providing a Step Forward in Targeted Therapy of Malignancies. </span><span class="cited-content_cbyCitation_journal-name">Current Drug Delivery</span><span> <strong>2020,</strong> <em>17 </em>
                                    (1)
                                     , 23-51. <a href="https://doi.org/10.2174/1567201816666191121145109" title="DOI URL">https://doi.org/10.2174/1567201816666191121145109</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1567201816666191121145109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1567201816666191121145109%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Drug%2520Delivery%26atitle%3DADCs%25252C%252Bas%252BNovel%252BRevolutionary%252BWeapons%252Bfor%252BProviding%252Ba%252BStep%252BForward%252Bin%252BTargeted%252BTherapy%252Bof%252BMalignancies%26aulast%3DAmani%26aufirst%3DNooshafarin%26date%3D2020%26volume%3D17%26issue%3D1%26spage%3D23%26epage%3D51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gundappa  Saha</span>, <span class="hlFld-ContribAuthor ">Prakash  Saudagar</span>, <span class="hlFld-ContribAuthor ">Vikash Kumar  Dubey</span>. </span><span class="cited-content_cbyCitation_article-title">Virus-like particles: nano-carriers in targeted therapeutics. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 197-210. <a href="https://doi.org/10.1016/B978-0-12-819363-1.00012-0" title="DOI URL">https://doi.org/10.1016/B978-0-12-819363-1.00012-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-819363-1.00012-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-819363-1.00012-0%26sid%3Dliteratum%253Aachs%26atitle%3DVirus-like%252Bparticles%25253A%252Bnano-carriers%252Bin%252Btargeted%252Btherapeutics%26aulast%3DSaha%26aufirst%3DGundappa%26date%3D2020%26spage%3D197%26epage%3D210%26pub%3DElsevier%26atitle%3DEncapsulation%252Bof%252BActive%252BMolecules%252Band%252BTheir%252BDelivery%252BSystem%26date%3D2020%26volume%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alain  Beck</span>, <span class="hlFld-ContribAuthor ">Charles  Dumontet</span>, <span class="hlFld-ContribAuthor ">Nicolas  Joubert</span>. </span><span class="cited-content_cbyCitation_article-title">Les immunoconjugués en oncologie. </span><span class="cited-content_cbyCitation_journal-name">médecine/sciences</span><span> <strong>2019,</strong> <em>35 </em>
                                    (12)
                                     , 1043-1053. <a href="https://doi.org/10.1051/medsci/2019228" title="DOI URL">https://doi.org/10.1051/medsci/2019228</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1051/medsci/2019228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1051%2Fmedsci%2F2019228%26sid%3Dliteratum%253Aachs%26jtitle%3Dm%25C3%25A9decine%252Fsciences%26atitle%3DLes%252Bimmunoconjugu%2525C3%2525A9s%252Ben%252Boncologie%26aulast%3DBeck%26aufirst%3DAlain%26date%3D2019%26date%3D2020%26volume%3D35%26issue%3D12%26spage%3D1043%26epage%3D1053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">K.  Varini</span>, <span class="hlFld-ContribAuthor ">P.  Lécorché</span>, <span class="hlFld-ContribAuthor ">R.  Sonnette</span>, <span class="hlFld-ContribAuthor ">F.  Gassiot</span>, <span class="hlFld-ContribAuthor ">B.  Broc</span>, <span class="hlFld-ContribAuthor ">M.  Godard</span>, <span class="hlFld-ContribAuthor ">M.  David</span>, <span class="hlFld-ContribAuthor ">A.  Faucon</span>, <span class="hlFld-ContribAuthor ">K.  Abouzid</span>, <span class="hlFld-ContribAuthor ">G.  Ferracci</span>, <span class="hlFld-ContribAuthor ">J.  Temsamani</span>, <span class="hlFld-ContribAuthor ">M.  Khrestchatisky</span>, <span class="hlFld-ContribAuthor ">G.  Jacquot</span>. </span><span class="cited-content_cbyCitation_article-title">Target engagement and intracellular delivery of mono- and bivalent LDL receptor-binding peptide-cargo conjugates: Implications for the rational design of new targeted drug therapies. </span><span class="cited-content_cbyCitation_journal-name">Journal of Controlled Release</span><span> <strong>2019,</strong> <em>314 </em>, 141-161. <a href="https://doi.org/10.1016/j.jconrel.2019.10.033" title="DOI URL">https://doi.org/10.1016/j.jconrel.2019.10.033</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jconrel.2019.10.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jconrel.2019.10.033%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Controlled%2520Release%26atitle%3DTarget%252Bengagement%252Band%252Bintracellular%252Bdelivery%252Bof%252Bmono-%252Band%252Bbivalent%252BLDL%252Breceptor-binding%252Bpeptide-cargo%252Bconjugates%25253A%252BImplications%252Bfor%252Bthe%252Brational%252Bdesign%252Bof%252Bnew%252Btargeted%252Bdrug%252Btherapies%26aulast%3DVarini%26aufirst%3DK.%26date%3D2019%26volume%3D314%26spage%3D141%26epage%3D161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nealie  Ngo</span>, <span class="hlFld-ContribAuthor ">Khalil  Choucair</span>, <span class="hlFld-ContribAuthor ">Justin F  Creeden</span>, <span class="hlFld-ContribAuthor ">Hanan  Qaqish</span>, <span class="hlFld-ContribAuthor ">Krupa  Bhavsar</span>, <span class="hlFld-ContribAuthor ">Chantal  Murphy</span>, <span class="hlFld-ContribAuthor ">Kendra  Lian</span>, <span class="hlFld-ContribAuthor ">Mary T  Albrethsen</span>, <span class="hlFld-ContribAuthor ">Laura  Stanbery</span>, <span class="hlFld-ContribAuthor ">Richard C  Phinney</span>, <span class="hlFld-ContribAuthor ">F Charles  Brunicardi</span>, <span class="hlFld-ContribAuthor ">Lance  Dworkin</span>, <span class="hlFld-ContribAuthor ">John  Nemunaitis</span>. </span><span class="cited-content_cbyCitation_article-title">Bifidobacterium spp
              : the promising Trojan Horse in the era of precision oncology. </span><span class="cited-content_cbyCitation_journal-name">Future Oncology</span><span> <strong>2019,</strong> <em>15 </em>
                                    (33)
                                     , 3861-3876. <a href="https://doi.org/10.2217/fon-2019-0374" title="DOI URL">https://doi.org/10.2217/fon-2019-0374</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2217/fon-2019-0374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2217%2Ffon-2019-0374%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Oncology%26atitle%3DBifidobacterium%252Bspp%252B%25253A%252Bthe%252Bpromising%252BTrojan%252BHorse%252Bin%252Bthe%252Bera%252Bof%252Bprecision%252Boncology%26aulast%3DNgo%26aufirst%3DNealie%26date%3D2019%26volume%3D15%26issue%3D33%26spage%3D3861%26epage%3D3876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kanwen  Yang</span>, <span class="hlFld-ContribAuthor ">Bo  Chen</span>, <span class="hlFld-ContribAuthor ">Diego A.  Gianolio</span>, <span class="hlFld-ContribAuthor ">James E.  Stefano</span>, <span class="hlFld-ContribAuthor ">Michelle  Busch</span>, <span class="hlFld-ContribAuthor ">Charlene  Manning</span>, <span class="hlFld-ContribAuthor ">Kim  Alving</span>, <span class="hlFld-ContribAuthor ">Richard C.  Gregory</span>, <span class="hlFld-ContribAuthor ">William H.  Brondyk</span>, <span class="hlFld-ContribAuthor ">Robert J.  Miller</span>, <span class="hlFld-ContribAuthor ">Pradeep K.  Dhal</span>. </span><span class="cited-content_cbyCitation_article-title">Convergent synthesis of hydrophilic monomethyl dolastatin 10 based drug linkers for antibody–drug conjugation. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2019,</strong> <em>17 </em>
                                    (35)
                                     , 8115-8124. <a href="https://doi.org/10.1039/C9OB01639B" title="DOI URL">https://doi.org/10.1039/C9OB01639B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9OB01639B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9OB01639B%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DConvergent%252Bsynthesis%252Bof%252Bhydrophilic%252Bmonomethyl%252Bdolastatin%252B10%252Bbased%252Bdrug%252Blinkers%252Bfor%252Bantibody%2525E2%252580%252593drug%252Bconjugation%26aulast%3DYang%26aufirst%3DKanwen%26date%3D2019%26date%3D2019%26volume%3D17%26issue%3D35%26spage%3D8115%26epage%3D8124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alexander Y.  Deneka</span>, <span class="hlFld-ContribAuthor ">Yanis  Boumber</span>, <span class="hlFld-ContribAuthor ">Tim  Beck</span>, <span class="hlFld-ContribAuthor ">Erica A.  Golemis</span>. </span><span class="cited-content_cbyCitation_article-title">Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC). </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2019,</strong> <em>11 </em>
                                    (9)
                                     , 1297. <a href="https://doi.org/10.3390/cancers11091297" title="DOI URL">https://doi.org/10.3390/cancers11091297</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers11091297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers11091297%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DTumor-Targeted%252BDrug%252BConjugates%252Bas%252Ban%252BEmerging%252BNovel%252BTherapeutic%252BApproach%252Bin%252BSmall%252BCell%252BLung%252BCancer%252B%252528SCLC%252529%26aulast%3DDeneka%26aufirst%3DAlexander%2BY.%26date%3D2019%26date%3D2019%26volume%3D11%26issue%3D9%26spage%3D1297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Romain  Tessier</span>, <span class="hlFld-ContribAuthor ">Javier  Ceballos</span>, <span class="hlFld-ContribAuthor ">Nora  Guidotti</span>, <span class="hlFld-ContribAuthor ">Raphael  Simonet-Davin</span>, <span class="hlFld-ContribAuthor ">Beat  Fierz</span>, <span class="hlFld-ContribAuthor ">Jerome  Waser</span>. </span><span class="cited-content_cbyCitation_article-title">“Doubly Orthogonal” Labeling of Peptides and Proteins. </span><span class="cited-content_cbyCitation_journal-name">Chem</span><span> <strong>2019,</strong> <em>5 </em>
                                    (8)
                                     , 2243-2263. <a href="https://doi.org/10.1016/j.chempr.2019.06.022" title="DOI URL">https://doi.org/10.1016/j.chempr.2019.06.022</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chempr.2019.06.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chempr.2019.06.022%26sid%3Dliteratum%253Aachs%26jtitle%3DChem%26atitle%3D%2525E2%252580%25259CDoubly%252BOrthogonal%2525E2%252580%25259D%252BLabeling%252Bof%252BPeptides%252Band%252BProteins%26aulast%3DTessier%26aufirst%3DRomain%26date%3D2019%26volume%3D5%26issue%3D8%26spage%3D2243%26epage%3D2263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Prathap Kumar  Mahalingaiah</span>, <span class="hlFld-ContribAuthor ">Rita  Ciurlionis</span>, <span class="hlFld-ContribAuthor ">Kenneth R.  Durbin</span>, <span class="hlFld-ContribAuthor ">Ronnie L.  Yeager</span>, <span class="hlFld-ContribAuthor ">Binu K.  Philip</span>, <span class="hlFld-ContribAuthor ">Bhupinder  Bawa</span>, <span class="hlFld-ContribAuthor ">Srinivasa R.  Mantena</span>, <span class="hlFld-ContribAuthor ">Brian P.  Enright</span>, <span class="hlFld-ContribAuthor ">Michael J.  Liguori</span>, <span class="hlFld-ContribAuthor ">Terry R.  Van Vleet</span>. </span><span class="cited-content_cbyCitation_article-title">Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology & Therapeutics</span><span> <strong>2019,</strong> <em>200 </em>, 110-125. <a href="https://doi.org/10.1016/j.pharmthera.2019.04.008" title="DOI URL">https://doi.org/10.1016/j.pharmthera.2019.04.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pharmthera.2019.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pharmthera.2019.04.008%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520%2526%2520Therapeutics%26atitle%3DPotential%252Bmechanisms%252Bof%252Btarget-independent%252Buptake%252Band%252Btoxicity%252Bof%252Bantibody-drug%252Bconjugates%26aulast%3DMahalingaiah%26aufirst%3DPrathap%2BKumar%26date%3D2019%26volume%3D200%26spage%3D110%26epage%3D125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lai-Xi  Wang</span>, <span class="hlFld-ContribAuthor ">Xin  Tong</span>, <span class="hlFld-ContribAuthor ">Chao  Li</span>, <span class="hlFld-ContribAuthor ">John P.  Giddens</span>, <span class="hlFld-ContribAuthor ">Tiezheng  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Glycoengineering of Antibodies for Modulating Functions. </span><span class="cited-content_cbyCitation_journal-name">Annual Review of Biochemistry</span><span> <strong>2019,</strong> <em>88 </em>
                                    (1)
                                     , 433-459. <a href="https://doi.org/10.1146/annurev-biochem-062917-012911" title="DOI URL">https://doi.org/10.1146/annurev-biochem-062917-012911</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1146/annurev-biochem-062917-012911&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1146%2Fannurev-biochem-062917-012911%26sid%3Dliteratum%253Aachs%26jtitle%3DAnnual%2520Review%2520of%2520Biochemistry%26atitle%3DGlycoengineering%252Bof%252BAntibodies%252Bfor%252BModulating%252BFunctions%26aulast%3DWang%26aufirst%3DLai-Xi%26date%3D2019%26volume%3D88%26issue%3D1%26spage%3D433%26epage%3D459" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yiwu  Zheng</span>, <span class="hlFld-ContribAuthor ">Yang  Shen</span>, <span class="hlFld-ContribAuthor ">Xiaoting  Meng</span>, <span class="hlFld-ContribAuthor ">Yaqi  Wu</span>, <span class="hlFld-ContribAuthor ">Yibing  Zhao</span>, <span class="hlFld-ContribAuthor ">Chuanliu  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Stabilizing
              p
              ‐Dithiobenzyl Urethane Linkers without Rate‐Limiting Self‐Immolation for Traceless Drug Release. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2019,</strong> <em>14 </em>
                                    (12)
                                     , 1196-1203. <a href="https://doi.org/10.1002/cmdc.201900248" title="DOI URL">https://doi.org/10.1002/cmdc.201900248</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201900248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201900248%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DStabilizing%252Bp%252B%2525E2%252580%252590Dithiobenzyl%252BUrethane%252BLinkers%252Bwithout%252BRate%2525E2%252580%252590Limiting%252BSelf%2525E2%252580%252590Immolation%252Bfor%252BTraceless%252BDrug%252BRelease%26aulast%3DZheng%26aufirst%3DYiwu%26date%3D2019%26date%3D2019%26volume%3D14%26issue%3D12%26spage%3D1196%26epage%3D1203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Charlotte  Baker</span>, <span class="hlFld-ContribAuthor ">Tiago  Rodrigues</span>, <span class="hlFld-ContribAuthor ">Bernardo P.  de Almeida</span>, <span class="hlFld-ContribAuthor ">Nuno L.  Barbosa-Morais</span>, <span class="hlFld-ContribAuthor ">Gonçalo J.L.  Bernardes</span>. </span><span class="cited-content_cbyCitation_article-title">Natural product–drug conjugates for modulation of TRPV1-expressing tumors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2019,</strong> <em>27 </em>
                                    (12)
                                     , 2531-2536. <a href="https://doi.org/10.1016/j.bmc.2019.03.025" title="DOI URL">https://doi.org/10.1016/j.bmc.2019.03.025</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2019.03.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2019.03.025%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DNatural%252Bproduct%2525E2%252580%252593drug%252Bconjugates%252Bfor%252Bmodulation%252Bof%252BTRPV1-expressing%252Btumors%26aulast%3DBaker%26aufirst%3DCharlotte%26date%3D2019%26volume%3D27%26issue%3D12%26spage%3D2531%26epage%3D2536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">André  Raposo Moreira Dias</span>, <span class="hlFld-ContribAuthor ">Lizeth  Bodero</span>, <span class="hlFld-ContribAuthor ">Ana  Martins</span>, <span class="hlFld-ContribAuthor ">Daniela  Arosio</span>, <span class="hlFld-ContribAuthor ">Silvia  Gazzola</span>, <span class="hlFld-ContribAuthor ">Laura  Belvisi</span>, <span class="hlFld-ContribAuthor ">Luca  Pignataro</span>, <span class="hlFld-ContribAuthor ">Christian  Steinkühler</span>, <span class="hlFld-ContribAuthor ">Alberto  Dal Corso</span>, <span class="hlFld-ContribAuthor ">Cesare  Gennari</span>, <span class="hlFld-ContribAuthor ">Umberto  Piarulli</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Biological Evaluation of RGD and
              iso
              DGR–Monomethyl Auristatin Conjugates Targeting Integrin α
              V
              β
              3. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2019,</strong> <em>14 </em>
                                    (9)
                                     , 938-942. <a href="https://doi.org/10.1002/cmdc.201900049" title="DOI URL">https://doi.org/10.1002/cmdc.201900049</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201900049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201900049%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252BRGD%252Band%252Biso%252BDGR%2525E2%252580%252593Monomethyl%252BAuristatin%252BConjugates%252BTargeting%252BIntegrin%252B%2525CE%2525B1%252BV%252B%2525CE%2525B2%252B3%26aulast%3DRaposo%25E2%2580%2585Moreira%25E2%2580%2585Dias%26aufirst%3DAndr%25C3%25A9%26date%3D2019%26date%3D2019%26volume%3D14%26issue%3D9%26spage%3D938%26epage%3D942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eduard  Figueras</span>, <span class="hlFld-ContribAuthor ">Ana  Martins</span>, <span class="hlFld-ContribAuthor ">Adina  Borbély</span>, <span class="hlFld-ContribAuthor ">Vadim  Le Joncour</span>, <span class="hlFld-ContribAuthor ">Paola  Cordella</span>, <span class="hlFld-ContribAuthor ">Raffaella  Perego</span>, <span class="hlFld-ContribAuthor ">Daniela  Modena</span>, <span class="hlFld-ContribAuthor ">Paolo  Pagani</span>, <span class="hlFld-ContribAuthor ">Simone  Esposito</span>, <span class="hlFld-ContribAuthor ">Giulio  Auciello</span>, <span class="hlFld-ContribAuthor ">Marcel  Frese</span>, <span class="hlFld-ContribAuthor ">Paola  Gallinari</span>, <span class="hlFld-ContribAuthor ">Pirjo  Laakkonen</span>, <span class="hlFld-ContribAuthor ">Christian  Steinkühler</span>, <span class="hlFld-ContribAuthor ">Norbert  Sewald</span>. </span><span class="cited-content_cbyCitation_article-title">Octreotide Conjugates for Tumor Targeting and Imaging. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceutics</span><span> <strong>2019,</strong> <em>11 </em>
                                    (5)
                                     , 220. <a href="https://doi.org/10.3390/pharmaceutics11050220" title="DOI URL">https://doi.org/10.3390/pharmaceutics11050220</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/pharmaceutics11050220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fpharmaceutics11050220%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceutics%26atitle%3DOctreotide%252BConjugates%252Bfor%252BTumor%252BTargeting%252Band%252BImaging%26aulast%3DFigueras%26aufirst%3DEduard%26date%3D2019%26date%3D2019%26volume%3D11%26issue%3D5%26spage%3D220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adina  Borbély</span>, <span class="hlFld-ContribAuthor ">Eduard  Figueras</span>, <span class="hlFld-ContribAuthor ">Ana  Martins</span>, <span class="hlFld-ContribAuthor ">Simone  Esposito</span>, <span class="hlFld-ContribAuthor ">Giulio  Auciello</span>, <span class="hlFld-ContribAuthor ">Edith  Monteagudo</span>, <span class="hlFld-ContribAuthor ">Annalise  Di Marco</span>, <span class="hlFld-ContribAuthor ">Vincenzo  Summa</span>, <span class="hlFld-ContribAuthor ">Paola  Cordella</span>, <span class="hlFld-ContribAuthor ">Raffaella  Perego</span>, <span class="hlFld-ContribAuthor ">Isabell  Kemker</span>, <span class="hlFld-ContribAuthor ">Marcel  Frese</span>, <span class="hlFld-ContribAuthor ">Paola  Gallinari</span>, <span class="hlFld-ContribAuthor ">Christian  Steinkühler</span>, <span class="hlFld-ContribAuthor ">Norbert  Sewald</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Biological Evaluation of RGD–Cryptophycin Conjugates for Targeted Drug Delivery. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceutics</span><span> <strong>2019,</strong> <em>11 </em>
                                    (4)
                                     , 151. <a href="https://doi.org/10.3390/pharmaceutics11040151" title="DOI URL">https://doi.org/10.3390/pharmaceutics11040151</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/pharmaceutics11040151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fpharmaceutics11040151%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceutics%26atitle%3DSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252BRGD%2525E2%252580%252593Cryptophycin%252BConjugates%252Bfor%252BTargeted%252BDrug%252BDelivery%26aulast%3DBorb%25C3%25A9ly%26aufirst%3DAdina%26date%3D2019%26date%3D2019%26volume%3D11%26issue%3D4%26spage%3D151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anne C.  Conibear</span>, <span class="hlFld-ContribAuthor ">Karine  Thewes</span>, <span class="hlFld-ContribAuthor ">Nadja  Groysbeck</span>, <span class="hlFld-ContribAuthor ">Christian F. W.  Becker</span>. </span><span class="cited-content_cbyCitation_article-title">Multifunctional Scaffolds for Assembling Cancer-Targeting Immune Stimulators Using Chemoselective Ligations. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Chemistry</span><span> <strong>2019,</strong> <em>7 </em><a href="https://doi.org/10.3389/fchem.2019.00113" title="DOI URL">https://doi.org/10.3389/fchem.2019.00113</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fchem.2019.00113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffchem.2019.00113%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Chemistry%26atitle%3DMultifunctional%252BScaffolds%252Bfor%252BAssembling%252BCancer-Targeting%252BImmune%252BStimulators%252BUsing%252BChemoselective%252BLigations%26aulast%3DConibear%26aufirst%3DAnne%2BC.%26date%3D2019%26date%3D2019%26volume%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew T.  Lucas</span>, <span class="hlFld-ContribAuthor ">Ryan  Robinson</span>, <span class="hlFld-ContribAuthor ">Allison N.  Schorzman</span>, <span class="hlFld-ContribAuthor ">Joseph A.  Piscitelli</span>, <span class="hlFld-ContribAuthor ">Juan F.  Razo</span>, <span class="hlFld-ContribAuthor ">William C.  Zamboni</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients. </span><span class="cited-content_cbyCitation_journal-name">Antibodies</span><span> <strong>2019,</strong> <em>8 </em>
                                    (1)
                                     , 3. <a href="https://doi.org/10.3390/antib8010003" title="DOI URL">https://doi.org/10.3390/antib8010003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/antib8010003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fantib8010003%26sid%3Dliteratum%253Aachs%26jtitle%3DAntibodies%26atitle%3DPharmacologic%252BConsiderations%252Bin%252Bthe%252BDisposition%252Bof%252BAntibodies%252Band%252BAntibody-Drug%252BConjugates%252Bin%252BPreclinical%252BModels%252Band%252Bin%252BPatients%26aulast%3DLucas%26aufirst%3DAndrew%2BT.%26date%3D2019%26date%3D2019%26volume%3D8%26issue%3D1%26spage%3D3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fabienne  Gaugaz</span>, <span class="hlFld-ContribAuthor ">Andrea  Chicca</span>, <span class="hlFld-ContribAuthor ">Mariano  Redondo-Horcajo</span>, <span class="hlFld-ContribAuthor ">Isabel  Barasoain</span>, <span class="hlFld-ContribAuthor ">J.  Díaz</span>, <span class="hlFld-ContribAuthor ">Karl-Heinz  Altmann</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, Microtubule-Binding Affinity, and Antiproliferative Activity of New Epothilone Analogs and of an EGFR-Targeted Epothilone-Peptide Conjugate. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2019,</strong> <em>20 </em>
                                    (5)
                                     , 1113. <a href="https://doi.org/10.3390/ijms20051113" title="DOI URL">https://doi.org/10.3390/ijms20051113</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms20051113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms20051113%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DSynthesis%25252C%252BMicrotubule-Binding%252BAffinity%25252C%252Band%252BAntiproliferative%252BActivity%252Bof%252BNew%252BEpothilone%252BAnalogs%252Band%252Bof%252Ban%252BEGFR-Targeted%252BEpothilone-Peptide%252BConjugate%26aulast%3DGaugaz%26aufirst%3DFabienne%26date%3D2019%26date%3D2019%26volume%3D20%26issue%3D5%26spage%3D1113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chunlin  Zhuang</span>, <span class="hlFld-ContribAuthor ">Xianghong  Guan</span>, <span class="hlFld-ContribAuthor ">Hao  Ma</span>, <span class="hlFld-ContribAuthor ">Hui  Cong</span>, <span class="hlFld-ContribAuthor ">Wannian  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhenyuan  Miao</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecule-drug conjugates: A novel strategy for cancer-targeted treatment. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>163 </em>, 883-895. <a href="https://doi.org/10.1016/j.ejmech.2018.12.035" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.12.035</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.12.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.12.035%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall%252Bmolecule-drug%252Bconjugates%25253A%252BA%252Bnovel%252Bstrategy%252Bfor%252Bcancer-targeted%252Btreatment%26aulast%3DZhuang%26aufirst%3DChunlin%26date%3D2019%26volume%3D163%26spage%3D883%26epage%3D895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kunal  Pal</span>, <span class="hlFld-ContribAuthor ">Shubham  Roy</span>, <span class="hlFld-ContribAuthor ">Pravat Kumar  Parida</span>, <span class="hlFld-ContribAuthor ">Ananya  Dutta</span>, <span class="hlFld-ContribAuthor ">Souravi  Bardhan</span>, <span class="hlFld-ContribAuthor ">Sukhen  Das</span>, <span class="hlFld-ContribAuthor ">Kuladip  Jana</span>, <span class="hlFld-ContribAuthor ">Parimal  Karmakar</span>. </span><span class="cited-content_cbyCitation_article-title">Folic acid conjugated curcumin loaded biopolymeric gum acacia microsphere for triple negative breast cancer therapy in invitro and invivo model. </span><span class="cited-content_cbyCitation_journal-name">Materials Science and Engineering: C</span><span> <strong>2019,</strong> <em>95 </em>, 204-216. <a href="https://doi.org/10.1016/j.msec.2018.10.071" title="DOI URL">https://doi.org/10.1016/j.msec.2018.10.071</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.msec.2018.10.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.msec.2018.10.071%26sid%3Dliteratum%253Aachs%26jtitle%3DMaterials%2520Science%2520and%2520Engineering%253A%2520C%26atitle%3DFolic%252Bacid%252Bconjugated%252Bcurcumin%252Bloaded%252Bbiopolymeric%252Bgum%252Bacacia%252Bmicrosphere%252Bfor%252Btriple%252Bnegative%252Bbreast%252Bcancer%252Btherapy%252Bin%252Binvitro%252Band%252Binvivo%252Bmodel%26aulast%3DPal%26aufirst%3DKunal%26date%3D2019%26volume%3D95%26spage%3D204%26epage%3D216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alexander H.  Staudacher</span>, <span class="hlFld-ContribAuthor ">Yanrui  Li</span>, <span class="hlFld-ContribAuthor ">Vasilios  Liapis</span>, <span class="hlFld-ContribAuthor ">Jeff Jia Cheng  Hou</span>, <span class="hlFld-ContribAuthor ">David  Chin</span>, <span class="hlFld-ContribAuthor ">Olan  Dolezal</span>, <span class="hlFld-ContribAuthor ">Timothy E.  Adams</span>, <span class="hlFld-ContribAuthor ">Patrick H.  van Berkel</span>, <span class="hlFld-ContribAuthor ">Michael P.  Brown</span>. </span><span class="cited-content_cbyCitation_article-title">APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective
              In Vivo. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2019,</strong> <em>18 </em>
                                    (2)
                                     , 335-345. <a href="https://doi.org/10.1158/1535-7163.MCT-18-0842" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-18-0842</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-18-0842&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-18-0842%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DAPOMAB%252BAntibody%2525E2%252580%252593Drug%252BConjugates%252BTargeting%252BDead%252BTumor%252BCells%252Bare%252BEffective%252BIn%252BVivo%26aulast%3DStaudacher%26aufirst%3DAlexander%2BH.%26date%3D2019%26date%3D2018%26volume%3D18%26issue%3D2%26spage%3D335%26epage%3D345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jisi  Zhao</span>, <span class="hlFld-ContribAuthor ">Shuang  Li</span>, <span class="hlFld-ContribAuthor ">Yingying  Jin</span>, <span class="hlFld-ContribAuthor ">Jessica  Wang</span>, <span class="hlFld-ContribAuthor ">Wenjing  Li</span>, <span class="hlFld-ContribAuthor ">Wenjie  Wu</span>, <span class="hlFld-ContribAuthor ">Zhangyong  Hong</span>. </span><span class="cited-content_cbyCitation_article-title">Multimerization Increases Tumor Enrichment of Peptide–Photosensitizer Conjugates. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (4)
                                     , 817. <a href="https://doi.org/10.3390/molecules24040817" title="DOI URL">https://doi.org/10.3390/molecules24040817</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24040817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24040817%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DMultimerization%252BIncreases%252BTumor%252BEnrichment%252Bof%252BPeptide%2525E2%252580%252593Photosensitizer%252BConjugates%26aulast%3DZhao%26aufirst%3DJisi%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D4%26spage%3D817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Weiwei  Wang</span>, <span class="hlFld-ContribAuthor ">Xiangyun  Li</span>, <span class="hlFld-ContribAuthor ">Zhaohong  Wang</span>, <span class="hlFld-ContribAuthor ">Jinfu  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiao  Dong</span>, <span class="hlFld-ContribAuthor ">Yunzhao  Wu</span>, <span class="hlFld-ContribAuthor ">Chao  Fang</span>, <span class="hlFld-ContribAuthor ">Aiwu  Zhou</span>, <span class="hlFld-ContribAuthor ">Yingli  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">A novel “mosaic-type” nanoparticle for selective drug release targeting hypoxic cancer cells. </span><span class="cited-content_cbyCitation_journal-name">Nanoscale</span><span> <strong>2019,</strong> <em>11 </em>
                                    (5)
                                     , 2211-2222. <a href="https://doi.org/10.1039/C8NR06452K" title="DOI URL">https://doi.org/10.1039/C8NR06452K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8NR06452K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8NR06452K%26sid%3Dliteratum%253Aachs%26jtitle%3DNanoscale%26atitle%3DA%252Bnovel%252B%2525E2%252580%25259Cmosaic-type%2525E2%252580%25259D%252Bnanoparticle%252Bfor%252Bselective%252Bdrug%252Brelease%252Btargeting%252Bhypoxic%252Bcancer%252Bcells%26aulast%3DWang%26aufirst%3DWeiwei%26date%3D2019%26date%3D2019%26volume%3D11%26issue%3D5%26spage%3D2211%26epage%3D2222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ningning  Song</span>, <span class="hlFld-ContribAuthor ">Lingzhou  Zhao</span>, <span class="hlFld-ContribAuthor ">Meilin  Zhu</span>, <span class="hlFld-ContribAuthor ">Jinhua  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Recent progress in LyP-1-based strategies for targeted imaging and therapy. </span><span class="cited-content_cbyCitation_journal-name">Drug Delivery</span><span> <strong>2019,</strong> <em>26 </em>
                                    (1)
                                     , 363-375. <a href="https://doi.org/10.1080/10717544.2019.1587047" title="DOI URL">https://doi.org/10.1080/10717544.2019.1587047</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/10717544.2019.1587047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F10717544.2019.1587047%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Delivery%26atitle%3DRecent%252Bprogress%252Bin%252BLyP-1-based%252Bstrategies%252Bfor%252Btargeted%252Bimaging%252Band%252Btherapy%26aulast%3DSong%26aufirst%3DNingning%26date%3D2019%26date%3D2019%26volume%3D26%26issue%3D1%26spage%3D363%26epage%3D375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nafsika  Forte</span>, <span class="hlFld-ContribAuthor ">Vijay  Chudasama</span>, <span class="hlFld-ContribAuthor ">James R.  Baker</span>. </span><span class="cited-content_cbyCitation_article-title">Homogeneous antibody-drug conjugates via site-selective disulfide bridging. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today: Technologies</span><span> <strong>2018,</strong> <em>30 </em>, 11-20. <a href="https://doi.org/10.1016/j.ddtec.2018.09.004" title="DOI URL">https://doi.org/10.1016/j.ddtec.2018.09.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ddtec.2018.09.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ddtec.2018.09.004%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Technologies%26atitle%3DHomogeneous%252Bantibody-drug%252Bconjugates%252Bvia%252Bsite-selective%252Bdisulfide%252Bbridging%26aulast%3DForte%26aufirst%3DNafsika%26date%3D2018%26volume%3D30%26spage%3D11%26epage%3D20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Grégory  Menchon</span>, <span class="hlFld-ContribAuthor ">Andrea E.  Prota</span>, <span class="hlFld-ContribAuthor ">Daniel  Lucena-Agell</span>, <span class="hlFld-ContribAuthor ">Pascal  Bucher</span>, <span class="hlFld-ContribAuthor ">Rolf  Jansen</span>, <span class="hlFld-ContribAuthor ">Herbert  Irschik</span>, <span class="hlFld-ContribAuthor ">Rolf  Müller</span>, <span class="hlFld-ContribAuthor ">Ian  Paterson</span>, <span class="hlFld-ContribAuthor ">J. Fernando  Díaz</span>, <span class="hlFld-ContribAuthor ">Karl-Heinz  Altmann</span>, <span class="hlFld-ContribAuthor ">Michel O.  Steinmetz</span>. </span><span class="cited-content_cbyCitation_article-title">A fluorescence anisotropy assay to discover and characterize ligands targeting the maytansine site of tubulin. </span><span class="cited-content_cbyCitation_journal-name">Nature Communications</span><span> <strong>2018,</strong> <em>9 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41467-018-04535-8" title="DOI URL">https://doi.org/10.1038/s41467-018-04535-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41467-018-04535-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41467-018-04535-8%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Communications%26atitle%3DA%252Bfluorescence%252Banisotropy%252Bassay%252Bto%252Bdiscover%252Band%252Bcharacterize%252Bligands%252Btargeting%252Bthe%252Bmaytansine%2525C2%2525A0site%252Bof%252Btubulin%26aulast%3DMenchon%26aufirst%3DGr%25C3%25A9gory%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Benoît  Bertrand</span>, <span class="hlFld-ContribAuthor ">Morwen R. M.  Williams</span>, <span class="hlFld-ContribAuthor ">Manfred  Bochmann</span>. </span><span class="cited-content_cbyCitation_article-title">Gold(III) Complexes for Antitumor Applications: An Overview. </span><span class="cited-content_cbyCitation_journal-name">Chemistry – A European Journal</span><span> <strong>2018,</strong> <em>24 </em>
                                    (46)
                                     , 11840-11851. <a href="https://doi.org/10.1002/chem.201800981" title="DOI URL">https://doi.org/10.1002/chem.201800981</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.201800981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.201800981%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%25E2%2580%2593%2520A%2520European%2520Journal%26atitle%3DGold%252528III%252529%252BComplexes%252Bfor%252BAntitumor%252BApplications%25253A%252BAn%252BOverview%26aulast%3DBertrand%26aufirst%3DBeno%25C3%25AEt%26date%3D2018%26date%3D2018%26volume%3D24%26issue%3D46%26spage%3D11840%26epage%3D11851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jarkko  Rautio</span>, <span class="hlFld-ContribAuthor ">Nicholas A.  Meanwell</span>, <span class="hlFld-ContribAuthor ">Li  Di</span>, <span class="hlFld-ContribAuthor ">Michael J.  Hageman</span>. </span><span class="cited-content_cbyCitation_article-title">The expanding role of prodrugs in contemporary drug design and development. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Drug Discovery</span><span> <strong>2018,</strong> <em>17 </em>
                                    (8)
                                     , 559-587. <a href="https://doi.org/10.1038/nrd.2018.46" title="DOI URL">https://doi.org/10.1038/nrd.2018.46</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/nrd.2018.46&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fnrd.2018.46%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Drug%2520Discovery%26atitle%3DThe%252Bexpanding%252Brole%252Bof%252Bprodrugs%252Bin%252Bcontemporary%252Bdrug%252Bdesign%252Band%252Bdevelopment%26aulast%3DRautio%26aufirst%3DJarkko%26date%3D2018%26date%3D2018%26volume%3D17%26issue%3D8%26spage%3D559%26epage%3D587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matteo  Floris</span>, <span class="hlFld-ContribAuthor ">Stefania  Olla</span>, <span class="hlFld-ContribAuthor ">David  Schlessinger</span>, <span class="hlFld-ContribAuthor ">Francesco  Cucca</span>. </span><span class="cited-content_cbyCitation_article-title">Genetic-Driven Druggable Target Identification and Validation. </span><span class="cited-content_cbyCitation_journal-name">Trends in Genetics</span><span> <strong>2018,</strong> <em>34 </em>
                                    (7)
                                     , 558-570. <a href="https://doi.org/10.1016/j.tig.2018.04.004" title="DOI URL">https://doi.org/10.1016/j.tig.2018.04.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tig.2018.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tig.2018.04.004%26sid%3Dliteratum%253Aachs%26jtitle%3DTrends%2520in%2520Genetics%26atitle%3DGenetic-Driven%252BDruggable%252BTarget%252BIdentification%252Band%252BValidation%26aulast%3DFloris%26aufirst%3DMatteo%26date%3D2018%26volume%3D34%26issue%3D7%26spage%3D558%26epage%3D570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paula  López Rivas</span>, <span class="hlFld-ContribAuthor ">Ivan  Ranđelović</span>, <span class="hlFld-ContribAuthor ">André  Raposo Moreira Dias</span>, <span class="hlFld-ContribAuthor ">Arianna  Pina</span>, <span class="hlFld-ContribAuthor ">Daniela  Arosio</span>, <span class="hlFld-ContribAuthor ">József  Tóvári</span>, <span class="hlFld-ContribAuthor ">Gábor  Mező</span>, <span class="hlFld-ContribAuthor ">Alberto  Dal Corso</span>, <span class="hlFld-ContribAuthor ">Luca  Pignataro</span>, <span class="hlFld-ContribAuthor ">Cesare  Gennari</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Biological Evaluation of Paclitaxel Conjugates Involving Linkers Cleavable by Lysosomal Enzymes and α
              V
              β
              3
              -Integrin Ligands for Tumor Targeting. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>2018 </em>
                                    (23)
                                     , 2902-2909. <a href="https://doi.org/10.1002/ejoc.201800447" title="DOI URL">https://doi.org/10.1002/ejoc.201800447</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201800447&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201800447%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252BPaclitaxel%252BConjugates%252BInvolving%252BLinkers%252BCleavable%252Bby%252BLysosomal%252BEnzymes%252Band%252B%2525CE%2525B1%252BV%252B%2525CE%2525B2%252B3%252B-Integrin%252BLigands%252Bfor%252BTumor%252BTargeting%26aulast%3DL%25C3%25B3pez%2BRivas%26aufirst%3DPaula%26date%3D2018%26date%3D2018%26volume%3D2018%26issue%3D23%26spage%3D2902%26epage%3D2909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marie R.G.  Kopp</span>, <span class="hlFld-ContribAuthor ">Paolo  Arosio</span>. </span><span class="cited-content_cbyCitation_article-title">Microfluidic Approaches for the Characterization of Therapeutic Proteins. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmaceutical Sciences</span><span> <strong>2018,</strong> <em>107 </em>
                                    (5)
                                     , 1228-1236. <a href="https://doi.org/10.1016/j.xphs.2018.01.001" title="DOI URL">https://doi.org/10.1016/j.xphs.2018.01.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.xphs.2018.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.xphs.2018.01.001%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmaceutical%2520Sciences%26atitle%3DMicrofluidic%252BApproaches%252Bfor%252Bthe%252BCharacterization%252Bof%252BTherapeutic%252BProteins%26aulast%3DKopp%26aufirst%3DMarie%2BR.G.%26date%3D2018%26volume%3D107%26issue%3D5%26spage%3D1228%26epage%3D1236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bo  Chen</span>, <span class="hlFld-ContribAuthor ">Diego A.  Gianolio</span>, <span class="hlFld-ContribAuthor ">James E.  Stefano</span>, <span class="hlFld-ContribAuthor ">Charlene M.  Manning</span>, <span class="hlFld-ContribAuthor ">Richard C.  Gregory</span>, <span class="hlFld-ContribAuthor ">Michelle M.  Busch</span>, <span class="hlFld-ContribAuthor ">William H.  Brondyk</span>, <span class="hlFld-ContribAuthor ">Robert J.  Miller</span>, <span class="hlFld-ContribAuthor ">Pradeep K.  Dhal</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and in vitro Evaluation of Multivalent Drug Linkers for High-Drug-Load Antibody-Drug Conjugates. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2018,</strong> <em>13 </em>
                                    (8)
                                     , 790-794. <a href="https://doi.org/10.1002/cmdc.201700722" title="DOI URL">https://doi.org/10.1002/cmdc.201700722</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201700722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201700722%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252Bin%2525E2%252580%252585vitro%252BEvaluation%252Bof%252BMultivalent%252BDrug%252BLinkers%252Bfor%252BHigh-Drug-Load%252BAntibody-Drug%252BConjugates%26aulast%3DChen%26aufirst%3DBo%26date%3D2018%26date%3D2018%26volume%3D13%26issue%3D8%26spage%3D790%26epage%3D794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Benoît  Bertrand</span>, <span class="hlFld-ContribAuthor ">Maria A.  O'Connell</span>, <span class="hlFld-ContribAuthor ">Zoë A. E.  Waller</span>, <span class="hlFld-ContribAuthor ">Manfred  Bochmann</span>. </span><span class="cited-content_cbyCitation_article-title">A Gold(III) Pincer Ligand Scaffold for the Synthesis of Binuclear and Bioconjugated Complexes: Synthesis and Anticancer Potential. </span><span class="cited-content_cbyCitation_journal-name">Chemistry - A European Journal</span><span> <strong>2018,</strong> <em>24 </em>
                                    (14)
                                     , 3613-3622. <a href="https://doi.org/10.1002/chem.201705902" title="DOI URL">https://doi.org/10.1002/chem.201705902</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.201705902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.201705902%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520-%2520A%2520European%2520Journal%26atitle%3DA%252BGold%252528III%252529%252BPincer%252BLigand%252BScaffold%252Bfor%252Bthe%252BSynthesis%252Bof%252BBinuclear%252Band%252BBioconjugated%252BComplexes%25253A%252BSynthesis%252Band%252BAnticancer%252BPotential%26aulast%3DBertrand%26aufirst%3DBeno%25C3%25AEt%26date%3D2018%26date%3D2018%26volume%3D24%26issue%3D14%26spage%3D3613%26epage%3D3622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laura  Kuhlmann</span>, <span class="hlFld-ContribAuthor ">Emma  Cummins</span>, <span class="hlFld-ContribAuthor ">Ismael  Samudio</span>, <span class="hlFld-ContribAuthor ">Thomas  Kislinger</span>. </span><span class="cited-content_cbyCitation_article-title">Cell-surface proteomics for the identification of novel therapeutic targets in cancer. </span><span class="cited-content_cbyCitation_journal-name">Expert Review of Proteomics</span><span> <strong>2018,</strong> <em>15 </em>
                                    (3)
                                     , 259-275. <a href="https://doi.org/10.1080/14789450.2018.1429924" title="DOI URL">https://doi.org/10.1080/14789450.2018.1429924</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14789450.2018.1429924&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14789450.2018.1429924%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Review%2520of%2520Proteomics%26atitle%3DCell-surface%252Bproteomics%252Bfor%252Bthe%252Bidentification%252Bof%252Bnovel%252Btherapeutic%252Btargets%252Bin%252Bcancer%26aulast%3DKuhlmann%26aufirst%3DLaura%26date%3D2018%26date%3D2018%26volume%3D15%26issue%3D3%26spage%3D259%26epage%3D275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anne C.  Conibear</span>, <span class="hlFld-ContribAuthor ">André J. G.  Pötgens</span>, <span class="hlFld-ContribAuthor ">Karine  Thewes</span>, <span class="hlFld-ContribAuthor ">Claudia  Altdorf</span>, <span class="hlFld-ContribAuthor ">Clarissa  Hilzendeger</span>, <span class="hlFld-ContribAuthor ">Christian F. W.  Becker</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic Cancer-Targeting Innate Immune Stimulators Give Insights into Avidity Effects. </span><span class="cited-content_cbyCitation_journal-name">ChemBioChem</span><span> <strong>2018,</strong> <em>19 </em>
                                    (5)
                                     , 459-469. <a href="https://doi.org/10.1002/cbic.201700522" title="DOI URL">https://doi.org/10.1002/cbic.201700522</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cbic.201700522&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcbic.201700522%26sid%3Dliteratum%253Aachs%26jtitle%3DChemBioChem%26atitle%3DSynthetic%252BCancer-Targeting%252BInnate%252BImmune%252BStimulators%252BGive%252BInsights%252Binto%252BAvidity%252BEffects%26aulast%3DConibear%26aufirst%3DAnne%2BC.%26date%3D2018%26date%3D2018%26volume%3D19%26issue%3D5%26spage%3D459%26epage%3D469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael L.  Miller</span>, <span class="hlFld-ContribAuthor ">Manami  Shizuka</span>, <span class="hlFld-ContribAuthor ">Alan  Wilhelm</span>, <span class="hlFld-ContribAuthor ">Paulin  Salomon</span>, <span class="hlFld-ContribAuthor ">Emily E.  Reid</span>, <span class="hlFld-ContribAuthor ">Leanne  Lanieri</span>, <span class="hlFld-ContribAuthor ">Surina  Sikka</span>, <span class="hlFld-ContribAuthor ">Erin K.  Maloney</span>, <span class="hlFld-ContribAuthor ">Lauren  Harvey</span>, <span class="hlFld-ContribAuthor ">Qifeng  Qiu</span>, <span class="hlFld-ContribAuthor ">Katie E.  Archer</span>, <span class="hlFld-ContribAuthor ">Chen  Bai</span>, <span class="hlFld-ContribAuthor ">Dilrukshi  Vitharana</span>, <span class="hlFld-ContribAuthor ">Luke  Harris</span>, <span class="hlFld-ContribAuthor ">Rajeeva  Singh</span>, <span class="hlFld-ContribAuthor ">Jose F.  Ponte</span>, <span class="hlFld-ContribAuthor ">Nicholas C.  Yoder</span>, <span class="hlFld-ContribAuthor ">Yelena  Kovtun</span>, <span class="hlFld-ContribAuthor ">Katharine C.  Lai</span>, <span class="hlFld-ContribAuthor ">Olga  Ab</span>, <span class="hlFld-ContribAuthor ">Jan  Pinkas</span>, <span class="hlFld-ContribAuthor ">Thomas A.  Keating</span>, <span class="hlFld-ContribAuthor ">Ravi V.J.  Chari</span>. </span><span class="cited-content_cbyCitation_article-title">A DNA-Interacting Payload Designed to Eliminate Cross-Linking Improves the Therapeutic Index of Antibody–Drug Conjugates (ADCs). </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2018,</strong> <em>17 </em>
                                    (3)
                                     , 650-660. <a href="https://doi.org/10.1158/1535-7163.MCT-17-0940" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-17-0940</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-17-0940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-17-0940%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DA%252BDNA-Interacting%252BPayload%252BDesigned%252Bto%252BEliminate%252BCross-Linking%252BImproves%252Bthe%252BTherapeutic%252BIndex%252Bof%252BAntibody%2525E2%252580%252593Drug%252BConjugates%252B%252528ADCs%252529%26aulast%3DMiller%26aufirst%3DMichael%2BL.%26date%3D2018%26date%3D2018%26volume%3D17%26issue%3D3%26spage%3D650%26epage%3D660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Karen M.  Nagel</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic Antibodies. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 55-86. <a href="https://doi.org/10.1007/978-3-319-98428-5_3" title="DOI URL">https://doi.org/10.1007/978-3-319-98428-5_3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-98428-5_3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-98428-5_3%26sid%3Dliteratum%253Aachs%26atitle%3DTherapeutic%252BAntibodies%26aulast%3DNagel%26aufirst%3DKaren%2BM.%26date%3D2018%26date%3D2018%26spage%3D55%26epage%3D86%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DIntroduction%252Bto%252BBiologic%252Band%252BBiosimilar%252BProduct%252BDevelopment%252Band%252BAnalysis%26aulast%3DNagel%26aufirst%3DKaren%2BM.%26date%3D2018%26volume%3D31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">E.  Péraudeau</span>, <span class="hlFld-ContribAuthor ">L.  Cronier</span>, <span class="hlFld-ContribAuthor ">A.  Monvoisin</span>, <span class="hlFld-ContribAuthor ">P.  Poinot</span>, <span class="hlFld-ContribAuthor ">C.  Mergault</span>, <span class="hlFld-ContribAuthor ">F.  Guilhot</span>, <span class="hlFld-ContribAuthor ">I.  Tranoy-Opalinski</span>, <span class="hlFld-ContribAuthor ">B.  Renoux</span>, <span class="hlFld-ContribAuthor ">S.  Papot</span>, <span class="hlFld-ContribAuthor ">J.  Clarhaut</span>. </span><span class="cited-content_cbyCitation_article-title">Enhancing tumor response to targeted chemotherapy through up-regulation of folate receptor α expression induced by dexamethasone and valproic acid. </span><span class="cited-content_cbyCitation_journal-name">Journal of Controlled Release</span><span> <strong>2018,</strong> <em>269 </em>, 36-44. <a href="https://doi.org/10.1016/j.jconrel.2017.11.011" title="DOI URL">https://doi.org/10.1016/j.jconrel.2017.11.011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jconrel.2017.11.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jconrel.2017.11.011%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Controlled%2520Release%26atitle%3DEnhancing%252Btumor%252Bresponse%252Bto%252Btargeted%252Bchemotherapy%252Bthrough%252Bup-regulation%252Bof%252Bfolate%252Breceptor%252B%2525CE%2525B1%252Bexpression%252Binduced%252Bby%252Bdexamethasone%252Band%252Bvalproic%252Bacid%26aulast%3DP%25C3%25A9raudeau%26aufirst%3DE.%26date%3D2018%26volume%3D269%26spage%3D36%26epage%3D44" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elena  Cini</span>, <span class="hlFld-ContribAuthor ">Valentina  Faltoni</span>, <span class="hlFld-ContribAuthor ">Elena  Petricci</span>, <span class="hlFld-ContribAuthor ">Maurizio  Taddei</span>, <span class="hlFld-ContribAuthor ">Laura  Salvini</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Giannini</span>, <span class="hlFld-ContribAuthor ">Loredana  Vesci</span>, <span class="hlFld-ContribAuthor ">Ferdinando Maria  Milazzo</span>, <span class="hlFld-ContribAuthor ">Anna Maria  Anastasi</span>, <span class="hlFld-ContribAuthor ">Gianfranco  Battistuzzi</span>, <span class="hlFld-ContribAuthor ">Rita  De Santis</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody drug conjugates (ADCs) charged with HDAC inhibitor for targeted epigenetic modulation. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2018,</strong> <em>9 </em>
                                    (31)
                                     , 6490-6496. <a href="https://doi.org/10.1039/C7SC05266A" title="DOI URL">https://doi.org/10.1039/C7SC05266A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7SC05266A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7SC05266A%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3DAntibody%252Bdrug%252Bconjugates%252B%252528ADCs%252529%252Bcharged%252Bwith%252BHDAC%252Binhibitor%252Bfor%252Btargeted%252Bepigenetic%252Bmodulation%26aulast%3DCini%26aufirst%3DElena%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D31%26spage%3D6490%26epage%3D6496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicolas  Joubert</span>, <span class="hlFld-ContribAuthor ">Caroline  Denevault-Sabourin</span>, <span class="hlFld-ContribAuthor ">Francesca  Bryden</span>, <span class="hlFld-ContribAuthor ">Marie-Claude  Viaud-Massuard</span>. </span><span class="cited-content_cbyCitation_article-title">Towards antibody-drug conjugates and prodrug strategies with extracellular stimuli-responsive drug delivery in the tumor microenvironment for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>142 </em>, 393-415. <a href="https://doi.org/10.1016/j.ejmech.2017.08.049" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.08.049</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.08.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.08.049%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTowards%252Bantibody-drug%252Bconjugates%252Band%252Bprodrug%252Bstrategies%252Bwith%252Bextracellular%252Bstimuli-responsive%252Bdrug%252Bdelivery%252Bin%252Bthe%252Btumor%252Bmicroenvironment%252Bfor%252Bcancer%252Btherapy%26aulast%3DJoubert%26aufirst%3DNicolas%26date%3D2017%26volume%3D142%26spage%3D393%26epage%3D415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">André  Raposo Moreira Dias</span>, <span class="hlFld-ContribAuthor ">Arianna  Pina</span>, <span class="hlFld-ContribAuthor ">Alberto  Dal Corso</span>, <span class="hlFld-ContribAuthor ">Daniela  Arosio</span>, <span class="hlFld-ContribAuthor ">Laura  Belvisi</span>, <span class="hlFld-ContribAuthor ">Luca  Pignataro</span>, <span class="hlFld-ContribAuthor ">Michele  Caruso</span>, <span class="hlFld-ContribAuthor ">Cesare  Gennari</span>. </span><span class="cited-content_cbyCitation_article-title">Multivalency Increases the Binding Strength of RGD Peptidomimetic-Paclitaxel Conjugates to Integrin α
              V
              β
              3. </span><span class="cited-content_cbyCitation_journal-name">Chemistry - A European Journal</span><span> <strong>2017,</strong> <em>23 </em>
                                    (58)
                                     , 14410-14415. <a href="https://doi.org/10.1002/chem.201703093" title="DOI URL">https://doi.org/10.1002/chem.201703093</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.201703093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.201703093%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520-%2520A%2520European%2520Journal%26atitle%3DMultivalency%252BIncreases%252Bthe%252BBinding%252BStrength%252Bof%252BRGD%252BPeptidomimetic-Paclitaxel%252BConjugates%252Bto%252BIntegrin%252B%2525CE%2525B1%252BV%252B%2525CE%2525B2%252B3%26aulast%3DRaposo%25E2%2580%2585Moreira%25E2%2580%2585Dias%26aufirst%3DAndr%25C3%25A9%26date%3D2017%26date%3D2017%26volume%3D23%26issue%3D58%26spage%3D14410%26epage%3D14415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Efrat  Dotan</span>, <span class="hlFld-ContribAuthor ">Steven J.  Cohen</span>, <span class="hlFld-ContribAuthor ">Alexander N.  Starodub</span>, <span class="hlFld-ContribAuthor ">Christopher H.  Lieu</span>, <span class="hlFld-ContribAuthor ">Wells A.  Messersmith</span>, <span class="hlFld-ContribAuthor ">Pamela S.  Simpson</span>, <span class="hlFld-ContribAuthor ">Michael J.  Guarino</span>, <span class="hlFld-ContribAuthor ">John L.  Marshall</span>, <span class="hlFld-ContribAuthor ">Richard M.  Goldberg</span>, <span class="hlFld-ContribAuthor ">J. Randolph  Hecht</span>, <span class="hlFld-ContribAuthor ">William A.  Wegener</span>, <span class="hlFld-ContribAuthor ">Robert M.  Sharkey</span>, <span class="hlFld-ContribAuthor ">Serengulam V.  Govindan</span>, <span class="hlFld-ContribAuthor ">David M.  Goldenberg</span>, <span class="hlFld-ContribAuthor ">Jordan D.  Berlin</span>. </span><span class="cited-content_cbyCitation_article-title">Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Clinical Oncology</span><span> <strong>2017,</strong> <em>35 </em>
                                    (29)
                                     , 3338-3346. <a href="https://doi.org/10.1200/JCO.2017.73.9011" title="DOI URL">https://doi.org/10.1200/JCO.2017.73.9011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1200/JCO.2017.73.9011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1200%2FJCO.2017.73.9011%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Clinical%2520Oncology%26atitle%3DPhase%252BI%25252FII%252BTrial%252Bof%252BLabetuzumab%252BGovitecan%252B%252528Anti-CEACAM5%25252FSN-38%252BAntibody-Drug%252BConjugate%252529%252Bin%252BPatients%252BWith%252BRefractory%252Bor%252BRelapsing%252BMetastatic%252BColorectal%252BCancer%26aulast%3DDotan%26aufirst%3DEfrat%26date%3D2017%26volume%3D35%26issue%3D29%26spage%3D3338%26epage%3D3346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Renato B.  Pereira</span>, <span class="hlFld-ContribAuthor ">Ramesh  Dasari</span>, <span class="hlFld-ContribAuthor ">Florence  Lefranc</span>, <span class="hlFld-ContribAuthor ">Alexander  Kornienko</span>, <span class="hlFld-ContribAuthor ">Robert  Kiss</span>, <span class="hlFld-ContribAuthor ">Nelson G. M.  Gomes</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Enzymatic Pathways with Marine-Derived Clinical Agents. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 255-275. <a href="https://doi.org/10.1002/9783527805921.ch10" title="DOI URL">https://doi.org/10.1002/9783527805921.ch10</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9783527805921.ch10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9783527805921.ch10%26sid%3Dliteratum%253Aachs%26atitle%3DTargeting%252BEnzymatic%252BPathways%252Bwith%252BMarine-Derived%252BClinical%252BAgents%26aulast%3DPereira%26aufirst%3DRenato%2BB.%26date%3D2017%26date%3D2017%26spage%3D255%26epage%3D275%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26atitle%3DNatural%252BProducts%252BTargeting%252BClinically%252BRelevant%252BEnzymes%26aulast%3DAndrade%26aufirst%3DPaula%2BB.%26date%3D2017%26volume%3D75" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alicja  Sochaj-Gregorczyk</span>, <span class="hlFld-ContribAuthor ">Patryk  Ludzia</span>, <span class="hlFld-ContribAuthor ">Emilia  Kozdrowska</span>, <span class="hlFld-ContribAuthor ">Piotr  Jakimowicz</span>, <span class="hlFld-ContribAuthor ">Aleksandra  Sokolowska-Wedzina</span>, <span class="hlFld-ContribAuthor ">Jacek  Otlewski</span>. </span><span class="cited-content_cbyCitation_article-title">Design and In Vitro Evaluation of a Cytotoxic Conjugate Based on the Anti-HER2 Affibody Fused to the Fc Fragment of IgG1. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2017,</strong> <em>18 </em>
                                    (8)
                                     , 1688. <a href="https://doi.org/10.3390/ijms18081688" title="DOI URL">https://doi.org/10.3390/ijms18081688</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms18081688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms18081688%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DDesign%252Band%252BIn%252BVitro%252BEvaluation%252Bof%252Ba%252BCytotoxic%252BConjugate%252BBased%252Bon%252Bthe%252BAnti-HER2%252BAffibody%252BFused%252Bto%252Bthe%252BFc%252BFragment%252Bof%252BIgG1%26aulast%3DSochaj-Gregorczyk%26aufirst%3DAlicja%26date%3D2017%26date%3D2017%26volume%3D18%26issue%3D8%26spage%3D1688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eric  Valeur</span>, <span class="hlFld-ContribAuthor ">Laurent  Knerr</span>, <span class="hlFld-ContribAuthor ">Maria  Ölwegård-Halvarsson</span>, <span class="hlFld-ContribAuthor ">Malin  Lemurell</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted delivery for regenerative medicines: an untapped opportunity for drug conjugates. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2017,</strong> <em>22 </em>
                                    (6)
                                     , 841-847. <a href="https://doi.org/10.1016/j.drudis.2016.12.004" title="DOI URL">https://doi.org/10.1016/j.drudis.2016.12.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2016.12.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2016.12.004%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DTargeted%252Bdelivery%252Bfor%252Bregenerative%252Bmedicines%25253A%252Ban%252Buntapped%252Bopportunity%252Bfor%252Bdrug%252Bconjugates%26aulast%3DValeur%26aufirst%3DEric%26date%3D2017%26volume%3D22%26issue%3D6%26spage%3D841%26epage%3D847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rasala  Mahesh</span>, <span class="hlFld-ContribAuthor ">Vadithe Lakshma  Nayak</span>, <span class="hlFld-ContribAuthor ">Korrapati Suresh  Babu</span>, <span class="hlFld-ContribAuthor ">Syed  Riyaz</span>, <span class="hlFld-ContribAuthor ">Thokhir Basha  Shaik</span>, <span class="hlFld-ContribAuthor ">Gajjela Bharth  Kumar</span>, <span class="hlFld-ContribAuthor ">Prema Latha  Mallipeddi</span>, <span class="hlFld-ContribAuthor ">Challa Ratna  Reddy</span>, <span class="hlFld-ContribAuthor ">Kunta Chandra  Shekar</span>, <span class="hlFld-ContribAuthor ">Jedy  Jose</span>, <span class="hlFld-ContribAuthor ">Narayana  Nagesh</span>, <span class="hlFld-ContribAuthor ">Ahmed  Kamal</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and in vitro and in vivo Evaluations of (
              Z
              )-3,4,5-Trimethoxystyrylbenzenesulfonamides/sulfonates as Highly Potent Tubulin Polymerization Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2017,</strong> <em>12 </em>
                                    (9)
                                     , 678-700. <a href="https://doi.org/10.1002/cmdc.201600643" title="DOI URL">https://doi.org/10.1002/cmdc.201600643</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201600643&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201600643%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252Bin%252Bvitro%252Band%252Bin%252Bvivo%252BEvaluations%252Bof%252B%252528%252BZ%252B%252529-3%25252C4%25252C5-Trimethoxystyrylbenzenesulfonamides%25252Fsulfonates%252Bas%252BHighly%252BPotent%252BTubulin%252BPolymerization%252BInhibitors%26aulast%3DMahesh%26aufirst%3DRasala%26date%3D2017%26date%3D2017%26volume%3D12%26issue%3D9%26spage%3D678%26epage%3D700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Benoit  Louage</span>, <span class="hlFld-ContribAuthor ">Olivier  De Wever</span>, <span class="hlFld-ContribAuthor ">Wim E.  Hennink</span>, <span class="hlFld-ContribAuthor ">Bruno G  De Geest</span>. </span><span class="cited-content_cbyCitation_article-title">Developments and future clinical outlook of taxane nanomedicines. </span><span class="cited-content_cbyCitation_journal-name">Journal of Controlled Release</span><span> <strong>2017,</strong> <em>253 </em>, 137-152. <a href="https://doi.org/10.1016/j.jconrel.2017.03.027" title="DOI URL">https://doi.org/10.1016/j.jconrel.2017.03.027</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jconrel.2017.03.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jconrel.2017.03.027%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Controlled%2520Release%26atitle%3DDevelopments%252Band%252Bfuture%252Bclinical%252Boutlook%252Bof%252Btaxane%252Bnanomedicines%26aulast%3DLouage%26aufirst%3DBenoit%26date%3D2017%26volume%3D253%26spage%3D137%26epage%3D152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rémy  Gébleux</span>, <span class="hlFld-ContribAuthor ">Marco  Stringhini</span>, <span class="hlFld-ContribAuthor ">Ruben  Casanova</span>, <span class="hlFld-ContribAuthor ">Alex  Soltermann</span>, <span class="hlFld-ContribAuthor ">Dario  Neri</span>. </span><span class="cited-content_cbyCitation_article-title">Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Cancer</span><span> <strong>2017,</strong> <em>140 </em>
                                    (7)
                                     , 1670-1679. <a href="https://doi.org/10.1002/ijc.30569" title="DOI URL">https://doi.org/10.1002/ijc.30569</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ijc.30569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fijc.30569%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Cancer%26atitle%3DNon-internalizing%252Bantibody-drug%252Bconjugates%252Bdisplay%252Bpotent%252Banti-cancer%252Bactivity%252Bupon%252Bproteolytic%252Brelease%252Bof%252Bmonomethyl%252Bauristatin%252BE%252Bin%252Bthe%252Bsubendothelial%252Bextracellular%252Bmatrix%26aulast%3DG%25C3%25A9bleux%26aufirst%3DR%25C3%25A9my%26date%3D2017%26date%3D2016%26volume%3D140%26issue%3D7%26spage%3D1670%26epage%3D1679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marcus J.  Rohovie</span>, <span class="hlFld-ContribAuthor ">Maya  Nagasawa</span>, <span class="hlFld-ContribAuthor ">James R.  Swartz</span>. </span><span class="cited-content_cbyCitation_article-title">Virus-like particles: Next-generation nanoparticles for targeted therapeutic delivery. </span><span class="cited-content_cbyCitation_journal-name">Bioengineering & Translational Medicine</span><span> <strong>2017,</strong> <em>2 </em>
                                    (1)
                                     , 43-57. <a href="https://doi.org/10.1002/btm2.10049" title="DOI URL">https://doi.org/10.1002/btm2.10049</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/btm2.10049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fbtm2.10049%26sid%3Dliteratum%253Aachs%26jtitle%3DBioengineering%2520%2526%2520Translational%2520Medicine%26atitle%3DVirus-like%252Bparticles%25253A%252BNext-generation%252Bnanoparticles%252Bfor%252Btargeted%252Btherapeutic%252Bdelivery%26aulast%3DRohovie%26aufirst%3DMarcus%2BJ.%26date%3D2017%26date%3D2017%26volume%3D2%26issue%3D1%26spage%3D43%26epage%3D57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Víctor  Fernández-Dueñas</span>, <span class="hlFld-ContribAuthor ">Jhonny  Azuaje</span>, <span class="hlFld-ContribAuthor ">Xavier  Morató</span>, <span class="hlFld-ContribAuthor ">Begoña  Cordobilla</span>, <span class="hlFld-ContribAuthor ">Joan  Domingo</span>, <span class="hlFld-ContribAuthor ">Eddy  Sotelo</span>, <span class="hlFld-ContribAuthor ">Francisco  Ciruela</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Characterization of a New  Bivalent Ligand Combining Caffeine and Docosahexaenoic Acid. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2017,</strong> <em>22 </em>
                                    (3)
                                     , 366. <a href="https://doi.org/10.3390/molecules22030366" title="DOI URL">https://doi.org/10.3390/molecules22030366</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules22030366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules22030366%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DSynthesis%252Band%252BCharacterization%252Bof%252Ba%252BNew%252BBivalent%252BLigand%252BCombining%252BCaffeine%252Band%252BDocosahexaenoic%252BAcid%26aulast%3DFern%25C3%25A1ndez-Due%25C3%25B1as%26aufirst%3DV%25C3%25ADctor%26date%3D2017%26date%3D2017%26volume%3D22%26issue%3D3%26spage%3D366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Khaldoun  Almhanna</span>, <span class="hlFld-ContribAuthor ">Gopi K.  Prithviraj</span>, <span class="hlFld-ContribAuthor ">Petter  Veiby</span>, <span class="hlFld-ContribAuthor ">Thea  Kalebic</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody–drug conjugate directed against the guanylyl cyclase antigen for the treatment of gastrointestinal malignancies. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology & Therapeutics</span><span> <strong>2017,</strong> <em>170 </em>, 8-13. <a href="https://doi.org/10.1016/j.pharmthera.2016.10.007" title="DOI URL">https://doi.org/10.1016/j.pharmthera.2016.10.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pharmthera.2016.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pharmthera.2016.10.007%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520%2526%2520Therapeutics%26atitle%3DAntibody%2525E2%252580%252593drug%252Bconjugate%252Bdirected%252Bagainst%252Bthe%252Bguanylyl%252Bcyclase%252Bantigen%252Bfor%252Bthe%252Btreatment%252Bof%252Bgastrointestinal%252Bmalignancies%26aulast%3DAlmhanna%26aufirst%3DKhaldoun%26date%3D2017%26volume%3D170%26spage%3D8%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anna  Serwotka-Suszczak</span>, <span class="hlFld-ContribAuthor ">Alicja  Sochaj-Gregorczyk</span>, <span class="hlFld-ContribAuthor ">Jerzy  Pieczykolan</span>, <span class="hlFld-ContribAuthor ">Daniel  Krowarsch</span>, <span class="hlFld-ContribAuthor ">Filip  Jelen</span>, <span class="hlFld-ContribAuthor ">Jacek  Otlewski</span>. </span><span class="cited-content_cbyCitation_article-title">A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2017,</strong> <em>18 </em>
                                    (2)
                                     , 401. <a href="https://doi.org/10.3390/ijms18020401" title="DOI URL">https://doi.org/10.3390/ijms18020401</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms18020401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms18020401%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DA%252BConjugate%252BBased%252Bon%252BAnti-HER2%252BDiaffibody%252Band%252BAuristatin%252BE%252BTargets%252BHER2-Positive%252BCancer%252BCells%26aulast%3DSerwotka-Suszczak%26aufirst%3DAnna%26date%3D2017%26date%3D2017%26volume%3D18%26issue%3D2%26spage%3D401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Surinder K.  Sharma</span>, <span class="hlFld-ContribAuthor ">Kenneth D.  Bagshawe</span>. </span><span class="cited-content_cbyCitation_article-title">Translating antibody directed enzyme prodrug therapy (ADEPT) and prospects for combination. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Biological Therapy</span><span> <strong>2017,</strong> <em>17 </em>
                                    (1)
                                     , 1-13. <a href="https://doi.org/10.1080/14712598.2017.1247802" title="DOI URL">https://doi.org/10.1080/14712598.2017.1247802</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14712598.2017.1247802&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14712598.2017.1247802%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Biological%2520Therapy%26atitle%3DTranslating%252Bantibody%252Bdirected%252Benzyme%252Bprodrug%252Btherapy%252B%252528ADEPT%252529%252Band%252Bprospects%252Bfor%252Bcombination%26aulast%3DSharma%26aufirst%3DSurinder%2BK.%26date%3D2017%26date%3D2016%26volume%3D17%26issue%3D1%26spage%3D1%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">C.  Homyak</span>, <span class="hlFld-ContribAuthor ">F.  Anson</span>, <span class="hlFld-ContribAuthor ">S.  Thayumanavan</span>. </span><span class="cited-content_cbyCitation_article-title">Supramolecular Polymers in Nanomedicine. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 227-254. <a href="https://doi.org/10.1016/B978-0-12-409547-2.12566-1" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.12566-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.12566-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.12566-1%26sid%3Dliteratum%253Aachs%26atitle%3DSupramolecular%252BPolymers%252Bin%252BNanomedicine%26aulast%3DHomyak%26aufirst%3DC.%26date%3D2017%26spage%3D227%26epage%3D254%26pub%3DElsevier%26atitle%3DComprehensive%252BSupramolecular%252BChemistry%252BII%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yaroslav  Staroseletz</span>, <span class="hlFld-ContribAuthor ">Aled  Williams</span>, <span class="hlFld-ContribAuthor ">Kepa K.  Burusco</span>, <span class="hlFld-ContribAuthor ">Irfan  Alibay</span>, <span class="hlFld-ContribAuthor ">Valentin V.  Vlassov</span>, <span class="hlFld-ContribAuthor ">Marina A.  Zenkova</span>, <span class="hlFld-ContribAuthor ">Elena V.  Bichenkova</span>. </span><span class="cited-content_cbyCitation_article-title">‘Dual’ peptidyl-oligonucleotide conjugates: Role of conformational flexibility in catalytic cleavage of RNA. </span><span class="cited-content_cbyCitation_journal-name">Biomaterials</span><span> <strong>2017,</strong> <em>112 </em>, 44-61. <a href="https://doi.org/10.1016/j.biomaterials.2016.09.033" title="DOI URL">https://doi.org/10.1016/j.biomaterials.2016.09.033</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.biomaterials.2016.09.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.biomaterials.2016.09.033%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomaterials%26atitle%3D%2525E2%252580%252598Dual%2525E2%252580%252599%252Bpeptidyl-oligonucleotide%252Bconjugates%25253A%252BRole%252Bof%252Bconformational%252Bflexibility%252Bin%252Bcatalytic%252Bcleavage%252Bof%252BRNA%26aulast%3DStaroseletz%26aufirst%3DYaroslav%26date%3D2017%26volume%3D112%26spage%3D44%26epage%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Samuele  Cazzamalli</span>, <span class="hlFld-ContribAuthor ">Alberto  Dal Corso</span>, <span class="hlFld-ContribAuthor ">Dario  Neri</span>. </span><span class="cited-content_cbyCitation_article-title">Linker stability influences the anti-tumor activity of acetazolamide-drug conjugates for the therapy of renal cell carcinoma. </span><span class="cited-content_cbyCitation_journal-name">Journal of Controlled Release</span><span> <strong>2017,</strong> <em>246 </em>, 39-45. <a href="https://doi.org/10.1016/j.jconrel.2016.11.023" title="DOI URL">https://doi.org/10.1016/j.jconrel.2016.11.023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jconrel.2016.11.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jconrel.2016.11.023%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Controlled%2520Release%26atitle%3DLinker%252Bstability%252Binfluences%252Bthe%252Banti-tumor%252Bactivity%252Bof%252Bacetazolamide-drug%252Bconjugates%252Bfor%252Bthe%252Btherapy%252Bof%252Brenal%252Bcell%252Bcarcinoma%26aulast%3DCazzamalli%26aufirst%3DSamuele%26date%3D2017%26volume%3D246%26spage%3D39%26epage%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Il  Minn</span>, <span class="hlFld-ContribAuthor ">Soo Min  Koo</span>, <span class="hlFld-ContribAuthor ">Hye Soo  Lee</span>, <span class="hlFld-ContribAuthor ">Mary  Brummet</span>, <span class="hlFld-ContribAuthor ">Steven P.  Rowe</span>, <span class="hlFld-ContribAuthor ">Michael A.  Gorin</span>, <span class="hlFld-ContribAuthor ">Polina  Sysa-Shah</span>, <span class="hlFld-ContribAuthor ">William D.  Lewis</span>, <span class="hlFld-ContribAuthor ">Hye-Hyun  Ahn</span>, <span class="hlFld-ContribAuthor ">Yuchuan  Wang</span>, <span class="hlFld-ContribAuthor ">Sangeeta Ray  Banerjee</span>, <span class="hlFld-ContribAuthor ">Ronnie C.  Mease</span>, <span class="hlFld-ContribAuthor ">Sridhar  Nimmagadda</span>, <span class="hlFld-ContribAuthor ">Mohamad E.  Allaf</span>, <span class="hlFld-ContribAuthor ">Martin G.  Pomper</span>, <span class="hlFld-ContribAuthor ">Xing  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">[64Cu]XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2016,</strong> <em>7 </em>
                                    (35)
                                     , 56471-56479. <a href="https://doi.org/10.18632/oncotarget.10602" title="DOI URL">https://doi.org/10.18632/oncotarget.10602</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.10602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.10602%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3D%25255B64Cu%25255DXYIMSR-06%25253A%252BA%252Bdual-motif%252BCAIX%252Bligand%252Bfor%252BPET%252Bimaging%252Bof%252Bclear%252Bcell%252Brenal%252Bcell%252Bcarcinoma%26aulast%3DMinn%26aufirst%3DIl%26date%3D2016%26date%3D2016%26volume%3D7%26issue%3D35%26spage%3D56471%26epage%3D56479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alicja M.  Sochaj-Gregorczyk</span>, <span class="hlFld-ContribAuthor ">Anna M.  Serwotka-Suszczak</span>, <span class="hlFld-ContribAuthor ">Jacek  Otlewski</span>. </span><span class="cited-content_cbyCitation_article-title">A Novel Affibody-Auristatin E Conjugate With a Potent and Selective Activity Against HER2+ Cell Lines. </span><span class="cited-content_cbyCitation_journal-name">Journal of Immunotherapy</span><span> <strong>2016,</strong> <em>39 </em>
                                    (6)
                                     , 223-232. <a href="https://doi.org/10.1097/CJI.0000000000000125" title="DOI URL">https://doi.org/10.1097/CJI.0000000000000125</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1097/CJI.0000000000000125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1097%2FCJI.0000000000000125%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Immunotherapy%26atitle%3DA%252BNovel%252BAffibody-Auristatin%252BE%252BConjugate%252BWith%252Ba%252BPotent%252Band%252BSelective%252BActivity%252BAgainst%252BHER2%25252B%252BCell%252BLines%26aulast%3DSochaj-Gregorczyk%26aufirst%3DAlicja%2BM.%26date%3D2016%26volume%3D39%26issue%3D6%26spage%3D223%26epage%3D232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chin S.  Kue</span>, <span class="hlFld-ContribAuthor ">Anyanee  Kamkaew</span>, <span class="hlFld-ContribAuthor ">Kevin  Burgess</span>, <span class="hlFld-ContribAuthor ">Lik V.  Kiew</span>, <span class="hlFld-ContribAuthor ">Lip Y.  Chung</span>, <span class="hlFld-ContribAuthor ">Hong B.  Lee</span>. </span><span class="cited-content_cbyCitation_article-title">Small Molecules for Active Targeting in Cancer. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2016,</strong> <em>36 </em>
                                    (3)
                                     , 494-575. <a href="https://doi.org/10.1002/med.21387" title="DOI URL">https://doi.org/10.1002/med.21387</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21387%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DSmall%252BMolecules%252Bfor%252BActive%252BTargeting%252Bin%252BCancer%26aulast%3DKue%26aufirst%3DChin%2BS.%26date%3D2016%26date%3D2016%26volume%3D36%26issue%3D3%26spage%3D494%26epage%3D575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pradeepkumar L.  Patel</span>, <span class="hlFld-ContribAuthor ">Niki K.  Rana</span>, <span class="hlFld-ContribAuthor ">Mayurbhai R.  Patel</span>, <span class="hlFld-ContribAuthor ">Stephen D.  Kozuch</span>, <span class="hlFld-ContribAuthor ">David  Sabatino</span>. </span><span class="cited-content_cbyCitation_article-title">Nucleic Acid Bioconjugates in Cancer Detection and Therapy. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2016,</strong> <em>11 </em>
                                    (3)
                                     , 252-269. <a href="https://doi.org/10.1002/cmdc.201500502" title="DOI URL">https://doi.org/10.1002/cmdc.201500502</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201500502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201500502%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DNucleic%252BAcid%252BBioconjugates%252Bin%252BCancer%252BDetection%252Band%252BTherapy%26aulast%3DPatel%26aufirst%3DPradeepkumar%2BL.%26date%3D2016%26date%3D2015%26volume%3D11%26issue%3D3%26spage%3D252%26epage%3D269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yichao  Huang</span>, <span class="hlFld-ContribAuthor ">Lei  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Standing out from the crowd. </span><span class="cited-content_cbyCitation_journal-name">Nature Chemistry</span><span> <strong>2016,</strong> <em>8 </em>
                                    (2)
                                     , 101-102. <a href="https://doi.org/10.1038/nchem.2443" title="DOI URL">https://doi.org/10.1038/nchem.2443</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/nchem.2443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fnchem.2443%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Chemistry%26atitle%3DStanding%252Bout%252Bfrom%252Bthe%252Bcrowd%26aulast%3DHuang%26aufirst%3DYichao%26date%3D2016%26date%3D2016%26volume%3D8%26issue%3D2%26spage%3D101%26epage%3D102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00457/20151119/images/medium/jm-2015-004574_0002.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00457/20151119/images/large/jm-2015-004574_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00457&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00457/20151119/images/medium/jm-2015-004574_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00457/20151119/images/large/jm-2015-004574_0004.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. PET images at multiple time points of a patient with metastatic mesothelioma, injected with <sup>11</sup>C-docetaxel. Drug uptake in the neoplastic lesions is not visible, while accumulation in the liver and in some other normal organ structures can be seen at multiple time points. The arrow to the chest indicates the pleural localization of the mesothelium. Reproduced with permission from  <cite>European Journal of Nuclear Medicine and Molecular Imaging</cite> (<contrib-group>van der Veldt, A. A. M.</contrib-group>; ), Vol. <em>37</em>, pp 1950–1958. Copyright <span class="NLM_year">2010</span>, Springer.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00457/20151119/images/large/jm-2015-004574_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00457&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00457/20151119/images/medium/jm-2015-004574_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00457/20151119/images/large/jm-2015-004574_0005.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (a) Schematic representation showing domain composition of engineered fragments including scFv (25 kDa), diabody (55 kDa), SIP/minibody (80 kDa), and intact antibodies (150 kDa). (b) Macroscopic distribution of <sup>64</sup>Cu-DOTA-trastuzumab in breast cancer patients (1, 24, and 48 h) following intravenous administration. The majority of injected antibody molecules do not reach their target in vivo: virtually all of them accumulate (at least transiently) in excretory organs (liver for intact antibodies, kidneys for small antibody fragments). This research was originally published in JNM. <contrib-group>Tamura, K.; Kurihara, H.; Yonemori, K.; Tsuda, H.; Suzuki, J.; Kono, Y.; Honda, N.; Kodaira, M.; Yamamoto, H.; Yunokawa, M.; Shimizu, C.; Hasegawa, K.; Kanayama, Y.; Nozaki, S.; Kinoshita, T.; Wada, Y.; Tazawa, S.; Takahashi, K.; Watanabe, Y.; Fujiwara, Y.</contrib-group><sup>64</sup>Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer.  <cite>J. Nucl. Med.</cite> <span class="NLM_year">2013</span>, <em>54</em>, 1869−1875. © by the Society of Nuclear Medicine and Molecular Imaging, Inc. (c) Microscopic images of tumor tissue after trastuzumab–FITC conjugate injection (green). Tumor blood vessels (red) and nuclei (blue) were also stained. The image depicts trapping of trastuzumab in the vicinity of blood vessels. Adapted by permission from  <cite>Cancer Research</cite>, <span class="NLM_year">2007</span>, Vol. <em>67</em>, pp 254–261, <contrib-group>Dennis, M. S.; Jin, H.; Dugger, D.; Yang, R.; McFarland, L.; Ogasawara, A.; Williams, S.; Cole, M. J.; Ross, S.; Schwall, R.</contrib-group>Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> with permission from American Association for Cancer Research.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00457/20151119/images/large/jm-2015-004574_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00457&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00457/20151119/images/medium/jm-2015-004574_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00457/20151119/images/large/jm-2015-004574_0006.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structures of the two antibody–drug conjugate products currently available on the market for cancer therapy: brentuximab vedotin (left) and trastuzumab emtansine (right).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00457/20151119/images/large/jm-2015-004574_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00457&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00457/20151119/images/medium/jm-2015-004574_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00457/20151119/images/large/jm-2015-004574_0007.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Structures of relevant classes of small molecule tumor targeting moieties. For a more comprehensive list of small molecule–drug conjugates (SMDCs) in preclinical and clinical development, see Low et al. (2015) [ref <a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">62</a>].</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00457/20151119/images/large/jm-2015-004574_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00457&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00457/20151119/images/medium/jm-2015-004574_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00457/20151119/images/large/jm-2015-004574_0001.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Evaluation of targeting performance of IRDye 750 conjugates in near-infrared fluorescence imaging of balb/c nu/nu mice bearing SK-RC-52 xenografts. An amount of 3 nmol of ligand–IRDye 750 conjugate was injected: untargeted control (a), targeted based on acetazolamide <b>1</b> (b), and targeted based on pharmacophore pair <b>2</b> (c). Chemical structures of <b>1</b> and <b>2</b> are provided in Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>. Reproduced with permission from  <cite>Nature Chemistry</cite> (<contrib-group>Wichert, M.</contrib-group>; ), Vol. <em>7</em>, pp 241–249. Copyright <span class="NLM_year">2015</span>, Nature Publishing Group.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-22/acs.jmedchem.5b00457/20151119/images/large/jm-2015-004574_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00457&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i11">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34146" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34146" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 112 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Hanna, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Einhorn, L. H.</span><span> </span><span class="NLM_article-title">Testicular cancer—discoveries and updates</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">371</span><span class="NLM_x">, </span> <span class="NLM_fpage">2005</span><span class="NLM_x">–</span> <span class="NLM_lpage">2016</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1056%2FNEJMra1407550" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=25409373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlslGlug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=2005-2016&author=N.+H.+Hannaauthor=L.+H.+Einhorn&title=Testicular+cancer%E2%80%94discoveries+and+updates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Testicular cancer - discoveries and updates</span></div><div class="casAuthors">Hanna, Nasser H.; Einhorn, Lawrence H.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2005-2016, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  This article discusses the recent discoveries, updates in care, and existing controversies in the treatment of patients with testicular cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomxoCgNGLH0LVg90H21EOLACvtfcHk0lh6dRPQ5FZJxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlslGlug%253D%253D&md5=395d0b507a4f9b1003785ff92bc4cfd0</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1407550&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1407550%26sid%3Dliteratum%253Aachs%26aulast%3DHanna%26aufirst%3DN.%2BH.%26aulast%3DEinhorn%26aufirst%3DL.%2BH.%26atitle%3DTesticular%2520cancer%25E2%2580%2594discoveries%2520and%2520updates%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26spage%3D2005%26epage%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Szakacs, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paterson, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwig, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Booth-Genthe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottesman, M. M.</span><span> </span><span class="NLM_article-title">Targeting multidrug resistance in cancer</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">–</span> <span class="NLM_lpage">234</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1038%2Fnrd1984" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=16518375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BD28XhvFOlsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=219-234&author=G.+Szakacsauthor=J.+K.+Patersonauthor=J.+A.+Ludwigauthor=C.+Booth-Gentheauthor=M.+M.+Gottesman&title=Targeting+multidrug+resistance+in+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting multidrug resistance in cancer</span></div><div class="casAuthors">Szakacs, Gergely; Paterson, Jill K.; Ludwig, Joseph A.; Booth-Genthe, Catherine; Gottesman, Michael M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">219-234</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Effective treatment of metastatic cancers usually requires the use of toxic chemotherapy.  In most cases, multiple drugs are used, as resistance to single agents occurs almost universally.  For this reason, elucidation of mechanisms that confer simultaneous resistance to different drugs with different targets and chem. structures - multidrug resistance - has been a major goal of cancer biologists during the past 35 years.  Here, we review the most common of these mechanisms, one that relies on drug efflux from cancer cells mediated by ATP-binding cassette (ABC) transporters.  We describe various approaches to combating multidrug-resistant cancer, including the development of drugs that engage, evade or exploit efflux by ABC transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7LUp3JikHr7Vg90H21EOLACvtfcHk0lh6dRPQ5FZJxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhvFOlsr8%253D&md5=67ca376f65aa58a71288167f6815a896</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrd1984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1984%26sid%3Dliteratum%253Aachs%26aulast%3DSzakacs%26aufirst%3DG.%26aulast%3DPaterson%26aufirst%3DJ.%2BK.%26aulast%3DLudwig%26aufirst%3DJ.%2BA.%26aulast%3DBooth-Genthe%26aufirst%3DC.%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26atitle%3DTargeting%2520multidrug%2520resistance%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D219%26epage%3D234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Bosslet, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Straub, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumrich, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czech, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerken, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sperker, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroemer, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gesson, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monneret, C.</span><span> </span><span class="NLM_article-title">Elucidation of the mechanism enabling tumor selective prodrug monotherapy</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">1195</span><span class="NLM_x">–</span> <span class="NLM_lpage">1201</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1998&pages=1195-1201&author=K.+Bossletauthor=R.+Straubauthor=M.+Blumrichauthor=J.+Czechauthor=M.+Gerkenauthor=B.+Sperkerauthor=H.+K.+Kroemerauthor=J.+P.+Gessonauthor=M.+Kochauthor=C.+Monneret&title=Elucidation+of+the+mechanism+enabling+tumor+selective+prodrug+monotherapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBosslet%26aufirst%3DK.%26aulast%3DStraub%26aufirst%3DR.%26aulast%3DBlumrich%26aufirst%3DM.%26aulast%3DCzech%26aufirst%3DJ.%26aulast%3DGerken%26aufirst%3DM.%26aulast%3DSperker%26aufirst%3DB.%26aulast%3DKroemer%26aufirst%3DH.%2BK.%26aulast%3DGesson%26aufirst%3DJ.%2BP.%26aulast%3DKoch%26aufirst%3DM.%26aulast%3DMonneret%26aufirst%3DC.%26atitle%3DElucidation%2520of%2520the%2520mechanism%2520enabling%2520tumor%2520selective%2520prodrug%2520monotherapy%26jtitle%3DCancer%2520Res.%26date%3D1998%26volume%3D58%26spage%3D1195%26epage%3D1201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Krall, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheuermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, D.</span><span> </span><span class="NLM_article-title">Small targeted cytotoxics: Current state and promises from DNA-encoded chemical libraries</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1384</span><span class="NLM_x">–</span> <span class="NLM_lpage">1402</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=1384-1402&author=N.+Krallauthor=J.+Scheuermannauthor=D.+Neri&title=Small+targeted+cytotoxics%3A+Current+state+and+promises+from+DNA-encoded+chemical+libraries"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKrall%26aufirst%3DN.%26aulast%3DScheuermann%26aufirst%3DJ.%26aulast%3DNeri%26aufirst%3DD.%26atitle%3DSmall%2520targeted%2520cytotoxics%253A%2520Current%2520state%2520and%2520promises%2520from%2520DNA-encoded%2520chemical%2520libraries%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26spage%3D1384%26epage%3D1402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">van der Veldt, A. A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendrikse, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smit, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooijer, M. P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rijnders, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerritsen, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Hoeven, J. J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Windhorst, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lammertsma, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubberink, M.</span><span> </span><span class="NLM_article-title">Biodistribution and radiation dosimetry of C-11-labelled docetaxel in cancer patients</span> <span class="citation_source-journal">Eur. J. Nucl. Med. Mol. Imaging</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1950</span><span class="NLM_x">–</span> <span class="NLM_lpage">1958</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1007%2Fs00259-010-1489-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=20508935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A280%3ADC%252BC3cjpsFersA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2010&pages=1950-1958&author=A.+A.+M.+van+der+Veldtauthor=N.+H.+Hendrikseauthor=E.+F.+Smitauthor=M.+P.+J.+Mooijerauthor=A.+Y.+Rijndersauthor=W.+R.+Gerritsenauthor=J.+J.+M.+van+der+Hoevenauthor=A.+D.+Windhorstauthor=A.+A.+Lammertsmaauthor=M.+Lubberink&title=Biodistribution+and+radiation+dosimetry+of+C-11-labelled+docetaxel+in+cancer+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Biodistribution and radiation dosimetry of 11C-labelled docetaxel in cancer patients</span></div><div class="casAuthors">van der Veldt Astrid A M; Hendrikse N Harry; Smit Egbert F; Mooijer Martien P J; Rijnders Anneloes Y; Gerritsen Winald R; van der Hoeven Jacobus J M; Windhorst Albert D; Lammertsma Adriaan A; Lubberink Mark</div><div class="citationInfo"><span class="NLM_cas:title">European journal of nuclear medicine and molecular imaging</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1950-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  Docetaxel is an important chemotherapeutic agent used for the treatment of several cancer types.  As radiolabelled anticancer agents provide a potential means for personalized treatment planning, docetaxel was labelled with the positron emitter (11)C.  Non-invasive measurements of [(11)C]docetaxel uptake in organs and tumours may provide additional information on pharmacokinetics and pharmacodynamics of the drug docetaxel.  The purpose of the present study was to determine the biodistribution and radiation absorbed dose of [(11)C]docetaxel in humans.  METHODS:  Biodistribution of [(11)C]docetaxel was measured in seven patients (five men and two women) with solid tumours using PET/CT.  Venous blood samples were collected to measure activity in blood and plasma.  Regions of interest (ROI) for various source organs were defined on PET (high [(11)C]docetaxel uptake) or CT (low [(11)C]docetaxel uptake).  ROI data were used to generate time-activity curves and to calculate percentage injected dose and residence times.  Radiation absorbed doses were calculated according to the MIRD method using OLINDA/EXM 1.0 software.  RESULTS:  Gall bladder and liver demonstrated high [(11)C]docetaxel uptake, whilst uptake in brain and normal lung was low.  The percentage injected dose at 1 h in the liver was 47 +/- 9%. [(11)C]docetaxel was rapidly cleared from plasma and no radiolabelled metabolites were detected. [(11)C]docetaxel uptake in tumours was moderate and highly variable between tumours.  CONCLUSION:  The effective dose of [(11)C]docetaxel was 4.7 microSv/MBq.  As uptake in normal lung is low, [(11)C]docetaxel may be a promising tracer for tumours in the thoracic region.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQxqGMXy1jiK-R_TJajKxJDfW6udTcc2eYvGQ3hYmDlLbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjpsFersA%253D%253D&md5=cc75d090de603c03f691b9c9a63adb95</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1007%2Fs00259-010-1489-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00259-010-1489-y%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bder%2BVeldt%26aufirst%3DA.%2BA.%2BM.%26aulast%3DHendrikse%26aufirst%3DN.%2BH.%26aulast%3DSmit%26aufirst%3DE.%2BF.%26aulast%3DMooijer%26aufirst%3DM.%2BP.%2BJ.%26aulast%3DRijnders%26aufirst%3DA.%2BY.%26aulast%3DGerritsen%26aufirst%3DW.%2BR.%26aulast%3Dvan%2Bder%2BHoeven%26aufirst%3DJ.%2BJ.%2BM.%26aulast%3DWindhorst%26aufirst%3DA.%2BD.%26aulast%3DLammertsma%26aufirst%3DA.%2BA.%26aulast%3DLubberink%26aufirst%3DM.%26atitle%3DBiodistribution%2520and%2520radiation%2520dosimetry%2520of%2520C-11-labelled%2520docetaxel%2520in%2520cancer%2520patients%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%2520Mol.%2520Imaging%26date%3D2010%26volume%3D37%26spage%3D1950%26epage%3D1958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">van der Veldt, A. A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubberink, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathijssen, R. H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loos, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herder, G. J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greuter, H. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comans, E. F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutten, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eriksson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Windhorst, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendrikse, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Postmus, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smit, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lammertsma, A. A.</span><span> </span><span class="NLM_article-title">Toward prediction of efficacy of chemotherapy: A proof of concept study in lung cancer patients using C-11 docetaxel and positron emission tomography</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">4163</span><span class="NLM_x">–</span> <span class="NLM_lpage">4173</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1158%2F1078-0432.CCR-12-3779" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=23620410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1amt7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=4163-4173&author=A.+A.+M.+van+der+Veldtauthor=M.+Lubberinkauthor=R.+H.+J.+Mathijssenauthor=W.+J.+Loosauthor=G.+J.+M.+Herderauthor=H.+N.+Greuterauthor=E.+F.+I.+Comansauthor=H.+B.+Ruttenauthor=J.+Erikssonauthor=A.+D.+Windhorstauthor=N.+H.+Hendrikseauthor=P.+E.+Postmusauthor=E.+F.+Smitauthor=A.+A.+Lammertsma&title=Toward+prediction+of+efficacy+of+chemotherapy%3A+A+proof+of+concept+study+in+lung+cancer+patients+using+C-11+docetaxel+and+positron+emission+tomography"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [11C]docetaxel and Positron Emission Tomography</span></div><div class="casAuthors">van der Veldt, Astrid A. M.; Lubberink, Mark; Mathijssen, Ron H. J.; Loos, Walter J.; Herder, Gerarda J. M.; Greuter, Henri N.; Comans, Emile F. I.; Rutten, Hugo B.; Eriksson, Jonas; Windhorst, Albert D.; Hendrikse, N. Harry; Postmus, Pieter E.; Smit, Egbert F.; Lammertsma, Adriaan A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4163-4173</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Pharmacokinetics of docetaxel can be measured in vivo using positron emission tomog. (PET) and a microdose of radiolabeled docetaxel ([11C]docetaxel).  The objective of this study was to investigate whether a [11C]docetaxel PET microdosing study could predict tumor uptake of therapeutic doses of docetaxel.  Exptl. Design: Docetaxel-naive lung cancer patients underwent 2 [11C]docetaxel PET scans; one after bolus injection of [11C]docetaxel and another during combined infusion of [11C]docetaxel and a therapeutic dose of docetaxel (75 mg·m-2).  Compartmental and spectral analyses were used to quantify [11C]docetaxel tumor kinetics. [11C]docetaxel PET measurements were used to est. the area under the curve (AUC) of docetaxel in tumors.  Tumor response was evaluated using computed tomog. scans.  Results: Net rates of influx (Ki) of [11C]docetaxel in tumors were comparable during microdosing and therapeutic scans. [11C]docetaxel AUCTumor during the therapeutic scan could be predicted reliably using an impulse response function derived from the microdosing scan together with the plasma curve of [11C]docetaxel during the therapeutic scan.  At 90 min, the accumulated amt. of docetaxel in tumors was less than 1% of the total infused dose of docetaxel. [11C]docetaxel Ki derived from the microdosing scan correlated with AUCTumor of docetaxel (Spearman ρ = 0.715; P = 0.004) during the therapeutic scan and with tumor response to docetaxel therapy (Spearman ρ = -0.800; P = 0.010).  Conclusions: Microdosing data of [11C]docetaxel PET can be used to predict tumor uptake of docetaxel during chemotherapy.  The present study provides a framework for investigating the PET microdosing concept for radiolabeled anticancer drugs in patients.  Clin Cancer Res; 19(15); 4163-73. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruvBXmmZcFRrVg90H21EOLACvtfcHk0lgHEaFpf0feIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1amt7%252FI&md5=b08e686ab324cef9051f5744e4b155a6</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-3779&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-3779%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bder%2BVeldt%26aufirst%3DA.%2BA.%2BM.%26aulast%3DLubberink%26aufirst%3DM.%26aulast%3DMathijssen%26aufirst%3DR.%2BH.%2BJ.%26aulast%3DLoos%26aufirst%3DW.%2BJ.%26aulast%3DHerder%26aufirst%3DG.%2BJ.%2BM.%26aulast%3DGreuter%26aufirst%3DH.%2BN.%26aulast%3DComans%26aufirst%3DE.%2BF.%2BI.%26aulast%3DRutten%26aufirst%3DH.%2BB.%26aulast%3DEriksson%26aufirst%3DJ.%26aulast%3DWindhorst%26aufirst%3DA.%2BD.%26aulast%3DHendrikse%26aufirst%3DN.%2BH.%26aulast%3DPostmus%26aufirst%3DP.%2BE.%26aulast%3DSmit%26aufirst%3DE.%2BF.%26aulast%3DLammertsma%26aufirst%3DA.%2BA.%26atitle%3DToward%2520prediction%2520of%2520efficacy%2520of%2520chemotherapy%253A%2520A%2520proof%2520of%2520concept%2520study%2520in%2520lung%2520cancer%2520patients%2520using%2520C-11%2520docetaxel%2520and%2520positron%2520emission%2520tomography%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D4163%26epage%3D4173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Chari, R. V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widdison, W. C.</span><span> </span><span class="NLM_article-title">Antibody-drug conjugates: An emerging concept in cancer therapy</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">3796</span><span class="NLM_x">–</span> <span class="NLM_lpage">3827</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1002%2Fanie.201307628" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtVGmsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=3796-3827&author=R.+V.+J.+Chariauthor=M.+L.+Millerauthor=W.+C.+Widdison&title=Antibody-drug+conjugates%3A+An+emerging+concept+in+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy</span></div><div class="casAuthors">Chari, Ravi V. J.; Miller, Michael L.; Widdison, Wayne C.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3796-3827</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Traditional cancer chemotherapy is often accompanied by systemic toxicity to the patient.  Monoclonal antibodies against antigens on cancer cells offer an alternative tumor-selective treatment approach.  However, most monoclonal antibodies are not sufficiently potent to be therapeutically active on their own.  Antibody-drug conjugates (ADCs) use antibodies to deliver a potent cytotoxic compd. selectively to tumor cells, thus improving the therapeutic index of chemotherapeutic agents.  The recent approval of two ADCs, brentuximab vedotin and ado-trastuzumab emtansine, for cancer treatment has spurred tremendous research interest in this field.  This Review touches upon the early efforts in the field, and describes how the lessons learned from the first-generation ADCs have led to improvements in every aspect of this technol., i.e., the antibody, the cytotoxic compd., and the linker connecting them, leading to the current successes.  The design of ADCs currently in clin. development, and results from mechanistic studies and preclin. and clin. evaluation are discussed.  Emerging technologies that seek to further advance this exciting area of research are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4T2rhmji6DLVg90H21EOLACvtfcHk0lgHEaFpf0feIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtVGmsr0%253D&md5=fbfb2f843f516654ea7c0eb98949604c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1002%2Fanie.201307628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201307628%26sid%3Dliteratum%253Aachs%26aulast%3DChari%26aufirst%3DR.%2BV.%2BJ.%26aulast%3DMiller%26aufirst%3DM.%2BL.%26aulast%3DWiddison%26aufirst%3DW.%2BC.%26atitle%3DAntibody-drug%2520conjugates%253A%2520An%2520emerging%2520concept%2520in%2520cancer%2520therapy%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D3796%26epage%3D3827" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Senter, P. D.</span><span> </span><span class="NLM_article-title">Potent antibody drug conjugates for cancer therapy</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">244</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1016%2Fj.cbpa.2009.03.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=19414278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVWltbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2009&pages=235-244&author=P.+D.+Senter&title=Potent+antibody+drug+conjugates+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Potent antibody drug conjugates for cancer therapy</span></div><div class="casAuthors">Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">235-244</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Significant progress has been made in the past few years in the area of antibody drug conjugates (ADCs) for the selective delivery of cytotoxic drugs to tumors.  Early work in this field incorporated clin. approved drugs and mouse monoclonal antibodies (mAbs), which had modest activities, and were generally immunogenic.  The results of these studies prompted investigation that led to the identity of several key parameters that influenced activity and tolerability.  These included the antigen target, the use of non-immunogenic mAb carriers, the incorporation of highly potent drugs and novel conditionally stable linker technologies, and the specific methods used to attach drugs to mAbs.  As a result of these investigations, new agents with pronounced clin. activities have been developed.  These include SGN-35, an ADC directed against the CD30-pos. malignancies such as Hodgkin's disease and anaplastic large cell lymphoma, and trastuzumab-DM1 which has shown activity in metastatic breast carcinoma.  This review details many of the technol. advancements, and provides examples of promising ADCs that are currently in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqomJSUUPIrcbVg90H21EOLACvtfcHk0lgHEaFpf0feIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVWltbg%253D&md5=3cf72b412351bae075fab1159c49d8c5</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2009.03.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2009.03.023%26sid%3Dliteratum%253Aachs%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DPotent%2520antibody%2520drug%2520conjugates%2520for%2520cancer%2520therapy%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2009%26volume%3D13%26spage%3D235%26epage%3D244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Gerber, H.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grewal, I. S.</span><span> </span><span class="NLM_article-title">Antibody drug-conjugates targeting the tumor vasculature. Current and future developments</span> <span class="citation_source-journal">MAbs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">247</span><span class="NLM_x">–</span> <span class="NLM_lpage">253</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2009&pages=247-253&author=H.-P.+Gerberauthor=P.+D.+Senterauthor=I.+S.+Grewal&title=Antibody+drug-conjugates+targeting+the+tumor+vasculature.+Current+and+future+developments"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGerber%26aufirst%3DH.-P.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26aulast%3DGrewal%26aufirst%3DI.%2BS.%26atitle%3DAntibody%2520drug-conjugates%2520targeting%2520the%2520tumor%2520vasculature.%2520Current%2520and%2520future%2520developments%26jtitle%3DMAbs%26date%3D2009%26volume%3D1%26spage%3D247%26epage%3D253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Poli, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bianchi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Virotta, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bettini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moretti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trachsel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giovannoni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruno, A.</span><span> </span><span class="NLM_article-title">Radretumab radioimmunotherapy in patients with brain metastasis: A I-124-L19SIP dosimetric PET study</span> <span class="citation_source-journal">Cancer Immunol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">134</span><span class="NLM_x">–</span> <span class="NLM_lpage">143</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1158%2F2326-6066.CIR-13-0007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=24777501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntlWku78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2013&pages=134-143&author=G.+L.+Poliauthor=C.+Bianchiauthor=G.+Virottaauthor=A.+Bettiniauthor=R.+Morettiauthor=E.+Trachselauthor=G.+Eliaauthor=L.+Giovannoniauthor=D.+Neriauthor=A.+Bruno&title=Radretumab+radioimmunotherapy+in+patients+with+brain+metastasis%3A+A+I-124-L19SIP+dosimetric+PET+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Radretumab radioimmunotherapy in patients with brain metastasis: A124I-L19SIP dosimetric PET study</span></div><div class="casAuthors">Poli, Gian Luca; Bianchi, Claudia; Virotta, Giorgio; Bettini, Anna; Moretti, Renzo; Trachsel, Eveline; Elia, Giuliano; Giovannoni, Leonardo; Neri, Dario; Bruno, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">134-143</span>CODEN:
                <span class="NLM_cas:coden">CIRACV</span>;
        ISSN:<span class="NLM_cas:issn">2326-6066</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Radioimmunotherapy (RIT) with 131I-labeled L19SIP (radretumab; a small immunoprotein format antibody directed against the ED-B domain of fibronectin; ∼80 kDa mol. wt.) has been investigated in several clin. trials.  Here, we describe the use of immuno-PET imaging with iodine-124 (124I)-labeled L19SIP to predict doses delivered to tumor lesions and healthy organs by a subsequent radretumab RIT in patients with brain metastases from solid cancer.  Bone marrow doses were evaluated both during the diagnostic phase and posttherapy, measuring activities in blood (germanium detector) and whole body (lanthanum bromide detector).  Expected doses for radretumab administration (4,107 MBq/m2) were calcd. from data obtained after administration of an av. of 167 MBq 124I-L19SIP to 6 patients.  To assess lesion av. doses, the positron emission tomog. (PET) scanner was calibrated for the use of 124I with an International Electrotech. Commission (IEC) Body Phantom and recovery coeffs. were calcd.  The av. dose to bone red marrow was 0.21 Gy/GBq, with high correlation between provisional and actual posttherapy doses.  Although the fraction of injected activity in normal organs was similar in different patients, the antibody uptake in the neoplastic lesions varied by as much as a factor of 60.  Immuno-PET with 124I-labeled L19SIP offers significant advantages over conventional 131I imaging, in particular accuracy of dosimetric results.  Furthermore, the study indicates that antibody uptake can be highly variable even in different lesions of the same patient and that immuno-PET procedures may guide product development with armed antibodies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCCv-YIUn28rVg90H21EOLACvtfcHk0lidpOmZHz9JeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntlWku78%253D&md5=fad3ed8a38f157a35f3a59b2706f0d86</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F2326-6066.CIR-13-0007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2326-6066.CIR-13-0007%26sid%3Dliteratum%253Aachs%26aulast%3DPoli%26aufirst%3DG.%2BL.%26aulast%3DBianchi%26aufirst%3DC.%26aulast%3DVirotta%26aufirst%3DG.%26aulast%3DBettini%26aufirst%3DA.%26aulast%3DMoretti%26aufirst%3DR.%26aulast%3DTrachsel%26aufirst%3DE.%26aulast%3DElia%26aufirst%3DG.%26aulast%3DGiovannoni%26aufirst%3DL.%26aulast%3DNeri%26aufirst%3DD.%26aulast%3DBruno%26aufirst%3DA.%26atitle%3DRadretumab%2520radioimmunotherapy%2520in%2520patients%2520with%2520brain%2520metastasis%253A%2520A%2520I-124-L19SIP%2520dosimetric%2520PET%2520study%26jtitle%3DCancer%2520Immunol.%2520Res.%26date%3D2013%26volume%3D1%26spage%3D134%26epage%3D143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Erba, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sollini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orciuolo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traino, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paganelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bombardieri, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grana, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giovannoni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menssen, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mariani, G.</span><span> </span><span class="NLM_article-title">Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">922</span><span class="NLM_x">–</span> <span class="NLM_lpage">927</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2012&pages=922-927&author=P.+A.+Erbaauthor=M.+Solliniauthor=E.+Orciuoloauthor=C.+Trainoauthor=M.+Petriniauthor=G.+Paganelliauthor=E.+Bombardieriauthor=C.+Granaauthor=L.+Giovannoniauthor=D.+Neriauthor=H.+D.+Menssenauthor=G.+Mariani&title=Radioimmunotherapy+with+radretumab+in+patients+with+relapsed+hematologic+malignancies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DErba%26aufirst%3DP.%2BA.%26aulast%3DSollini%26aufirst%3DM.%26aulast%3DOrciuolo%26aufirst%3DE.%26aulast%3DTraino%26aufirst%3DC.%26aulast%3DPetrini%26aufirst%3DM.%26aulast%3DPaganelli%26aufirst%3DG.%26aulast%3DBombardieri%26aufirst%3DE.%26aulast%3DGrana%26aufirst%3DC.%26aulast%3DGiovannoni%26aufirst%3DL.%26aulast%3DNeri%26aufirst%3DD.%26aulast%3DMenssen%26aufirst%3DH.%2BD.%26aulast%3DMariani%26aufirst%3DG.%26atitle%3DRadioimmunotherapy%2520with%2520radretumab%2520in%2520patients%2520with%2520relapsed%2520hematologic%2520malignancies%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2012%26volume%3D53%26spage%3D922%26epage%3D927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Stillebroer, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zegers, C. M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boerman, O. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oosterwijk, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulders, P. F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donoghue, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Visser, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyen, W. J. G.</span><span> </span><span class="NLM_article-title">Dosimetric analysis of Lu-177-cG250 radioimmunotherapy in renal cell carcinoma patients: Correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on In-111-cG250 imaging</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">82</span><span class="NLM_x">–</span> <span class="NLM_lpage">89</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2012&pages=82-89&author=A.+B.+Stillebroerauthor=C.+M.+L.+Zegersauthor=O.+C.+Boermanauthor=E.+Oosterwijkauthor=P.+F.+A.+Muldersauthor=J.+A.+O%E2%80%99Donoghueauthor=E.+P.+Visserauthor=W.+J.+G.+Oyen&title=Dosimetric+analysis+of+Lu-177-cG250+radioimmunotherapy+in+renal+cell+carcinoma+patients%3A+Correlation+with+myelotoxicity+and+pretherapeutic+absorbed+dose+predictions+based+on+In-111-cG250+imaging"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStillebroer%26aufirst%3DA.%2BB.%26aulast%3DZegers%26aufirst%3DC.%2BM.%2BL.%26aulast%3DBoerman%26aufirst%3DO.%2BC.%26aulast%3DOosterwijk%26aufirst%3DE.%26aulast%3DMulders%26aufirst%3DP.%2BF.%2BA.%26aulast%3DO%25E2%2580%2599Donoghue%26aufirst%3DJ.%2BA.%26aulast%3DVisser%26aufirst%3DE.%2BP.%26aulast%3DOyen%26aufirst%3DW.%2BJ.%2BG.%26atitle%3DDosimetric%2520analysis%2520of%2520Lu-177-cG250%2520radioimmunotherapy%2520in%2520renal%2520cell%2520carcinoma%2520patients%253A%2520Correlation%2520with%2520myelotoxicity%2520and%2520pretherapeutic%2520absorbed%2520dose%2520predictions%2520based%2520on%2520In-111-cG250%2520imaging%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2012%26volume%3D53%26spage%3D82%26epage%3D89" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Sharkey, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajjar, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeldell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brenner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldenberg, D. M.</span><span> </span><span class="NLM_article-title">A phase I trial combining high-dose Y-90-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">620</span><span class="NLM_x">–</span> <span class="NLM_lpage">633</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2005&pages=620-633&author=R.+M.+Sharkeyauthor=G.+Hajjarauthor=D.+Yeldellauthor=A.+Brennerauthor=J.+Burtonauthor=A.+Rubinauthor=D.+M.+Goldenberg&title=A+phase+I+trial+combining+high-dose+Y-90-labeled+humanized+anti-CEA+monoclonal+antibody+with+doxorubicin+and+peripheral+blood+stem+cell+rescue+in+advanced+medullary+thyroid+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSharkey%26aufirst%3DR.%2BM.%26aulast%3DHajjar%26aufirst%3DG.%26aulast%3DYeldell%26aufirst%3DD.%26aulast%3DBrenner%26aufirst%3DA.%26aulast%3DBurton%26aufirst%3DJ.%26aulast%3DRubin%26aufirst%3DA.%26aulast%3DGoldenberg%26aufirst%3DD.%2BM.%26atitle%3DA%2520phase%2520I%2520trial%2520combining%2520high-dose%2520Y-90-labeled%2520humanized%2520anti-CEA%2520monoclonal%2520antibody%2520with%2520doxorubicin%2520and%2520peripheral%2520blood%2520stem%2520cell%2520rescue%2520in%2520advanced%2520medullary%2520thyroid%2520cancer%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2005%26volume%3D46%26spage%3D620%26epage%3D633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Carrasquillo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandit-Taskar, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donoghue, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humm, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zanzonico, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith-Jones, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Divgi, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pryma, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruan, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kemeny, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaggi, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheinberg, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panageas, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ritter, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jungbluth, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Old, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, S. M.</span><span> </span><span class="NLM_article-title">I-124-huA33 antibody PET of colorectal cancer</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1173</span><span class="NLM_x">–</span> <span class="NLM_lpage">1180</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2011&pages=1173-1180&author=J.+A.+Carrasquilloauthor=N.+Pandit-Taskarauthor=J.+A.+O%E2%80%99Donoghueauthor=J.+L.+Hummauthor=P.+Zanzonicoauthor=P.+M.+Smith-Jonesauthor=C.+R.+Divgiauthor=D.+A.+Prymaauthor=S.+T.+Ruanauthor=N.+E.+Kemenyauthor=Y.+M.+Fongauthor=D.+Wongauthor=J.+S.+Jaggiauthor=D.+A.+Scheinbergauthor=M.+Gonenauthor=K.+S.+Panageasauthor=G.+Ritterauthor=A.+A.+Jungbluthauthor=L.+J.+Oldauthor=S.+M.+Larson&title=I-124-huA33+antibody+PET+of+colorectal+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCarrasquillo%26aufirst%3DJ.%2BA.%26aulast%3DPandit-Taskar%26aufirst%3DN.%26aulast%3DO%25E2%2580%2599Donoghue%26aufirst%3DJ.%2BA.%26aulast%3DHumm%26aufirst%3DJ.%2BL.%26aulast%3DZanzonico%26aufirst%3DP.%26aulast%3DSmith-Jones%26aufirst%3DP.%2BM.%26aulast%3DDivgi%26aufirst%3DC.%2BR.%26aulast%3DPryma%26aufirst%3DD.%2BA.%26aulast%3DRuan%26aufirst%3DS.%2BT.%26aulast%3DKemeny%26aufirst%3DN.%2BE.%26aulast%3DFong%26aufirst%3DY.%2BM.%26aulast%3DWong%26aufirst%3DD.%26aulast%3DJaggi%26aufirst%3DJ.%2BS.%26aulast%3DScheinberg%26aufirst%3DD.%2BA.%26aulast%3DGonen%26aufirst%3DM.%26aulast%3DPanageas%26aufirst%3DK.%2BS.%26aulast%3DRitter%26aufirst%3DG.%26aulast%3DJungbluth%26aufirst%3DA.%2BA.%26aulast%3DOld%26aufirst%3DL.%2BJ.%26aulast%3DLarson%26aufirst%3DS.%2BM.%26atitle%3DI-124-huA33%2520antibody%2520PET%2520of%2520colorectal%2520cancer%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2011%26volume%3D52%26spage%3D1173%26epage%3D1180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Borjesson, P. K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jauw, Y. W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bree, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roos, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castelijns, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leemans, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Dongen, G. A. M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boellaard, R.</span><span> </span><span class="NLM_article-title">Radiation dosimetry of Zr-89-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1828</span><span class="NLM_x">–</span> <span class="NLM_lpage">1836</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.2967%2Fjnumed.109.065862" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=19837762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A280%3ADC%252BD1MjisFWnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2009&pages=1828-1836&author=P.+K.+E.+Borjessonauthor=Y.+W.+S.+Jauwauthor=R.+de+Breeauthor=J.+C.+Roosauthor=J.+A.+Castelijnsauthor=C.+R.+Leemansauthor=G.+A.+M.+S.+van+Dongenauthor=R.+Boellaard&title=Radiation+dosimetry+of+Zr-89-labeled+chimeric+monoclonal+antibody+U36+as+used+for+immuno-PET+in+head+and+neck+cancer+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients</span></div><div class="casAuthors">Borjesson Pontus K E; Jauw Yvonne W S; de Bree Remco; Roos Jan C; Castelijns Jonas A; Leemans C Rene; van Dongen Guus A M S; Boellaard Ronald</div><div class="citationInfo"><span class="NLM_cas:title">Journal of nuclear medicine : official publication, Society of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1828-36</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">UNLABELLED:  Immuno-PET is an appealing concept in the detection of tumors and planning of antibody-based therapy.  For this purpose, the long-lived positron emitter (89)Zr (half-life, 78.4 h) recently became available.  The aim of the present first-in-humans (89)Zr immuno-PET study was to assess safety, biodistribution, radiation dose, and quantification of the (89)Zr-labeled chimeric monoclonal antibody (cmAb) U36 in patients with head and neck squamous cell carcinoma (HNSCC).  In addition, the performance of immuno-PET for detecting lymph node metastases was evaluated, as described previously.  METHODS:  Twenty HNSCC patients, scheduled to undergo surgical tumor resection, received 75 MBq of (89)Zr-cmAb U36 (10 mg).  Immuno-PET scans were acquired at 1, 24, 72, or 144 h after injection.  The biodistribution of the radioimmunoconjugate was evaluated by ex vivo radioactivity measurement in blood and in biopsies from the surgical specimen obtained at 168 h after injection.  Uptake levels and residence times in blood, tumors, and organs of interest were derived from quantitative immuno-PET studies, and absorbed doses were calculated using OLINDA/EXM 1.0.  The red marrow dose was calculated using the residence time for blood.  RESULTS:  (89)Zr-cmAb U36 was well tolerated by all subjects.  PET quantification of blood-pool activity in the left ventricle of the heart showed a good agreement with sampled blood activity (difference equals 0.2% +/- 16.9% [mean +/- SD]) except for heavy-weight patients (>100 kg).  A good agreement was also found for the assessment of mAb uptake in primary tumors (mean deviation, -8.4% +/- 34.5%).  The mean absorbed red marrow dose was 0.07 +/- 0.02 mSv/MBq and 0.09 +/- 0.01 mSv/MBq in men and women, respectively.  The normal organ with the highest absorbed dose was the liver (mean dose, 1.25 +/- 0.27 mSv/MBq in men and 1.35 +/- 0.21 mSv/MBq in women), thereafter followed by kidneys, thyroid, lungs, and spleen.  The mean effective dose was 0.53 +/- 0.03 mSv/MBq in men and 0.66 +/- 0.03 mSv/MBq in women.  Measured excretion via the urinary tract was less than 3% during the first 72 h.  CONCLUSION:  (89)Zr immuno-PET can be safely used to quantitatively assess biodistribution, uptake, organ residence times, and radiation dose, justifying its further clinical exploitation in the detection of tumors and planning of mAb-based therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQu901ddEA7J0NHe_gFldTbfW6udTcc2ebJGkQpGl-5-Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MjisFWnsw%253D%253D&md5=730800af4c7381d55b17649402858308</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.109.065862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.109.065862%26sid%3Dliteratum%253Aachs%26aulast%3DBorjesson%26aufirst%3DP.%2BK.%2BE.%26aulast%3DJauw%26aufirst%3DY.%2BW.%2BS.%26aulast%3Dde%2BBree%26aufirst%3DR.%26aulast%3DRoos%26aufirst%3DJ.%2BC.%26aulast%3DCastelijns%26aufirst%3DJ.%2BA.%26aulast%3DLeemans%26aufirst%3DC.%2BR.%26aulast%3Dvan%2BDongen%26aufirst%3DG.%2BA.%2BM.%2BS.%26aulast%3DBoellaard%26aufirst%3DR.%26atitle%3DRadiation%2520dosimetry%2520of%2520Zr-89-labeled%2520chimeric%2520monoclonal%2520antibody%2520U36%2520as%2520used%2520for%2520immuno-PET%2520in%2520head%2520and%2520neck%2520cancer%2520patients%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2009%26volume%3D50%26spage%3D1828%26epage%3D1836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Muselaers, C. H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stillebroer, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desar, I. M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boers-Sonderen, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Herpen, C. M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Weijert, M. C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langenhuijsen, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oosterwijk, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leenders, W. P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boerman, O. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulders, P. F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyen, W. J. G.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitor sorafenib decreases In-111-girentuximab uptake in patients with clear cell renal cell carcinoma</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">242</span><span class="NLM_x">–</span> <span class="NLM_lpage">247</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2014&pages=242-247&author=C.+H.+J.+Muselaersauthor=A.+B.+Stillebroerauthor=I.+M.+E.+Desarauthor=M.+J.+Boers-Sonderenauthor=C.+M.+L.+van+Herpenauthor=M.+C.+A.+de+Weijertauthor=J.+F.+Langenhuijsenauthor=E.+Oosterwijkauthor=W.+P.+J.+Leendersauthor=O.+C.+Boermanauthor=P.+F.+A.+Muldersauthor=W.+J.+G.+Oyen&title=Tyrosine+kinase+inhibitor+sorafenib+decreases+In-111-girentuximab+uptake+in+patients+with+clear+cell+renal+cell+carcinoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMuselaers%26aufirst%3DC.%2BH.%2BJ.%26aulast%3DStillebroer%26aufirst%3DA.%2BB.%26aulast%3DDesar%26aufirst%3DI.%2BM.%2BE.%26aulast%3DBoers-Sonderen%26aufirst%3DM.%2BJ.%26aulast%3Dvan%2BHerpen%26aufirst%3DC.%2BM.%2BL.%26aulast%3Dde%2BWeijert%26aufirst%3DM.%2BC.%2BA.%26aulast%3DLangenhuijsen%26aufirst%3DJ.%2BF.%26aulast%3DOosterwijk%26aufirst%3DE.%26aulast%3DLeenders%26aufirst%3DW.%2BP.%2BJ.%26aulast%3DBoerman%26aufirst%3DO.%2BC.%26aulast%3DMulders%26aufirst%3DP.%2BF.%2BA.%26aulast%3DOyen%26aufirst%3DW.%2BJ.%2BG.%26atitle%3DTyrosine%2520kinase%2520inhibitor%2520sorafenib%2520decreases%2520In-111-girentuximab%2520uptake%2520in%2520patients%2520with%2520clear%2520cell%2520renal%2520cell%2520carcinoma%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2014%26volume%3D55%26spage%3D242%26epage%3D247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Breitz, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjorn, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiden, P. L.</span><span> </span><span class="NLM_article-title">Clinical experience with Tc-99m nofetumomab merpentan (Verluma) radioimmunoscintigraphy</span> <span class="citation_source-journal">Clin. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">615</span><span class="NLM_x">–</span> <span class="NLM_lpage">620</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1097%2F00003072-199709000-00007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=9298295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A280%3ADyaK2svktlCmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1997&pages=615-620&author=H.+B.+Breitzauthor=A.+Tylerauthor=M.+J.+Bjornauthor=T.+Lesleyauthor=P.+L.+Weiden&title=Clinical+experience+with+Tc-99m+nofetumomab+merpentan+%28Verluma%29+radioimmunoscintigraphy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical experience with Tc-99m nofetumomab merpentan (Verluma) radioimmunoscintigraphy</span></div><div class="casAuthors">Breitz H B; Tyler A; Bjorn M J; Lesley T; Weiden P L</div><div class="citationInfo"><span class="NLM_cas:title">Clinical nuclear medicine</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">615-20</span>
        ISSN:<span class="NLM_cas:issn">0363-9762</span>.
    </div><div class="casAbstract">Tc-99m nofetumomab merpentan (Verluma), consisting of a Fab fragment of the pancarcinoma murine antibody NR-LU-10, has been previously evaluated as a diagnostic imaging agent in staging patients with lung cancer.  The authors have taken advantage of the pancarcinoma reactivity of this antibody to select patients with a variety of carcinomas for radioimmunotherapy trials.  These have included gastrointestinal, breast, ovary, pancreas, kidney, cervix, and bladder carcinoma.  This article documents the range of tumor types and locations that can be identified by gamma camera imaging with this radioimmunoconjugate.  Tumor was positively identified in 92% of 107 patients studied.  In 15 patients, the images led to suspicion of previously unknown disease.  The authors conclude that this radioimmunoconjugate is useful in assessing patients with advanced disease.  Additional studies may be warranted to explore further the potential benefit of this diagnostic imaging agent in evaluating the extent of disease in patients with a variety of carcinomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS10S5FU1N0Q02yPDyEFiigfW6udTcc2ebJGkQpGl-5-Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2svktlCmuw%253D%253D&md5=f16b14dfe321799f2b8f44a902c9c8c0</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1097%2F00003072-199709000-00007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00003072-199709000-00007%26sid%3Dliteratum%253Aachs%26aulast%3DBreitz%26aufirst%3DH.%2BB.%26aulast%3DTyler%26aufirst%3DA.%26aulast%3DBjorn%26aufirst%3DM.%2BJ.%26aulast%3DLesley%26aufirst%3DT.%26aulast%3DWeiden%26aufirst%3DP.%2BL.%26atitle%3DClinical%2520experience%2520with%2520Tc-99m%2520nofetumomab%2520merpentan%2520%2528Verluma%2529%2520radioimmunoscintigraphy%26jtitle%3DClin.%2520Nucl.%2520Med.%26date%3D1997%26volume%3D22%26spage%3D615%26epage%3D620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Heuveling, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bree, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vugts, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huisman, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giovannoni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoekstra, O. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leemans, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Dongen, G. A. M. S.</span><span> </span><span class="NLM_article-title">Phase 0 microdosing PET study using the human mini antibody F16SIP in head and neck cancer patients</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">397</span><span class="NLM_x">–</span> <span class="NLM_lpage">401</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2013&pages=397-401&author=D.+A.+Heuvelingauthor=R.+de+Breeauthor=D.+J.+Vugtsauthor=M.+C.+Huismanauthor=L.+Giovannoniauthor=O.+S.+Hoekstraauthor=C.+R.+Leemansauthor=D.+Neriauthor=G.+A.+M.+S.+van+Dongen&title=Phase+0+microdosing+PET+study+using+the+human+mini+antibody+F16SIP+in+head+and+neck+cancer+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHeuveling%26aufirst%3DD.%2BA.%26aulast%3Dde%2BBree%26aufirst%3DR.%26aulast%3DVugts%26aufirst%3DD.%2BJ.%26aulast%3DHuisman%26aufirst%3DM.%2BC.%26aulast%3DGiovannoni%26aufirst%3DL.%26aulast%3DHoekstra%26aufirst%3DO.%2BS.%26aulast%3DLeemans%26aufirst%3DC.%2BR.%26aulast%3DNeri%26aufirst%3DD.%26aulast%3Dvan%2BDongen%26aufirst%3DG.%2BA.%2BM.%2BS.%26atitle%3DPhase%25200%2520microdosing%2520PET%2520study%2520using%2520the%2520human%2520mini%2520antibody%2520F16SIP%2520in%2520head%2520and%2520neck%2520cancer%2520patients%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2013%26volume%3D54%26spage%3D397%26epage%3D401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Ychou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelegrin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faurous, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saccavini, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerreau, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossi, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchegger, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mach, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artus, J. C.</span><span> </span><span class="NLM_article-title">Phase-I/II radio-immunotherapy study with iodine-131-labeled anti-CEA monoclonal antibody F6 F(ab′)2 in patients with non-resectable liver metastases from colorectal cancer</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">615</span><span class="NLM_x">–</span> <span class="NLM_lpage">619</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1002%2F%28SICI%291097-0215%2819980209%2975%3A4%3C615%3A%3AAID-IJC20%3E3.0.CO%3B2-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=9466665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADyaK1cXhtV2lu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=1998&pages=615-619&author=M.+Ychouauthor=A.+Pelegrinauthor=P.+Faurousauthor=B.+Robertauthor=J.+C.+Saccaviniauthor=D.+Guerreauauthor=J.+F.+Rossiauthor=M.+Fabbroauthor=F.+Bucheggerauthor=J.+P.+Machauthor=J.+C.+Artus&title=Phase-I%2FII+radio-immunotherapy+study+with+iodine-131-labeled+anti-CEA+monoclonal+antibody+F6+F%28ab%E2%80%B2%292+in+patients+with+non-resectable+liver+metastases+from+colorectal+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Phase-I/II radioimmunotherapy study with iodine-131-labeled anti-CEA monoclonal antibody F6 F(ab')2 in patients with non-resectable liver metastases from colorectal cancer</span></div><div class="casAuthors">Ychou, Marc; Pelegrin, Andre; Faurous, Patrick; Robert, Bruno; Saccavini, Jean-Claude; Guerreau, Dominique; Rossi, Jean-Francois; Fabbro, Michel; Buchegger, Franz; Mach, Jean-Pierre; Artus, Jean-Claude</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">615-619</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Exptl. studies in nude mice with human colon-carcinoma grafts demonstrated the therapeutic efficiency of F(ab')2 fragments to carcinoembryonic antigen (CEA) labeled with a high dose of 131I.  A phase I/II study was designed to det. the max. tolerated dose of 131I-labeled F(ab')2 fragments (131I-F(ab')2) from anti-CEA monoclonal antibody F6, its limiting organ toxicity and tumor uptake.  Ten patients with non-resectable liver metastases from colorectal cancer (9 detected by CT scan and I by laparotomy) were treated with 131I-F(ab')2, doses ranging from 87 to 300 mCi for the first 5 patients, with a const. 300-mCi dose for the last 5 patients.  For all the patients, autologous bone marrow was harvested and stored before treatment.  Circulating CEA ranged from 2 to 126 ng/mI.  No severe adverse events were obsd. during or immediately following infusion of therapeutic doses.  The 9 patients with radiol. evidence of liver metastases showed uptake of 131I-F(ab')2 in the metastases, as obsd. by single-photon-emission tomog.  The only toxicity was hematol., and no severe aplasia was obsd. when up to 250 mCi was infused.  At the 300-mCi dose, 5 out of 6 patients presented grade-3 or -4 hematol. toxicity, with a nadir for neutrophiles and thrombocytes ranging from 25 to 35 days after infusion.  In these 5 cases, bone marrow was re-infused.  No clin. complications were obsd. during aplasia.  The tumor response could be evaluated in 9 out of 10 patients.  One patient showed a partial response of one small liver metastasis (2 cm in diam.) and a stable evolution of the other metastases, 2 patients had stable disease, and 6 showed tumor progression at the time of evaluation (2 or 3 mo after injection) by CT scan.  A dose of 300 mCi 131I-F(ab')2 from the anti-CEA Mab F6 is well tolerated with bone-marrow rescue, whereas a dose of 200 mCi can be infused without severe bone-marrow toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqK1bOLNatdALVg90H21EOLACvtfcHk0lgCfYpP5MDZKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhtV2lu7o%253D&md5=fe84d6fc7b289cfbd0eae0fb993f0a59</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291097-0215%2819980209%2975%3A4%3C615%3A%3AAID-IJC20%3E3.0.CO%3B2-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291097-0215%252819980209%252975%253A4%253C615%253A%253AAID-IJC20%253E3.0.CO%253B2-6%26sid%3Dliteratum%253Aachs%26aulast%3DYchou%26aufirst%3DM.%26aulast%3DPelegrin%26aufirst%3DA.%26aulast%3DFaurous%26aufirst%3DP.%26aulast%3DRobert%26aufirst%3DB.%26aulast%3DSaccavini%26aufirst%3DJ.%2BC.%26aulast%3DGuerreau%26aufirst%3DD.%26aulast%3DRossi%26aufirst%3DJ.%2BF.%26aulast%3DFabbro%26aufirst%3DM.%26aulast%3DBuchegger%26aufirst%3DF.%26aulast%3DMach%26aufirst%3DJ.%2BP.%26aulast%3DArtus%26aufirst%3DJ.%2BC.%26atitle%3DPhase-I%252FII%2520radio-immunotherapy%2520study%2520with%2520iodine-131-labeled%2520anti-CEA%2520monoclonal%2520antibody%2520F6%2520F%2528ab%25E2%2580%25B2%25292%2520in%2520patients%2520with%2520non-resectable%2520liver%2520metastases%2520from%2520colorectal%2520cancer%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D1998%26volume%3D75%26spage%3D615%26epage%3D619" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Wu, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span> </span><span class="NLM_article-title">Arming antibodies: prospects and challenges for immunoconjugates</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">1137</span><span class="NLM_x">–</span> <span class="NLM_lpage">1146</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1038%2Fnbt1141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=16151407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpvVyrtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=1137-1146&author=A.+M.+Wuauthor=P.+D.+Senter&title=Arming+antibodies%3A+prospects+and+challenges+for+immunoconjugates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Arming antibodies: prospects and challenges for immunoconjugates</span></div><div class="casAuthors">Wu, Anna M.; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1137-1146</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Immunoconjugates-monoclonal antibodies (mAbs) coupled to highly toxic agents, including radioisotopes and toxic drugs (ineffective when administered systemically alone)-are becoming a significant component of anticancer treatments.  By combining the exquisite targeting specificity of mAbs with the enhanced tumor-killing power of toxic effector mols., immunoconjugates permit sensitive discrimination between target and normal tissue, resulting in fewer toxic side effects than most conventional chemotherapeutic drugs.  Two radioimmunoconjugates, ibritumomab tiuxetan (Zevalin) and tositumomab-131I (Bexxar), and one drug conjugate, gemtuzumab ozogamicin (Mylotarg), are now on the market.  For the next generation of immunoconjugates, advances in protein engineering will permit greater control of mAb targeting, clearance and pharmacokinetics, resulting in significantly improved delivery to tumors of radioisotopes and potent anticancer drugs.  Pretargeting strategies, which sep. the two functions of antibody-based localization and delivery or generation of the toxic agent into two steps, also promise to afford superior tumor targeting and therapeutic efficacy.  Several challenges in optimizing immunoconjugates remain, however, including poor intratumoral mAb uptake, normal tissue conjugate exposure and issues surrounding drug potency and conditional release from mAb carriers.  Nonetheless, highly promising results from preclin. models will continue to drive the clin. development of this therapeutic class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQIsb1wtkWs7Vg90H21EOLACvtfcHk0lgCfYpP5MDZKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpvVyrtrk%253D&md5=6c2d10cdcffad09d516386607d2223a9</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnbt1141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1141%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DA.%2BM.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DArming%2520antibodies%253A%2520prospects%2520and%2520challenges%2520for%2520immunoconjugates%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D1137%26epage%3D1146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Borsi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balza, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bestagno, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castellani, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carnemolla, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leprini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sepulveda, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrone, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zardi, L.</span><span> </span><span class="NLM_article-title">Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">75</span><span class="NLM_x">–</span> <span class="NLM_lpage">85</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1002%2Fijc.10662" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=12353237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BD38XnvFCru7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2002&pages=75-85&author=L.+Borsiauthor=E.+Balzaauthor=M.+Bestagnoauthor=P.+Castellaniauthor=B.+Carnemollaauthor=A.+Biroauthor=A.+Lepriniauthor=J.+Sepulvedaauthor=O.+Burroneauthor=D.+Neriauthor=L.+Zardi&title=Selective+targeting+of+tumoral+vasculature%3A+Comparison+of+different+formats+of+an+antibody+%28L19%29+to+the+ED-B+domain+of+fibronectin"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin</span></div><div class="casAuthors">Borsi, Laura; Balza, Enrica; Bestagno, Marco; Castellani, Patrizia; Carnemolla, Barbara; Biro, Attila; Leprini, Alessandra; Sepulveda, Jorge; Burrone, Oscar; Neri, Dario; Zardi, Luciano</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">75-85</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">We recently demonstrated that a human recombinant scFv, L19, reacting with the ED-B domain of fibronectin, a marker of angiogenesis, selectively targets tumoral vasculature in vivo.  Using the variable regions of L19, we constructed and expressed a human "small immunoprotein" (SIP) and a complete human IgG1 and performed biodistribution studies in tumor-bearing mice to compare the blood clearance rate, in vivo stability and performance in tumor targeting of the 3 L19 formats [dimeric scFv (scFv)2, SIP and IgG1].  The accumulation of the different antibody formats in the tumors studied was a consequence of the clearance rate and in vivo stability of the mols.  Using the SIP, the %ID/g in tumors was 2-5 times higher than that of the (scFv)2, reaching a max. 4-6 h after injection.  By contrast, the accumulation of IgGI in tumors constantly rose during the expts.  However, due to its slow clearance, the tumor-blood ratio of the %ID/g after 144 h was only about 3 compared to a ratio of 10 for the (scFv)2 and 70 for the SIP after the same period of time.  The different in vivo behavior of these 3 completely human L19 formats could be exploited for different diagnostic and/or therapeutic purposes, depending on clin. needs and disease.  Furthermore, the fact that ED-B is 100% homologous in human and mouse, which ensures that L19 reacts equally well with the human and the murine antigen, should expedite the transfer of these reagents to clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOGonxkjQSFLVg90H21EOLACvtfcHk0lgCfYpP5MDZKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnvFCru7g%253D&md5=5dab3c4e4245b8cc213769d8eb9d8306</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2Fijc.10662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.10662%26sid%3Dliteratum%253Aachs%26aulast%3DBorsi%26aufirst%3DL.%26aulast%3DBalza%26aufirst%3DE.%26aulast%3DBestagno%26aufirst%3DM.%26aulast%3DCastellani%26aufirst%3DP.%26aulast%3DCarnemolla%26aufirst%3DB.%26aulast%3DBiro%26aufirst%3DA.%26aulast%3DLeprini%26aufirst%3DA.%26aulast%3DSepulveda%26aufirst%3DJ.%26aulast%3DBurrone%26aufirst%3DO.%26aulast%3DNeri%26aufirst%3DD.%26aulast%3DZardi%26aufirst%3DL.%26atitle%3DSelective%2520targeting%2520of%2520tumoral%2520vasculature%253A%2520Comparison%2520of%2520different%2520formats%2520of%2520an%2520antibody%2520%2528L19%2529%2520to%2520the%2520ED-B%2520domain%2520of%2520fibronectin%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2002%26volume%3D102%26spage%3D75%26epage%3D85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Berndorff, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borkowski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sieger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rother, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friebe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilger, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cyr, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinkelborg, L. M.</span><span> </span><span class="NLM_article-title">Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: Identification of the best-suited radioimmunoconjugate</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">7053S</span><span class="NLM_x">–</span> <span class="NLM_lpage">7063S</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=7053S-7063S&author=D.+Berndorffauthor=S.+Borkowskiauthor=S.+Siegerauthor=A.+Rotherauthor=M.+Friebeauthor=F.+Vitiauthor=C.+S.+Hilgerauthor=J.+E.+Cyrauthor=L.+M.+Dinkelborg&title=Radioimmunotherapy+of+solid+tumors+by+targeting+extra+domain+B+fibronectin%3A+Identification+of+the+best-suited+radioimmunoconjugate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBerndorff%26aufirst%3DD.%26aulast%3DBorkowski%26aufirst%3DS.%26aulast%3DSieger%26aufirst%3DS.%26aulast%3DRother%26aufirst%3DA.%26aulast%3DFriebe%26aufirst%3DM.%26aulast%3DViti%26aufirst%3DF.%26aulast%3DHilger%26aufirst%3DC.%2BS.%26aulast%3DCyr%26aufirst%3DJ.%2BE.%26aulast%3DDinkelborg%26aufirst%3DL.%2BM.%26atitle%3DRadioimmunotherapy%2520of%2520solid%2520tumors%2520by%2520targeting%2520extra%2520domain%2520B%2520fibronectin%253A%2520Identification%2520of%2520the%2520best-suited%2520radioimmunoconjugate%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D7053S%26epage%3D7063S" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Moreau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raguin, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vrigneaud, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernhard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tizon, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschetti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duchamp, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunotte, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denat, F.</span><span> </span><span class="NLM_article-title">DOTAGA-trastuzumab. A new antibody conjugate targeting HER2/Neu antigen for diagnostic purposes</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">1181</span><span class="NLM_x">–</span> <span class="NLM_lpage">1188</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc200680x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvVGjtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=1181-1188&author=M.+Moreauauthor=O.+Raguinauthor=J.+M.+Vrigneaudauthor=B.+Collinauthor=C.+Bernhardauthor=X.+Tizonauthor=F.+Boschettiauthor=O.+Duchampauthor=F.+Brunotteauthor=F.+Denat&title=DOTAGA-trastuzumab.+A+new+antibody+conjugate+targeting+HER2%2FNeu+antigen+for+diagnostic+purposes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">DOTAGA-Trastuzumab. A New Antibody Conjugate Targeting HER2/Neu Antigen for Diagnostic Purposes</span></div><div class="casAuthors">Moreau, Mathieu; Raguin, Olivier; Vrigneaud, Jean-Marc; Collin, Bertrand; Bernhard, Claire; Tizon, Xavier; Boschetti, Frederic; Duchamp, Olivier; Brunotte, Francois; Denat, Franck</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1181-1188</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Improved bifunctional chelating agents (BFC) are required for indium-111 radiolabeling of monoclonal antibodies (mAbs) under mild conditions to yield stable, target-specific agents. 2,2,2-(10-(2,6-Dioxotetrahydro-2H-pyran-3-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (DOTAGA-anhydride) was evaluated for mAb conjugation and labeling with indium-111.  The DOTA analog was synthesized and conjugated to trastuzumab which targets the HER2/neu receptor in mild conditions (PBS pH 7.4, 25 C, 30 min) and gave a mean degree of conjugation of 2.6 macrocycle per antibody.  Labeling of this immunoconjugate with indium-111 was performed in 75% yield after 1 h at 37 C, and the proportion of 111In-DOTAGA-trastuzumab reached 97% after purifn.  The affinity of DOTAGA-trastuzumab was 5.5, 0.6 nM as evaluated by in vitro satn. assays using HCC1954 breast cancer cell line.  SPECT/CT imaging and biodistribution studies were performed in mice bearing breast cancer BT-474 xenografts.  BT-474 tumors were clearly visualized on SPECT images at 24, 48, and 72 h postinjection.  The tumor uptake of [111In-DOTAGA]-trastuzumab reached 65%ID/g 72 h postinjection.  These results show that the DOTAGA BFC appears to be a valuable tool for biologics conjugation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxTIrhdIOo9bVg90H21EOLACvtfcHk0liUo4tsgrwjxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvVGjtLk%253D&md5=a2552569ece81de76b49e12f9ee8c393</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fbc200680x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc200680x%26sid%3Dliteratum%253Aachs%26aulast%3DMoreau%26aufirst%3DM.%26aulast%3DRaguin%26aufirst%3DO.%26aulast%3DVrigneaud%26aufirst%3DJ.%2BM.%26aulast%3DCollin%26aufirst%3DB.%26aulast%3DBernhard%26aufirst%3DC.%26aulast%3DTizon%26aufirst%3DX.%26aulast%3DBoschetti%26aufirst%3DF.%26aulast%3DDuchamp%26aufirst%3DO.%26aulast%3DBrunotte%26aufirst%3DF.%26aulast%3DDenat%26aufirst%3DF.%26atitle%3DDOTAGA-trastuzumab.%2520A%2520new%2520antibody%2520conjugate%2520targeting%2520HER2%252FNeu%2520antigen%2520for%2520diagnostic%2520purposes%26jtitle%3DBioconjugate%2520Chem.%26date%3D2012%26volume%3D23%26spage%3D1181%26epage%3D1188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Brouwers, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Eerd, J. E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frielink, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oosterwijk, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyen, W. J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corstens, F. H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boerman, O. C.</span><span> </span><span class="NLM_article-title">Optimization of radioimmunotherapy of renal cell carcinoma: Labeling of monoclonal antibody cG250 with I-131, Y-90, Lu-177, or Re-186</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">327</span><span class="NLM_x">–</span> <span class="NLM_lpage">337</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2004&pages=327-337&author=A.+H.+Brouwersauthor=J.+E.+M.+van+Eerdauthor=C.+Frielinkauthor=E.+Oosterwijkauthor=W.+J.+G.+Oyenauthor=F.+H.+M.+Corstensauthor=O.+C.+Boerman&title=Optimization+of+radioimmunotherapy+of+renal+cell+carcinoma%3A+Labeling+of+monoclonal+antibody+cG250+with+I-131%2C+Y-90%2C+Lu-177%2C+or+Re-186"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrouwers%26aufirst%3DA.%2BH.%26aulast%3Dvan%2BEerd%26aufirst%3DJ.%2BE.%2BM.%26aulast%3DFrielink%26aufirst%3DC.%26aulast%3DOosterwijk%26aufirst%3DE.%26aulast%3DOyen%26aufirst%3DW.%2BJ.%2BG.%26aulast%3DCorstens%26aufirst%3DF.%2BH.%2BM.%26aulast%3DBoerman%26aufirst%3DO.%2BC.%26atitle%3DOptimization%2520of%2520radioimmunotherapy%2520of%2520renal%2520cell%2520carcinoma%253A%2520Labeling%2520of%2520monoclonal%2520antibody%2520cG250%2520with%2520I-131%252C%2520Y-90%252C%2520Lu-177%252C%2520or%2520Re-186%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2004%26volume%3D45%26spage%3D327%26epage%3D337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Dennis, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dugger, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFarland, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogasawara, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwall, R.</span><span> </span><span class="NLM_article-title">Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">254</span><span class="NLM_x">–</span> <span class="NLM_lpage">261</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=254-261&author=M.+S.+Dennisauthor=H.+Jinauthor=D.+Duggerauthor=R.+Yangauthor=L.+McFarlandauthor=A.+Ogasawaraauthor=S.+Williamsauthor=M.+J.+Coleauthor=S.+Rossauthor=R.+Schwall&title=Imaging+tumors+with+an+albumin-binding+Fab%2C+a+novel+tumor-targeting+agent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDennis%26aufirst%3DM.%2BS.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DDugger%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DR.%26aulast%3DMcFarland%26aufirst%3DL.%26aulast%3DOgasawara%26aufirst%3DA.%26aulast%3DWilliams%26aufirst%3DS.%26aulast%3DCole%26aufirst%3DM.%2BJ.%26aulast%3DRoss%26aufirst%3DS.%26aulast%3DSchwall%26aufirst%3DR.%26atitle%3DImaging%2520tumors%2520with%2520an%2520albumin-binding%2520Fab%252C%2520a%2520novel%2520tumor-targeting%2520agent%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D254%26epage%3D261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Saga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neumann, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heya, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinuya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paik, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinstein, J. N.</span><span> </span><span class="NLM_article-title">Targeting cancer micrometastases with monoclonal-antibodies—A binding-site barrier</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">8999</span><span class="NLM_x">–</span> <span class="NLM_lpage">9003</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=1995&pages=8999-9003&author=T.+Sagaauthor=R.+D.+Neumannauthor=T.+Heyaauthor=J.+Satoauthor=S.+Kinuyaauthor=N.+Leauthor=C.+H.+Paikauthor=J.+N.+Weinstein&title=Targeting+cancer+micrometastases+with+monoclonal-antibodies%E2%80%94A+binding-site+barrier"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSaga%26aufirst%3DT.%26aulast%3DNeumann%26aufirst%3DR.%2BD.%26aulast%3DHeya%26aufirst%3DT.%26aulast%3DSato%26aufirst%3DJ.%26aulast%3DKinuya%26aufirst%3DS.%26aulast%3DLe%26aufirst%3DN.%26aulast%3DPaik%26aufirst%3DC.%2BH.%26aulast%3DWeinstein%26aufirst%3DJ.%2BN.%26atitle%3DTargeting%2520cancer%2520micrometastases%2520with%2520monoclonal-antibodies%25E2%2580%2594A%2520binding-site%2520barrier%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1995%26volume%3D92%26spage%3D8999%26epage%3D9003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Adams, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schier, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCall, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmons, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horak, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alpaugh, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marks, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiner, L. M.</span><span> </span><span class="NLM_article-title">High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">4750</span><span class="NLM_x">–</span> <span class="NLM_lpage">4755</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=11406547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BD3MXks1Grtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=4750-4755&author=G.+P.+Adamsauthor=R.+Schierauthor=A.+M.+McCallauthor=H.+H.+Simmonsauthor=E.+M.+Horakauthor=R.+K.+Alpaughauthor=J.+D.+Marksauthor=L.+M.+Weiner&title=High+affinity+restricts+the+localization+and+tumor+penetration+of+single-chain+Fv+antibody+molecules"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules</span></div><div class="casAuthors">Adams, Gregory P.; Schier, Robert; McCall, Adrian M.; Simmons, Heidi H.; Horak, Eva M.; Alpaugh, R. Katherine; Marks, James D.; Weiner, Louis M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4750-4755</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Antitumor monoclonal antibodies must bind to tumor antigens with high affinity to achieve durable tumor retention.  This has spurred efforts to generate high affinity antibodies for use in cancer therapy.  However, it has been hypothesized that very high affinity interactions between antibodies and tumor antigens may impair efficient tumor penetration of the monoclonal antibodies and thus diminish effective in vivo targeting.  Here the authors show that intrinsic affinity properties regulate the quant. delivery of antitumor single-chain Fv (scFv) mols. to solid tumors and the penetration of scFv from the vasculature into tumor masses.  In biodistribution studies examg. a series of radioiodinated scFv mutants with affinities ranging from 10-7-10-11 M, quant. tumor retention did not significantly increase with enhancements in affinity beyond 10-9 M.  Similar distribution patterns were obsd. when the scFv were evaluated in the absence of renal clearance in anephric mice, indicating that the rapid renal clearance of the scFv was not responsible for these observations.  IHC and IF evaluations of tumor sections after the i.v. administration of scFv affinity mutants revealed that the lowest affinity mol. exhibited diffuse tumor staining whereas the highest affinity scFv was primarily retained in the perivascular regions of the tumor.  These results indicate that antibody-based mols. with extremely high affinity have impaired tumor penetration properties that must be considered in the design of antibody-based cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmzJy0rEvErLVg90H21EOLACvtfcHk0ljcSEamP6XgdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXks1Grtbs%253D&md5=ac011358d042f75f21df3d40c626cfc5</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DG.%2BP.%26aulast%3DSchier%26aufirst%3DR.%26aulast%3DMcCall%26aufirst%3DA.%2BM.%26aulast%3DSimmons%26aufirst%3DH.%2BH.%26aulast%3DHorak%26aufirst%3DE.%2BM.%26aulast%3DAlpaugh%26aufirst%3DR.%2BK.%26aulast%3DMarks%26aufirst%3DJ.%2BD.%26aulast%3DWeiner%26aufirst%3DL.%2BM.%26atitle%3DHigh%2520affinity%2520restricts%2520the%2520localization%2520and%2520tumor%2520penetration%2520of%2520single-chain%2520Fv%2520antibody%2520molecules%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D4750%26epage%3D4755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Rudnick, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaller, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein-Szanto, A. J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiner, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marks, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, G. P.</span><span> </span><span class="NLM_article-title">Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">2250</span><span class="NLM_x">–</span> <span class="NLM_lpage">2259</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1158%2F0008-5472.CAN-10-2277" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=21406401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtFWgtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=2250-2259&author=S.+I.+Rudnickauthor=J.+L.+Louauthor=C.+C.+Shallerauthor=Y.+Tangauthor=A.+J.+P.+Klein-Szantoauthor=L.+M.+Weinerauthor=J.+D.+Marksauthor=G.+P.+Adams&title=Influence+of+affinity+and+antigen+internalization+on+the+uptake+and+penetration+of+Anti-HER2+antibodies+in+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Influence of Affinity and Antigen Internalization on the Uptake and Penetration of Anti-HER2 Antibodies in Solid Tumors</span></div><div class="casAuthors">Rudnick, Stephen I.; Lou, Jianlong; Shaller, Calvin C.; Tang, Yong; Klein-Szanto, Andres J. P.; Weiner, Louis M.; Marks, James D.; Adams, Gregory P.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2250-2259</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Antibody drugs are widely used in cancer therapy, but conditions to maximize tumor penetration and efficacy have yet to be fully elucidated.  In this study, we investigated the impact of antibody binding affinity on tumor targeting and penetration with affinity variants that recognize the same epitope.  Specifically, we compared four derivs. of the C6.5 monoclonal antibody (mAb), which recognizes the same HER2 epitope (monovalent KD values ranging from 270 to 0.56 nmol/L).  Moderate affinity was assocd. with the highest tumor accumulation at 24 and 120 h after i.v. injection, whereas high affinity was found to produce the lowest tumor accumulation.  Highest affinity mAbs were confined to the perivascular space of tumors with an av. penetration of 20.4 ± 7.5 μm from tumor blood vessels.  Conversely, lowest affinity mAbs exhibited a broader distribution pattern with an av. penetration of 84.8 ± 12.8 μm.  In vitro internalization assays revealed that antibody internalization and catabolism generally increased with affinity, plateauing once the rate of HER2 internalization exceeded the rate of antibody dissocn.  Effects of internalization and catabolism on tumor targeting were further examd. using antibodies of moderate (C6.5) or high-affinity (trastuzumab), labeled with residualizing (111In-labeled) or nonresidualizing (125I-labeled) radioisotopes.  Significant amts. of antibody of both affinities were degraded by tumors in vivo.  Furthermore, moderate- to high-affinity mAbs targeting the same HER2 epitope with monovalent affinity above 23 nmol/L had equal tumor accumulation of residualizing radiolabel over 120 h.  Results indicated equal tumor exposure, suggesting that mAb penetration and retention in tumors reflected affinity-based differences in tumor catabolism.  Together, these results suggest that high-d., rapidly internalizing antigens subject high-affinity antibodies to greater internalization and degrdn., thereby limiting their penetration of tumors.  In contrast, lower-affinity antibodies penetrate tumors more effectively when rates of antibody-antigen dissocn. are higher than those of antigen internalization.  Together, our findings offer insights into how to optimize the ability of therapeutic antibodies to penetrate tumors.  Cancer Res; 71(6); 2250-9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkntN8xRbgdrVg90H21EOLACvtfcHk0ljcSEamP6XgdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtFWgtLg%253D&md5=b14f4516bc938c4b54df8f66b55ef42b</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-2277&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-2277%26sid%3Dliteratum%253Aachs%26aulast%3DRudnick%26aufirst%3DS.%2BI.%26aulast%3DLou%26aufirst%3DJ.%2BL.%26aulast%3DShaller%26aufirst%3DC.%2BC.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DKlein-Szanto%26aufirst%3DA.%2BJ.%2BP.%26aulast%3DWeiner%26aufirst%3DL.%2BM.%26aulast%3DMarks%26aufirst%3DJ.%2BD.%26aulast%3DAdams%26aufirst%3DG.%2BP.%26atitle%3DInfluence%2520of%2520affinity%2520and%2520antigen%2520internalization%2520on%2520the%2520uptake%2520and%2520penetration%2520of%2520Anti-HER2%2520antibodies%2520in%2520solid%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D2250%26epage%3D2259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Trail, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willner, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasch, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henderson, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofstead, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casazza, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Firestone, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hellström, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hellström, K. E.</span><span> </span><span class="NLM_article-title">Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">261</span><span class="NLM_x">, </span> <span class="NLM_fpage">212</span><span class="NLM_x">–</span> <span class="NLM_lpage">215</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1126%2Fscience.8327892" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=8327892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADyaK3sXltlWjtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=261&publication_year=1993&pages=212-215&author=P.+A.+Trailauthor=D.+Willnerauthor=S.+J.+Laschauthor=A.+J.+Hendersonauthor=S.+Hofsteadauthor=A.+M.+Casazzaauthor=R.+A.+Firestoneauthor=I.+Hellstr%C3%B6mauthor=K.+E.+Hellstr%C3%B6m&title=Cure+of+xenografted+human+carcinomas+by+BR96-doxorubicin+immunoconjugates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates</span></div><div class="casAuthors">Trail, P. A.; Willner, D.; Lasch, S. J.; Henderson, A. J.; Hofstead, S.; Casazza, A. M.; Firestone, R. A.; Hellstrom, I.; Hellstrom, K. E.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">261</span>
        (<span class="NLM_cas:issue">5118</span>),
    <span class="NLM_cas:pages">212-15</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">Immunoconjugates (BR96-DOX) were prepd. between chimeric monoclonal antibody BR96 and the anticancer drug doxorubicin.  The monoclonal antibody binds an antigen related to Lewis Y that is abundantly expressed at the surface of cells from many human carcinomas; it has a high degree of tumor selectivity and is internalized after binding.  BR96-DOX induced complete regressions and cures of xenografted human lung, breast, and colon carcinomas growing s.c. in athymic mice and cured 70 percent of mice bearing extensive metastasis of a human lung carcinoma.  Also, BR96-DOX cured 94 percent of athymic rats with s.c. human lung carcinoma, even though the rats, like humans and in contrast to mice, expressed the BR96 target antigen in normal tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkJ15RWFve9rVg90H21EOLACvtfcHk0ljcSEamP6XgdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXltlWjtLk%253D&md5=3a366cdac960b3324fd1100c1dc97653</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1126%2Fscience.8327892&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.8327892%26sid%3Dliteratum%253Aachs%26aulast%3DTrail%26aufirst%3DP.%2BA.%26aulast%3DWillner%26aufirst%3DD.%26aulast%3DLasch%26aufirst%3DS.%2BJ.%26aulast%3DHenderson%26aufirst%3DA.%2BJ.%26aulast%3DHofstead%26aufirst%3DS.%26aulast%3DCasazza%26aufirst%3DA.%2BM.%26aulast%3DFirestone%26aufirst%3DR.%2BA.%26aulast%3DHellstr%25C3%25B6m%26aufirst%3DI.%26aulast%3DHellstr%25C3%25B6m%26aufirst%3DK.%2BE.%26atitle%3DCure%2520of%2520xenografted%2520human%2520carcinomas%2520by%2520BR96-doxorubicin%2520immunoconjugates%26jtitle%3DScience%26date%3D1993%26volume%3D261%26spage%3D212%26epage%3D215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Lowinger, T. B.</span><span> </span><span class="NLM_article-title">Applications of biodegradable and biocompatible polyacetal drug conjugates to improve drug delivery</span>.  <span class="citation_source-book">Abstracts of Papers—American Chemical Society</span>; <span class="NLM_publisher-name">American Chemical Society</span>: <span class="NLM_publisher-loc">Washington, DC</span>,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=T.+B.+Lowinger&title=Abstracts+of+Papers%E2%80%94American+Chemical+Society"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DLowinger%26aufirst%3DT.%2BB.%26atitle%3DApplications%2520of%2520biodegradable%2520and%2520biocompatible%2520polyacetal%2520drug%2520conjugates%2520to%2520improve%2520drug%2520delivery%26btitle%3DAbstracts%2520of%2520Papers%25E2%2580%2594American%2520Chemical%2520Society%26pub%3DAmerican%2520Chemical%2520Society%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">de Claro, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGinn, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwitkowski, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bullock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khandelwal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habtemariam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouyang, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saber, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koti, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borrego, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clouse, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akinsanya, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kane, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaminskas, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farrell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pazdur, R.</span><span> </span><span class="NLM_article-title">U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">5845</span><span class="NLM_x">–</span> <span class="NLM_lpage">5849</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1158%2F1078-0432.CCR-12-1803" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=22962441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1GhtrzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=5845-5849&author=R.+A.+de+Claroauthor=K.+McGinnauthor=V.+Kwitkowskiauthor=J.+Bullockauthor=A.+Khandelwalauthor=B.+Habtemariamauthor=Y.+L.+Ouyangauthor=H.+Saberauthor=K.+Leeauthor=K.+Kotiauthor=M.+Rothmannauthor=M.+Shapiroauthor=F.+Borregoauthor=K.+Clouseauthor=X.+H.+Chenauthor=J.+Brownauthor=L.+Akinsanyaauthor=R.+Kaneauthor=E.+Kaminskasauthor=A.+Farrellauthor=R.+Pazdur&title=U.S.+Food+and+Drug+Administration+approval+summary%3A+brentuximab+vedotin+for+the+treatment+of+relapsed+Hodgkin+lymphoma+or+relapsed+systemic+anaplastic+large-cell+lymphoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma</span></div><div class="casAuthors">de Claro, R. Angelo; McGinn, Karen; Kwitkowski, Virginia; Bullock, Julie; Khandelwal, Aakanksha; Habtemariam, Bahru; Ouyang, Yanli; Saber, Haleh; Lee, Kyung; Koti, Kallappa; Rothmann, Mark; Shapiro, Marjorie; Borrego, Francisco; Clouse, Kathleen; Chen, Xiao Hong; Brown, Janice; Akinsanya, Lara; Kane, Robert; Kaminskas, Edvardas; Farrell, Ann; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5845-5849</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The U.S. Food and Drug Administration (FDA) describes the accelerated approval of brentuximab vedotin for patients with relapsed Hodgkin lymphoma and relapsed systemic anaplastic large-cell lymphoma (sALCL).  FDA analyzed the results of two single-arm trials, enrolling 102 patients with Hodgkin lymphoma and 58 patients with sALCL.  Both trials had primary endpoints of objective response rate (ORR) and key secondary endpoints of response duration and complete response (CR) rate.  For patients with Hodgkin lymphoma, ORR was 73% (95% CI, 65-83%); median response duration was 6.7 mo, and CR was 32% (95% CI, 23-42%).  For patients with sALCL, ORR was 86% (95% CI, 77-95%), median response duration was 12.6 mo, and CR was 57% (95% CI, 44-70%).  The most common adverse reactions were neutropenia, peripheral sensory neuropathy, fatigue, nausea, anemia, upper respiratory infection, diarrhea, pyrexia, rash, thrombocytopenia, cough, and vomiting.  FDA granted accelerated approval of brentuximab vedotin for the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplantation (ASCT) or after failure of at least two prior multiagent chemotherapy regimens in patients who are not ASCT candidates, and for the treatment of patients with sALCL after failure of at least one prior multiagent chemotherapy regimen.  Clin Cancer Res; 18(21); 5845-9. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofSyQY_xMc87Vg90H21EOLACvtfcHk0lgalpYFIIW7bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1GhtrzI&md5=c974edc86d32673b060b912932585c09</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-1803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-1803%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BClaro%26aufirst%3DR.%2BA.%26aulast%3DMcGinn%26aufirst%3DK.%26aulast%3DKwitkowski%26aufirst%3DV.%26aulast%3DBullock%26aufirst%3DJ.%26aulast%3DKhandelwal%26aufirst%3DA.%26aulast%3DHabtemariam%26aufirst%3DB.%26aulast%3DOuyang%26aufirst%3DY.%2BL.%26aulast%3DSaber%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DKoti%26aufirst%3DK.%26aulast%3DRothmann%26aufirst%3DM.%26aulast%3DShapiro%26aufirst%3DM.%26aulast%3DBorrego%26aufirst%3DF.%26aulast%3DClouse%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DX.%2BH.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DAkinsanya%26aufirst%3DL.%26aulast%3DKane%26aufirst%3DR.%26aulast%3DKaminskas%26aufirst%3DE.%26aulast%3DFarrell%26aufirst%3DA.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DU.S.%2520Food%2520and%2520Drug%2520Administration%2520approval%2520summary%253A%2520brentuximab%2520vedotin%2520for%2520the%2520treatment%2520of%2520relapsed%2520Hodgkin%2520lymphoma%2520or%2520relapsed%2520systemic%2520anaplastic%2520large-cell%2520lymphoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D5845%26epage%3D5849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Erickson, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, P. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widdison, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovtun, Y. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldmacher, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blättler, W. A.</span><span> </span><span class="NLM_article-title">Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">4426</span><span class="NLM_x">–</span> <span class="NLM_lpage">4433</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1158%2F0008-5472.CAN-05-4489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=16618769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BD28XjsFSlurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=4426-4433&author=H.+K.+Ericksonauthor=P.+U.+Parkauthor=W.+C.+Widdisonauthor=Y.+V.+Kovtunauthor=L.+M.+Garrettauthor=K.+Hoffmanauthor=R.+J.+Lutzauthor=V.+S.+Goldmacherauthor=W.+A.+Bl%C3%A4ttler&title=Antibody-maytansinoid+conjugates+are+activated+in+targeted+cancer+cells+by+lysosomal+degradation+and+linker-dependent+intracellular+processing"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-Maytansinoid Conjugates Are Activated in Targeted Cancer Cells by Lysosomal Degradation and Linker-Dependent Intracellular Processing</span></div><div class="casAuthors">Erickson, Hans K.; Park, Peter U.; Widdison, Wayne C.; Kovtun, Yelena V.; Garrett, Lisa M.; Hoffman, Karen; Lutz, Robert J.; Goldmacher, Victor S.; Blaettler, Walter A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4426-4433</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Antibody-drug conjugates are targeted anticancer agents consisting of a cytotoxic drug covalently linked to a monoclonal antibody for tumor antigen-specific activity.  Once bound to the target cell-surface antigen, the conjugate must be processed to release an active form of the drug, which can reach its intracellular target.  Here, we used both biol. and biochem. methods to better define this process for antibody-maytansinoid conjugates.  In particular, we examd. the metabolic fate in cells of huC242-maytansinoid conjugates contg. either a disulfide linker (huC242-SPDB-DM4) or a thioether linker (huC242-SMCC-DM1).  Using cell cycle anal. combined with lysosomal inhibitors, we showed that lysosomal processing is required for the activity of antibody-maytansinoid conjugates, irresp. of the linker.  We also identified and characterized the released maytansinoid mols. from these conjugates, and measured their rate of release compared with the kinetics of cell cycle arrest.  Both conjugates are efficiently degraded in lysosomes to yield metabolites consisting of the intact maytansinoid drug and linker attached to lysine.  The lysine adduct is the sole metabolite from the thioether-linked conjugate.  However, the lysine metabolite generated from the disulfide-linked conjugate is reduced and S-methylated to yield the lipophilic and potently cytotoxic metabolite, S-methyl-DM4.  These findings provide insight into the mechanism of action of antibody-maytansinoid conjugates in general, and more specifically, identify a biochem. mechanism that may account for the significantly enhanced antitumor efficacy obsd. with disulfide-linked conjugates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZZDy7Sl_BxrVg90H21EOLACvtfcHk0lgalpYFIIW7bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjsFSlurs%253D&md5=aaf42c96e596e17a7896a265d5e1d158</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-4489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-4489%26sid%3Dliteratum%253Aachs%26aulast%3DErickson%26aufirst%3DH.%2BK.%26aulast%3DPark%26aufirst%3DP.%2BU.%26aulast%3DWiddison%26aufirst%3DW.%2BC.%26aulast%3DKovtun%26aufirst%3DY.%2BV.%26aulast%3DGarrett%26aufirst%3DL.%2BM.%26aulast%3DHoffman%26aufirst%3DK.%26aulast%3DLutz%26aufirst%3DR.%2BJ.%26aulast%3DGoldmacher%26aufirst%3DV.%2BS.%26aulast%3DBl%25C3%25A4ttler%26aufirst%3DW.%2BA.%26atitle%3DAntibody-maytansinoid%2520conjugates%2520are%2520activated%2520in%2520targeted%2520cancer%2520cells%2520by%2520lysosomal%2520degradation%2520and%2520linker-dependent%2520intracellular%2520processing%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D4426%26epage%3D4433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Kovtun, Y. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Audette, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayo, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maloney, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erickson, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, X. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilhelm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ab, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widdison, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kellogg, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinkas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldmacher, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chari, R. V. J.</span><span> </span><span class="NLM_article-title">Antibody-maytansinoid conjugates designed to bypass multidrug resistance</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">2528</span><span class="NLM_x">–</span> <span class="NLM_lpage">2537</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1158%2F0008-5472.CAN-09-3546" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=20197459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtFygur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=2528-2537&author=Y.+V.+Kovtunauthor=C.+A.+Audetteauthor=M.+F.+Mayoauthor=G.+E.+Jonesauthor=H.+Dohertyauthor=E.+K.+Maloneyauthor=H.+K.+Ericksonauthor=X.+X.+Sunauthor=S.+Wilhelmauthor=O.+Abauthor=K.+C.+Laiauthor=W.+C.+Widdisonauthor=B.+Kelloggauthor=H.+Johnsonauthor=J.+Pinkasauthor=R.+J.+Lutzauthor=R.+Singhauthor=V.+S.+Goldmacherauthor=R.+V.+J.+Chari&title=Antibody-maytansinoid+conjugates+designed+to+bypass+multidrug+resistance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance</span></div><div class="casAuthors">Kovtun, Yelena V.; Audette, Charlene A.; Mayo, Michele F.; Jones, Gregory E.; Doherty, Heather; Maloney, Erin K.; Erickson, Hans K.; Sun, Xiuxia; Wilhelm, Sharon; Ab, Olga; Lai, Katharine C.; Widdison, Wayne C.; Kellogg, Brenda; Johnson, Holly; Pinkas, Jan; Lutz, Robert J.; Singh, Rajeeva; Goldmacher, Victor S.; Chari, Ravi V. J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2528-2537</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Conjugation of cytotoxic compds. to antibodies that bind to cancer-specific antigens makes these drugs selective in killing cancer cells.  However, many of the compds. used in such antibody-drug conjugates (ADC) are substrates for the multidrug transporter MDR1.  To evade the MDR1-mediated resistance, we conjugated the highly cytotoxic maytansinoid DM1 to antibodies via the maleimidyl-based hydrophilic linker PEG4Mal.  Following uptake into target cells, conjugates made with the PEG4Mal linker were processed to a cytotoxic metabolite that was retained by MDR1-expressing cells better than a metabolite of similar conjugates prepd. with the nonpolar linker N-succinimidyl-4-(maleimidomethyl)cyclohexane-1-carboxylate (SMCC).  In accord, PEG4Mal-linked conjugates were more potent in killing MDR1-expressing cells in culture.  In addn., PEG4Mal-linked conjugates were markedly more effective in eradicating MDR1-expressing human xenograft tumors than SMCC-linked conjugates while being tolerated similarly, thus showing an improved therapeutic index.  This study points the way to the development of ADCs that bypass multidrug resistance.  Cancer Res; 70(6); 2528-37.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreA_G5nmeju7Vg90H21EOLACvtfcHk0lgalpYFIIW7bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtFygur4%253D&md5=17a2600cc85203b3bace74e31d346daa</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-3546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-3546%26sid%3Dliteratum%253Aachs%26aulast%3DKovtun%26aufirst%3DY.%2BV.%26aulast%3DAudette%26aufirst%3DC.%2BA.%26aulast%3DMayo%26aufirst%3DM.%2BF.%26aulast%3DJones%26aufirst%3DG.%2BE.%26aulast%3DDoherty%26aufirst%3DH.%26aulast%3DMaloney%26aufirst%3DE.%2BK.%26aulast%3DErickson%26aufirst%3DH.%2BK.%26aulast%3DSun%26aufirst%3DX.%2BX.%26aulast%3DWilhelm%26aufirst%3DS.%26aulast%3DAb%26aufirst%3DO.%26aulast%3DLai%26aufirst%3DK.%2BC.%26aulast%3DWiddison%26aufirst%3DW.%2BC.%26aulast%3DKellogg%26aufirst%3DB.%26aulast%3DJohnson%26aufirst%3DH.%26aulast%3DPinkas%26aufirst%3DJ.%26aulast%3DLutz%26aufirst%3DR.%2BJ.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DGoldmacher%26aufirst%3DV.%2BS.%26aulast%3DChari%26aufirst%3DR.%2BV.%2BJ.%26atitle%3DAntibody-maytansinoid%2520conjugates%2520designed%2520to%2520bypass%2520multidrug%2520resistance%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D2528%26epage%3D2537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Chudasama, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stark, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrold, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibbitts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girish, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frey, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mager, D. E.</span><span> </span><span class="NLM_article-title">Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">520</span><span class="NLM_x">–</span> <span class="NLM_lpage">527</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1038%2Fclpt.2012.153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=22968044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtl2iurfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2012&pages=520-527&author=V.+L.+Chudasamaauthor=F.+S.+Starkauthor=J.+M.+Harroldauthor=J.+Tibbittsauthor=S.+R.+Girishauthor=M.+Guptaauthor=N.+Freyauthor=D.+E.+Mager&title=Semi-mechanistic+population+pharmacokinetic+model+of+multivalent+trastuzumab+emtansine+in+patients+with+metastatic+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Semi-mechanistic Population Pharmacokinetic Model of Multivalent Trastuzumab Emtansine in Patients with Metastatic Breast Cancer</span></div><div class="casAuthors">Chudasama, V. L.; Schaedeli Stark, F.; Harrold, J. M.; Tibbitts, J.; Girish, S. R.; Gupta, M.; Frey, N.; Mager, D. E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">520-527</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate (ADC) composed of multiple mols. of the antimicrotubule agent DM1 linked to trastuzumab, a humanized anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibody.  Pharmacokinetics data from phase I (n = 52) and phase II (n = 111) studies in HER2-pos. metastatic breast cancer patients show a shorter terminal half-life for T-DM1 than for total trastuzumab (TTmAb).  In this work, we translated prior preclin. modeling in monkeys to develop a semi-mechanistic population pharmacokinetics model to characterize T-DM1 and TTmAb concn. profiles.  A series of transit compartments with the same disposition parameters was used to describe the deconjugation process from higher to lower drug-to-antibody ratios (DARs).  The structure could explain the shorter terminal half-life of T-DM1 relative to TTmab.  The final model integrates prior knowledge of T-DM1 DARs from preclin. studies and could provide a platform for understanding and characterizing the pharmacokinetics of other ADC systems.  Clin. Pharmacol. & Therapeutics (2012); 92 4, 520-527. doi:10.1038/clpt.2012.153.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsh_7mNP3TbrVg90H21EOLACvtfcHk0ljjMA1yYJdFAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtl2iurfP&md5=1d04057bdead10453770c704e5ed28f4</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2012.153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2012.153%26sid%3Dliteratum%253Aachs%26aulast%3DChudasama%26aufirst%3DV.%2BL.%26aulast%3DStark%26aufirst%3DF.%2BS.%26aulast%3DHarrold%26aufirst%3DJ.%2BM.%26aulast%3DTibbitts%26aufirst%3DJ.%26aulast%3DGirish%26aufirst%3DS.%2BR.%26aulast%3DGupta%26aufirst%3DM.%26aulast%3DFrey%26aufirst%3DN.%26aulast%3DMager%26aufirst%3DD.%2BE.%26atitle%3DSemi-mechanistic%2520population%2520pharmacokinetic%2520model%2520of%2520multivalent%2520trastuzumab%2520emtansine%2520in%2520patients%2520with%2520metastatic%2520breast%2520cancer%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2012%26volume%3D92%26spage%3D520%26epage%3D527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Peddi, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurvitz, S. A.</span><span> </span><span class="NLM_article-title">Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer</span> <span class="citation_source-journal">Future Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">319</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.2217%2Ffon.13.7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=23469968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjs1ektrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=319-326&author=P.+F.+Peddiauthor=S.+A.+Hurvitz&title=Trastuzumab+emtansine%3A+the+first+targeted+chemotherapy+for+treatment+of+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer</span></div><div class="casAuthors">Peddi, Parvin F.; Hurvitz, Sara A.</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">319-326</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Trastuzumab emtansine (T-DM1) is a novel antibody-drug conjugate, comprised of a potent cytotoxic drug connected via a stable linker to the anti-HER2 antibody, trastuzumab, thereby primarily targeting chemotherapy delivery to cells overexpressing the HER2 receptor.  A Phase II randomized trial of T-DM1 in the front-line metastatic breast cancer setting revealed promising activity and improved safety compared with std. chemotherapy plus trastuzumab.  Subsequently, a Phase III trial in patients with trastuzumab-pretreated metastatic breast cancer showed T-DM1 to be assocd. with prolonged progression-free and overall survival compared with lapatinib plus capecitabine.  T-DM1 represents a major shift in the treatment of patients with breast cancer as it replaces traditional nontargeted chemotherapy with a smart' medication that directs the cytotoxic therapy to cancer cells by using a known biomarker.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHjKcoGj06urVg90H21EOLACvtfcHk0ljjMA1yYJdFAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjs1ektrY%253D&md5=00757349fb840db6f78d4418981d362c</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.2217%2Ffon.13.7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.13.7%26sid%3Dliteratum%253Aachs%26aulast%3DPeddi%26aufirst%3DP.%2BF.%26aulast%3DHurvitz%26aufirst%3DS.%2BA.%26atitle%3DTrastuzumab%2520emtansine%253A%2520the%2520first%2520targeted%2520chemotherapy%2520for%2520treatment%2520of%2520breast%2520cancer%26jtitle%3DFuture%2520Oncol.%26date%3D2013%26volume%3D9%26spage%3D319%26epage%3D326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Phillips, G. D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dugger, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crocker, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mai, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blattler, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chari, R. V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, W. L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeppen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwall, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenkare-Mitra, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span> </span><span class="NLM_article-title">Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">9280</span><span class="NLM_x">–</span> <span class="NLM_lpage">9290</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1158%2F0008-5472.CAN-08-1776" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=19010901" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=9280-9290&author=G.+D.+L.+Phillipsauthor=G.+Liauthor=D.+L.+Duggerauthor=L.+M.+Crockerauthor=K.+L.+Parsonsauthor=E.+Maiauthor=W.+A.+Blattlerauthor=J.+M.+Lambertauthor=R.+V.+J.+Chariauthor=R.+J.+Lutzauthor=W.+L.+T.+Wongauthor=F.+S.+Jacobsonauthor=H.+Koeppenauthor=R.+H.+Schwallauthor=S.+R.+Kenkare-Mitraauthor=S.+D.+Spencerauthor=M.+X.+Sliwkowski&title=Targeting+HER2-positive+breast+cancer+with+trastuzumab-DM1%2C+an+antibody-cytotoxic+drug+conjugate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-1776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-1776%26sid%3Dliteratum%253Aachs%26aulast%3DPhillips%26aufirst%3DG.%2BD.%2BL.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DDugger%26aufirst%3DD.%2BL.%26aulast%3DCrocker%26aufirst%3DL.%2BM.%26aulast%3DParsons%26aufirst%3DK.%2BL.%26aulast%3DMai%26aufirst%3DE.%26aulast%3DBlattler%26aufirst%3DW.%2BA.%26aulast%3DLambert%26aufirst%3DJ.%2BM.%26aulast%3DChari%26aufirst%3DR.%2BV.%2BJ.%26aulast%3DLutz%26aufirst%3DR.%2BJ.%26aulast%3DWong%26aufirst%3DW.%2BL.%2BT.%26aulast%3DJacobson%26aufirst%3DF.%2BS.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DSchwall%26aufirst%3DR.%2BH.%26aulast%3DKenkare-Mitra%26aufirst%3DS.%2BR.%26aulast%3DSpencer%26aufirst%3DS.%2BD.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DTargeting%2520HER2-positive%2520breast%2520cancer%2520with%2520trastuzumab-DM1%252C%2520an%2520antibody-cytotoxic%2520drug%2520conjugate%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D9280%26epage%3D9290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Tian, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manibusan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phuong, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hehli, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeGuzman, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ensari, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinkstaff, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biroc, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiJoseph, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dougher, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dushin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tchistiakova, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feyfant, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerber, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sapra, P.</span><span> </span><span class="NLM_article-title">A general approach to site-specific antibody drug conjugates</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">1766</span><span class="NLM_x">–</span> <span class="NLM_lpage">1771</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1073%2Fpnas.1321237111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=24443552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFyjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=1766-1771&author=F.+Tianauthor=Y.+C.+Luauthor=A.+Manibusanauthor=A.+Sellersauthor=H.+Tranauthor=Y.+Sunauthor=T.+Phuongauthor=R.+Barnettauthor=B.+Hehliauthor=F.+Songauthor=M.+J.+DeGuzmanauthor=S.+Ensariauthor=J.+K.+Pinkstaffauthor=L.+M.+Sullivanauthor=S.+L.+Birocauthor=H.+Choauthor=P.+G.+Schultzauthor=J.+DiJosephauthor=M.+Dougherauthor=D.+S.+Maauthor=R.+Dushinauthor=M.+Lealauthor=L.+Tchistiakovaauthor=E.+Feyfantauthor=H.+P.+Gerberauthor=P.+Sapra&title=A+general+approach+to+site-specific+antibody+drug+conjugates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">A general approach to site-specific antibody drug conjugates</span></div><div class="casAuthors">Tian, Feng; Lu, Yingchun; Manibusan, Anthony; Sellers, Aaron; Tran, Hon; Sun, Ying; Phuong, Trung; Barnett, Richard; Hehli, Brad; Song, Frank; De Guzman, Michael J.; Ensari, Semsi; Pinkstaff, Jason K.; Sullivan, Lorraine M.; Biroc, Sandra L.; Cho, Ho; Schultz, Peter G.; Di Joseph, John; Dougher, Maureen; Ma, Dangshe; Dushin, Russell; Leal, Mauricio; Tchistiakova, Lioudmila; Feyfant, Eric; Gerber, Hans-Peter; Sapra, Puja</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1766-1771</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Using an expanded genetic code, antibodies with site-specifically incorporated nonnative amino acids were produced in stable cell lines derived from a CHO cell line with titers over 1 g/L.  Using anti-5T4 and anti-Her2 antibodies as model systems, site-specific antibody drug conjugates (NDCs) were produced, via oxime bond formation between ketones on the side chain of the incorporated nonnative amino acid and hydroxylamine functionalized monomethyl auristatin D with either protease-cleavable or noncleavable linkers.  When noncleavable linkers were used, these conjugates were highly stable and displayed improved in vitro efficacy as well as in vivo efficacy and pharmacokinetic stability in rodent models relative to conventional antibody drug conjugates conjugated through either engineered surface-exposed or reduced interchain disulfide bond cysteine residues.  The advantages of the oxime-bonded, site-specific NDCs were even more apparent when low-antigen-expressing (2+) target cell lines were used in the comparative studies.  NDCs generated with protease-cleavable linkers demonstrated that the site of conjugation had a significant impact on the stability of these rationally designed prodrug linkers.  In a single-dose rat toxicol. study, a site-specific anti-Her2 NDC was well tolerated at dose levels up to 90 mg/kg.  These expts. support the notion that chem. defined antibody conjugates can be synthesized in com. relevant yields and can lead to antibody drug conjugates with improved properties relative to the heterogeneous conjugates formed by nonspecific chem. modification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSiiFYqUipo7Vg90H21EOLACvtfcHk0lg2Se8OqHnWXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFyjs7g%253D&md5=293401bcfaa0d74ce03daca26e9ad18e</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1321237111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1321237111%26sid%3Dliteratum%253Aachs%26aulast%3DTian%26aufirst%3DF.%26aulast%3DLu%26aufirst%3DY.%2BC.%26aulast%3DManibusan%26aufirst%3DA.%26aulast%3DSellers%26aufirst%3DA.%26aulast%3DTran%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DPhuong%26aufirst%3DT.%26aulast%3DBarnett%26aufirst%3DR.%26aulast%3DHehli%26aufirst%3DB.%26aulast%3DSong%26aufirst%3DF.%26aulast%3DDeGuzman%26aufirst%3DM.%2BJ.%26aulast%3DEnsari%26aufirst%3DS.%26aulast%3DPinkstaff%26aufirst%3DJ.%2BK.%26aulast%3DSullivan%26aufirst%3DL.%2BM.%26aulast%3DBiroc%26aufirst%3DS.%2BL.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DDiJoseph%26aufirst%3DJ.%26aulast%3DDougher%26aufirst%3DM.%26aulast%3DMa%26aufirst%3DD.%2BS.%26aulast%3DDushin%26aufirst%3DR.%26aulast%3DLeal%26aufirst%3DM.%26aulast%3DTchistiakova%26aufirst%3DL.%26aulast%3DFeyfant%26aufirst%3DE.%26aulast%3DGerber%26aufirst%3DH.%2BP.%26aulast%3DSapra%26aufirst%3DP.%26atitle%3DA%2520general%2520approach%2520to%2520site-specific%2520antibody%2520drug%2520conjugates%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2014%26volume%3D111%26spage%3D1766%26epage%3D1771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Shen, B.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raab, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhakta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenrick, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons-Reponte, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tien, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, S.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mai, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibbitts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baudys, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saadi, O. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scales, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hass, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trung, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solis, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuji, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flagella, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khawlil, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebens, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandlen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaur, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheller, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polakis, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Junutula, J. R.</span><span> </span><span class="NLM_article-title">Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">184</span><span class="NLM_x">–</span> <span class="NLM_lpage">189</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1038%2Fnbt.2108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=22267010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVGqtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=184-189&author=B.-Q.+Shenauthor=K.+Xuauthor=L.+Liuauthor=H.+Raabauthor=S.+Bhaktaauthor=M.+Kenrickauthor=K.+L.+Parsons-Reponteauthor=J.+Tienauthor=S.-F.+Yuauthor=E.+Maiauthor=D.+Liauthor=J.+Tibbittsauthor=J.+Baudysauthor=O.+M.+Saadiauthor=S.+J.+Scalesauthor=P.+J.+McDonaldauthor=P.+E.+Hassauthor=C.+Eigenbrotauthor=N.+Trungauthor=W.+A.+Solisauthor=R.+N.+Fujiauthor=K.+M.+Flagellaauthor=D.+Patelauthor=S.+D.+Spencerauthor=L.+A.+Khawlilauthor=A.+Ebensauthor=W.+L.+Wongauthor=R.+Vandlenauthor=S.+Kaurauthor=M.+X.+Sliwkowskiauthor=R.+H.+Schellerauthor=P.+Polakisauthor=J.+R.+Junutula&title=Conjugation+site+modulates+the+in+vivo+stability+and+therapeutic+activity+of+antibody-drug+conjugates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates</span></div><div class="casAuthors">Shen, Ben-Quan; Xu, Keyang; Liu, Luna; Raab, Helga; Bhakta, Sunil; Kenrick, Margaret; Parsons-Reponte, Kathryn L.; Tien, Janet; Yu, Shang-Fan; Mai, Elaine; Li, Dongwei; Tibbitts, Jay; Baudys, Jakub; Saad, Ola M.; Scales, Suzie J.; McDonald, Paul J.; Hass, Philip E.; Eigenbrot, Charles; Nguyen, Trung; Solis, Willy A.; Fuji, Reina N.; Flagella, Kelly M.; Patel, Darshana; Spencer, Susan D.; Khawli, Leslie A.; Ebens, Allen; Wong, Wai Lee; Vandlen, Richard; Kaur, Surinder; Sliwkowski, Mark X.; Scheller, Richard H.; Polakis, Paul; Junutula, Jagath R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">184-189</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The reactive thiol in cysteine is used for coupling maleimide linkers in the generation of antibody conjugates.  To assess the impact of the conjugation site, we engineered cysteines into a therapeutic HER2/neu antibody at three sites differing in solvent accessibility and local charge.  The highly solvent-accessible site rapidly lost conjugated thiol-reactive linkers in plasma owing to maleimide exchange with reactive thiols in albumin, free cysteine or glutathione.  In contrast, a partially accessible site with a pos. charged environment promoted hydrolysis of the succinimide ring in the linker, thereby preventing this exchange reaction.  The site with partial solvent-accessibility and neutral charge displayed both properties.  In a mouse mammary tumor model, the stability and therapeutic activity of the antibody conjugate were affected pos. by succinimide ring hydrolysis and neg. by maleimide exchange with thiol-reactive constituents in plasma.  Thus, the chem. and structural dynamics of the conjugation site can influence antibody conjugate performance by modulating the stability of the antibody-linker interface.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkINkMwQTMFrVg90H21EOLACvtfcHk0lg2Se8OqHnWXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVGqtLg%253D&md5=c647fc5bdfe93dfdabb15ca40934837f</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2108%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DB.-Q.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DRaab%26aufirst%3DH.%26aulast%3DBhakta%26aufirst%3DS.%26aulast%3DKenrick%26aufirst%3DM.%26aulast%3DParsons-Reponte%26aufirst%3DK.%2BL.%26aulast%3DTien%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DS.-F.%26aulast%3DMai%26aufirst%3DE.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DTibbitts%26aufirst%3DJ.%26aulast%3DBaudys%26aufirst%3DJ.%26aulast%3DSaadi%26aufirst%3DO.%2BM.%26aulast%3DScales%26aufirst%3DS.%2BJ.%26aulast%3DMcDonald%26aufirst%3DP.%2BJ.%26aulast%3DHass%26aufirst%3DP.%2BE.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DTrung%26aufirst%3DN.%26aulast%3DSolis%26aufirst%3DW.%2BA.%26aulast%3DFuji%26aufirst%3DR.%2BN.%26aulast%3DFlagella%26aufirst%3DK.%2BM.%26aulast%3DPatel%26aufirst%3DD.%26aulast%3DSpencer%26aufirst%3DS.%2BD.%26aulast%3DKhawlil%26aufirst%3DL.%2BA.%26aulast%3DEbens%26aufirst%3DA.%26aulast%3DWong%26aufirst%3DW.%2BL.%26aulast%3DVandlen%26aufirst%3DR.%26aulast%3DKaur%26aufirst%3DS.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DScheller%26aufirst%3DR.%2BH.%26aulast%3DPolakis%26aufirst%3DP.%26aulast%3DJunutula%26aufirst%3DJ.%2BR.%26atitle%3DConjugation%2520site%2520modulates%2520the%2520in%2520vivo%2520stability%2520and%2520therapeutic%2520activity%2520of%2520antibody-drug%2520conjugates%26jtitle%3DNat.%2520Biotechnol.%26date%3D2012%26volume%3D30%26spage%3D184%26epage%3D189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Junutula, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flagella, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ha, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raab, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhakta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dugger, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mai, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, G. D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiraragi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuji, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibbitts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandlen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheller, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polakis, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span> </span><span class="NLM_article-title">Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">4769</span><span class="NLM_x">–</span> <span class="NLM_lpage">4778</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1158%2F1078-0432.CCR-10-0987" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=20805300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1aktbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=4769-4778&author=J.+R.+Junutulaauthor=K.+M.+Flagellaauthor=R.+A.+Grahamauthor=K.+L.+Parsonsauthor=E.+Haauthor=H.+Raabauthor=S.+Bhaktaauthor=T.+Nguyenauthor=D.+L.+Duggerauthor=G.+M.+Liauthor=E.+Maiauthor=G.+D.+L.+Phillipsauthor=H.+Hiraragiauthor=R.+N.+Fujiauthor=J.+Tibbittsauthor=R.+Vandlenauthor=S.+D.+Spencerauthor=R.+H.+Schellerauthor=P.+Polakisauthor=M.+X.+Sliwkowski&title=Engineered+thio-trastuzumab-DM1+conjugate+with+an+improved+therapeutic+index+to+target+human+epidermal+growth+factor+receptor+2-positive+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer</span></div><div class="casAuthors">Junutula, Jagath R.; Flagella, Kelly M.; Graham, Richard A.; Parsons, Kathryn L.; Ha, Edward; Raab, Helga; Bhakta, Sunil; Nguyen, Trung; Dugger, Debra L.; Li, Guangmin; Mai, Elaine; Lewis Phillips, Gail D.; Hiraragi, Hajime; Fuji, Reina N.; Tibbitts, Jay; Vandlen, Richard; Spencer, Susan D.; Scheller, Richard H.; Polakis, Paul; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4769-4778</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Antibody drug conjugates (ADCs) combine the ideal properties of both antibodies and cytotoxic drugs by targeting potent drugs to the antigen-expressing tumor cells, thereby enhancing their antitumor activity.  Successful ADC development for a given target antigen depends on optimization of antibody selection, linker stability, cytotoxic drug potency, and mode of linker-drug conjugation to the antibody.  Here, we systematically examd. the in vitro potency as well as in vivo preclin. efficacy and safety profiles of a heterogeneous prepn. of conventional trastuzumab-mcc-DM1 (TMAb-mcc-DM1) ADC with that of a homogeneous engineered thio-trastuzumab-mpeo-DM1 (thioTMAb-mpeo-DM1) conjugate.  To generate thioTMAb-mpeo-DM1, one drug maytansinoid 1 (DM1) mol. was conjugated to an engineered cysteine residue at Ala114 (Kabat numbering) on each trastuzumab-heavy chain, resulting in two DM1 mols. per antibody.  ThioTMAb-mpeo-DM1 retained similar in vitro anti-cell proliferation activity and human epidermal growth factor receptor 2 (HER2) binding properties to that of the conventional ADC.  Furthermore, it showed improved efficacy over the conventional ADC at DM1-equiv doses (μg/m2) and retained efficacy at equiv. antibody doses (mg/kg).  An improved safety profile of >2-fold was obsd. in a short-term target-independent rat safety study.  In cynomolgus monkey safety studies, thioTMAb-mpeo-DM1 was tolerated at higher antibody doses (up to 48 mg/kg or 6000 μg DM1/m2) compared with the conventional ADC that had dose-limiting toxicity at 30 mg/kg (6000 μg DM1/m2).  The engineered thioTMAb-mpeo-DM1 with broadened therapeutic index represents a promising antibody drug conjugate for future clin. development of HER2-pos. targeted breast cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowkqzAMGHmA7Vg90H21EOLACvtfcHk0ljkkGit3CK2_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1aktbjK&md5=888bda7f06d1ed864111b607dae5f969</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-0987&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-0987%26sid%3Dliteratum%253Aachs%26aulast%3DJunutula%26aufirst%3DJ.%2BR.%26aulast%3DFlagella%26aufirst%3DK.%2BM.%26aulast%3DGraham%26aufirst%3DR.%2BA.%26aulast%3DParsons%26aufirst%3DK.%2BL.%26aulast%3DHa%26aufirst%3DE.%26aulast%3DRaab%26aufirst%3DH.%26aulast%3DBhakta%26aufirst%3DS.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DDugger%26aufirst%3DD.%2BL.%26aulast%3DLi%26aufirst%3DG.%2BM.%26aulast%3DMai%26aufirst%3DE.%26aulast%3DPhillips%26aufirst%3DG.%2BD.%2BL.%26aulast%3DHiraragi%26aufirst%3DH.%26aulast%3DFuji%26aufirst%3DR.%2BN.%26aulast%3DTibbitts%26aufirst%3DJ.%26aulast%3DVandlen%26aufirst%3DR.%26aulast%3DSpencer%26aufirst%3DS.%2BD.%26aulast%3DScheller%26aufirst%3DR.%2BH.%26aulast%3DPolakis%26aufirst%3DP.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DEngineered%2520thio-trastuzumab-DM1%2520conjugate%2520with%2520an%2520improved%2520therapeutic%2520index%2520to%2520target%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202-positive%2520breast%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26spage%3D4769%26epage%3D4778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Junutula, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raab, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhakta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leipold, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weir, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simpson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dennis, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, Y. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duenas, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorrell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katta, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDorman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flagella, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venook, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowman, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandlen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheller, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polakis, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallet, W.</span><span> </span><span class="NLM_article-title">Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">925</span><span class="NLM_x">–</span> <span class="NLM_lpage">932</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1038%2Fnbt.1480" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=18641636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1Wmu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=925-932&author=J.+R.+Junutulaauthor=H.+Raabauthor=S.+Clarkauthor=S.+Bhaktaauthor=D.+D.+Leipoldauthor=S.+Weirauthor=Y.+Chenauthor=M.+Simpsonauthor=S.+P.+Tsaiauthor=M.+S.+Dennisauthor=Y.+Luauthor=Y.+G.+Mengauthor=C.+Ngauthor=J.+Yangauthor=C.+C.+Leeauthor=E.+Duenasauthor=J.+Gorrellauthor=V.+Kattaauthor=A.+Kimauthor=K.+McDormanauthor=K.+Flagellaauthor=R.+Venookauthor=S.+Rossauthor=S.+D.+Spencerauthor=W.+L.+Wongauthor=H.+B.+Lowmanauthor=R.+Vandlenauthor=M.+X.+Sliwkowskiauthor=R.+H.+Schellerauthor=P.+Polakisauthor=W.+Mallet&title=Site-specific+conjugation+of+a+cytotoxic+drug+to+an+antibody+improves+the+therapeutic+index"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index</span></div><div class="casAuthors">Junutula, Jagath R.; Raab, Helga; Clark, Suzanna; Bhakta, Sunil; Leipold, Douglas D.; Weir, Sylvia; Chen, Yvonne; Simpson, Michelle; Tsai, Siao Ping; Dennis, Mark S.; Lu, Yanmei; Meng, Y. Gloria; Ng, Carl; Yang, Jihong; Lee, Chien C.; Duenas, Eileen; Gorrell, Jeffrey; Katta, Viswanatham; Kim, Amy; McDorman, Kevin; Flagella, Kelly; Venook, Rayna; Ross, Sarajane; Spencer, Susan D.; Wong, Wai Lee; Lowman, Henry B.; Vandlen, Richard; Sliwkowski, Mark X.; Scheller, Richard H.; Polakis, Paul; Mallet, William</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">925-932</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Antibody-drug conjugates enhance the antitumor effects of antibodies and reduce adverse systemic effects of potent cytotoxic drugs.  However, conventional drug conjugation strategies yield heterogeneous conjugates with relatively narrow therapeutic index (max. tolerated dose/curative dose).  Using leads from the authors' previously described phage display-based method to predict suitable conjugation sites, the authors engineered cysteine substitutions at positions on light and heavy chains that provide reactive thiol groups and do not perturb Ig folding and assembly, or alter antigen binding.  When conjugated to monomethyl auristatin E, an antibody against the ovarian cancer antigen MUC16 is as efficacious as a conventional conjugate in mouse xenograft models.  Moreover, it is tolerated at higher doses in rats and cynomolgus monkeys than the same conjugate prepd. by conventional approaches.  The favorable in vivo properties of the near-homogeneous compn. of this conjugate suggest that this strategy offers a general approach to retaining the antitumor efficacy of antibody-drug conjugates, while minimizing their systemic toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4HIiPBABzRLVg90H21EOLACvtfcHk0ljkkGit3CK2_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1Wmu7s%253D&md5=d55f59594fb6349d0337dfed2783e83c</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1480&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1480%26sid%3Dliteratum%253Aachs%26aulast%3DJunutula%26aufirst%3DJ.%2BR.%26aulast%3DRaab%26aufirst%3DH.%26aulast%3DClark%26aufirst%3DS.%26aulast%3DBhakta%26aufirst%3DS.%26aulast%3DLeipold%26aufirst%3DD.%2BD.%26aulast%3DWeir%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DSimpson%26aufirst%3DM.%26aulast%3DTsai%26aufirst%3DS.%2BP.%26aulast%3DDennis%26aufirst%3DM.%2BS.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DMeng%26aufirst%3DY.%2BG.%26aulast%3DNg%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DDuenas%26aufirst%3DE.%26aulast%3DGorrell%26aufirst%3DJ.%26aulast%3DKatta%26aufirst%3DV.%26aulast%3DKim%26aufirst%3DA.%26aulast%3DMcDorman%26aufirst%3DK.%26aulast%3DFlagella%26aufirst%3DK.%26aulast%3DVenook%26aufirst%3DR.%26aulast%3DRoss%26aufirst%3DS.%26aulast%3DSpencer%26aufirst%3DS.%2BD.%26aulast%3DWong%26aufirst%3DW.%2BL.%26aulast%3DLowman%26aufirst%3DH.%2BB.%26aulast%3DVandlen%26aufirst%3DR.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DScheller%26aufirst%3DR.%2BH.%26aulast%3DPolakis%26aufirst%3DP.%26aulast%3DMallet%26aufirst%3DW.%26atitle%3DSite-specific%2520conjugation%2520of%2520a%2520cytotoxic%2520drug%2520to%2520an%2520antibody%2520improves%2520the%2520therapeutic%2520index%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D925%26epage%3D932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Boghaert, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khandke, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sridharan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armellino, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dougher, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiJoseph, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamann, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sridharan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damle, N. K.</span><span> </span><span class="NLM_article-title">Tumoricidal effect of calicheamicin immuno-conjugates using a passive targeting strategy</span> <span class="citation_source-journal">Int. J. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">675</span><span class="NLM_x">–</span> <span class="NLM_lpage">684</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=16465373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BD28XitFWitro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2006&pages=675-684&author=E.+R.+Boghaertauthor=K.+Khandkeauthor=L.+Sridharanauthor=D.+Armellinoauthor=M.+Dougherauthor=J.+F.+DiJosephauthor=A.+Kunzauthor=P.+R.+Hamannauthor=A.+Sridharanauthor=S.+Jonesauthor=C.+Discafaniauthor=N.+K.+Damle&title=Tumoricidal+effect+of+calicheamicin+immuno-conjugates+using+a+passive+targeting+strategy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Tumoricidal effect of calicheamicin immuno-conjugates using a passive targeting strategy</span></div><div class="casAuthors">Boghaert, Erwin R.; Khandke, Kiran; Sridharan, Latha; Armellino, Douglas; Dougher, Maureen; DiJoseph, John F.; Kunz, Arthur; Hamann, Philip R.; Sridharan, Ashwin; Jones, Stanley; Discafani, Carolyn; Damle, Nitin K.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">675-684</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1019-6439</span>.
    
            (<span class="NLM_cas:orgname">International Journal of Oncology</span>)
        </div><div class="casAbstract">Calicheamicin is a potent chemotherapeutic with a low therapeutic index that requires targeting to tumor cells for its use in the clinic.  To treat acute myeloid leukemia, calicheamicin has been conjugated to an antibody that recognizes CD33 (gemtuzumab ozogamicin).  The application range of this 'active' targeting strategy is limited since it depends on specific antigen expression by tumor cells.  This limitation could be reduced by using an antigen-independent 'passive targeting' strategy for calicheamicin.  'Passive targeting' relies on the dysfunctional vasculature of a neoplastic tumor that allows enhanced retention of macromols.  We studied the efficacy of calicheamicin conjugated to various carrier mols.: i.e. Ig, albumin or PEGylated Fc fragments.  In nude mice, a conjugate of anti-CD33 and calicheamicin accumulates in human tumor xenografts in the absence of detectable amts. of targeting antigen.  Passive targeting provided sufficient accumulation of this conjugate to inhibit tumor growth of 10 different CD33-neg. xenograft models.  This efficacy depended on the use of an acid-labile linker between antibody and calicheamicin.  Substitution of Ig as a carrier with either albumin or PEGylated Fc reduced or eliminated the efficacy of the conjugate.  The results showed that using 'non-specific' Ig for passive targeting of calicheamicin might be an effective mode of cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8fLdjEgE99rVg90H21EOLACvtfcHk0ljkkGit3CK2_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XitFWitro%253D&md5=0641078e0bc35ea2cee475421ca63795</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoghaert%26aufirst%3DE.%2BR.%26aulast%3DKhandke%26aufirst%3DK.%26aulast%3DSridharan%26aufirst%3DL.%26aulast%3DArmellino%26aufirst%3DD.%26aulast%3DDougher%26aufirst%3DM.%26aulast%3DDiJoseph%26aufirst%3DJ.%2BF.%26aulast%3DKunz%26aufirst%3DA.%26aulast%3DHamann%26aufirst%3DP.%2BR.%26aulast%3DSridharan%26aufirst%3DA.%26aulast%3DJones%26aufirst%3DS.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DDamle%26aufirst%3DN.%2BK.%26atitle%3DTumoricidal%2520effect%2520of%2520calicheamicin%2520immuno-conjugates%2520using%2520a%2520passive%2520targeting%2520strategy%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2006%26volume%3D28%26spage%3D675%26epage%3D684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Jedema, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barge, R. M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Velden, V. H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nijmeijer, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Dongen, J. J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willemze, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falkenburg, J. H. F.</span><span> </span><span class="NLM_article-title">Internalization and cell cycle-dependent killing of leukemic cells by gemtuzumab ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">316</span><span class="NLM_x">–</span> <span class="NLM_lpage">325</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2004&pages=316-325&author=I.+Jedemaauthor=R.+M.+Y.+Bargeauthor=V.+H.+J.+van+der+Veldenauthor=B.+A.+Nijmeijerauthor=J.+J.+M.+van+Dongenauthor=R.+Willemzeauthor=J.+H.+F.+Falkenburg&title=Internalization+and+cell+cycle-dependent+killing+of+leukemic+cells+by+gemtuzumab+ozogamicin%3A+rationale+for+efficacy+in+CD33-negative+malignancies+with+endocytic+capacity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJedema%26aufirst%3DI.%26aulast%3DBarge%26aufirst%3DR.%2BM.%2BY.%26aulast%3Dvan%2Bder%2BVelden%26aufirst%3DV.%2BH.%2BJ.%26aulast%3DNijmeijer%26aufirst%3DB.%2BA.%26aulast%3Dvan%2BDongen%26aufirst%3DJ.%2BJ.%2BM.%26aulast%3DWillemze%26aufirst%3DR.%26aulast%3DFalkenburg%26aufirst%3DJ.%2BH.%2BF.%26atitle%3DInternalization%2520and%2520cell%2520cycle-dependent%2520killing%2520of%2520leukemic%2520cells%2520by%2520gemtuzumab%2520ozogamicin%253A%2520rationale%2520for%2520efficacy%2520in%2520CD33-negative%2520malignancies%2520with%2520endocytic%2520capacity%26jtitle%3DLeukemia%26date%3D2004%26volume%3D18%26spage%3D316%26epage%3D325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Farhat, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reman, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raffoux, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berthon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pautas, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kammoun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chantepie, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rousselot, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chevret, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dombret, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castaigne, S.</span><span> </span><span class="NLM_article-title">Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: A phase 1/2 study of the acute leukemia French association</span> <span class="citation_source-journal">Am. J. Hematol</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">62</span><span class="NLM_x">–</span> <span class="NLM_lpage">65</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1002%2Fajh.22201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=22072535" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1egs77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2012&pages=62-65&author=H.+Farhatauthor=O.+Remanauthor=E.+Raffouxauthor=C.+Berthonauthor=C.+Pautasauthor=L.+Kammounauthor=S.+Chantepieauthor=C.+Gardinauthor=P.+Rousselotauthor=S.+Chevretauthor=H.+Dombretauthor=S.+Castaigne&title=Fractionated+doses+of+gemtuzumab+ozogamicin+with+escalated+doses+of+daunorubicin+and+cytarabine+as+first+acute+myeloid+leukemia+salvage+in+patients+aged+50-70-year+old%3A+A+phase+1%2F2+study+of+the+acute+leukemia+French+association"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: A phase 1/2 study of the acute leukemia French association</span></div><div class="casAuthors">Farhat, Hassan; Reman, Oumedaly; Raffoux, Emmanuel; Berthon, Celine; Pautas, Cecile; Kammoun, Leila; Chantepie, Sylvain; Gardin, Claude; Rousselot, Philippe; Chevret, Sylvie; Dombret, Herve; Castaigne, Sylvie</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Hematology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">62-65</span>CODEN:
                <span class="NLM_cas:coden">AJHEDD</span>;
        ISSN:<span class="NLM_cas:issn">0361-8609</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">This Phase 1/2 study aimed to det. optimal doses of daunorubicin (DNR; mg/m2) and cytarabine (mg/m2) to be combined with fractionated doses of gemtuzumab ozogamicin (GO, Mylotarg; 3 mg/m2 on day 1, 4, and 7) satisfying safety requirements.  Three dose levels of DNR/AraC were investigated namely (45, 100), (60, 100), and (60, 200).  Patients included were acute myeloid leukemia in first relapse, aged 50-70 years.  Hematol. recovery was 31 days for neutrophil and 32 days for platelet counts.  A documented infectious episode > Grade 2 occurred in 11/20 patients (55%).  None of the 20 patients had signs of veno-occlusive disease.  Overall, eleven patients reached complete remission (CR), two CR with incomplete platelets recovery.  The results showed that combination of fractionated GO doses with DNR at 60 mg/m2/d for 3 days and cytarabine at 200 mg/m2/d for 7 days is tolerable and could be further investigated in the front-line therapy.  Am. J. Hematol., 2012. © 2011 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkWuEf9jmMhbVg90H21EOLACvtfcHk0ljQVn4Vf4xsig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1egs77O&md5=c4979646949d3b5309590549b99c91e6</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1002%2Fajh.22201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fajh.22201%26sid%3Dliteratum%253Aachs%26aulast%3DFarhat%26aufirst%3DH.%26aulast%3DReman%26aufirst%3DO.%26aulast%3DRaffoux%26aufirst%3DE.%26aulast%3DBerthon%26aufirst%3DC.%26aulast%3DPautas%26aufirst%3DC.%26aulast%3DKammoun%26aufirst%3DL.%26aulast%3DChantepie%26aufirst%3DS.%26aulast%3DGardin%26aufirst%3DC.%26aulast%3DRousselot%26aufirst%3DP.%26aulast%3DChevret%26aufirst%3DS.%26aulast%3DDombret%26aufirst%3DH.%26aulast%3DCastaigne%26aufirst%3DS.%26atitle%3DFractionated%2520doses%2520of%2520gemtuzumab%2520ozogamicin%2520with%2520escalated%2520doses%2520of%2520daunorubicin%2520and%2520cytarabine%2520as%2520first%2520acute%2520myeloid%2520leukemia%2520salvage%2520in%2520patients%2520aged%252050-70-year%2520old%253A%2520A%2520phase%25201%252F2%2520study%2520of%2520the%2520acute%2520leukemia%2520French%2520association%26jtitle%3DAm.%2520J.%2520Hematol%26date%3D2012%26volume%3D87%26spage%3D62%26epage%3D65" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Taksin, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Legrand, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raffoux, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Revel, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Contentin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouabdallah, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pautas, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turlure, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reman, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varet, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Botton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pousset, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farhat, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chevret, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dombret, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castaigne, S.</span><span> </span><span class="NLM_article-title">High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">66</span><span class="NLM_x">–</span> <span class="NLM_lpage">71</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=66-71&author=A.+L.+Taksinauthor=O.+Legrandauthor=E.+Raffouxauthor=T.+de+Revelauthor=X.+Thomasauthor=N.+Contentinauthor=R.+Bouabdallahauthor=C.+Pautasauthor=P.+Turlureauthor=O.+Remanauthor=C.+Gardinauthor=B.+Varetauthor=S.+de+Bottonauthor=F.+Poussetauthor=H.+Farhatauthor=S.+Chevretauthor=H.+Dombretauthor=S.+Castaigne&title=High+efficacy+and+safety+profile+of+fractionated+doses+of+Mylotarg+as+induction+therapy+in+patients+with+relapsed+acute+myeloblastic+leukemia%3A+a+prospective+study+of+the+alfa+group"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTaksin%26aufirst%3DA.%2BL.%26aulast%3DLegrand%26aufirst%3DO.%26aulast%3DRaffoux%26aufirst%3DE.%26aulast%3Dde%2BRevel%26aufirst%3DT.%26aulast%3DThomas%26aufirst%3DX.%26aulast%3DContentin%26aufirst%3DN.%26aulast%3DBouabdallah%26aufirst%3DR.%26aulast%3DPautas%26aufirst%3DC.%26aulast%3DTurlure%26aufirst%3DP.%26aulast%3DReman%26aufirst%3DO.%26aulast%3DGardin%26aufirst%3DC.%26aulast%3DVaret%26aufirst%3DB.%26aulast%3Dde%2BBotton%26aufirst%3DS.%26aulast%3DPousset%26aufirst%3DF.%26aulast%3DFarhat%26aufirst%3DH.%26aulast%3DChevret%26aufirst%3DS.%26aulast%3DDombret%26aufirst%3DH.%26aulast%3DCastaigne%26aufirst%3DS.%26atitle%3DHigh%2520efficacy%2520and%2520safety%2520profile%2520of%2520fractionated%2520doses%2520of%2520Mylotarg%2520as%2520induction%2520therapy%2520in%2520patients%2520with%2520relapsed%2520acute%2520myeloblastic%2520leukemia%253A%2520a%2520prospective%2520study%2520of%2520the%2520alfa%2520group%26jtitle%3DLeukemia%26date%3D2007%26volume%3D21%26spage%3D66%26epage%3D71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Burnett, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hills, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milligan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kjeldsen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, J. A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstone, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wheatley, K.</span><span> </span><span class="NLM_article-title">Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: Results of the MRC AML15 trial</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">369</span><span class="NLM_x">–</span> <span class="NLM_lpage">377</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1200%2FJCO.2010.31.4310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=21172891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivFWmsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=369-377&author=A.+K.+Burnettauthor=R.+K.+Hillsauthor=D.+Milliganauthor=L.+Kjeldsenauthor=J.+Kellauthor=N.+H.+Russellauthor=J.+A.+L.+Yinauthor=A.+Hunterauthor=A.+H.+Goldstoneauthor=K.+Wheatley&title=Identification+of+patients+with+acute+myeloblastic+leukemia+who+benefit+from+the+addition+of+gemtuzumab+ozogamicin%3A+Results+of+the+MRC+AML15+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial</span></div><div class="casAuthors">Burnett, Alan K.; Hills, Robert K.; Milligan, Donald; Kjeldsen, Lars; Kell, Jonathan; Russell, Nigel H.; Yin, John A. L.; Hunter, Ann; Goldstone, Anthony H.; Wheatley, Keith</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">369-377</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Antibody-directed chemotherapy for acute myeloid leukemia (AML) may permit more treatment to be administered without escalating toxicity.  Gemtuzumab ozogamicin (GO) is an immunoconjugate between CD33 and calicheamicin that is internalized when binding to the epitope.  We previously established that it is feasible to combine GO with conventional chemotherapy.  We now report a large randomized trial testing the addn. of GO to induction and/or consolidation chemotherapy in untreated younger patients.  Patients and Methods In this open-label trial, 1,113 patients, predominantly younger than age 60 years, were randomly assigned to receive a single dose of GO (3 mg/m2) on day 1 of induction course 1 with one of the following three induction schedules: daunorubicin and cytarabine; cytarabine, daunorubicin, and etoposide; or fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin.  In remission, 948 patients were randomly assigned to GO in course 3 in combination with amsacrine, cytarabine, and etoposide or high-dose cytarabine.  The primary end points were response rate and survival.  Results The addn. of GO was well tolerated with no significant increase in toxicity.  There was no overall difference in response or survival in either induction of consolidation.  However, a predefined anal. by cytogenetics showed highly significant interaction with induction GO (P = .001), with significant survival benefit for patients with favorable cytogenetics, no benefit for patients with poor-risk disease, and a trend for benefit in intermediate-risk patients.  An internally validated prognostic index identified approx. 70% of patients with a predicted benefit of 10% in 5-yr survival.  Conclusion A substantial proportion of younger patients with AML have improved survival with the addn. of GO to induction chemotherapy with little addnl. toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreGPpBKujaYLVg90H21EOLACvtfcHk0ljQVn4Vf4xsig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivFWmsrY%253D&md5=908d4ab8c1a9d3ad27fdc397708034d2</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1200%2FJCO.2010.31.4310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2010.31.4310%26sid%3Dliteratum%253Aachs%26aulast%3DBurnett%26aufirst%3DA.%2BK.%26aulast%3DHills%26aufirst%3DR.%2BK.%26aulast%3DMilligan%26aufirst%3DD.%26aulast%3DKjeldsen%26aufirst%3DL.%26aulast%3DKell%26aufirst%3DJ.%26aulast%3DRussell%26aufirst%3DN.%2BH.%26aulast%3DYin%26aufirst%3DJ.%2BA.%2BL.%26aulast%3DHunter%26aufirst%3DA.%26aulast%3DGoldstone%26aufirst%3DA.%2BH.%26aulast%3DWheatley%26aufirst%3DK.%26atitle%3DIdentification%2520of%2520patients%2520with%2520acute%2520myeloblastic%2520leukemia%2520who%2520benefit%2520from%2520the%2520addition%2520of%2520gemtuzumab%2520ozogamicin%253A%2520Results%2520of%2520the%2520MRC%2520AML15%2520trial%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3D369%26epage%3D377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Burnett, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hills, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freeman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kjeldsen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Craddock, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dufva, I. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wheatley, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milligan, D.</span><span> </span><span class="NLM_article-title">Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">3924</span><span class="NLM_x">–</span> <span class="NLM_lpage">3931</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1200%2FJCO.2012.42.2964" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=22851554" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvValtbfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=3924-3931&author=A.+K.+Burnettauthor=N.+H.+Russellauthor=R.+K.+Hillsauthor=J.+Kellauthor=S.+Freemanauthor=L.+Kjeldsenauthor=A.+E.+Hunterauthor=J.+Yinauthor=C.+F.+Craddockauthor=I.+H.+Dufvaauthor=K.+Wheatleyauthor=D.+Milligan&title=Addition+of+gemtuzumab+ozogamicin+to+induction+chemotherapy+improves+survival+in+older+patients+with+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia</span></div><div class="casAuthors">Burnett, Alan K.; Russell, Nigel H.; Hills, Robert K.; Kell, Jonathan; Freeman, Sylvie; Kjeldsen, Lars; Hunter, Ann E.; Yin, John; Craddock, Charles F.; Dufva, Inge Hoegh; Wheatley, Keith; Milligan, Donald</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">3924-3931</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose There has been little survival improvement in older patients with acute myeloid leukemia (AML) in the last two decades.  Improving induction treatment may improve the rate and quality of remission and consequently survival.  In our previous trial, in younger patients, we showed improved survival for the majority of patients when adding gemtuzumab ozogamicin (GO) to induction chemotherapy.  Patients and Methods Untreated patients with AML or high-risk myelodysplastic syndrome (median age, 67 years; range, 51 to 84 years) were randomly assigned to receive induction chemotherapy with either daunorubicin/ara-C or daunorubicin/clofarabine, with (n = 559) or without (n = 556) GO 3 mg/m2 on day 1 of course one of therapy.  The primary end point was overall survival (OS).  Results The overall response rate was 69% (complete remission [CR], 60%; CR with incomplete recovery [CRi], 9%), with no difference between GO (70%) and no GO (68%) arms.  There was no difference in 30- or 60-day mortality and no major increase in toxicity with GO.  With median follow-up of 30 mo (range, 5.5 to 54.6 mo), 3-yr cumulative incidence of relapse was significantly lower with GO (68% v76%; hazard ratio [HR], 0.78; 95% Cl, 0.66 to 0.93; P = .007), and 3-yr survival was significantly better (25% v20%; HR, 0.87; 95% Cl. 0.76 to 1.00; P = .05).  The benefit was apparent across subgroups.  There was no interaction with other treatment interventions.  A meta-anal. of 2,228 patients in two United Kingdom National Cancer Research Institute trials showed significant improvements in relapse (HR, 0.82; 95% Cl, 0.72 to 0.93; P = .002) and OS (HR, 0.88; 95% Cl, 0.79 to 0.98; P = .02).  Conclusion. Adding GO (3 mg/m2) to induction chemotherapy reduces relapse risk and improves survival with little increase in toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqokpkqhoUJ7bVg90H21EOLACvtfcHk0lhTxri6iGYYDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvValtbfM&md5=98d118c9fa65d6d0168c7162997c6681</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.42.2964&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.42.2964%26sid%3Dliteratum%253Aachs%26aulast%3DBurnett%26aufirst%3DA.%2BK.%26aulast%3DRussell%26aufirst%3DN.%2BH.%26aulast%3DHills%26aufirst%3DR.%2BK.%26aulast%3DKell%26aufirst%3DJ.%26aulast%3DFreeman%26aufirst%3DS.%26aulast%3DKjeldsen%26aufirst%3DL.%26aulast%3DHunter%26aufirst%3DA.%2BE.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DCraddock%26aufirst%3DC.%2BF.%26aulast%3DDufva%26aufirst%3DI.%2BH.%26aulast%3DWheatley%26aufirst%3DK.%26aulast%3DMilligan%26aufirst%3DD.%26atitle%3DAddition%2520of%2520gemtuzumab%2520ozogamicin%2520to%2520induction%2520chemotherapy%2520improves%2520survival%2520in%2520older%2520patients%2520with%2520acute%2520myeloid%2520leukemia%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D3924%26epage%3D3931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Castaigne, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pautas, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terre, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raffoux, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bordessoule, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bastie, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Legrand, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turlure, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reman, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Revel, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gastaud, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Gunzburg, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Contentin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henry, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marolleau, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aljijakli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rousselot, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenaux, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preudhomme, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chevret, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dombret, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acute Leukemia French Association</span><span> </span><span class="NLM_article-title">Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">379</span><span class="NLM_x">, </span> <span class="NLM_fpage">1508</span><span class="NLM_x">–</span> <span class="NLM_lpage">1516</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2012&pages=1508-1516&author=S.+Castaigneauthor=C.+Pautasauthor=C.+Terreauthor=E.+Raffouxauthor=D.+Bordessouleauthor=J.+N.+Bastieauthor=O.+Legrandauthor=X.+Thomasauthor=P.+Turlureauthor=O.+Remanauthor=T.+de+Revelauthor=L.+Gastaudauthor=N.+de+Gunzburgauthor=N.+Contentinauthor=E.+Henryauthor=J.+P.+Marolleauauthor=A.+Aljijakliauthor=P.+Rousselotauthor=P.+Fenauxauthor=C.+Preudhommeauthor=S.+Chevretauthor=H.+Dombretauthor=Acute+Leukemia+French+Association&title=Effect+of+gemtuzumab+ozogamicin+on+survival+of+adult+patients+with+de-novo+acute+myeloid+leukaemia+%28ALFA-0701%29%3A+a+randomised%2C+open-label%2C+phase+3+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCastaigne%26aufirst%3DS.%26aulast%3DPautas%26aufirst%3DC.%26aulast%3DTerre%26aufirst%3DC.%26aulast%3DRaffoux%26aufirst%3DE.%26aulast%3DBordessoule%26aufirst%3DD.%26aulast%3DBastie%26aufirst%3DJ.%2BN.%26aulast%3DLegrand%26aufirst%3DO.%26aulast%3DThomas%26aufirst%3DX.%26aulast%3DTurlure%26aufirst%3DP.%26aulast%3DReman%26aufirst%3DO.%26aulast%3Dde%2BRevel%26aufirst%3DT.%26aulast%3DGastaud%26aufirst%3DL.%26aulast%3Dde%2BGunzburg%26aufirst%3DN.%26aulast%3DContentin%26aufirst%3DN.%26aulast%3DHenry%26aufirst%3DE.%26aulast%3DMarolleau%26aufirst%3DJ.%2BP.%26aulast%3DAljijakli%26aufirst%3DA.%26aulast%3DRousselot%26aufirst%3DP.%26aulast%3DFenaux%26aufirst%3DP.%26aulast%3DPreudhomme%26aufirst%3DC.%26aulast%3DChevret%26aufirst%3DS.%26aulast%3DDombret%26aufirst%3DH.%26aulast%3D%26atitle%3DEffect%2520of%2520gemtuzumab%2520ozogamicin%2520on%2520survival%2520of%2520adult%2520patients%2520with%2520de-novo%2520acute%2520myeloid%2520leukaemia%2520%2528ALFA-0701%2529%253A%2520a%2520randomised%252C%2520open-label%252C%2520phase%25203%2520study%26jtitle%3DLancet%26date%3D2012%26volume%3D379%26spage%3D1508%26epage%3D1516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Delaunay, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Recher, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pigneux, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witz, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vey, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanchet, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefebvre, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luquet, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guillerme, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volteau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gyan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lioure, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jourdan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouscary, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guieze, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Randriamalala, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uribe, M. E. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreyfus, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacombe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bene, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cahn, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harousseau, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ifrah, N.</span><span> </span><span class="NLM_article-title">Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation. Results of the GOELAMS AML 2006 IR study</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x">, </span> <span class="NLM_fpage">37</span><span class="NLM_x">–</span> <span class="NLM_lpage">38</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2011&pages=37-38&author=J.+Delaunayauthor=C.+Recherauthor=A.+Pigneuxauthor=F.+Witzauthor=N.+Veyauthor=O.+Blanchetauthor=P.+Lefebvreauthor=I.+Luquetauthor=I.+Guillermeauthor=C.+Volteauauthor=E.+Gyanauthor=B.+Lioureauthor=E.+Jourdanauthor=D.+Bouscaryauthor=R.+Guiezeauthor=E.+Randriamalalaauthor=M.+E.+O.+Uribeauthor=F.+Dreyfusauthor=C.+Lacombeauthor=M.+C.+Beneauthor=J.+Y.+Cahnauthor=J.+L.+Harousseauauthor=N.+Ifrah&title=Addition+of+gemtuzumab+ozogamycin+to+chemotherapy+improves+event-free+survival+but+not+overall+survival+of+AML+patients+with+intermediate+cytogenetics+not+eligible+for+allogeneic+transplantation.+Results+of+the+GOELAMS+AML+2006+IR+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDelaunay%26aufirst%3DJ.%26aulast%3DRecher%26aufirst%3DC.%26aulast%3DPigneux%26aufirst%3DA.%26aulast%3DWitz%26aufirst%3DF.%26aulast%3DVey%26aufirst%3DN.%26aulast%3DBlanchet%26aufirst%3DO.%26aulast%3DLefebvre%26aufirst%3DP.%26aulast%3DLuquet%26aufirst%3DI.%26aulast%3DGuillerme%26aufirst%3DI.%26aulast%3DVolteau%26aufirst%3DC.%26aulast%3DGyan%26aufirst%3DE.%26aulast%3DLioure%26aufirst%3DB.%26aulast%3DJourdan%26aufirst%3DE.%26aulast%3DBouscary%26aufirst%3DD.%26aulast%3DGuieze%26aufirst%3DR.%26aulast%3DRandriamalala%26aufirst%3DE.%26aulast%3DUribe%26aufirst%3DM.%2BE.%2BO.%26aulast%3DDreyfus%26aufirst%3DF.%26aulast%3DLacombe%26aufirst%3DC.%26aulast%3DBene%26aufirst%3DM.%2BC.%26aulast%3DCahn%26aufirst%3DJ.%2BY.%26aulast%3DHarousseau%26aufirst%3DJ.%2BL.%26aulast%3DIfrah%26aufirst%3DN.%26atitle%3DAddition%2520of%2520gemtuzumab%2520ozogamycin%2520to%2520chemotherapy%2520improves%2520event-free%2520survival%2520but%2520not%2520overall%2520survival%2520of%2520AML%2520patients%2520with%2520intermediate%2520cytogenetics%2520not%2520eligible%2520for%2520allogeneic%2520transplantation.%2520Results%2520of%2520the%2520GOELAMS%2520AML%25202006%2520IR%2520study%26jtitle%3DBlood%26date%3D2011%26volume%3D118%26spage%3D37%26epage%3D38" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Sutherland, M. S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffrey, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kostner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sussman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyon, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrington, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klussman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westendorf, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernstein, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benjamin, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drachman, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McEarchern, J. A.</span><span> </span><span class="NLM_article-title">SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">1455</span><span class="NLM_x">–</span> <span class="NLM_lpage">1463</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2013&pages=1455-1463&author=M.+S.+K.+Sutherlandauthor=R.+B.+Walterauthor=S.+C.+Jeffreyauthor=P.+J.+Burkeauthor=C.+P.+Yuauthor=H.+Kostnerauthor=I.+Stoneauthor=M.+C.+Ryanauthor=D.+Sussmanauthor=R.+P.+Lyonauthor=W.+P.+Zengauthor=K.+H.+Harringtonauthor=K.+Klussmanauthor=L.+Westendorfauthor=D.+Meyerauthor=I.+D.+Bernsteinauthor=P.+D.+Senterauthor=D.+R.+Benjaminauthor=J.+G.+Drachmanauthor=J.+A.+McEarchern&title=SGN-CD33A%3A+a+novel+CD33-targeting+antibody-drug+conjugate+using+a+pyrrolobenzodiazepine+dimer+is+active+in+models+of+drug-resistant+AML"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSutherland%26aufirst%3DM.%2BS.%2BK.%26aulast%3DWalter%26aufirst%3DR.%2BB.%26aulast%3DJeffrey%26aufirst%3DS.%2BC.%26aulast%3DBurke%26aufirst%3DP.%2BJ.%26aulast%3DYu%26aufirst%3DC.%2BP.%26aulast%3DKostner%26aufirst%3DH.%26aulast%3DStone%26aufirst%3DI.%26aulast%3DRyan%26aufirst%3DM.%2BC.%26aulast%3DSussman%26aufirst%3DD.%26aulast%3DLyon%26aufirst%3DR.%2BP.%26aulast%3DZeng%26aufirst%3DW.%2BP.%26aulast%3DHarrington%26aufirst%3DK.%2BH.%26aulast%3DKlussman%26aufirst%3DK.%26aulast%3DWestendorf%26aufirst%3DL.%26aulast%3DMeyer%26aufirst%3DD.%26aulast%3DBernstein%26aufirst%3DI.%2BD.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26aulast%3DBenjamin%26aufirst%3DD.%2BR.%26aulast%3DDrachman%26aufirst%3DJ.%2BG.%26aulast%3DMcEarchern%26aufirst%3DJ.%2BA.%26atitle%3DSGN-CD33A%253A%2520a%2520novel%2520CD33-targeting%2520antibody-drug%2520conjugate%2520using%2520a%2520pyrrolobenzodiazepine%2520dimer%2520is%2520active%2520in%2520models%2520of%2520drug-resistant%2520AML%26jtitle%3DBlood%26date%3D2013%26volume%3D122%26spage%3D1455%26epage%3D1463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Bander, N. H.</span><span> </span><span class="NLM_article-title">Antibody–drug conjugate target selection: critical factors</span>. In  <span class="citation_source-book">Methods in Molecular Biology: Antibody–Drug Conjugates</span>; <span class="NLM_contrib-group">Ducry, L.</span>, Ed.; <span class="NLM_publisher-name">Humana Press</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">1045</span>, pp  <span class="NLM_fpage">29</span><span class="NLM_x">–</span> <span class="NLM_lpage">40</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1007%2F978-1-62703-541-5_2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&pages=29-40&author=N.+H.+Banderauthor=L.+Ducry&title=Methods+in+Molecular+Biology%3A+Antibody%E2%80%93Drug+Conjugates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1007%2F978-1-62703-541-5_2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-62703-541-5_2%26sid%3Dliteratum%253Aachs%26aulast%3DBander%26aufirst%3DN.%2BH.%26atitle%3DAntibody%25E2%2580%2593drug%2520conjugate%2520target%2520selection%253A%2520critical%2520factors%26btitle%3DMethods%2520in%2520Molecular%2520Biology%253A%2520Antibody%25E2%2580%2593Drug%2520Conjugates%26aulast%3DDucry%26aufirst%3DL.%26pub%3DHumana%2520Press%26date%3D2013%26volume%3D1045%26spage%3D29%26epage%3D40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Tarli, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balza, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borsi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castellani, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berndorff, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinkelborg, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zardi, L.</span><span> </span><span class="NLM_article-title">A high-affinity human antibody that targets tumoral blood vessels</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">192</span><span class="NLM_x">–</span> <span class="NLM_lpage">198</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1999&pages=192-198&author=L.+Tarliauthor=E.+Balzaauthor=F.+Vitiauthor=L.+Borsiauthor=P.+Castellaniauthor=D.+Berndorffauthor=L.+Dinkelborgauthor=D.+Neriauthor=L.+Zardi&title=A+high-affinity+human+antibody+that+targets+tumoral+blood+vessels"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTarli%26aufirst%3DL.%26aulast%3DBalza%26aufirst%3DE.%26aulast%3DViti%26aufirst%3DF.%26aulast%3DBorsi%26aufirst%3DL.%26aulast%3DCastellani%26aufirst%3DP.%26aulast%3DBerndorff%26aufirst%3DD.%26aulast%3DDinkelborg%26aufirst%3DL.%26aulast%3DNeri%26aufirst%3DD.%26aulast%3DZardi%26aufirst%3DL.%26atitle%3DA%2520high-affinity%2520human%2520antibody%2520that%2520targets%2520tumoral%2520blood%2520vessels%26jtitle%3DBlood%26date%3D1999%26volume%3D94%26spage%3D192%26epage%3D198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Viti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarli, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giovannoni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zardi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, D.</span><span> </span><span class="NLM_article-title">Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">347</span><span class="NLM_x">–</span> <span class="NLM_lpage">352</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1999&pages=347-352&author=F.+Vitiauthor=L.+Tarliauthor=L.+Giovannoniauthor=L.+Zardiauthor=D.+Neri&title=Increased+binding+affinity+and+valence+of+recombinant+antibody+fragments+lead+to+improved+targeting+of+tumoral+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DViti%26aufirst%3DF.%26aulast%3DTarli%26aufirst%3DL.%26aulast%3DGiovannoni%26aufirst%3DL.%26aulast%3DZardi%26aufirst%3DL.%26aulast%3DNeri%26aufirst%3DD.%26atitle%3DIncreased%2520binding%2520affinity%2520and%2520valence%2520of%2520recombinant%2520antibody%2520fragments%2520lead%2520to%2520improved%2520targeting%2520of%2520tumoral%2520angiogenesis%26jtitle%3DCancer%2520Res.%26date%3D1999%26volume%3D59%26spage%3D347%26epage%3D352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Pini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santucci, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carnemolla, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zardi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, D.</span><span> </span><span class="NLM_article-title">Design and use of a phage display library—Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">273</span><span class="NLM_x">, </span> <span class="NLM_fpage">21769</span><span class="NLM_x">–</span> <span class="NLM_lpage">21776</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1998&pages=21769-21776&author=A.+Piniauthor=F.+Vitiauthor=A.+Santucciauthor=B.+Carnemollaauthor=L.+Zardiauthor=P.+Neriauthor=D.+Neri&title=Design+and+use+of+a+phage+display+library%E2%80%94Human+antibodies+with+subnanomolar+affinity+against+a+marker+of+angiogenesis+eluted+from+a+two-dimensional+gel"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPini%26aufirst%3DA.%26aulast%3DViti%26aufirst%3DF.%26aulast%3DSantucci%26aufirst%3DA.%26aulast%3DCarnemolla%26aufirst%3DB.%26aulast%3DZardi%26aufirst%3DL.%26aulast%3DNeri%26aufirst%3DP.%26aulast%3DNeri%26aufirst%3DD.%26atitle%3DDesign%2520and%2520use%2520of%2520a%2520phage%2520display%2520library%25E2%2580%2594Human%2520antibodies%2520with%2520subnanomolar%2520affinity%2520against%2520a%2520marker%2520of%2520angiogenesis%2520eluted%2520from%2520a%2520two-dimensional%2520gel%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1998%26volume%3D273%26spage%3D21769%26epage%3D21776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Villa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trachsel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaspar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schliemann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sommavilla, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rybak, J.-N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rösli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borsi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, D.</span><span> </span><span class="NLM_article-title">A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">2405</span><span class="NLM_x">–</span> <span class="NLM_lpage">2413</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1002%2Fijc.23408" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=18271006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltlaitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2008&pages=2405-2413&author=A.+Villaauthor=E.+Trachselauthor=M.+Kasparauthor=C.+Schliemannauthor=R.+Sommavillaauthor=J.-N.+Rybakauthor=C.+R%C3%B6sliauthor=L.+Borsiauthor=D.+Neri&title=A+high-affinity+human+monoclonal+antibody+specific+to+the+alternatively+spliced+EDA+domain+of+fibronectin+efficiently+targets+tumor+neo-vasculature+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo</span></div><div class="casAuthors">Villa, Alessandra; Trachsel, Eveline; Kaspar, Manuela; Schliemann, Christoph; Sommavilla, Roberto; Rybak, Jascha-N.; Rosli, Christoph; Borsi, Laura; Neri, Dario</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2405-2413</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The alternatively spliced extra-domain B of fibronectin is one of the best characterized markers of tumor angiogenesis.  Similarly, the extra-domain A (EDA), which can also be inserted in the fibronectin transcript by a mechanism of alternative splicing, has been shown to preferentially accumulate around new blood vessels in certain tumors, but this antigen has not been investigated so far as a target for antibody-based biomol. intervention.  We here describe the generation of 3 human monoclonal antibodies (named F8, B7 and D5), which recognize the same epitope of EDA, but which differ in terms of their dissocn. const. to the human antigen (KD = 3.1, 16 and 17 nM, measured for monomeric prepns. of the F8, B7 and D5 antibodies, resp., in recombinant scFv format).  When the 3 antibody fragments were cloned and expressed with a 5 amino acid linker, the 3 resulting homodimeric antibody prepns. displayed comparable tumor: organ ratios in quant. biodistribution studies, performed in immunocompetent 129SvEv mice, bearing s.c. syngeneic F9 murine tumors.  The percent injected dose per g (%ID/g) values in tumors 24 h after i.v. injection were 9.3, 10.2 and 13 for F8, B7 and D5, resp.  The F8 antibody may serve as useful building block for the development of antibody-based targeted anti-cancer therapeutics.  Preclin. and clin. investigations are facilitated by the fact that F8 recognizes the human and mouse antigen with comparable affinity, and by the observation that EDA over-expression is detectable not only in solid tumors, but also in hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCDNzvnkQ667Vg90H21EOLACvtfcHk0liTGsaFTMDgZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltlaitbs%253D&md5=0e5b83f216d9f14026542d56f9c47697</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1002%2Fijc.23408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.23408%26sid%3Dliteratum%253Aachs%26aulast%3DVilla%26aufirst%3DA.%26aulast%3DTrachsel%26aufirst%3DE.%26aulast%3DKaspar%26aufirst%3DM.%26aulast%3DSchliemann%26aufirst%3DC.%26aulast%3DSommavilla%26aufirst%3DR.%26aulast%3DRybak%26aufirst%3DJ.-N.%26aulast%3DR%25C3%25B6sli%26aufirst%3DC.%26aulast%3DBorsi%26aufirst%3DL.%26aulast%3DNeri%26aufirst%3DD.%26atitle%3DA%2520high-affinity%2520human%2520monoclonal%2520antibody%2520specific%2520to%2520the%2520alternatively%2520spliced%2520EDA%2520domain%2520of%2520fibronectin%2520efficiently%2520targets%2520tumor%2520neo-vasculature%2520in%2520vivo%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2008%26volume%3D122%26spage%3D2405%26epage%3D2413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Neri, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bicknell, R.</span><span> </span><span class="NLM_article-title">Tumour vascular targeting</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">436</span><span class="NLM_x">–</span> <span class="NLM_lpage">446</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1038%2Fnrc1627" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=15928674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1Gmsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=436-446&author=D.+Neriauthor=R.+Bicknell&title=Tumour+vascular+targeting"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor vascular targeting</span></div><div class="casAuthors">Neri, Dario; Bicknell, Roy</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">436-446</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  It is now accepted that the growth of solid tumors is dependent on their capacity to acquire a blood supply, and much effort has been directed towards the development of agents (known as anti-angiogenics) that disrupt this process.  More recently, it has become apparent that targeted destruction of the established tumor vasculature is another avenue for exciting therapeutic opportunities.  In this article, we present evidence that vascular targeting is an effective antitumor strategy in animal models, describe strategies for identifying putative tumor vascular targets and discuss future prospects for vascular targeting in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHDz-gycOPj7Vg90H21EOLACvtfcHk0lgWaS-8tFRUXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1Gmsrw%253D&md5=42e0398a709c0158a4dee3437b2b765e</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Fnrc1627&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1627%26sid%3Dliteratum%253Aachs%26aulast%3DNeri%26aufirst%3DD.%26aulast%3DBicknell%26aufirst%3DR.%26atitle%3DTumour%2520vascular%2520targeting%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D436%26epage%3D446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Perrino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steiner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krall, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernardes, G. J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pretto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, D.</span><span> </span><span class="NLM_article-title">Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">2569</span><span class="NLM_x">–</span> <span class="NLM_lpage">2578</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=2569-2578&author=E.+Perrinoauthor=M.+Steinerauthor=N.+Krallauthor=G.+J.+L.+Bernardesauthor=F.+Prettoauthor=G.+Casiauthor=D.+Neri&title=Curative+properties+of+noninternalizing+antibody-drug+conjugates+based+on+maytansinoids"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPerrino%26aufirst%3DE.%26aulast%3DSteiner%26aufirst%3DM.%26aulast%3DKrall%26aufirst%3DN.%26aulast%3DBernardes%26aufirst%3DG.%2BJ.%2BL.%26aulast%3DPretto%26aufirst%3DF.%26aulast%3DCasi%26aufirst%3DG.%26aulast%3DNeri%26aufirst%3DD.%26atitle%3DCurative%2520properties%2520of%2520noninternalizing%2520antibody-drug%2520conjugates%2520based%2520on%2520maytansinoids%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D2569%26epage%3D2578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Bernardes, G. J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trüssel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwager, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheuermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, D.</span><span> </span><span class="NLM_article-title">A traceless vascular-targeting antibody-drug conjugate for cancer therapy</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">941</span><span class="NLM_x">–</span> <span class="NLM_lpage">944</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=941-944&author=G.+J.+L.+Bernardesauthor=G.+Casiauthor=I.+Hartmannauthor=S.+Tr%C3%BCsselauthor=K.+Schwagerauthor=J.+Scheuermannauthor=D.+Neri&title=A+traceless+vascular-targeting+antibody-drug+conjugate+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBernardes%26aufirst%3DG.%2BJ.%2BL.%26aulast%3DCasi%26aufirst%3DG.%26aulast%3DHartmann%26aufirst%3DI.%26aulast%3DTr%25C3%25BCssel%26aufirst%3DS.%26aulast%3DSchwager%26aufirst%3DK.%26aulast%3DScheuermann%26aufirst%3DJ.%26aulast%3DNeri%26aufirst%3DD.%26atitle%3DA%2520traceless%2520vascular-targeting%2520antibody-drug%2520conjugate%2520for%2520cancer%2520therapy%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2012%26volume%3D51%26spage%3D941%26epage%3D944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Krall, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pretto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decurtins, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernardes, G. J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Supuran, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, D.</span><span> </span><span class="NLM_article-title">A small-molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">4231</span><span class="NLM_x">–</span> <span class="NLM_lpage">4235</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1002%2Fanie.201310709" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=24623670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkt1Slu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=4231-4235&author=N.+Krallauthor=F.+Prettoauthor=W.+Decurtinsauthor=G.+J.+L.+Bernardesauthor=C.+T.+Supuranauthor=D.+Neri&title=A+small-molecule+drug+conjugate+for+the+treatment+of+carbonic+anhydrase+IX+expressing+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">A small-molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors</span></div><div class="casAuthors">Krall, Nikolaus; Pretto, Francesca; Decurtins, Willy; Bernardes, Goncalo J. L.; Supuran, Claudiu T.; Neri, Dario</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4231-4235</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Antibody-drug conjugates are a very promising class of new anticancer agents, but the use of small-mol. ligands for the targeted delivery of cytotoxic drugs into solid tumors is less well established.  Here, we describe the first small-mol. drug conjugates for the treatment of carbonic anhydrase IX expressing solid tumors.  Using ligand-dye conjugates we demonstrate that such mols. can preferentially accumulate inside antigen-pos. lesions, have fast targeting kinetics and good tumor-penetrating properties, and are easily accessible by total synthesis.  A disulfide-linked drug conjugate with the maytansinoid DM1 as the cytotoxic payload and a deriv. of acetazolamide as the targeting ligand exhibited a potent antitumor effect in SKRC52 renal cell carcinoma in vivo.  It was furthermore superior to sunitinib and sorafenib, both small-mol. std.-of-care drugs for the treatment of kidney cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAXXWLN4ez_LVg90H21EOLACvtfcHk0lgUZM21XnCAIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkt1Slu7s%253D&md5=77086a5a6f22815497b62470a7a09c6d</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1002%2Fanie.201310709&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201310709%26sid%3Dliteratum%253Aachs%26aulast%3DKrall%26aufirst%3DN.%26aulast%3DPretto%26aufirst%3DF.%26aulast%3DDecurtins%26aufirst%3DW.%26aulast%3DBernardes%26aufirst%3DG.%2BJ.%2BL.%26aulast%3DSupuran%26aufirst%3DC.%2BT.%26aulast%3DNeri%26aufirst%3DD.%26atitle%3DA%2520small-molecule%2520drug%2520conjugate%2520for%2520the%2520treatment%2520of%2520carbonic%2520anhydrase%2520IX%2520expressing%2520tumors%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D4231%26epage%3D4235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Rothberg, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wojtkowiak, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ben-Nun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bogyo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blum, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattingly, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillies, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sloane, B. F.</span><span> </span><span class="NLM_article-title">Acid-mediated tumor proteolysis: Contribution of cysteine cathepsins</span> <span class="citation_source-journal">Neoplasia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1111</span><span class="NLM_x">–</span> <span class="NLM_lpage">1123</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=1111-1123&author=J.+M.+Rothbergauthor=K.+M.+Baileyauthor=J.+W.+Wojtkowiakauthor=Y.+Ben-Nunauthor=M.+Bogyoauthor=E.+Weberauthor=K.+Moinauthor=G.+Blumauthor=R.+R.+Mattinglyauthor=R.+J.+Gilliesauthor=B.+F.+Sloane&title=Acid-mediated+tumor+proteolysis%3A+Contribution+of+cysteine+cathepsins"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRothberg%26aufirst%3DJ.%2BM.%26aulast%3DBailey%26aufirst%3DK.%2BM.%26aulast%3DWojtkowiak%26aufirst%3DJ.%2BW.%26aulast%3DBen-Nun%26aufirst%3DY.%26aulast%3DBogyo%26aufirst%3DM.%26aulast%3DWeber%26aufirst%3DE.%26aulast%3DMoin%26aufirst%3DK.%26aulast%3DBlum%26aufirst%3DG.%26aulast%3DMattingly%26aufirst%3DR.%2BR.%26aulast%3DGillies%26aufirst%3DR.%2BJ.%26aulast%3DSloane%26aufirst%3DB.%2BF.%26atitle%3DAcid-mediated%2520tumor%2520proteolysis%253A%2520Contribution%2520of%2520cysteine%2520cathepsins%26jtitle%3DNeoplasia%26date%3D2013%26volume%3D15%26spage%3D1111%26epage%3D1123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Fuhrmann, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauthier, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leroux, J. C.</span><span> </span><span class="NLM_article-title">Targeting of injectable drug nanocrystals</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1762</span><span class="NLM_x">–</span> <span class="NLM_lpage">1771</span></span><div class="citationLinks">[<a href="/doi/10.1021/mp5001247" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmvF2nu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=1762-1771&author=K.+Fuhrmannauthor=M.+A.+Gauthierauthor=J.+C.+Leroux&title=Targeting+of+injectable+drug+nanocrystals"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting of Injectable Drug Nanocrystals</span></div><div class="casAuthors">Fuhrmann, Kathrin; Gauthier, Marc A.; Leroux, Jean-Christophe</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1762-1771</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  "Nano" drug delivery carriers are established technologies for improving the therapeutic index of chemotherapeutic drugs and overcoming formulation challenges of poorly water-sol. compds.  Two important remaining challenges, however, are the need to formulate drugs on a case-by-case basis (due to the specific chem. of each drug) and the difficulty assocd. with transporting large amts. of drug specifically to the site of the tumor (in part because of moderate to poor drug loadings).  One of the most valuable "nano" opportunities in this field is to address these challenges by creating nanocarriers composed of the drug itself, in the form of so-called nanocrystals.  However, "nano" creates both opportunities and challenges for targeted drug delivery, which are critically discussed in both in vitro and in vivo settings in this contribution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmwlOcCH7PX7Vg90H21EOLACvtfcHk0lhyv0RXAzLahg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmvF2nu7s%253D&md5=88322a39eada4523e770667fd8a50c40</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Fmp5001247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp5001247%26sid%3Dliteratum%253Aachs%26aulast%3DFuhrmann%26aufirst%3DK.%26aulast%3DGauthier%26aufirst%3DM.%2BA.%26aulast%3DLeroux%26aufirst%3DJ.%2BC.%26atitle%3DTargeting%2520of%2520injectable%2520drug%2520nanocrystals%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2014%26volume%3D11%26spage%3D1762%26epage%3D1771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Winter, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoogenboom, H. R.</span><span> </span><span class="NLM_article-title">Making antibodies by phage display technology</span> <span class="citation_source-journal">Annu. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">433</span><span class="NLM_x">–</span> <span class="NLM_lpage">455</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1146%2Fannurev.iy.12.040194.002245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=8011287" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADyaK2cXivFKju7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1994&pages=433-455&author=G.+Winterauthor=A.+D.+Griffithsauthor=R.+E.+Hawkinsauthor=H.+R.+Hoogenboom&title=Making+antibodies+by+phage+display+technology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Making antibodies by phage display technology</span></div><div class="casAuthors">Winter, Greg; Griffiths, Andrew D.; Hawkins, Robert E.; Hoogenboom, Hennie R.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Immunology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">433-55</span>CODEN:
                <span class="NLM_cas:coden">ARIMDU</span>;
        ISSN:<span class="NLM_cas:issn">0732-0582</span>.
    </div><div class="casAbstract">Antibody fragments of predetd. binding specificity have recently been constructed from repertoires of antibody V genes, bypassing hybridoma technol. and even immunization.  The V gene repertoires are harvested from populations of lymphocytes, or assembled in vitro, and cloned for display of assocd. heavy and light chain variable domains on the surface of filamentous bacteriophage.  Rare phage are selected from the repertoire by binding to antigen; sol. antibody fragments are expressed from infected bacteria; and the affinity of binding of selected antibodies is improved by mutation.  The process mimics immune selection, and antibodies with many different binding specificities have been isolated from the same phage repertoire.  Thus, human antibody fragments have been isolated with specificities against both foreign and self antigens, including haptens, carbohydrates, secreted and cell surface proteins, viral coat proteins, and intracellular antigens from the lumen of the endoplasmic reticulum and the nucleus.  Such antibodies have potential as reagents for research and in therapy.  A review with 112 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocC4KWhSvU6bVg90H21EOLACvtfcHk0lhyv0RXAzLahg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXivFKju7g%253D&md5=5fa4f90f05fac0b475cee59772fcd992</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1146%2Fannurev.iy.12.040194.002245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.iy.12.040194.002245%26sid%3Dliteratum%253Aachs%26aulast%3DWinter%26aufirst%3DG.%26aulast%3DGriffiths%26aufirst%3DA.%2BD.%26aulast%3DHawkins%26aufirst%3DR.%2BE.%26aulast%3DHoogenboom%26aufirst%3DH.%2BR.%26atitle%3DMaking%2520antibodies%2520by%2520phage%2520display%2520technology%26jtitle%3DAnnu.%2520Rev.%2520Immunol.%26date%3D1994%26volume%3D12%26spage%3D433%26epage%3D455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Srinivasarao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galliford, C. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Low, P. S.</span><span> </span><span class="NLM_article-title">Principles in the design of ligand-targeted cancer therapeutics and imaging agents</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">203</span><span class="NLM_x">–</span> <span class="NLM_lpage">219</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1038%2Fnrd4519" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=25698644" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtVylsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=203-219&author=M.+Srinivasaraoauthor=C.+V.+Gallifordauthor=P.+S.+Low&title=Principles+in+the+design+of+ligand-targeted+cancer+therapeutics+and+imaging+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Principles in the design of ligand-targeted cancer therapeutics and imaging agents</span></div><div class="casAuthors">Srinivasarao, Madduri; Galliford, Chris V.; Low, Philip S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">203-219</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Most cancer drugs are designed to interfere with one or more events in cell proliferation or survival.  As healthy cells may also need to proliferate and avoid apoptosis, anticancer agents can be toxic to such cells.  To minimize these toxicities, strategies have been developed wherein the therapeutic agent is targeted to tumor cells through conjugation to a tumor-cell-specific small-mol. ligand, thereby reducing delivery to normal cells and the assocd. collateral toxicity.  This Review describes the major principles in the design of ligand-targeted drugs and provides an overview of ligand-drug conjugates and ligand-imaging-agent conjugates that are currently in development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSVpXZcVlh_bVg90H21EOLACvtfcHk0lhyv0RXAzLahg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtVylsb4%253D&md5=71e2e7ad51f7f55415ccddb9ed1ea3db</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1038%2Fnrd4519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4519%26sid%3Dliteratum%253Aachs%26aulast%3DSrinivasarao%26aufirst%3DM.%26aulast%3DGalliford%26aufirst%3DC.%2BV.%26aulast%3DLow%26aufirst%3DP.%2BS.%26atitle%3DPrinciples%2520in%2520the%2520design%2520of%2520ligand-targeted%2520cancer%2520therapeutics%2520and%2520imaging%2520agents%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D203%26epage%3D219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Low, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henne, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doorneweerd, D. D.</span><span> </span><span class="NLM_article-title">Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases</span> <span class="citation_source-journal">Acc. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">120</span><span class="NLM_x">–</span> <span class="NLM_lpage">129</span></span><div class="citationLinks">[<a href="/doi/10.1021/ar7000815" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BD2sXot1Gltbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2008&pages=120-129&author=P.+S.+Lowauthor=W.+A.+Henneauthor=D.+D.+Doorneweerd&title=Discovery+and+development+of+folic-acid-based+receptor+targeting+for+imaging+and+therapy+of+cancer+and+inflammatory+diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Folic-Acid-Based Receptor Targeting for Imaging and Therapy of Cancer and Inflammatory Diseases</span></div><div class="casAuthors">Low, Philip S.; Henne, Walter A.; Doorneweerd, Derek D.</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">120-129</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The field of folic-acid-targeted drug delivery has grown rapidly over the past decade, with several applications currently in human clin. trials.  Owing to the small size of the vitamin, its high affinity for the folate receptor (Kd = 10-10 M), the limited distribution of its receptor in normal tissues (primarily in kidney proximal tubules), the overexpression of its receptor in pathol. cells (upregulated in cancer cells and activated macrophages/monocytes), and its ease of conjugation to imaging and therapeutic agents, the use of folate as a targeting ligand for selective delivery of attached mols. to tumor tissues and sites of inflammation has attracted considerable interest.  This account reviews the discovery of folic acid as a targeting ligand and its current use in the selective targeting of drugs to malignant masses and sites of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpM5t9sRmCOBbVg90H21EOLACvtfcHk0lhii1Al1Ady4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXot1Gltbk%253D&md5=20620eb124d19634b10c27a48ed46849</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Far7000815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far7000815%26sid%3Dliteratum%253Aachs%26aulast%3DLow%26aufirst%3DP.%2BS.%26aulast%3DHenne%26aufirst%3DW.%2BA.%26aulast%3DDoorneweerd%26aufirst%3DD.%2BD.%26atitle%3DDiscovery%2520and%2520development%2520of%2520folic-acid-based%2520receptor%2520targeting%2520for%2520imaging%2520and%2520therapy%2520of%2520cancer%2520and%2520inflammatory%2520diseases%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2008%26volume%3D41%26spage%3D120%26epage%3D129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Hillier, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maresca, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Femia, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marquis, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foss, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmerman, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckelman, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pomper, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joyal, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babich, J. W.</span><span> </span><span class="NLM_article-title">Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">6932</span><span class="NLM_x">–</span> <span class="NLM_lpage">6940</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1158%2F0008-5472.CAN-09-1682" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=19706750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVOmtLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=6932-6940&author=S.+M.+Hillierauthor=K.+P.+Marescaauthor=F.+J.+Femiaauthor=J.+C.+Marquisauthor=C.+A.+Fossauthor=N.+Nguyenauthor=C.+N.+Zimmermanauthor=J.+A.+Barrettauthor=W.+C.+Eckelmanauthor=M.+G.+Pomperauthor=J.+L.+Joyalauthor=J.+W.+Babich&title=Preclinical+evaluation+of+novel+glutamate-urea-lysine+analogues+that+target+prostate-specific+membrane+antigen+as+molecular+imaging+pharmaceuticals+for+prostate+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical Evaluation of Novel Glutamate-Urea-Lysine Analogues That Target Prostate-Specific Membrane Antigen as Molecular Imaging Pharmaceuticals for Prostate Cancer</span></div><div class="casAuthors">Hillier, Shawn M.; Maresca, Kevin P.; Femia, Frank J.; Marquis, John C.; Foss, Catherine A.; Nguyen, Nghi; Zimmerman, Craig N.; Barrett, John A.; Eckelman, William C.; Pomper, Martin G.; Joyal, John L.; Babich, John W.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6932-6940</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Prostate-specific membrane antigen (PSMA) is expressed in normal human prostate epithelium and is highly up-regulated in prostate cancer.  We previously reported a series of novel small mol. inhibitors targeting PSMA.  Two compds., MIP-1072, (S)-2-(3-((S)-1-carboxy-5-(4-iodobenzylamino)pentyl)ureido)pentanedioic acid, and MIP-1095, (S)-2-(3-((S)-1-carboxy-5-(3-(4-iodophenyl)ureido)pentyl)ureido)pentanedioic acid, were selected for further evaluation.  MIP-1072 and MIP-1095 potently inhibited the glutamate carboxypeptidase activity of PSMA (Ki = 4.6 ± 1.6 nM and 0.24 ± 0.14 nM, resp.) and, when radiolabeled with 123I, exhibited high affinity for PSMA on human prostate cancer LNCaP cells (Kd = 3.8 ± 1.3 nM and 0.81 ± 0.39 nM, resp.).  The assocn. of [123I]MIP-1072 and [123I]MIP-1095 with PSMA was specific; there was no binding to human prostate cancer PC3 cells, which lack PSMA, and binding was abolished by coincubation with a structurally unrelated NAALADase inhibitor, 2-(phosphonomethyl)pentanedioic acid (PMPA).  [123I]MIP-1072 and [123I]MIP-1095 internalized into LNCaP cells at 37°C.  Tissue distribution studies in mice showed 17.3 ± 6.3% (at 1 h) and 34.3 ± 12.7% (at 4 h) injected dose per g of LNCaP xenograft tissue, for [123I]MIP-1072 and [123I]MIP-1095, resp.  [123I]MIP-1095 exhibited greater tumor uptake but slower washout from blood and nontarget tissues compared with [123I]MIP-1072.  Specific binding to PSMA in vivo was shown by competition with PMPA in LNCaP xenografts, and the absence of uptake in PC3 xenografts.  The uptake of [123I]MIP-1072 and [123I]MIP-1095 in tumor-bearing mice was corroborated by single-photon emission computed tomog./computed tomog. (SPECT/CT) imaging.  PSMA-specific radiopharmaceuticals should provide a novel mol. targeting option for the detection and staging of prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmETFDEvmsZLVg90H21EOLACvtfcHk0lhii1Al1Ady4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVOmtLzE&md5=f222208c3c3fbcaa376306c49c9ec80b</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-1682&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-1682%26sid%3Dliteratum%253Aachs%26aulast%3DHillier%26aufirst%3DS.%2BM.%26aulast%3DMaresca%26aufirst%3DK.%2BP.%26aulast%3DFemia%26aufirst%3DF.%2BJ.%26aulast%3DMarquis%26aufirst%3DJ.%2BC.%26aulast%3DFoss%26aufirst%3DC.%2BA.%26aulast%3DNguyen%26aufirst%3DN.%26aulast%3DZimmerman%26aufirst%3DC.%2BN.%26aulast%3DBarrett%26aufirst%3DJ.%2BA.%26aulast%3DEckelman%26aufirst%3DW.%2BC.%26aulast%3DPomper%26aufirst%3DM.%2BG.%26aulast%3DJoyal%26aufirst%3DJ.%2BL.%26aulast%3DBabich%26aufirst%3DJ.%2BW.%26atitle%3DPreclinical%2520evaluation%2520of%2520novel%2520glutamate-urea-lysine%2520analogues%2520that%2520target%2520prostate-specific%2520membrane%2520antigen%2520as%2520molecular%2520imaging%2520pharmaceuticals%2520for%2520prostate%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D6932%26epage%3D6940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Vallabhajosula, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nikolopoulou, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babich, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborne, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tagawa, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipai, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solnes, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maresca, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armor, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joyal, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crummet, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stubbs, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, S. J.</span><span> </span><span class="NLM_article-title">Tc-99m-labeled small-molecule inhibitors of prostate-specific membrane antigen: Pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1791</span><span class="NLM_x">–</span> <span class="NLM_lpage">1798</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2014&pages=1791-1798&author=S.+Vallabhajosulaauthor=A.+Nikolopoulouauthor=J.+W.+Babichauthor=J.+R.+Osborneauthor=S.+T.+Tagawaauthor=I.+Lipaiauthor=L.+Solnesauthor=K.+P.+Marescaauthor=T.+Armorauthor=J.+L.+Joyalauthor=R.+Crummetauthor=J.+B.+Stubbsauthor=S.+J.+Goldsmith&title=Tc-99m-labeled+small-molecule+inhibitors+of+prostate-specific+membrane+antigen%3A+Pharmacokinetics+and+biodistribution+studies+in+healthy+subjects+and+patients+with+metastatic+prostate+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVallabhajosula%26aufirst%3DS.%26aulast%3DNikolopoulou%26aufirst%3DA.%26aulast%3DBabich%26aufirst%3DJ.%2BW.%26aulast%3DOsborne%26aufirst%3DJ.%2BR.%26aulast%3DTagawa%26aufirst%3DS.%2BT.%26aulast%3DLipai%26aufirst%3DI.%26aulast%3DSolnes%26aufirst%3DL.%26aulast%3DMaresca%26aufirst%3DK.%2BP.%26aulast%3DArmor%26aufirst%3DT.%26aulast%3DJoyal%26aufirst%3DJ.%2BL.%26aulast%3DCrummet%26aufirst%3DR.%26aulast%3DStubbs%26aufirst%3DJ.%2BB.%26aulast%3DGoldsmith%26aufirst%3DS.%2BJ.%26atitle%3DTc-99m-labeled%2520small-molecule%2520inhibitors%2520of%2520prostate-specific%2520membrane%2520antigen%253A%2520Pharmacokinetics%2520and%2520biodistribution%2520studies%2520in%2520healthy%2520subjects%2520and%2520patients%2520with%2520metastatic%2520prostate%2520cancer%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2014%26volume%3D55%26spage%3D1791%26epage%3D1798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">Hillier, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maresca, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merkin, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marquis, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmerman, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckelman, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joyal, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babich, J. W.</span><span> </span><span class="NLM_article-title">Tc-99m-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1369</span><span class="NLM_x">–</span> <span class="NLM_lpage">1376</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2013&pages=1369-1376&author=S.+M.+Hillierauthor=K.+P.+Marescaauthor=G.+Luauthor=R.+D.+Merkinauthor=J.+C.+Marquisauthor=C.+N.+Zimmermanauthor=W.+C.+Eckelmanauthor=J.+L.+Joyalauthor=J.+W.+Babich&title=Tc-99m-labeled+small-molecule+inhibitors+of+prostate-specific+membrane+antigen+for+molecular+imaging+of+prostate+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHillier%26aufirst%3DS.%2BM.%26aulast%3DMaresca%26aufirst%3DK.%2BP.%26aulast%3DLu%26aufirst%3DG.%26aulast%3DMerkin%26aufirst%3DR.%2BD.%26aulast%3DMarquis%26aufirst%3DJ.%2BC.%26aulast%3DZimmerman%26aufirst%3DC.%2BN.%26aulast%3DEckelman%26aufirst%3DW.%2BC.%26aulast%3DJoyal%26aufirst%3DJ.%2BL.%26aulast%3DBabich%26aufirst%3DJ.%2BW.%26atitle%3DTc-99m-labeled%2520small-molecule%2520inhibitors%2520of%2520prostate-specific%2520membrane%2520antigen%2520for%2520molecular%2520imaging%2520of%2520prostate%2520cancer%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2013%26volume%3D54%26spage%3D1369%26epage%3D1376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Ginj, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waser, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cescato, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wild, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erchegyi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivier, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maecke, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reubi, J. C.</span><span> </span><span class="NLM_article-title">Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">16436</span><span class="NLM_x">–</span> <span class="NLM_lpage">16441</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1073%2Fpnas.0607761103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=17056720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1WmsLjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=16436-16441&author=M.+Ginjauthor=H.+Zhangauthor=B.+Waserauthor=R.+Cescatoauthor=D.+Wildauthor=X.+Wangauthor=J.+Erchegyiauthor=J.+Rivierauthor=H.+R.+Maeckeauthor=J.+C.+Reubi&title=Radiolabeled+somatostatin+receptor+antagonists+are+preferable+to+agonists+for+in+vivo+peptide+receptor+targeting+of+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors</span></div><div class="casAuthors">Ginj, Mihaela; Zhang, Hanwen; Waser, Beatrice; Cescato, Renzo; Wild, Damian; Wang, Xuejuan; Erchegyi, Judit; Rivier, Jean; Macke, Helmut R.; Reubi, Jean Claude</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">16436-16441</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Targeting neuroendocrine tumors expressing somatostatin receptor subtypes (sst) with radiolabeled somatostatin agonists is an established diagnostic and therapeutic approach in oncol.  While agonists readily internalize into tumor cells, permitting accumulation of radioactivity, radiolabeled antagonists do not, and they have not been considered for tumor targeting.  The macrocyclic chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) was coupled to two potent somatostatin receptor-selective peptide antagonists [NH2-CO-c(DCys-Phe-Tyr-DAgl8(Me,2-naphthoyl)-Lys-Thr-Phe-Cys)-OH (sst3-ODN-8) and a sst2-selective antagonist (sst2-ANT)], for labeling with 111/natIn.  111Ln-DOTA-sst3-ODN-8 and 111/natIn-DOTA-[4-NO2-Phe-c(DCys-Tyr-DTrp-Lys-Thr-Cys)-DTyr-NH2] (111/natIn-DOTA-sst2-ANT) showed high sst3- and sst2-binding affinity, resp.  They did not trigger sst3 or sst2 internalization but prevented agonist-stimulated internalization.  111In-DOTA-sst3-ODN-8 and 111In-DOTA-sst2-ANT were injected i.v. into mice bearing sst3- and sst2-expressing tumors, and their biodistribution was monitored.  In the sst3-expressing tumors, strong accumulation of 111In-DOTA-sst3-ODN-8 was obsd., peaking at 1 h with 60% injected radioactivity per g of tissue and remaining at a high level for >72 h.  Excess of sst3-ODN-8 blocked uptake.  As a control, the potent agonist 111In-DOTA-[1-Nal3]-octreotide, with strong sst3-binding and internalization properties showed a much lower and shorter-lasting uptake in sst3-expressing tumors.  Similarly, 111In-DOTA-sst2-ANT was injected into mice bearing sst2-expressing tumors.  Tumor uptake was considerably higher than with the highly potent sst2-selective agonist 111In-diethylenetriaminepentaacetic acid-[Tyr3,Thr8]-octreotide (111In-DTPA-TATE).  Scatchard plots showed that antagonists labeled many more sites than agonists.  Somatostatin antagonist radiotracers therefore are preferable over agonists for the in vivo targeting of sst3- or sst2-expressing tumors.  Antagonist radioligands for other peptide receptors need to be evaluated in nuclear oncol. as a result of this paradigm shift.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQVLwhowXQV7Vg90H21EOLACvtfcHk0limOT8tk-H5Kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1WmsLjJ&md5=7cc5c4608ed7591a096b9514863bbdea</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0607761103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0607761103%26sid%3Dliteratum%253Aachs%26aulast%3DGinj%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWaser%26aufirst%3DB.%26aulast%3DCescato%26aufirst%3DR.%26aulast%3DWild%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DErchegyi%26aufirst%3DJ.%26aulast%3DRivier%26aufirst%3DJ.%26aulast%3DMaecke%26aufirst%3DH.%2BR.%26aulast%3DReubi%26aufirst%3DJ.%2BC.%26atitle%3DRadiolabeled%2520somatostatin%2520receptor%2520antagonists%2520are%2520preferable%2520to%2520agonists%2520for%2520in%2520vivo%2520peptide%2520receptor%2520targeting%2520of%2520tumors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2006%26volume%3D103%26spage%3D16436%26epage%3D16441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group">Neri, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Supuran, C. T.</span><span> </span><span class="NLM_article-title">Interfering with pH regulation in tumours as a therapeutic strategy</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">767</span><span class="NLM_x">–</span> <span class="NLM_lpage">777</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1038%2Fnrd3554" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=21921921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFOlsL7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=767-777&author=D.+Neriauthor=C.+T.+Supuran&title=Interfering+with+pH+regulation+in+tumours+as+a+therapeutic+strategy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Interfering with pH regulation in tumours as a therapeutic strategy</span></div><div class="casAuthors">Neri, Dario; Supuran, Claudiu T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">767-777</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The high metabolic rate of tumors often leads to acidosis and hypoxia in poorly perfused regions.  Tumor cells have thus evolved the ability to function in a more acidic environment than normal cells.  Key pH regulators in tumor cells include: isoforms 2, 9 and 12 of carbonic anhydrase, isoforms of anion exchangers, Na+/HCO3- co-transporters, Na+/H+ exchangers, monocarboxylate transporters and the vacuolar ATPase.  Both small mols. and antibodies targeting these pH regulators are currently at various stages of clin. development.  These antitumor mechanisms are not exploited by the classical cancer drugs and therefore represent a new anticancer drug discovery strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrl7enRfSHzprVg90H21EOLACvtfcHk0limOT8tk-H5Kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFOlsL7L&md5=7a1e1b7badcf7d2e26bd70da2bfe0925</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1038%2Fnrd3554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3554%26sid%3Dliteratum%253Aachs%26aulast%3DNeri%26aufirst%3DD.%26aulast%3DSupuran%26aufirst%3DC.%2BT.%26atitle%3DInterfering%2520with%2520pH%2520regulation%2520in%2520tumours%2520as%2520a%2520therapeutic%2520strategy%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D767%26epage%3D777" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group">Krall, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pretto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, D.</span><span> </span><span class="NLM_article-title">A bivalent small molecule-drug conjugate directed against carbonic anhydrase IX can elicit complete tumour regression in mice</span> <span class="citation_source-journal">Chem. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">3640</span><span class="NLM_x">–</span> <span class="NLM_lpage">3644</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1039%2FC4SC00685B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFSgs7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=3640-3644&author=N.+Krallauthor=F.+Prettoauthor=D.+Neri&title=A+bivalent+small+molecule-drug+conjugate+directed+against+carbonic+anhydrase+IX+can+elicit+complete+tumour+regression+in+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">A bivalent small molecule-drug conjugate directed against carbonic anhydrase IX can elicit complete tumour regression in mice</span></div><div class="casAuthors">Krall, N.; Pretto, F.; Neri, D.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3640-3644</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">There is a pressing need for the development of innovative chem. drug delivery strategies in oncol., since conventional chemotherapeutic agents typically do not localize to solid tumors in vivo.  It is widely accepted that bivalent antibody formats accumulate in tumors more strongly than monovalent ones and that they should thus be preferred for antibody-based drug delivery approaches.  For small mol.-drug conjugates this is less clear.  Here, the authors show that a bivalent ligand against the tumor marker carbonic anhydrase IX leads to an improved tumor-targeting performance compared with the corresponding monovalent counterpart in the SKRC52 model of constitutively CAIX-pos. renal cell carcinoma.  A bivalent disulfide-linked small drug conjugate with the potent cytotoxic maytansinoid DM1 as the payload can mediate complete eradication of the same tumors, which are resistant to std.-of-care therapeutics, in a proportion of treated mice.  In the A375 melanoma model, which preferentially expresses CAIX at sites distant to blood vessels, no measurable tumor accumulation could be obsd.  The authors' results suggest that the use of bivalent small mol. ligand-drug conjugates against CAIX may represent an attractive chem. strategy for the treatment of constitutively CAIX-pos. kidney cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZslzjAAno7rVg90H21EOLACvtfcHk0limOT8tk-H5Kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFSgs7fL&md5=87c92eed915589fd3c8c9f4bfebdb5e0</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1039%2FC4SC00685B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4SC00685B%26sid%3Dliteratum%253Aachs%26aulast%3DKrall%26aufirst%3DN.%26aulast%3DPretto%26aufirst%3DF.%26aulast%3DNeri%26aufirst%3DD.%26atitle%3DA%2520bivalent%2520small%2520molecule-drug%2520conjugate%2520directed%2520against%2520carbonic%2520anhydrase%2520IX%2520can%2520elicit%2520complete%2520tumour%2520regression%2520in%2520mice%26jtitle%3DChem.%2520Sci.%26date%3D2014%26volume%3D5%26spage%3D3640%26epage%3D3644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group">Wichert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krall, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decurtins, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franzini, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pretto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheuermann, J.</span><span> </span><span class="NLM_article-title">Dual-display of small molecules enables the discovery of ligand pairs and facilitates affinity maturation</span> <span class="citation_source-journal">Nat. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">241</span><span class="NLM_x">–</span> <span class="NLM_lpage">249</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1038%2Fnchem.2158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=25698334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFSgtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=241-249&author=M.+Wichertauthor=N.+Krallauthor=W.+Decurtinsauthor=R.+M.+Franziniauthor=F.+Prettoauthor=P.+Schneiderauthor=D.+Neriauthor=J.+Scheuermann&title=Dual-display+of+small+molecules+enables+the+discovery+of+ligand+pairs+and+facilitates+affinity+maturation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-display of small molecules enables the discovery of ligand pairs and facilitates affinity maturation</span></div><div class="casAuthors">Wichert, Moreno; Krall, Nikolaus; Decurtins, Willy; Franzini, Raphael M.; Pretto, Francesca; Schneider, Petra; Neri, Dario; Scheuermann, Jorg</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">241-249</span>CODEN:
                <span class="NLM_cas:coden">NCAHBB</span>;
        ISSN:<span class="NLM_cas:issn">1755-4330</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In contrast to std. fragment-based drug discovery approaches, dual-display DNA-encoded chem. libraries have the potential to identify fragment pairs that bind simultaneously and benefit from the chelate effect.  However, the technol. has been limited by the difficulty in unambiguously decoding the ligand pairs from large combinatorial libraries.  Here we report a strategy that overcomes this limitation and enables the efficient identification of ligand pairs that bind to a target protein.  Small org. mols. were conjugated to the 5' and 3' ends of complementary DNA strands that contain a unique identifying code.  DNA hybridization followed by an inter-strand code-transfer created a stable dual-display DNA-encoded chem. library of 111,100 members.  Using this approach we report the discovery of a low micromolar binder to alpha-1-acid glycoprotein and the affinity maturation of a ligand to carbonic anhydrase IX, an established marker of renal cell carcinoma.  The newly discovered subnanomolar carbonic anhydrase IX binder dramatically improved tumor targeting performance in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUqxl8F6d-3LVg90H21EOLACvtfcHk0limOT8tk-H5Kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFSgtr4%253D&md5=760dcbd3bb22f0f2affa980b3df3286b</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1038%2Fnchem.2158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchem.2158%26sid%3Dliteratum%253Aachs%26aulast%3DWichert%26aufirst%3DM.%26aulast%3DKrall%26aufirst%3DN.%26aulast%3DDecurtins%26aufirst%3DW.%26aulast%3DFranzini%26aufirst%3DR.%2BM.%26aulast%3DPretto%26aufirst%3DF.%26aulast%3DSchneider%26aufirst%3DP.%26aulast%3DNeri%26aufirst%3DD.%26aulast%3DScheuermann%26aufirst%3DJ.%26atitle%3DDual-display%2520of%2520small%2520molecules%2520enables%2520the%2520discovery%2520of%2520ligand%2520pairs%2520and%2520facilitates%2520affinity%2520maturation%26jtitle%3DNat.%2520Chem.%26date%3D2015%26volume%3D7%26spage%3D241%26epage%3D249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group">Doss, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolb, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mocharla, V. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alpaugh, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D. Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J. Q.</span><span> </span><span class="NLM_article-title">Biodistribution and radiation dosimetry of the carbonic anhydrase IX imaging agent [(18) F]VM4-037 determined from PET/CT scans in healthy volunteers</span> <span class="citation_source-journal">Mol. Imaging Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">739</span><span class="NLM_x">–</span> <span class="NLM_lpage">746</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1007%2Fs11307-014-0730-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=24696183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A280%3ADC%252BC2cngtVSnuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2014&pages=739-746&author=M.+Dossauthor=H.+C.+Kolbauthor=J.+C.+Walshauthor=V.+P.+Mocharlaauthor=Z.+H.+Zhuauthor=M.+Hakaauthor=R.+K.+Alpaughauthor=D.+Y.+T.+Chenauthor=J.+Q.+Yu&title=Biodistribution+and+radiation+dosimetry+of+the+carbonic+anhydrase+IX+imaging+agent+%5B%2818%29+F%5DVM4-037+determined+from+PET%2FCT+scans+in+healthy+volunteers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Biodistribution and radiation dosimetry of the carbonic anhydrase IX imaging agent [(18) F]VM4-037 determined from PET/CT scans in healthy volunteers</span></div><div class="casAuthors">Doss Mohan; Kolb Hartmuth C; Walsh Joseph C; Mocharla Vani P; Zhu Zhihong; Haka Michael; Alpaugh R Katherine; Chen David Y T; Yu Jian Q</div><div class="citationInfo"><span class="NLM_cas:title">Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">739-46</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  [(18) F]VM4-037 has been developed as a positron emission tomography (PET) imaging marker to detect carbonic anhydrase IX (CA-IX) overexpression and is being investigated for use as a surrogate marker for tissue hypoxia.  The purpose of this study was to determine the biodistribution and estimate the radiation dose from [(18) F]VM4-037 using whole-body PET/CT scans in healthy human volunteers.  PROCEDURES:  Successive whole-body PET/CT scans were performed after intravenous injection of [(18) F]VM4-037 in four healthy humans.  The radiotracer uptakes in different organs were determined from the analysis of the PET scans.  Human radiation doses were estimated using OLINDA/EXM software.  RESULTS:  High uptake of [(18) F]VM4-037 was observed in the liver and kidneys, with little clearance of activity during the study period, with mean standardized uptake values of ~35 in liver and ~22 in kidneys at ~1 h after injection.  The estimated effective dose was 28 ± 1 μSv/MBq and the absorbed doses for the kidneys and liver were 273 ± 31 and 240 ± 68 μGy/MBq, respectively, for the adult male phantom.  Hence, the effective dose would be 10 ± 0.5 mSv for the anticipated injected activity of 370 MBq, and the kidney and liver doses would be 101 ± 11 and 89 ± 25 mGy, respectively.  CONCLUSIONS:  [(18) F]VM4-037 displayed very high uptake in the liver and kidneys with little clearance of activity during the study period, resulting in these organs receiving the highest radiation doses among all bodily organs.  Though the effective dose and the organ doses are within the limits considered as safe, the enhanced uptake of [(18) F]VM4-037 in the kidneys and liver will make the compound unsuitable for imaging overexpression of CA-IX in those two organs.  However, the tracer may be suitable for imaging overexpression of CA-IX in lesions in other regions of the body such as in the lungs or head and neck region.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQn4Ys9iwIVwSEJCPKhJPuqfW6udTcc2eY-0fDROdRu8bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cngtVSnuw%253D%253D&md5=f7a58fc6b3cbdc1ae4658d91f4dbfdbd</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1007%2Fs11307-014-0730-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11307-014-0730-7%26sid%3Dliteratum%253Aachs%26aulast%3DDoss%26aufirst%3DM.%26aulast%3DKolb%26aufirst%3DH.%2BC.%26aulast%3DWalsh%26aufirst%3DJ.%2BC.%26aulast%3DMocharla%26aufirst%3DV.%2BP.%26aulast%3DZhu%26aufirst%3DZ.%2BH.%26aulast%3DHaka%26aufirst%3DM.%26aulast%3DAlpaugh%26aufirst%3DR.%2BK.%26aulast%3DChen%26aufirst%3DD.%2BY.%2BT.%26aulast%3DYu%26aufirst%3DJ.%2BQ.%26atitle%3DBiodistribution%2520and%2520radiation%2520dosimetry%2520of%2520the%2520carbonic%2520anhydrase%2520IX%2520imaging%2520agent%2520%255B%252818%2529%2520F%255DVM4-037%2520determined%2520from%2520PET%252FCT%2520scans%2520in%2520healthy%2520volunteers%26jtitle%3DMol.%2520Imaging%2520Biol.%26date%3D2014%26volume%3D16%26spage%3D739%26epage%3D746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group">Lepenies, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sonkaria, S.</span><span> </span><span class="NLM_article-title">Targeting C-type lectin receptors with multivalent carbohydrate ligands</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">1271</span><span class="NLM_x">–</span> <span class="NLM_lpage">1281</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=1271-1281&author=B.+Lepeniesauthor=J.+Leeauthor=S.+Sonkaria&title=Targeting+C-type+lectin+receptors+with+multivalent+carbohydrate+ligands"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLepenies%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DSonkaria%26aufirst%3DS.%26atitle%3DTargeting%2520C-type%2520lectin%2520receptors%2520with%2520multivalent%2520carbohydrate%2520ligands%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2013%26volume%3D65%26spage%3D1271%26epage%3D1281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group">Chittasupho, C.</span><span> </span><span class="NLM_article-title">Multivalent ligand: design principle for targeted therapeutic delivery approach</span> <span class="citation_source-journal">Ther. Delivery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1171</span><span class="NLM_x">–</span> <span class="NLM_lpage">1187</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.4155%2Ftde.12.99" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=23116010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFCrurbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=1171-1187&author=C.+Chittasupho&title=Multivalent+ligand%3A+design+principle+for+targeted+therapeutic+delivery+approach"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Multivalent ligand: design principle for targeted therapeutic delivery approach</span></div><div class="casAuthors">Chittasupho, Chuda</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Delivery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1171-1187</span>CODEN:
                <span class="NLM_cas:coden">TDHEA7</span>;
        ISSN:<span class="NLM_cas:issn">2041-5990</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Multivalent interactions of biol. mols. play an important role in many biochem. events.  A multivalent ligand comprises of multiple copies of ligands conjugated to scaffolds, allowing the simultaneous binding of multivalent ligands to multiple binding sites or receptors.  Many research groups have successfully designed and synthesized multivalent ligands to increase the binding affinity, avidity and specificity of the ligand to the receptor.  A multimeric ligand is a promising option for the specific treatment of diseases.  In this review, the factors affecting multivalent interactions, including the size and shape of the ligand, geometry and an arrangement of ligands on the scaffold, linker length, thermodn., and kinetics of the interactions are discussed.  Examples of the multivalent ligand applications for therapeutic delivery are also summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWWDU1KszkuLVg90H21EOLACvtfcHk0lhKx6aFD6w_LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFCrurbJ&md5=0b30d1d1675cfb7bbdc38dfbf7168b7e</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.4155%2Ftde.12.99&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ftde.12.99%26sid%3Dliteratum%253Aachs%26aulast%3DChittasupho%26aufirst%3DC.%26atitle%3DMultivalent%2520ligand%253A%2520design%2520principle%2520for%2520targeted%2520therapeutic%2520delivery%2520approach%26jtitle%3DTher.%2520Delivery%26date%3D2012%26volume%3D3%26spage%3D1171%26epage%3D1187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group">Guillemard, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nedev, H. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berezov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murali, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saragovi, H. U.</span><span> </span><span class="NLM_article-title">HER2-mediated internalization of a targeted prodrug cytotoxic conjugate is dependent on the valency of the targeting ligand</span> <span class="citation_source-journal">DNA Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">350</span><span class="NLM_x">–</span> <span class="NLM_lpage">358</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2005&pages=350-358&author=V.+Guillemardauthor=H.+N.+Nedevauthor=A.+Berezovauthor=R.+Muraliauthor=H.+U.+Saragovi&title=HER2-mediated+internalization+of+a+targeted+prodrug+cytotoxic+conjugate+is+dependent+on+the+valency+of+the+targeting+ligand"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGuillemard%26aufirst%3DV.%26aulast%3DNedev%26aufirst%3DH.%2BN.%26aulast%3DBerezov%26aufirst%3DA.%26aulast%3DMurali%26aufirst%3DR.%26aulast%3DSaragovi%26aufirst%3DH.%2BU.%26atitle%3DHER2-mediated%2520internalization%2520of%2520a%2520targeted%2520prodrug%2520cytotoxic%2520conjugate%2520is%2520dependent%2520on%2520the%2520valency%2520of%2520the%2520targeting%2520ligand%26jtitle%3DDNA%2520Cell%2520Biol.%26date%3D2005%26volume%3D24%26spage%3D350%26epage%3D358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group">Daguer, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zambaldo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciobanu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morieux, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barluenga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winssinger, N.</span><span> </span><span class="NLM_article-title">DNA display of fragment pairs as a tool for the discovery of novel biologically active small molecules</span> <span class="citation_source-journal">Chem. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">739</span><span class="NLM_x">–</span> <span class="NLM_lpage">744</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1039%2FC4SC01654H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=30154995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFyhu73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=739-744&author=J.+P.+Daguerauthor=C.+Zambaldoauthor=M.+Ciobanuauthor=P.+Morieuxauthor=S.+Barluengaauthor=N.+Winssinger&title=DNA+display+of+fragment+pairs+as+a+tool+for+the+discovery+of+novel+biologically+active+small+molecules"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">DNA display of fragment pairs as a tool for the discovery of novel biologically active small molecules</span></div><div class="casAuthors">Daguer, J.-P.; Zambaldo, C.; Ciobanu, M.; Morieux, P.; Barluenga, S.; Winssinger, N.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">739-744</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Fragment-based lead discovery has proven to be a powerful method in the drug discovery process.  The combinatorial output that is accessible by combining fragments is very attractive; however, identifying fragment pairs that bind synergistically and linking them productively can be challenging.  Several technologies have now been established to prep. and screen nucleic acid-encoded libraries (ssDNA, dsDNA, PNA), and it has been shown that pairs of mols. combined by hybridization can bind synergistically to a target.  Herein we apply this concept to combinatorially pair two libraries of small mol. fragments, use the fittest fragments supplemented with closely related analogs to build a focused library covalently linking the fragments with different spacers, and apply this strategy to the discovery of a potent ligand for Hsp70.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhgZK31sH7tLVg90H21EOLACvtfcHk0lj_KBgPU0FyQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFyhu73I&md5=98216526b528a7fb92d3d5759f215bb3</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1039%2FC4SC01654H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4SC01654H%26sid%3Dliteratum%253Aachs%26aulast%3DDaguer%26aufirst%3DJ.%2BP.%26aulast%3DZambaldo%26aufirst%3DC.%26aulast%3DCiobanu%26aufirst%3DM.%26aulast%3DMorieux%26aufirst%3DP.%26aulast%3DBarluenga%26aufirst%3DS.%26aulast%3DWinssinger%26aufirst%3DN.%26atitle%3DDNA%2520display%2520of%2520fragment%2520pairs%2520as%2520a%2520tool%2520for%2520the%2520discovery%2520of%2520novel%2520biologically%2520active%2520small%2520molecules%26jtitle%3DChem.%2520Sci.%26date%3D2015%26volume%3D6%26spage%3D739%26epage%3D744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group">Franzini, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheuermann, J.</span><span> </span><span class="NLM_article-title">DNA-encoded chemical libraries: Advancing beyond conventional small-molecule libraries</span> <span class="citation_source-journal">Acc. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1247</span><span class="NLM_x">–</span> <span class="NLM_lpage">1255</span></span><div class="citationLinks">[<a href="/doi/10.1021/ar400284t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltF2ls7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2014&pages=1247-1255&author=R.+M.+Franziniauthor=D.+Neriauthor=J.+Scheuermann&title=DNA-encoded+chemical+libraries%3A+Advancing+beyond+conventional+small-molecule+libraries"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">DNA-Encoded Chemical Libraries: Advancing beyond Conventional Small-Molecule Libraries</span></div><div class="casAuthors">Franzini, Raphael M.; Neri, Dario; Scheuermann, Jorg</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1247-1255</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  DNA-encoded chem. libraries (DECLs) represent a promising tool in drug discovery.  DECL technol. allows the synthesis and screening of chem. libraries of unprecedented size at moderate costs.  In analogy to phage-display technol., where large antibody libraries are displayed on the surface of filamentous phage and are genetically encoded in the phage genome, DECLs feature the display of individual small org. chem. moieties on DNA fragments serving as amplifiable identification barcodes.  The DNA-tag facilitates the synthesis and allows the simultaneous screening of very large sets of compds. (up to billions of mols.), because the hit compds. can easily be identified and quantified by PCR-amplification of the DNA-barcode followed by high-throughput DNA sequencing.  Several approaches have been used to generate DECLs, differing both in the methods used for library encoding and for the combinatorial assembly of chem. moieties.  For example, DECLs can be used for fragment-based drug discovery, displaying a single mol. on DNA or two chem. moieties at the extremities of complementary DNA strands.  DECLs can vary substantially in the chem. structures and the library size.  While ultralarge libraries contg. billions of compds. have been reported contg. four or more sets of building blocks, also smaller libraries have been shown to be efficient for ligand discovery.  In general, it has been found that the overall library size is a poor predictor for library performance and that the no. and diversity of the building blocks are rather important indicators.  Smaller libraries consisting of two to three sets of building blocks better fulfill the criteria of drug-likeness and often have higher quality.  In this Account, we present advances in the DECL field from proof-of-principle studies to practical applications for drug discovery, both in industry and in academia.  DECL technol. can yield specific binders to a variety of target proteins and is likely to become a std. tool for pharmaceutical hit discovery, lead expansion, and Chem. Biol. research.  The introduction of new methodologies for library encoding and for compd. synthesis in the presence of DNA is an exciting research field and will crucially contribute to the performance and the propagation of the technol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcaCmssNgPLLVg90H21EOLACvtfcHk0lj_KBgPU0FyQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltF2ls7g%253D&md5=c37bd1625b668e869fcc26d5ef0a017a</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Far400284t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far400284t%26sid%3Dliteratum%253Aachs%26aulast%3DFranzini%26aufirst%3DR.%2BM.%26aulast%3DNeri%26aufirst%3DD.%26aulast%3DScheuermann%26aufirst%3DJ.%26atitle%3DDNA-encoded%2520chemical%2520libraries%253A%2520Advancing%2520beyond%2520conventional%2520small-molecule%2520libraries%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2014%26volume%3D47%26spage%3D1247%26epage%3D1255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group">Chan, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGregor, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D. R.</span><span> </span><span class="NLM_article-title">Novel selection methods for DNA-encoded chemical libraries</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">26C</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">61</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1016%2Fj.cbpa.2015.02.010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26C&publication_year=2015&pages=55-61&author=A.+I.+Chanauthor=L.+M.+McGregorauthor=D.+R.+Liu&title=Novel+selection+methods+for+DNA-encoded+chemical+libraries"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2015.02.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2015.02.010%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DA.%2BI.%26aulast%3DMcGregor%26aufirst%3DL.%2BM.%26aulast%3DLiu%26aufirst%3DD.%2BR.%26atitle%3DNovel%2520selection%2520methods%2520for%2520DNA-encoded%2520chemical%2520libraries%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2015%26volume%3D26C%26spage%3D55%26epage%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group">Morioka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loik, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hipolito, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suga, H.</span><span> </span><span class="NLM_article-title">Selection-based discovery of macrocyclic peptides for the next generation therapeutics</span> <span class="citation_source-journal">Curr. Opin Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">26C</span><span class="NLM_x">, </span> <span class="NLM_fpage">34</span><span class="NLM_x">–</span> <span class="NLM_lpage">41</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1016%2Fj.cbpa.2015.01.023" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26C&publication_year=2015&pages=34-41&author=T.+Moriokaauthor=N.+D.+Loikauthor=C.+J.+Hipolitoauthor=Y.+Gotoauthor=H.+Suga&title=Selection-based+discovery+of+macrocyclic+peptides+for+the+next+generation+therapeutics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2015.01.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2015.01.023%26sid%3Dliteratum%253Aachs%26aulast%3DMorioka%26aufirst%3DT.%26aulast%3DLoik%26aufirst%3DN.%2BD.%26aulast%3DHipolito%26aufirst%3DC.%2BJ.%26aulast%3DGoto%26aufirst%3DY.%26aulast%3DSuga%26aufirst%3DH.%26atitle%3DSelection-based%2520discovery%2520of%2520macrocyclic%2520peptides%2520for%2520the%2520next%2520generation%2520therapeutics%26jtitle%3DCurr.%2520Opin%2520Chem.%2520Biol.%26date%3D2015%26volume%3D26C%26spage%3D34%26epage%3D41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group">Heinis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutherford, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freund, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winter, G.</span><span> </span><span class="NLM_article-title">Phage-encoded combinatorial chemical libraries based on bicyclic peptides</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">502</span><span class="NLM_x">–</span> <span class="NLM_lpage">507</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1038%2Fnchembio.184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=19483697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BD1MXms1altbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=502-507&author=C.+Heinisauthor=T.+Rutherfordauthor=S.+Freundauthor=G.+Winter&title=Phage-encoded+combinatorial+chemical+libraries+based+on+bicyclic+peptides"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Phage-encoded combinatorial chemical libraries based on bicyclic peptides</span></div><div class="casAuthors">Heinis, Christian; Rutherford, Trevor; Freund, Stephan; Winter, Greg</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">502-507</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here we describe a phage strategy for the selection of ligands based on bicyclic or linear peptides attached covalently to an org. core.  We designed peptide repertoires with three reactive cysteine residues, each spaced apart by several random amino acid residues, and we fused the repertoires to the phage gene-3-protein.  Conjugation with tris-(bromomethyl)benzene via the reactive cysteines generated repertoires of peptide conjugates with two peptide loops anchored to a mesitylene core.  Iterative affinity selections yielded several enzyme inhibitors; after further mutagenesis and selection, we were able to chem. synthesize a lead inhibitor (PK15; Ki = 1.5 nM) specific to human plasma kallikrein that efficiently interrupted the intrinsic coagulation pathway in human plasma tested ex vivo.  This approach offers a powerful means of generating and selecting bicyclic macrocycles (or if cleaved, linear derivs. thereof) as ligands poised at the interface of small-mol. drugs and biologics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZhJRZyldisLVg90H21EOLACvtfcHk0lj_KBgPU0FyQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXms1altbs%253D&md5=0634460f77b185fbcf85309c6dbf93e3</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.184%26sid%3Dliteratum%253Aachs%26aulast%3DHeinis%26aufirst%3DC.%26aulast%3DRutherford%26aufirst%3DT.%26aulast%3DFreund%26aufirst%3DS.%26aulast%3DWinter%26aufirst%3DG.%26atitle%3DPhage-encoded%2520combinatorial%2520chemical%2520libraries%2520based%2520on%2520bicyclic%2520peptides%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2009%26volume%3D5%26spage%3D502%26epage%3D507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group">Parker, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turk, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westrick, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Low, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leamon, C. P.</span><span> </span><span class="NLM_article-title">Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">338</span><span class="NLM_x">, </span> <span class="NLM_fpage">284</span><span class="NLM_x">–</span> <span class="NLM_lpage">293</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1016%2Fj.ab.2004.12.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=15745749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitVaqur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=2005&pages=284-293&author=N.+Parkerauthor=M.+J.+Turkauthor=E.+Westrickauthor=J.+D.+Lewisauthor=P.+S.+Lowauthor=C.+P.+Leamon&title=Folate+receptor+expression+in+carcinomas+and+normal+tissues+determined+by+a+quantitative+radioligand+binding+assay"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay</span></div><div class="casAuthors">Parker, Nikki; Turk, Mary Jo; Westrick, Elaine; Lewis, Jeffrey D.; Low, Philip S.; Leamon, Christopher P.</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">284-293</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The folate receptor (FR) is a valuable therapeutic target that is highly expressed on a variety of cancers.  The current development of folate-targeted cancer therapies has created the need for quantitating functional FRs in clin. specimens.  In this article, we report on the creation of a highly sensitive radioactive binding method for quant. measuring FR expression in frozen tissue homogenates.  Expression was pos. in approx. 89% of human ovarian carcinomas but was negligible in both mucinous ovarian carcinomas and normal ovary.  Expression was also significant in carcinomas of the kidney, endometrium, lung, breast, bladder, and pancreas.  Normal tissues from humans and six different lab. species were also analyzed; surprisingly, some interspecies variability in FR expression (esp. in kidney, spleen, and lung tissue) was found.  Interestingly, normal human lung tissue displayed high expression levels, whereas expression in normal lung of the other species was negligible.  However, considering that folate-drug conjugates fail to accumulate in the lungs of patients, the consequence of this finding was not considered to be of clin. concern.  Overall, this new methodol. is reliable for detg. functional FR expression levels in tissues, and it could possibly be a useful clin. test to det. patient candidacy for FR-targeted therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwtgdifJwHuLVg90H21EOLACvtfcHk0ljn0nyrZ9EaxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitVaqur0%253D&md5=cec9651fddccd602d715a27ab93f288c</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.ab.2004.12.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ab.2004.12.026%26sid%3Dliteratum%253Aachs%26aulast%3DParker%26aufirst%3DN.%26aulast%3DTurk%26aufirst%3DM.%2BJ.%26aulast%3DWestrick%26aufirst%3DE.%26aulast%3DLewis%26aufirst%3DJ.%2BD.%26aulast%3DLow%26aufirst%3DP.%2BS.%26aulast%3DLeamon%26aufirst%3DC.%2BP.%26atitle%3DFolate%2520receptor%2520expression%2520in%2520carcinomas%2520and%2520normal%2520tissues%2520determined%2520by%2520a%2520quantitative%2520radioligand%2520binding%2520assay%26jtitle%3DAnal.%2520Biochem.%26date%3D2005%26volume%3D338%26spage%3D284%26epage%3D293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group">Morris, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joyrich, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naumann, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurer, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strauss, H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uszler, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Symanowski, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harb, W. A.</span><span> </span><span class="NLM_article-title">Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (Tc-99m-etarfolatide)</span> <span class="citation_source-journal">Ann. Oncol</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">852</span><span class="NLM_x">–</span> <span class="NLM_lpage">858</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1093%2Fannonc%2Fmdu024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=24667717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A280%3ADC%252BC2crnt1ymsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=852-858&author=R.+T.+Morrisauthor=R.+N.+Joyrichauthor=R.+W.+Naumannauthor=N.+P.+Shahauthor=A.+H.+Maurerauthor=H.+W.+Straussauthor=J.+M.+Uszlerauthor=J.+T.+Symanowskiauthor=P.+R.+Ellisauthor=W.+A.+Harb&title=Phase+II+study+of+treatment+of+advanced+ovarian+cancer+with+folate-receptor-targeted+therapeutic+%28vintafolide%29+and+companion+SPECT-based+imaging+agent+%28Tc-99m-etarfolatide%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide)</span></div><div class="casAuthors">Morris R T; Joyrich R N; Naumann R W; Symanowski J T; Shah N P; Maurer A H; Strauss H W; Uszler J M; Ellis P R; Harb W A</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">852-858</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  This report examines (99m)Tc-etarfolatide imaging to identify the presence of folate receptor (FR) on tumors of women with recurrent/refractory ovarian or endometrial cancer and correlates expression with response to FR-targeted therapy (vintafolide).  PATIENTS AND METHODS:  In this phase II, single-arm, multicenter study, patients with advanced ovarian cancer were imaged with (99m)Tc-etarfolatide before vintafolide treatment.  Up to 10 target lesions (TLs) were selected based on Response Evaluation Criteria In Solid Tumors criteria using computed tomography scans.  Single-photon emission computed tomography images of TLs were assessed for (99m)Tc-etarfolatide uptake as either FR positive or negative.  Patients were categorized by percentage of TLs positive and grouped as FR(100%), FR(10%-90%), and FR(0%).  Lesion and patient response were correlated with etarfolatide uptake.  RESULTS:  Forty-nine patients were enrolled; 43 were available for analysis.  One hundred thirty-nine lesions were (99m)Tc-etarfolatide evaluable: 110 FR positive and 29 FR negative.  Lesion disease control rate (DCR = stable or response) was observed in 56.4% of FR-positive lesions versus 20.7% of FR-negative lesions (P < 0.001).  Patient DCR was 57%, 36%, and 33% in FR(100%), FR(10%-90%), and FR(0%) patients, respectively.  Median overall survival was 14.6, 9.6, and 3.0 months in FR(100%), FR(10%-90%), and FR(0%) patients, respectively.  CONCLUSIONS:  Overall response to FR-targeted therapy and DCR correlate with FR positivity demonstrated by (99m)Tc-etarfolatide imaging.  CLINICAL TRIAL NUMBER:  NCT00507741.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTm3hC1BFRecGPgL4LrC-0VfW6udTcc2eak1LB2wZ8nd7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2crnt1ymsw%253D%253D&md5=69bfa70dba6ad5b1da9e763e12e795fc</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdu024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdu024%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DR.%2BT.%26aulast%3DJoyrich%26aufirst%3DR.%2BN.%26aulast%3DNaumann%26aufirst%3DR.%2BW.%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DMaurer%26aufirst%3DA.%2BH.%26aulast%3DStrauss%26aufirst%3DH.%2BW.%26aulast%3DUszler%26aufirst%3DJ.%2BM.%26aulast%3DSymanowski%26aufirst%3DJ.%2BT.%26aulast%3DEllis%26aufirst%3DP.%2BR.%26aulast%3DHarb%26aufirst%3DW.%2BA.%26atitle%3DPhase%2520II%2520study%2520of%2520treatment%2520of%2520advanced%2520ovarian%2520cancer%2520with%2520folate-receptor-targeted%2520therapeutic%2520%2528vintafolide%2529%2520and%2520companion%2520SPECT-based%2520imaging%2520agent%2520%2528Tc-99m-etarfolatide%2529%26jtitle%3DAnn.%2520Oncol%26date%3D2014%26volume%3D25%26spage%3D852%26epage%3D858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group">Naumann, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burger, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sausville, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kutarska, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghamande, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabrail, N. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depasquale, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nowara, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gersh, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teneriello, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harb, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konstantinopoulos, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penson, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Symanowski, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovejoy, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leamon, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgenstern, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messmann, R. A.</span><span> </span><span class="NLM_article-title">PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">4400</span><span class="NLM_x">–</span> <span class="NLM_lpage">4406</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1200%2FJCO.2013.49.7685" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=24127448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjt1Shtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=4400-4406&author=R.+W.+Naumannauthor=R.+L.+Colemanauthor=R.+A.+Burgerauthor=E.+A.+Sausvilleauthor=E.+Kutarskaauthor=S.+A.+Ghamandeauthor=N.+Y.+Gabrailauthor=S.+E.+Depasqualeauthor=E.+Nowaraauthor=L.+Gilbertauthor=R.+H.+Gershauthor=M.+G.+Tenerielloauthor=W.+A.+Harbauthor=P.+A.+Konstantinopoulosauthor=R.+T.+Pensonauthor=J.+T.+Symanowskiauthor=C.+D.+Lovejoyauthor=C.+P.+Leamonauthor=D.+E.+Morgensternauthor=R.+A.+Messmann&title=PRECEDENT%3A+a+randomized+phase+II+trial+comparing+vintafolide+%28EC145%29+and+pegylated+liposomal+doxorubicin+%28PLD%29+in+combination+versus+PLD+alone+in+patients+with+platinum-resistant+ovarian+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer</span></div><div class="casAuthors">Naumann, R. Wendel; Coleman, Robert L.; Burger, Robert A.; Sausville, Edward A.; Kutarska, Elzbieta; Ghamande, Sharad A.; Gabrail, Nashat Y.; DePasquale, Stephen E.; Nowara, Elzbieta; Gilbert, Lucy; Gersh, Robert H.; Teneriello, Michael G.; Harb, Wael A.; Konstantinopoulos, Panagiotis A.; Penson, Richard T.; Symanowski, James T.; Lovejoy, Chandra D.; Leanon, Christopher P.; Morgenstern, David E.; Messmann, Richar A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">4400-4406</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Vintafolide (EC145) is a folic acid-desacetylvinblastine conjugate that binds to the folate receptor (FR), which is expressed on the majority of epithelial ovarian cancers.  This randomized phase II trial evaluated vintafolide combined with pegylated liposomal doxorubicin (PLD) compared with PLD alone.  The utility of an FR-targeted imaging agent, 99mTc-etarfolatide (EC20), in selecting patients likely to benefit from vintafolide was also examd.  Patients and Methods Women with recurrent platinum-resistant ovarian cancer who had undergone ≤ two prior cytotoxic regimens were randomly assigned at a 2:1 ratio to PLD (50 mg/m2 i.v. [IV] once every 28 days) with or without vintafolide (2.5 mg IV three times per wk during weeks 1 and 3).  Etarfolatide scanning was optional.  The primary objective was to compare progression-free survival (PFS) between the groups.  Results The intent-to-treat population comprised 149 patients.  Median PFS was 5.0 and 2.7 mo for the vintafolide plus PLD and PLD-alone arms, resp. (hazard ratio [HR], 0.63; 95% CI, 0.41 to 0.96; P = .031).  The greatest benefit was obsd. in patients with 100% of lesions pos. for FR, with median PFS of 5.5 compared with 1.5 mo for PLD alone (HR, 0.38; 95% CI, 0.17 to 0.85; P = .013).  The group of patients with FR-pos. disease (10% to 90%) experienced some PFS improvement (HR, 0.873), whereas patients with disease that did not express FR experienced no PFS benefit (HR, 1.806).  Conclusion Vintafolide plus PLD is the first combination to demonstrate an improvement over std. therapy in a randomized trial of patients with platinum-resistant ovarian cancer.  Etarfolatide can identify patients likely to benefit from vintafolide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjeCxk34QG_LVg90H21EOLACvtfcHk0ljn0nyrZ9EaxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjt1Shtrc%253D&md5=6f242890f38c502872b4bf7b49241f28</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1200%2FJCO.2013.49.7685&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2013.49.7685%26sid%3Dliteratum%253Aachs%26aulast%3DNaumann%26aufirst%3DR.%2BW.%26aulast%3DColeman%26aufirst%3DR.%2BL.%26aulast%3DBurger%26aufirst%3DR.%2BA.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26aulast%3DKutarska%26aufirst%3DE.%26aulast%3DGhamande%26aufirst%3DS.%2BA.%26aulast%3DGabrail%26aufirst%3DN.%2BY.%26aulast%3DDepasquale%26aufirst%3DS.%2BE.%26aulast%3DNowara%26aufirst%3DE.%26aulast%3DGilbert%26aufirst%3DL.%26aulast%3DGersh%26aufirst%3DR.%2BH.%26aulast%3DTeneriello%26aufirst%3DM.%2BG.%26aulast%3DHarb%26aufirst%3DW.%2BA.%26aulast%3DKonstantinopoulos%26aufirst%3DP.%2BA.%26aulast%3DPenson%26aufirst%3DR.%2BT.%26aulast%3DSymanowski%26aufirst%3DJ.%2BT.%26aulast%3DLovejoy%26aufirst%3DC.%2BD.%26aulast%3DLeamon%26aufirst%3DC.%2BP.%26aulast%3DMorgenstern%26aufirst%3DD.%2BE.%26aulast%3DMessmann%26aufirst%3DR.%2BA.%26atitle%3DPRECEDENT%253A%2520a%2520randomized%2520phase%2520II%2520trial%2520comparing%2520vintafolide%2520%2528EC145%2529%2520and%2520pegylated%2520liposomal%2520doxorubicin%2520%2528PLD%2529%2520in%2520combination%2520versus%2520PLD%2520alone%2520in%2520patients%2520with%2520platinum-resistant%2520ovarian%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D4400%26epage%3D4406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group">LoRusso, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edelman, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bever, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forman, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilat, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heath, E. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malburg, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leamon, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messmann, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sausville, E. A.</span><span> </span><span class="NLM_article-title">Phase I study of folate conjugate EC145 (vintafolide) in patients with refractory solid tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">4011</span><span class="NLM_x">–</span> <span class="NLM_lpage">4016</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1200%2FJCO.2011.41.4946" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=23032618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A280%3ADC%252BC3s%252FitFCrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=4011-4016&author=P.+M.+LoRussoauthor=M.+J.+Edelmanauthor=S.+L.+Beverauthor=K.+M.+Formanauthor=M.+Pilatauthor=M.+F.+Quinnauthor=J.+Liauthor=E.+I.+Heathauthor=L.+M.+Malburgauthor=P.+J.+Kleinauthor=C.+P.+Leamonauthor=R.+A.+Messmannauthor=E.+A.+Sausville&title=Phase+I+study+of+folate+conjugate+EC145+%28vintafolide%29+in+patients+with+refractory+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors</span></div><div class="casAuthors">Lorusso Patricia M; Edelman Martin J; Bever Susan L; Forman Karen M; Pilat Maryjo; Quinn Mary F; Li Jing; Heath Elisabeth I; Malburg Lisa M; Klein Patrick J; Leamon Christopher P; Messmann Richard A; Sausville Edward A</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">4011-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  EC145 (vintafolide), a conjugate of folic acid and the vinca alkaloid desacetylvinblastine hydrazide (DAVLBH), is a ligand for the folate receptor (FR), with activity against FR-positive tumor xenografts in vivo.  This phase I study determined the maximum-tolerated dose (MTD) of EC145 administered as a bolus intravenous injection or 1-hour infusion in patients with refractory solid tumors.  PATIENTS AND METHODS:  EC145 was administered as a bolus injection or 1-hour infusion on days 1, 3, and 5 and days 15, 17, and 19 of each 28-day cycle with dose escalation in cohorts of three to six patients until the MTD was identified.  Plasma pharmacokinetics were determined on days 1 and 3 of the first cycle.  RESULTS:  The MTD of EC145 was 2.5 mg when administered as either a bolus injection or 1-hour infusion.  Constipation was the dose-limiting toxicity with both routes.  Constipation, nausea, fatigue, and vomiting were the most commonly reported adverse events.  One partial response to therapy was observed in a patient with metastatic ovarian cancer.  CONCLUSION:  EC145 administered by bolus injection or as a 1-hour infusion at a dose of 2.5 mg on days 1, 3, and 5 and days 15, 17, and 19 of a 28-day cycle has an acceptable safety profile in patients with advanced cancer.  On the basis of these findings, phase II studies of EC145 have been initiated in patients with advanced epithelial ovarian cancer and non-small-cell lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTgjStBWJ3DPJQHPYJuLg8TfW6udTcc2ebpGK7kZ-X81Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s%252FitFCrsA%253D%253D&md5=cfbc76346785033ebb51e7cf4494cd68</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.41.4946&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.41.4946%26sid%3Dliteratum%253Aachs%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26aulast%3DEdelman%26aufirst%3DM.%2BJ.%26aulast%3DBever%26aufirst%3DS.%2BL.%26aulast%3DForman%26aufirst%3DK.%2BM.%26aulast%3DPilat%26aufirst%3DM.%26aulast%3DQuinn%26aufirst%3DM.%2BF.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DHeath%26aufirst%3DE.%2BI.%26aulast%3DMalburg%26aufirst%3DL.%2BM.%26aulast%3DKlein%26aufirst%3DP.%2BJ.%26aulast%3DLeamon%26aufirst%3DC.%2BP.%26aulast%3DMessmann%26aufirst%3DR.%2BA.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26atitle%3DPhase%2520I%2520study%2520of%2520folate%2520conjugate%2520EC145%2520%2528vintafolide%2529%2520in%2520patients%2520with%2520refractory%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D4011%26epage%3D4016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group">Uhlen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fagerberg, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallstrom, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindskog, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oksvold, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mardinoglu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sivertsson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kampf, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sjostedt, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asplund, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edlund, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szigyarto, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Odeberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Djureinovic, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takanen, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hober, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alm, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edqvist, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berling, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tegel, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulder, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rockberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwenk, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamsten, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Feilitzen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forsberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Persson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johansson, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwahlen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Heijne, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ponten, F.</span><span> </span><span class="NLM_article-title">Proteomics. Tissue-based map of the human proteome</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">347</span><span class="NLM_x">, </span> <span class="NLM_fpage">394</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2015&pages=394&author=M.+Uhlenauthor=L.+Fagerbergauthor=B.+M.+Hallstromauthor=C.+Lindskogauthor=P.+Oksvoldauthor=A.+Mardinogluauthor=A.+Sivertssonauthor=C.+Kampfauthor=E.+Sjostedtauthor=A.+Asplundauthor=I.+Olssonauthor=K.+Edlundauthor=E.+Lundbergauthor=S.+Navaniauthor=C.+A.+Szigyartoauthor=J.+Odebergauthor=D.+Djureinovicauthor=J.+O.+Takanenauthor=S.+Hoberauthor=T.+Almauthor=P.+H.+Edqvistauthor=H.+Berlingauthor=H.+Tegelauthor=J.+Mulderauthor=J.+Rockbergauthor=P.+Nilssonauthor=J.+M.+Schwenkauthor=M.+Hamstenauthor=K.+von+Feilitzenauthor=M.+Forsbergauthor=L.+Perssonauthor=F.+Johanssonauthor=M.+Zwahlenauthor=G.+von+Heijneauthor=J.+Nielsenauthor=F.+Ponten&title=Proteomics.+Tissue-based+map+of+the+human+proteome"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DUhlen%26aufirst%3DM.%26aulast%3DFagerberg%26aufirst%3DL.%26aulast%3DHallstrom%26aufirst%3DB.%2BM.%26aulast%3DLindskog%26aufirst%3DC.%26aulast%3DOksvold%26aufirst%3DP.%26aulast%3DMardinoglu%26aufirst%3DA.%26aulast%3DSivertsson%26aufirst%3DA.%26aulast%3DKampf%26aufirst%3DC.%26aulast%3DSjostedt%26aufirst%3DE.%26aulast%3DAsplund%26aufirst%3DA.%26aulast%3DOlsson%26aufirst%3DI.%26aulast%3DEdlund%26aufirst%3DK.%26aulast%3DLundberg%26aufirst%3DE.%26aulast%3DNavani%26aufirst%3DS.%26aulast%3DSzigyarto%26aufirst%3DC.%2BA.%26aulast%3DOdeberg%26aufirst%3DJ.%26aulast%3DDjureinovic%26aufirst%3DD.%26aulast%3DTakanen%26aufirst%3DJ.%2BO.%26aulast%3DHober%26aufirst%3DS.%26aulast%3DAlm%26aufirst%3DT.%26aulast%3DEdqvist%26aufirst%3DP.%2BH.%26aulast%3DBerling%26aufirst%3DH.%26aulast%3DTegel%26aufirst%3DH.%26aulast%3DMulder%26aufirst%3DJ.%26aulast%3DRockberg%26aufirst%3DJ.%26aulast%3DNilsson%26aufirst%3DP.%26aulast%3DSchwenk%26aufirst%3DJ.%2BM.%26aulast%3DHamsten%26aufirst%3DM.%26aulast%3Dvon%2BFeilitzen%26aufirst%3DK.%26aulast%3DForsberg%26aufirst%3DM.%26aulast%3DPersson%26aufirst%3DL.%26aulast%3DJohansson%26aufirst%3DF.%26aulast%3DZwahlen%26aufirst%3DM.%26aulast%3Dvon%2BHeijne%26aufirst%3DG.%26aulast%3DNielsen%26aufirst%3DJ.%26aulast%3DPonten%26aufirst%3DF.%26atitle%3DProteomics.%2520Tissue-based%2520map%2520of%2520the%2520human%2520proteome%26jtitle%3DScience%26date%3D2015%26volume%3D347%26spage%3D394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group">Uhlen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oksvold, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fagerberg, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonasson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forsberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwahlen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kampf, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wester, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hober, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wernerus, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjorling, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ponten, F.</span><span> </span><span class="NLM_article-title">Towards a knowledge-based human protein atlas</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">1248</span><span class="NLM_x">–</span> <span class="NLM_lpage">1250</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1038%2Fnbt1210-1248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=21139605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFals7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=1248-1250&author=M.+Uhlenauthor=P.+Oksvoldauthor=L.+Fagerbergauthor=E.+Lundbergauthor=K.+Jonassonauthor=M.+Forsbergauthor=M.+Zwahlenauthor=C.+Kampfauthor=K.+Westerauthor=S.+Hoberauthor=H.+Wernerusauthor=L.+Bjorlingauthor=F.+Ponten&title=Towards+a+knowledge-based+human+protein+atlas"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Towards a knowledge-based Human Protein Atlas</span></div><div class="casAuthors">Uhlen, Mathias; Oksvold, Per; Fagerberg, Linn; Lundberg, Emma; Jonasson, Kalle; Forsberg, Mattias; Zwahlen, Martin; Kampf, Caroline; Wester, Kenneth; Hober, Sophia; Wernerus, Henrik; Bjoerling, Lisa; Ponten, Fredrik</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1248-1250</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrBEKpb82v_rVg90H21EOLACvtfcHk0lhp8aDpc3p1Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFals7nO&md5=2d71435d159298360fa71b2c5f71b7d7</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1038%2Fnbt1210-1248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1210-1248%26sid%3Dliteratum%253Aachs%26aulast%3DUhlen%26aufirst%3DM.%26aulast%3DOksvold%26aufirst%3DP.%26aulast%3DFagerberg%26aufirst%3DL.%26aulast%3DLundberg%26aufirst%3DE.%26aulast%3DJonasson%26aufirst%3DK.%26aulast%3DForsberg%26aufirst%3DM.%26aulast%3DZwahlen%26aufirst%3DM.%26aulast%3DKampf%26aufirst%3DC.%26aulast%3DWester%26aufirst%3DK.%26aulast%3DHober%26aufirst%3DS.%26aulast%3DWernerus%26aufirst%3DH.%26aulast%3DBjorling%26aufirst%3DL.%26aulast%3DPonten%26aufirst%3DF.%26atitle%3DTowards%2520a%2520knowledge-based%2520human%2520protein%2520atlas%26jtitle%3DNat.%2520Biotechnol.%26date%3D2010%26volume%3D28%26spage%3D1248%26epage%3D1250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group">Zechmann, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Afshar-Oromieh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armor, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stubbs, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hadaschik, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joyal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kopka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debus, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babich, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haberkorn, U.</span><span> </span><span class="NLM_article-title">Radiation dosimetry and first therapy results with a I-124/I-131-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy</span> <span class="citation_source-journal">Eur. J. Nucl. Med. Mol. Imaging</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">1280</span><span class="NLM_x">–</span> <span class="NLM_lpage">1292</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1007%2Fs00259-014-2713-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=24577951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpvFGltrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2014&pages=1280-1292&author=C.+M.+Zechmannauthor=A.+Afshar-Oromiehauthor=T.+Armorauthor=J.+B.+Stubbsauthor=W.+Mierauthor=B.+Hadaschikauthor=J.+Joyalauthor=K.+Kopkaauthor=J.+Debusauthor=J.+W.+Babichauthor=U.+Haberkorn&title=Radiation+dosimetry+and+first+therapy+results+with+a+I-124%2FI-131-labeled+small+molecule+%28MIP-1095%29+targeting+PSMA+for+prostate+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy</span></div><div class="casAuthors">Zechmann, Christian M.; Afshar-Oromieh, Ali; Armor, Tom; Stubbs, James B.; Mier, Walter; Hadaschik, Boris; Joyal, John; Kopka, Klaus; Debus, Juergen; Babich, John W.; Haberkorn, Uwe</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Nuclear Medicine and Molecular Imaging</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1280-1292</span>CODEN:
                <span class="NLM_cas:coden">EJNMA6</span>;
        ISSN:<span class="NLM_cas:issn">1619-7070</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Introduction: Since the prostate-specific membrane antigen (PSMA) is frequently over-expressed in prostate cancer (PCa) several PSMA-targeting mols. are under development to detect and treat metastatic castration resistant prostate cancer (mCRPC).  We investigated the tissue kinetics of a small mol. inhibitor of PSMA ((S)-2-(3-((S)-1-carboxy-5-(3-(4-[124I]iodophenyl)ureido)pentyl)ureido)pentanedioicacid;MIP-1095) using PET/CT to est. radiation dosimetry for the potential therapeutic use of 131I-MIP-1095 in men with mCRPC.  We also report preliminary safety and efficacy of the first 28 consecutive patients treated under a compassionate-use protocol with a single cycle of 131I-MIP-1095.  Methods: Sixteen patients with known prostate cancer underwent PET/CT imaging after i.v. administration of 124I-MIP-1095 (mean activity: 67.4 MBq).  Each patient was scanned using PET/CT up to five times at 1, 4, 24, 48 and 72 h post injection.  Vols. of interest were defined for tumor lesions and normal organs at each time point followed by dose calcns. using the OLINDA/EXM software.  Twenty-eight men with mCRPC were treated with a single cycle of 131I-MIP-1095 (mean activity: 4.8 GBq, range 2 to 7.2 GBq) and followed for safety and efficacy.  Baseline and follow up examns. included a complete blood count, liver and kidney function tests, and measurement of serum PSA.  Results: I-124-MIP-1095 PET/CT images showed excellent tumor uptake and moderate uptake in liver, proximal intestine and within a few hours post-injection also in the kidneys.  High uptake values were obsd. only in salivary and lacrimal glands.  Dosimetry ests. for I-131-MIP-1095 revealed that the highest absorbed doses were delivered to the salivary glands (3.8 mSv/MBq), liver (1.7 mSv/MBq) and kidneys (1.4 mSv/MBq).  The absorbed dose calcd. for the red marrow was 0.37 mSv/MBq.  PSA values decreased by >50 % in 60.7 % of the men treated.  Of men with bone pain, 84.6 % showed complete or moderate redn. in pain.  Hematol. toxicities were mild.  Of men treated, 25 % had a transient slight to moderate dry mouth.  No adverse effects on renal function were obsd.  Conclusion: Based on the biodistribution and dose calcns. of the PSMA-targeted small mol. 124I-MIP-1095 therapy with the authentic analog 131I-MIP-1095 enables a targeted tumor therapy with unprecedented doses delivered to the tumor lesions.  Involved lymph node and bone metastases were exposed to estd. absorbed doses upwards of 300 Gy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoglz6WiJ4cwrVg90H21EOLACvtfcHk0lhp8aDpc3p1Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpvFGltrs%253D&md5=ceeddb0e8e38069a9f683302334d0529</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1007%2Fs00259-014-2713-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00259-014-2713-y%26sid%3Dliteratum%253Aachs%26aulast%3DZechmann%26aufirst%3DC.%2BM.%26aulast%3DAfshar-Oromieh%26aufirst%3DA.%26aulast%3DArmor%26aufirst%3DT.%26aulast%3DStubbs%26aufirst%3DJ.%2BB.%26aulast%3DMier%26aufirst%3DW.%26aulast%3DHadaschik%26aufirst%3DB.%26aulast%3DJoyal%26aufirst%3DJ.%26aulast%3DKopka%26aufirst%3DK.%26aulast%3DDebus%26aufirst%3DJ.%26aulast%3DBabich%26aufirst%3DJ.%2BW.%26aulast%3DHaberkorn%26aufirst%3DU.%26atitle%3DRadiation%2520dosimetry%2520and%2520first%2520therapy%2520results%2520with%2520a%2520I-124%252FI-131-labeled%2520small%2520molecule%2520%2528MIP-1095%2529%2520targeting%2520PSMA%2520for%2520prostate%2520cancer%2520therapy%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%2520Mol.%2520Imaging%26date%3D2014%26volume%3D41%26spage%3D1280%26epage%3D1292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group">Silver, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicer, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fair, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heston, W. D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">CordonCardo, C.</span><span> </span><span class="NLM_article-title">Prostate-specific membrane antigen expression in normal and malignant human tissues</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">81</span><span class="NLM_x">–</span> <span class="NLM_lpage">85</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=9815541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A280%3ADyaK1M%252FjsFamtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1997&pages=81-85&author=D.+A.+Silverauthor=I.+Pellicerauthor=W.+R.+Fairauthor=W.+D.+W.+Hestonauthor=C.+CordonCardo&title=Prostate-specific+membrane+antigen+expression+in+normal+and+malignant+human+tissues"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Prostate-specific membrane antigen expression in normal and malignant human tissues</span></div><div class="casAuthors">Silver D A; Pellicer I; Fair W R; Heston W D; Cordon-Cardo C</div><div class="citationInfo"><span class="NLM_cas:title">Clinical cancer research : an official journal of the American Association for Cancer Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">81-5</span>
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    </div><div class="casAbstract">Prostate-specific membrane antigen is a type II membrane protein with folate hydrolase activity produced by prostatic epithelium.  The expression of this molecule has also been documented in extraprostatic tissues, including small bowel and brain.  In the present study, an extensive immunohistochemical analysis was performed on a panel of well-characterized normal and malignant human tissues to further define the pattern of prostate-specific membrane antigen (PSMA) expression.  Detectable PSMA levels were identified in prostatic epithelium, duodenal mucosa, and a subset of proximal renal tubules.  A subpopulation of neuroendocrine cells in the colonic crypts also exhibited PSMA immunoreactivity.  All other normal tissues, including cerebral cortex and cerebellum, had undetectable levels of PSMA.  Thirty-three of 35 primary prostate adenocarcinomas and 7 of 8 lymph node metastases displayed tumor cell PSMA immunostaining.  Eight of 18 prostate tumors metastatic to bone expressed PSMA.  All of the other nonprostatic primary tumors studied had undetectable PSMA levels.  However, intense staining was observed in endothelial cells of capillary vessels in peritumoral and endotumoral areas of certain malignancies, including 8 of 17 renal cell carcinomas, 7 of 13 transitional cell carcinomas, and 3 of 19 colon carcinomas.  Extraprostatic PSMA expression appears to be highly restricted.  Nevertheless, its diverse anatomical distribution implies a broader functional significance than previously suspected.  The decrease in PSMA immunoreactivity noted in advanced prostate cancer suggests that expression of this molecule may be linked to the degree of tumor differentiation.  The neoexpression of PSMA in endothelial cells of capillary beds in certain tumors may be related to tumor angiogenesis and suggests a potential mechanism for specific targeting of tumor neovasculature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQa3hRIf6mlYUcLvDNbOD4DfW6udTcc2eYfgWnboKtrtLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M%252FjsFamtA%253D%253D&md5=06fb3a1b21fc371a5e42843ed558e5eb</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSilver%26aufirst%3DD.%2BA.%26aulast%3DPellicer%26aufirst%3DI.%26aulast%3DFair%26aufirst%3DW.%2BR.%26aulast%3DHeston%26aufirst%3DW.%2BD.%2BW.%26aulast%3DCordonCardo%26aufirst%3DC.%26atitle%3DProstate-specific%2520membrane%2520antigen%2520expression%2520in%2520normal%2520and%2520malignant%2520human%2520tissues%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D1997%26volume%3D3%26spage%3D81%26epage%3D85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group">Israeli, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fair, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heston, W. D. W.</span><span> </span><span class="NLM_article-title">Molecular-cloning of a complementary-DNA encoding a prostate-specific membrane antigen</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">227</span><span class="NLM_x">–</span> <span class="NLM_lpage">230</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1993&pages=227-230&author=R.+S.+Israeliauthor=C.+T.+Powellauthor=W.+R.+Fairauthor=W.+D.+W.+Heston&title=Molecular-cloning+of+a+complementary-DNA+encoding+a+prostate-specific+membrane+antigen"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIsraeli%26aufirst%3DR.%2BS.%26aulast%3DPowell%26aufirst%3DC.%2BT.%26aulast%3DFair%26aufirst%3DW.%2BR.%26aulast%3DHeston%26aufirst%3DW.%2BD.%2BW.%26atitle%3DMolecular-cloning%2520of%2520a%2520complementary-DNA%2520encoding%2520a%2520prostate-specific%2520membrane%2520antigen%26jtitle%3DCancer%2520Res.%26date%3D1993%26volume%3D53%26spage%3D227%26epage%3D230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group">Chang, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuter, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heston, W. D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bander, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grauer, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaudin, P. B.</span><span> </span><span class="NLM_article-title">Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">3192</span><span class="NLM_x">–</span> <span class="NLM_lpage">3198</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10397265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADyaK1MXksVCqtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1999&pages=3192-3198&author=S.+S.+Changauthor=V.+E.+Reuterauthor=W.+D.+W.+Hestonauthor=N.+H.+Banderauthor=L.+S.+Grauerauthor=P.+B.+Gaudin&title=Five+different+anti-prostate-specific+membrane+antigen+%28PSMA%29+antibodies+confirm+PSMA+expression+in+tumor-associated+neovasculature"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature</span></div><div class="casAuthors">Chang, Sam S.; Reuter, Victor E.; Heston, W. D. W.; Bander, Neil H.; Grauer, Lana S.; Gaudin, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3192-3198</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">AACR Subscription Office</span>)
        </div><div class="casAbstract">Prostate-specific membrane antigen (PSMA) is a type II integral membrane glycoprotein that was initially characterized by the monoclonal antibody (mAb) 7E11.  PSMA is highly expressed in prostate secretory-acinar epithelium and prostate cancer as well as in several extraprostatic tissues.  Recent evidence suggests that PSMA is also expressed in tumor-assocd. neovasculature.  We examd. the immunohistochem. characteristics of 7E11 and those of four recently developed anti-PSMA mAbs (J591, J415, and Hybritech PEQ226.5 and PM2J004.5), each of which binds a distinct epitope of PSMA.  Using the streptavidin-biotin method, we evaluated these mAbs in viable prostate cancer cell lines and various fresh-frozen benign and malignant tissue specimens.  In the latter, we compared the localization of the anti-PSMA mAbs to that of the anti-endothelial cell mAb CD34.  With rare exceptions, all five anti-PSMA mAbs reacted strongly with the neovasculature of a wide spectrum of malignant neoplasms: conventional (clear cell) renal carcinoma (11 of 11 cases), transitional cell carcinoma of the urinary bladder (6 of 6 cases), testicular embryonal carcinoma (1 of 1 case), colonic adenocarcinoma (5 of 5 cases), neuroendocrine carcinoma (5 of 5 cases), glioblastoma multiforme (1 of 1 cases), malignant melanoma (5 of 5 cases), pancreatic duct carcinoma (4 of 4 cases), non-small cell lung carcinoma (5 of 5 cases), soft tissue sarcoma (5 of 6 cases), breast carcinoma (5 of 6 cases), and prostatic adenocarcinoma (2 of 12 cases).  Localization of the anti-PSMA mAbs to tumor-assocd. neovasculature was confirmed by CD34 immunohistochem. in sequential tissue sections.  Normal vascular endothelium in non-cancer-bearing tissue was consistently PSMA neg.  The anti-PSMA mAbs reacted with the neoplastic cells of prostatic adenocarcinoma (12 of 12 cases) but not with the neoplastic cells of any other tumor type, including those of benign and malignant vascular tumors (0 of 3 hemangiomas, 0 of 1 hemangioendothelioma, and 0 of 1 angiosarcoma).  The mAbs to the extracellular PSMA domain (J591, J415, and Hybritech PEQ226.5) bound viable prostate cancer cells (LNCaP and PC3-PIP), whereas the mAbs to the intracellular domain (7E11 and Hybritech PM2J004.5) did not.  All five anti-PSMA mAbs reacted with fresh-frozen benign prostate secretory-acinar epithelium (28 of 28 cases), duodenal columnar (brush border) epithelium (11 of 11 cases), proximal renal tubular epithelium (5 of 5 cases), colonic ganglion cells (1 of 12 cases), and benign breast epithelium (8 of 8 cases).  A subset of skeletal muscle cells was pos. with 7E11 (7 of 7 cases) and neg. with the other four anti-PSMA mAbs.  PSMA was consistently expressed in the neovasculature of a wide variety of malignant neoplasms and may be an effective target for mAb-based antineovasculature therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaiAU2o4bdlrVg90H21EOLACvtfcHk0lipQDgpx8ftnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXksVCqtbs%253D&md5=9da67909245aeb912538d4d5ec571472</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DS.%2BS.%26aulast%3DReuter%26aufirst%3DV.%2BE.%26aulast%3DHeston%26aufirst%3DW.%2BD.%2BW.%26aulast%3DBander%26aufirst%3DN.%2BH.%26aulast%3DGrauer%26aufirst%3DL.%2BS.%26aulast%3DGaudin%26aufirst%3DP.%2BB.%26atitle%3DFive%2520different%2520anti-prostate-specific%2520membrane%2520antigen%2520%2528PSMA%2529%2520antibodies%2520confirm%2520PSMA%2520expression%2520in%2520tumor-associated%2520neovasculature%26jtitle%3DCancer%2520Res.%26date%3D1999%26volume%3D59%26spage%3D3192%26epage%3D3198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajasekaran, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navarro, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knudsen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bander, N. H.</span><span> </span><span class="NLM_article-title">Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">3629</span><span class="NLM_x">–</span> <span class="NLM_lpage">3634</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=9288760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADyaK2sXlvFensbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1997&pages=3629-3634&author=H.+Liuauthor=P.+Moyauthor=S.+Kimauthor=Y.+Xiaauthor=A.+Rajasekaranauthor=V.+Navarroauthor=B.+Knudsenauthor=N.+H.+Bander&title=Monoclonal+antibodies+to+the+extracellular+domain+of+prostate-specific+membrane+antigen+also+react+with+tumor+vascular+endothelium"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium</span></div><div class="casAuthors">Liu, He; Moy, Peggy; Kim, Sae; Xia, Yan; Rajasekaran, Ayyappan; Navarro, Vincent; Knudsen, Beatrice; Bander, Neil H.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3629-3634</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Prostate-specific membrane antigen (PSMA), initially defined by monoclonal antibody (mAb) 7E11, is a now well-characterized type 2 integral membrane glycoprotein expressed in a highly restricted manner by prostate epithelial cells.  7E11 has been shown to bind an intracellular epitope of PSMA that, in viable cells, is not available for binding.  Herein, the authors report the initial characterization of the first 4 reported IgG mAbs that bind the external domain of PSMA.  Competitive binding studies indicate these antibodies define 2 distinct, noncompeting epitopes on the extracellular domain of PSMA.  In contrast to 7E11, these mAbs bind to viable LNCaP cells in vitro.  In addn., they show strong immunohistochem. reactivity to tissue sections of prostate epithelia, including prostate cancer.  These mAbs were also strongly reactive with vascular endothelium within a wide variety of carcinomas (including lung, colon, breast, and others) but not with normal vascular endothelium.  These antibodies should prove useful for in vivo targeting to prostate cancer, as well as to the vascular compartment of a wide variety of carcinomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnfwsJ-92adbVg90H21EOLACvtfcHk0lipQDgpx8ftnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXlvFensbo%253D&md5=35bfbebbbca72a6d5ef3667d84a772c3</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DMoy%26aufirst%3DP.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DXia%26aufirst%3DY.%26aulast%3DRajasekaran%26aufirst%3DA.%26aulast%3DNavarro%26aufirst%3DV.%26aulast%3DKnudsen%26aufirst%3DB.%26aulast%3DBander%26aufirst%3DN.%2BH.%26atitle%3DMonoclonal%2520antibodies%2520to%2520the%2520extracellular%2520domain%2520of%2520prostate-specific%2520membrane%2520antigen%2520also%2520react%2520with%2520tumor%2520vascular%2520endothelium%26jtitle%3DCancer%2520Res.%26date%3D1997%26volume%3D57%26spage%3D3629%26epage%3D3634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group">De Simone, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alterio, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Supuran, C. T.</span><span> </span><span class="NLM_article-title">Exploiting the hydrophobic and hydrophilic binding sites for designing carbonic anhydrase inhibitors</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">793</span><span class="NLM_x">–</span> <span class="NLM_lpage">810</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1517%2F17460441.2013.795145" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=23627619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpslCnsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=793-810&author=G.+De+Simoneauthor=V.+Alterioauthor=C.+T.+Supuran&title=Exploiting+the+hydrophobic+and+hydrophilic+binding+sites+for+designing+carbonic+anhydrase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Exploiting the hydrophobic and hydrophilic binding sites for designing carbonic anhydrase inhibitors</span></div><div class="casAuthors">De Simone, Giuseppina; Alterio, Vincenzo; Supuran, Claudiu T.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">793-810</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Carbonic anhydrases (CAs, EC 4.2.1.1) exist as five genetically distinct families (α, β, γ, δ and ζ) in organisms all over the phylogenetic tree.  Due to the ubiquity of such enzymes, the selective inhibition and polypharmacol. of inhibitors is an important aspect of all drug design campaigns.  There are several classes of CA inhibitors (CAIs): i) metal ion binders (sulfonamides and their isosteres [sulfamates/sulfamides], dithiocarbamates, mercaptans and hydroxamates); ii) compds. anchoring to the zinc-coordinated water mol./hydroxide ion (phenols, carboxylates, polyamines, esters and sulfocoumarins) and iii) coumarins and related compds. which apparently bind even further away from the metal ion.  Areas covered: The authors rationalize the drug design strategies of inhibitors belonging to the first two classes, based on recent X-ray crystallog. data.  More precisely, this is achieved by analyzing how the hydrophobic and hydrophilic halves of the enzyme active site interact with inhibitors.  This task has been eased by the recent report of β-CA-like enzymes possessing carbon disulfide and carbonyl sulfide hydrolase activities, resp., allowing the authors to propose a general approach of structure-based drug design of CAIs.  Expert opinion: Although amazing progress has been made in the structure-based drug design of CAIs, this field is still in progress, with many constantly emerging new findings.  Indeed, several new such enzymes were discovered and characterized recently and novel chemotypes were explored for finding compds. with a better inhibition profile.  It is anticipated that this will continue to be one of the main frontiers in the search of pharmacol. relevant enzyme inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolHwWEtsN36rVg90H21EOLACvtfcHk0lipQDgpx8ftnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpslCnsb0%253D&md5=a17278d030023ae0a92e1efd33531e93</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1517%2F17460441.2013.795145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2013.795145%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSimone%26aufirst%3DG.%26aulast%3DAlterio%26aufirst%3DV.%26aulast%3DSupuran%26aufirst%3DC.%2BT.%26atitle%3DExploiting%2520the%2520hydrophobic%2520and%2520hydrophilic%2520binding%2520sites%2520for%2520designing%2520carbonic%2520anhydrase%2520inhibitors%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2013%26volume%3D8%26spage%3D793%26epage%3D810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group">Thiry, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dogne, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masereel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Supuran, C. T.</span><span> </span><span class="NLM_article-title">Targeting tumor-associated carbonic anhydrase IX in cancer therapy</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">566</span><span class="NLM_x">–</span> <span class="NLM_lpage">573</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2006&pages=566-573&author=A.+Thiryauthor=J.+M.+Dogneauthor=B.+Masereelauthor=C.+T.+Supuran&title=Targeting+tumor-associated+carbonic+anhydrase+IX+in+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DThiry%26aufirst%3DA.%26aulast%3DDogne%26aufirst%3DJ.%2BM.%26aulast%3DMasereel%26aufirst%3DB.%26aulast%3DSupuran%26aufirst%3DC.%2BT.%26atitle%3DTargeting%2520tumor-associated%2520carbonic%2520anhydrase%2520IX%2520in%2520cancer%2520therapy%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2006%26volume%3D27%26spage%3D566%26epage%3D573" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group">Bui, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seligson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pantuck, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorey, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horvath, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leibovich, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chopra, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanbridge, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerman, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palotie, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Figlin, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belldegrun, A. S.</span><span> </span><span class="NLM_article-title">Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">802</span><span class="NLM_x">–</span> <span class="NLM_lpage">811</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=12576453" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtVKksbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=802-811&author=M.+H.+Buiauthor=D.+Seligsonauthor=K.+R.+Hanauthor=A.+J.+Pantuckauthor=F.+J.+Doreyauthor=Y.+Huangauthor=S.+Horvathauthor=B.+C.+Leibovichauthor=S.+Chopraauthor=S.+Y.+Liaoauthor=E.+Stanbridgeauthor=M.+I.+Lermanauthor=A.+Palotieauthor=R.+A.+Figlinauthor=A.+S.+Belldegrun&title=Carbonic+anhydrase+IX+is+an+independent+predictor+of+survival+in+advanced+renal+clear+cell+carcinoma%3A+implications+for+prognosis+and+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: Implications for prognosis and therapy</span></div><div class="casAuthors">Bui, Matthew H. T.; Seligson, David; Han, Ken-ryu; Pantuck, Allan J.; Dorey, Frederick J.; Huang, Yunda; Horvath, Steve; Leibovich, Bradley C.; Chopra, Shefali; Liao, Shu-Yuan; Stanbridge, Eric; Lerman, Michael I.; Palotie, Aarno; Figlin, Robert A.; Belldegrun, Arie S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">802-811</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Metastatic renal cell carcinoma (RCC) has a poor prognosis and an unpredictable course.  To date, there are no mol. markers which can reliably predict RCC outcome.  We investigated whether a novel kidney cancer marker, carbonic anhydrase IX (CAIX), is assocd. with progression and survival.  Immunohistochem. anal. using a CAIX monoclonal antibody was performed on tissue microarrays constructed from paraffin-embedded specimens from patients (N = 321) treated by nephrectomy for clear cell RCC.  CAIX staining was correlated with response to treatment, clin. factors, pathol. features, and survival.  CAIX staining was present in 94% of clear cell RCCs.  Survival tree anal. detd. that a cutoff of 85% CAIX staining provided the most accurate prediction of survival.  Low CAIX (≤85%) staining was an independent poor prognostic factor for survival for patients with metastatic RCC, with a hazard ratio of 3.10 (P < 0.001).  CAIX significantly substratified patients with metastatic disease when analyzed by T stage, Fuhrman grade, nodal involvement, and performance status.  For patients with nonmetastatic RCC and at high risk for progression, low CAIX predicted a worse outcome similar to patients with metastatic disease.  Overall expression of CAIX decreased with development of metastasis; as demonstrated by the lower CAIX staining levels in metastatic lesions relative to matched primary tumor specimens.  On the basis of our data, CAIX is the most significant mol. marker described in kidney cancer to date.  Decreased CAIX levels are independently assocd. with poor survival in advanced RCC.  CAIX reflects significant changes in tumor biol., which should be used to predict clin. outcome and identify high-risk patients in need for adjuvant immunotherapy and CAIX-targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn0CJC-APRsrVg90H21EOLACvtfcHk0liV-f6GwyBPxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtVKksbg%253D&md5=f112d99528227748821a97213fdf45ea</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBui%26aufirst%3DM.%2BH.%26aulast%3DSeligson%26aufirst%3DD.%26aulast%3DHan%26aufirst%3DK.%2BR.%26aulast%3DPantuck%26aufirst%3DA.%2BJ.%26aulast%3DDorey%26aufirst%3DF.%2BJ.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DHorvath%26aufirst%3DS.%26aulast%3DLeibovich%26aufirst%3DB.%2BC.%26aulast%3DChopra%26aufirst%3DS.%26aulast%3DLiao%26aufirst%3DS.%2BY.%26aulast%3DStanbridge%26aufirst%3DE.%26aulast%3DLerman%26aufirst%3DM.%2BI.%26aulast%3DPalotie%26aufirst%3DA.%26aulast%3DFiglin%26aufirst%3DR.%2BA.%26aulast%3DBelldegrun%26aufirst%3DA.%2BS.%26atitle%3DCarbonic%2520anhydrase%2520IX%2520is%2520an%2520independent%2520predictor%2520of%2520survival%2520in%2520advanced%2520renal%2520clear%2520cell%2520carcinoma%253A%2520implications%2520for%2520prognosis%2520and%2520therapy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2003%26volume%3D9%26spage%3D802%26epage%3D811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group">Svastova, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hulikova, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rafajova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zat’ovicova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibadulinova, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cecchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scozzafava, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Supuran, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pastorek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pastorekova, S.</span><span> </span><span class="NLM_article-title">Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH</span> <span class="citation_source-journal">FEBS Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">577</span><span class="NLM_x">, </span> <span class="NLM_fpage">439</span><span class="NLM_x">–</span> <span class="NLM_lpage">445</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=577&publication_year=2004&pages=439-445&author=E.+Svastovaauthor=A.+Hulikovaauthor=M.+Rafajovaauthor=M.+Zat%E2%80%99ovicovaauthor=A.+Gibadulinovaauthor=A.+Casiniauthor=A.+Cecchiauthor=A.+Scozzafavaauthor=C.+T.+Supuranauthor=J.+Pastorekauthor=S.+Pastorekova&title=Hypoxia+activates+the+capacity+of+tumor-associated+carbonic+anhydrase+IX+to+acidify+extracellular+pH"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSvastova%26aufirst%3DE.%26aulast%3DHulikova%26aufirst%3DA.%26aulast%3DRafajova%26aufirst%3DM.%26aulast%3DZat%25E2%2580%2599ovicova%26aufirst%3DM.%26aulast%3DGibadulinova%26aufirst%3DA.%26aulast%3DCasini%26aufirst%3DA.%26aulast%3DCecchi%26aufirst%3DA.%26aulast%3DScozzafava%26aufirst%3DA.%26aulast%3DSupuran%26aufirst%3DC.%2BT.%26aulast%3DPastorek%26aufirst%3DJ.%26aulast%3DPastorekova%26aufirst%3DS.%26atitle%3DHypoxia%2520activates%2520the%2520capacity%2520of%2520tumor-associated%2520carbonic%2520anhydrase%2520IX%2520to%2520acidify%2520extracellular%2520pH%26jtitle%3DFEBS%2520Lett.%26date%3D2004%26volume%3D577%26spage%3D439%26epage%3D445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group">Scheurer, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rybak, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elia, G.</span><span> </span><span class="NLM_article-title">Modulation of gene expression by hypoxia in human umbilical cord vein endothelial cells: A transcriptomic and proteomic study</span> <span class="citation_source-journal">Proteomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1737</span><span class="NLM_x">–</span> <span class="NLM_lpage">1760</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=1737-1760&author=S.+B.+Scheurerauthor=J.+N.+Rybakauthor=C.+Rosliauthor=D.+Neriauthor=G.+Elia&title=Modulation+of+gene+expression+by+hypoxia+in+human+umbilical+cord+vein+endothelial+cells%3A+A+transcriptomic+and+proteomic+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DScheurer%26aufirst%3DS.%2BB.%26aulast%3DRybak%26aufirst%3DJ.%2BN.%26aulast%3DRosli%26aufirst%3DC.%26aulast%3DNeri%26aufirst%3DD.%26aulast%3DElia%26aufirst%3DG.%26atitle%3DModulation%2520of%2520gene%2520expression%2520by%2520hypoxia%2520in%2520human%2520umbilical%2520cord%2520vein%2520endothelial%2520cells%253A%2520A%2520transcriptomic%2520and%2520proteomic%2520study%26jtitle%3DProteomics%26date%3D2004%26volume%3D4%26spage%3D1737%26epage%3D1760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group">Petrul, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schatz, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kopitz, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adnane, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCabe, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trail, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ha, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voznesensky, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranges, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamburini, P. P.</span><span> </span><span class="NLM_article-title">Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9</span> <span class="citation_source-journal">Mol. Cancer. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">340</span><span class="NLM_x">–</span> <span class="NLM_lpage">349</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1158%2F1535-7163.MCT-11-0523" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=22147747" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFWltbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=340-349&author=H.+M.+Petrulauthor=C.+A.+Schatzauthor=C.+C.+Kopitzauthor=L.+Adnaneauthor=T.+J.+McCabeauthor=P.+Trailauthor=S.+Haauthor=Y.+S.+Changauthor=A.+Voznesenskyauthor=G.+Rangesauthor=P.+P.+Tamburini&title=Therapeutic+mechanism+and+efficacy+of+the+antibody-drug+conjugate+BAY+79-4620+targeting+human+carbonic+anhydrase+9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Mechanism and Efficacy of the Antibody-Drug Conjugate BAY 79-4620 Targeting Human Carbonic Anhydrase 9</span></div><div class="casAuthors">Petrul, Heike M.; Schatz, Christoph A.; Kopitz, Charlotte C.; Adnane, Lila; McCabe, Timothy J.; Trail, Pamela; Ha, Sha; Chang, Yong S.; Voznesensky, Andrei; Ranges, Gerald; Tamburini, Paul P.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">340-349</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Carbonic anhydrase IX (CAIX) is a cell surface glycoprotein that is expressed in many different tumors and yet restricted in normal tissues to the gastrointestinal tract.  It is upregulated by hypoxia and correlates with tumor grade and poor survival in several tumor indications.  Monoclonal antibodies (mAb) with single digit nanomolar binding affinity for CAIX were derived by panning with the recombinant ectodomain of CAIX against the MorphoSys HUCAL Gold library of human Fabs.  Highest affinity Fabs were converted to full-length IgGs and subjected to further characterization based upon their avidity and selectivity for CAIX, their capacity to undergo internalization in CAIX-expressing cell lines, and their selective localization to CAIX-pos. human xenografted tumors when administered to mice as fluorescent conjugates.  Through this selection process, the 3ee9 mAb was identified, which upon conjugation to monomethyl auristatin E through a self-immolative enzyme-cleavable linker yielded the potent and selective CAIX antibody-drug conjugate CAIX-ADC (BAY 79-4620).  In preclin. human xenograft models in mice representing several tumor indications, BAY 79-4620 showed potent antitumor efficacy and in some models showed partial and complete tumor shrinkage even following a single dose.  The mechanism of action was shown by histol. to involve the sequelae of events typical of antitubulin agents.  Efficacy in murine preclin. models correlated semiquant., with CAIX expression levels as detd. by immunohistochem. and ELISA.  These preclin. data collectively support the development of BAY 79-4620 for the treatment of cancer patients with CAIX overexpressing tumors.  Mol Cancer Ther; 11(2); 340-9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzBKmx-bIGLrVg90H21EOLACvtfcHk0liV-f6GwyBPxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFWltbg%253D&md5=93d29b1c4b8b23cb39a8efd6e8490322</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0523%26sid%3Dliteratum%253Aachs%26aulast%3DPetrul%26aufirst%3DH.%2BM.%26aulast%3DSchatz%26aufirst%3DC.%2BA.%26aulast%3DKopitz%26aufirst%3DC.%2BC.%26aulast%3DAdnane%26aufirst%3DL.%26aulast%3DMcCabe%26aufirst%3DT.%2BJ.%26aulast%3DTrail%26aufirst%3DP.%26aulast%3DHa%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DY.%2BS.%26aulast%3DVoznesensky%26aufirst%3DA.%26aulast%3DRanges%26aufirst%3DG.%26aulast%3DTamburini%26aufirst%3DP.%2BP.%26atitle%3DTherapeutic%2520mechanism%2520and%2520efficacy%2520of%2520the%2520antibody-drug%2520conjugate%2520BAY%252079-4620%2520targeting%2520human%2520carbonic%2520anhydrase%25209%26jtitle%3DMol.%2520Cancer.%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D340%26epage%3D349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group">Dubois, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lieuwes, N. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maresca, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thiry, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Supuran, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scozzafava, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wouters, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambin, P.</span><span> </span><span class="NLM_article-title">Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model</span> <span class="citation_source-journal">Radiother. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">423</span><span class="NLM_x">–</span> <span class="NLM_lpage">428</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1016%2Fj.radonc.2009.06.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=19616332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFajtL%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2009&pages=423-428&author=L.+Duboisauthor=N.+G.+Lieuwesauthor=A.+Marescaauthor=A.+Thiryauthor=C.+T.+Supuranauthor=A.+Scozzafavaauthor=B.+G.+Woutersauthor=P.+Lambin&title=Imaging+of+CA+IX+with+fluorescent+labelled+sulfonamides+distinguishes+hypoxic+and+%28re%29-oxygenated+cells+in+a+xenograft+tumour+model"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model</span></div><div class="casAuthors">Dubois, Ludwig; Lieuwes, Natasja G.; Maresca, Alfonso; Thiry, Anne; Supuran, Claudiu T.; Scozzafava, Andrea; Wouters, Bradly G.; Lambin, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">Radiotherapy and Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">423-428</span>CODEN:
                <span class="NLM_cas:coden">RAONDT</span>;
        ISSN:<span class="NLM_cas:issn">0167-8140</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Background and purpose: Carbonic anhydrase (CA) IX is suggested to be an endogenous marker of hypoxia.  Fluorescent sulfonamides with a high affinity for CA IX (CAI) have been developed and shown to bind to cells only when CA IX protein was expressed and while cells were hypoxic.  The aim of this study was to investigate the in vivo CAI binding properties in a xenograft tumor model using fluorescent imaging.  Materials and methods: NMRI-nu mice s.c. transplanted with HT-29 colorectal tumors were treated with 7% oxygen or with nicotinamide and carbogen and were compared with control animals.  CAI accumulation was monitored by non-invasive fluorescent imaging.  Results: Specific CAI accumulation could be obsd. in delineated tumor areas as compared with a non-sulfonamide analog (P < 0.01).  Administration of nicotinamide and carbogen, decreasing acute and chronic hypoxia, resp., prevented CAI accumulation (P < 0.05).  When treated with 7% oxygen breathing, a 3-fold higher CAI accumulation (P < 0.01) was obsd.  Furthermore, the bound CAI fraction was rapidly reduced upon tumor reoxygenation (P < 0.01).  Conclusions: Our in vivo imaging results confirm previous in vitro data demonstrating that CAI binding and retention require exposure to hypoxia.  Fluorescent labeled sulfonamides provide a powerful tool to visualize hypoxia response.  An important step is made towards clin. applicability, indicating the potential of patient selection for CA IX-directed therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqflu9ig3U107Vg90H21EOLACvtfcHk0lhVsbkjm6eXMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFajtL%252FE&md5=281fab357f99b53bd768aa4c2c77eadd</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2Fj.radonc.2009.06.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.radonc.2009.06.019%26sid%3Dliteratum%253Aachs%26aulast%3DDubois%26aufirst%3DL.%26aulast%3DLieuwes%26aufirst%3DN.%2BG.%26aulast%3DMaresca%26aufirst%3DA.%26aulast%3DThiry%26aufirst%3DA.%26aulast%3DSupuran%26aufirst%3DC.%2BT.%26aulast%3DScozzafava%26aufirst%3DA.%26aulast%3DWouters%26aufirst%3DB.%2BG.%26aulast%3DLambin%26aufirst%3DP.%26atitle%3DImaging%2520of%2520CA%2520IX%2520with%2520fluorescent%2520labelled%2520sulfonamides%2520distinguishes%2520hypoxic%2520and%2520%2528re%2529-oxygenated%2520cells%2520in%2520a%2520xenograft%2520tumour%2520model%26jtitle%3DRadiother.%2520Oncol.%26date%3D2009%26volume%3D92%26spage%3D423%26epage%3D428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group">Maurer, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elsinga, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyen, W. J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, W. A.</span><span> </span><span class="NLM_article-title">Imaging the folate receptor on cancer cells with Tc-99m-etarfolatide: Properties, clinical use, and future potential of folate receptor imaging</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">701</span><span class="NLM_x">–</span> <span class="NLM_lpage">704</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2014&pages=701-704&author=A.+H.+Maurerauthor=P.+Elsingaauthor=S.+Fantiauthor=B.+Nguyenauthor=W.+J.+G.+Oyenauthor=W.+A.+Weber&title=Imaging+the+folate+receptor+on+cancer+cells+with+Tc-99m-etarfolatide%3A+Properties%2C+clinical+use%2C+and+future+potential+of+folate+receptor+imaging"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMaurer%26aufirst%3DA.%2BH.%26aulast%3DElsinga%26aufirst%3DP.%26aulast%3DFanti%26aufirst%3DS.%26aulast%3DNguyen%26aufirst%3DB.%26aulast%3DOyen%26aufirst%3DW.%2BJ.%2BG.%26aulast%3DWeber%26aufirst%3DW.%2BA.%26atitle%3DImaging%2520the%2520folate%2520receptor%2520on%2520cancer%2520cells%2520with%2520Tc-99m-etarfolatide%253A%2520Properties%252C%2520clinical%2520use%252C%2520and%2520future%2520potential%2520of%2520folate%2520receptor%2520imaging%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2014%26volume%3D55%26spage%3D701%26epage%3D704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group">Kularatne, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santhapuram, H. K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Low, P. S.</span><span> </span><span class="NLM_article-title">Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">780</span><span class="NLM_x">–</span> <span class="NLM_lpage">789</span></span><div class="citationLinks">[<a href="/doi/10.1021/mp900069d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsF2hsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2009&pages=780-789&author=S.+A.+Kularatneauthor=K.+Wangauthor=H.+K.+R.+Santhapuramauthor=P.+S.+Low&title=Prostate-specific+membrane+antigen+targeted+imaging+and+therapy+of+prostate+cancer+using+a+PSMA+inhibitor+as+a+homing+ligand"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand</span></div><div class="casAuthors">Kularatne, Sumith A.; Wang, Kevin; Santhapuram, Hari-Krishna R.; Low, Philip S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">780-789</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Prostate cancer (PCa) is a major cause of mortality and morbidity in Western society today.  Current methods for detecting PCa are limited, leaving most early malignancies undiagnosed and sites of metastasis in advanced disease undetected.  Major deficiencies also exist in the treatment of PCa, esp. metastatic disease.  In an effort to improve both detection and therapy of PCa, we have developed a PSMA-targeted ligand that delivers attached imaging and therapeutic agents selectively to PCa cells without targeting normal cells.  The PSMA-targeted radioimaging agent (DUPA-99mTc) was found to bind PSMA-pos. human PCa cells (LNCaP cell line) with nanomolar affinity (KD = 14 nM).  Imaging and biodistribution studies revealed that DUPA-99mTc localizes primarily to LNCaP cell tumor xenografts in nu/nu mice (% injected dose/g = 11.3 at 4 h postinjection; tumor-to-muscle ratio = 75:1).  Two PSMA-targeted optical imaging agents (DUPA-FITC and DUPA-rhodamine B) were also shown to efficiently label PCa cells and to internalize and traffic to intracellular endosomes.  A PSMA-targeted chemotherapeutic agent (DUPA-TubH) was demonstrated to kill PSMA-pos. LNCaP cells in culture (IC50 = 3 nM) and to eliminate established tumor xenografts in nu/nu mice with no detectable wt. loss.  Blockade of tumor targeting upon administration of excess PSMA inhibitor (PMPA) and the absence of targeting to PSMA-neg. tumors confirmed the specificity of each of the above targeted reagents for PSMA.  Tandem use of the imaging and therapeutic agents targeted to the same receptor could allow detection, staging, monitoring, and treatment of PCa with improved accuracy and efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoF7vaoehkEsrVg90H21EOLACvtfcHk0lhVsbkjm6eXMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsF2hsrw%253D&md5=2fba93274e7f4c4ff0910e2edef9e189</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1021%2Fmp900069d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp900069d%26sid%3Dliteratum%253Aachs%26aulast%3DKularatne%26aufirst%3DS.%2BA.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DSanthapuram%26aufirst%3DH.%2BK.%2BR.%26aulast%3DLow%26aufirst%3DP.%2BS.%26atitle%3DProstate-specific%2520membrane%2520antigen%2520targeted%2520imaging%2520and%2520therapy%2520of%2520prostate%2520cancer%2520using%2520a%2520PSMA%2520inhibitor%2520as%2520a%2520homing%2520ligand%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2009%26volume%3D6%26spage%3D780%26epage%3D789" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group">Cohen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vugts, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Visser, G. W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stigter-Van Walsum, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolijn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spiga, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lazzari, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shankar, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zanda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Dongen, G. A. M. S.</span><span> </span><span class="NLM_article-title">Development of novel ADCs: Conjugation of tubulysin analogues to trastuzumab monitored by dual radiolabeling</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">5700</span><span class="NLM_x">–</span> <span class="NLM_lpage">5710</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=5700-5710&author=R.+Cohenauthor=D.+J.+Vugtsauthor=G.+W.+M.+Visserauthor=M.+Stigter-Van+Walsumauthor=M.+Bolijnauthor=M.+Spigaauthor=P.+Lazzariauthor=E.+Shankarauthor=M.+Saniauthor=M.+Zandaauthor=G.+A.+M.+S.+Van+Dongen&title=Development+of+novel+ADCs%3A+Conjugation+of+tubulysin+analogues+to+trastuzumab+monitored+by+dual+radiolabeling"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DR.%26aulast%3DVugts%26aufirst%3DD.%2BJ.%26aulast%3DVisser%26aufirst%3DG.%2BW.%2BM.%26aulast%3DStigter-Van%2BWalsum%26aufirst%3DM.%26aulast%3DBolijn%26aufirst%3DM.%26aulast%3DSpiga%26aufirst%3DM.%26aulast%3DLazzari%26aufirst%3DP.%26aulast%3DShankar%26aufirst%3DE.%26aulast%3DSani%26aufirst%3DM.%26aulast%3DZanda%26aufirst%3DM.%26aulast%3DVan%2BDongen%26aufirst%3DG.%2BA.%2BM.%2BS.%26atitle%3DDevelopment%2520of%2520novel%2520ADCs%253A%2520Conjugation%2520of%2520tubulysin%2520analogues%2520to%2520trastuzumab%2520monitored%2520by%2520dual%2520radiolabeling%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D5700%26epage%3D5710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group">Erez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Segal, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satchi-Fainaro, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shabat, D.</span><span> </span><span class="NLM_article-title">Enhanced cytotoxicity of a polymer-drug conjugate with triple payload of paclitaxel</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">4327</span><span class="NLM_x">–</span> <span class="NLM_lpage">4335</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1016%2Fj.bmc.2009.05.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=19482477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnt1Gru78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=4327-4335&author=R.+Erezauthor=E.+Segalauthor=K.+Millerauthor=R.+Satchi-Fainaroauthor=D.+Shabat&title=Enhanced+cytotoxicity+of+a+polymer-drug+conjugate+with+triple+payload+of+paclitaxel"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced cytotoxicity of a polymer-drug conjugate with triple payload of paclitaxel</span></div><div class="casAuthors">Erez, Rotem; Segal, Ehud; Miller, Keren; Satchi-Fainaro, Ronit; Shabat, Doron</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4327-4335</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The development of targeting approaches to selectively release chemotherapeutic drugs into malignant tissue is a major challenge in anticancer therapy.  We have synthesized an N-(2-hydroxypropyl)-methacrylamide (HPMA) copolymer-drug conjugate with an AB3 self-immolative dendritic linker.  HPMA copolymers are known to accumulate selectively in tumors.  The water-sol. polymer-drug conjugate was designed to release a triple payload of the hydrophobic drug paclitaxel as a result of cleavage by the endogenous enzyme cathepsin B. The polymer-drug conjugate exhibited enhanced cytotoxicity on murine prostate adenocarcinoma (TRAMP C2) cells in comparison to a classic monomeric drug-polymer conjugate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTGwHdZDyk2bVg90H21EOLACvtfcHk0lgQszwx3pXsjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnt1Gru78%253D&md5=80c0b9b2c90d9bd6cbbbd2810263b77c</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2009.05.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2009.05.028%26sid%3Dliteratum%253Aachs%26aulast%3DErez%26aufirst%3DR.%26aulast%3DSegal%26aufirst%3DE.%26aulast%3DMiller%26aufirst%3DK.%26aulast%3DSatchi-Fainaro%26aufirst%3DR.%26aulast%3DShabat%26aufirst%3DD.%26atitle%3DEnhanced%2520cytotoxicity%2520of%2520a%2520polymer-drug%2520conjugate%2520with%2520triple%2520payload%2520of%2520paclitaxel%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2009%26volume%3D17%26spage%3D4327%26epage%3D4335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group">Ojima, I.</span><span> </span><span class="NLM_article-title">Guided molecular missiles for tumor-targeting chemotherapy-case studies using the second-generation taxolds as warheads</span> <span class="citation_source-journal">Acc. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">108</span><span class="NLM_x">–</span> <span class="NLM_lpage">119</span></span><div class="citationLinks">[<a href="/doi/10.1021/ar700093f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2008&pages=108-119&author=I.+Ojima&title=Guided+molecular+missiles+for+tumor-targeting+chemotherapy-case+studies+using+the+second-generation+taxolds+as+warheads"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1021%2Far700093f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far700093f%26sid%3Dliteratum%253Aachs%26aulast%3DOjima%26aufirst%3DI.%26atitle%3DGuided%2520molecular%2520missiles%2520for%2520tumor-targeting%2520chemotherapy-case%2520studies%2520using%2520the%2520second-generation%2520taxolds%2520as%2520warheads%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2008%26volume%3D41%26spage%3D108%26epage%3D119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group">Weinstain, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Segal, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satchi-Fainaro, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shabat, D.</span><span> </span><span class="NLM_article-title">Real-time monitoring of drug release</span> <span class="citation_source-journal">Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">553</span><span class="NLM_x">–</span> <span class="NLM_lpage">555</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1039%2FB919329D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=20062859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisFWqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2010&pages=553-555&author=R.+Weinstainauthor=E.+Segalauthor=R.+Satchi-Fainaroauthor=D.+Shabat&title=Real-time+monitoring+of+drug+release"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Real-time monitoring of drug release</span></div><div class="casAuthors">Weinstain, Roy; Segal, Ehud; Satchi-Fainaro, Ronit; Shabat, Doron</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">553-555</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A new prodrug system, assembled using a distinctive coumarin linker, was demonstrated to report real-time activation and drug release in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriuAN_vhaJSrVg90H21EOLACvtfcHk0lgQszwx3pXsjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisFWqug%253D%253D&md5=a6e8dc9cd68a8b5fdfc6a03a446b6513</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1039%2FB919329D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FB919329D%26sid%3Dliteratum%253Aachs%26aulast%3DWeinstain%26aufirst%3DR.%26aulast%3DSegal%26aufirst%3DE.%26aulast%3DSatchi-Fainaro%26aufirst%3DR.%26aulast%3DShabat%26aufirst%3DD.%26atitle%3DReal-time%2520monitoring%2520of%2520drug%2520release%26jtitle%3DChem.%2520Commun.%26date%3D2010%26volume%3D46%26spage%3D553%26epage%3D555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group">Bernardes, G. J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steiner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casi, G.</span><span> </span><span class="NLM_article-title">Site-specific chemical modification of antibody fragments using traceless cleavable linkers</span> <span class="citation_source-journal">Nat. Protoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">2079</span><span class="NLM_x">–</span> <span class="NLM_lpage">2089</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=2079-2089&author=G.+J.+L.+Bernardesauthor=M.+Steinerauthor=I.+Hartmannauthor=D.+Neriauthor=G.+Casi&title=Site-specific+chemical+modification+of+antibody+fragments+using+traceless+cleavable+linkers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBernardes%26aufirst%3DG.%2BJ.%2BL.%26aulast%3DSteiner%26aufirst%3DM.%26aulast%3DHartmann%26aufirst%3DI.%26aulast%3DNeri%26aufirst%3DD.%26aulast%3DCasi%26aufirst%3DG.%26atitle%3DSite-specific%2520chemical%2520modification%2520of%2520antibody%2520fragments%2520using%2520traceless%2520cleavable%2520linkers%26jtitle%3DNat.%2520Protoc.%26date%3D2013%26volume%3D8%26spage%3D2079%26epage%3D2089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group">Casi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huguenin-Dezot, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuberbühler, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheuermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, D.</span><span> </span><span class="NLM_article-title">Site-specific traceless coupling of potent cytotoxic drugs to recombinant antibodies for pharmacodelivery</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">134</span><span class="NLM_x">, </span> <span class="NLM_fpage">5887</span><span class="NLM_x">–</span> <span class="NLM_lpage">5892</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja211589m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2012&pages=5887-5892&author=G.+Casiauthor=N.+Huguenin-Dezotauthor=K.+Zuberb%C3%BChlerauthor=J.+Scheuermannauthor=D.+Neri&title=Site-specific+traceless+coupling+of+potent+cytotoxic+drugs+to+recombinant+antibodies+for+pharmacodelivery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1021%2Fja211589m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja211589m%26sid%3Dliteratum%253Aachs%26aulast%3DCasi%26aufirst%3DG.%26aulast%3DHuguenin-Dezot%26aufirst%3DN.%26aulast%3DZuberb%25C3%25BChler%26aufirst%3DK.%26aulast%3DScheuermann%26aufirst%3DJ.%26aulast%3DNeri%26aufirst%3DD.%26atitle%3DSite-specific%2520traceless%2520coupling%2520of%2520potent%2520cytotoxic%2520drugs%2520to%2520recombinant%2520antibodies%2520for%2520pharmacodelivery%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2012%26volume%3D134%26spage%3D5887%26epage%3D5892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group">Santi, D. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reid, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashley, G. W.</span><span> </span><span class="NLM_article-title">Predictable and tunable half-life extension of therapeutic agents by controlled chemical release from macromolecular conjugates</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">6211</span><span class="NLM_x">–</span> <span class="NLM_lpage">6216</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1073%2Fpnas.1117147109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=22474378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmt12murc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=6211-6216&author=D.+V.+Santiauthor=E.+L.+Schneiderauthor=R.+Reidauthor=L.+Robinsonauthor=G.+W.+Ashley&title=Predictable+and+tunable+half-life+extension+of+therapeutic+agents+by+controlled+chemical+release+from+macromolecular+conjugates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Predictable and tunable half-life extension of therapeutic agents by controlled chemical release from macromolecular conjugates</span></div><div class="casAuthors">Santi, Daniel V.; Schneider, Eric L.; Reid, Ralph; Robinson, Louise; Ashley, Gary W.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6211-6216, S6211/1-S6211/9</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Conjugation to macromol. carriers is a proven strategy for improving the pharmacokinetics of drugs, with many stable polyethylene glycol conjugates having reached the market.  Stable conjugates suffer several limitations: loss of drug potency due to conjugation, confining the drug to the extracellular space, and the requirement for a circulating conjugate.  Current research is directed toward overcoming such limitations through releasable conjugates in which the drug is covalently linked to the carrier through a cleavable linker.  Satisfactory linkers that provide predictable cleavage rates tunable over a wide time range that are useful for both circulating and noncirculating conjugates are not yet available.  The authors describe such conjugation linkers on the basis of a nonenzymic β-elimination reaction with preprogrammed, highly tunable cleavage rates.  A set of modular linkers is described that bears a succinimidyl carbonate group for attachment to an amine-contg. drug or prodrug, an azido group for conjugation to the carrier, and a tunable modulator that controls the rate of β-eliminative cleavage.  The linkers provide predictable, tunable release rates of ligands from macromol. conjugates both in vitro and in vivo, with half-lives spanning from a range of hours to >1 y at physiol. pH.  A circulating PEG conjugate achieved a 56-fold half-life extension of the 39-aa peptide exenatide in rats, and a noncirculating s.c. hydrogel conjugate achieved a 150-fold extension.  Using slow-cleaving linkers, the latter may provide a generic format for once-a-month dosage forms of potent drugs.  The releasable linkers provide addnl. benefits that include lowering Cmax and pharmacokinetic coordination of drug combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZxfMMxiRWb7Vg90H21EOLACvtfcHk0lhPKNLk3Y8ebQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmt12murc%253D&md5=78dbf59f2e209ee4e119aa0d2462f64c</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1117147109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1117147109%26sid%3Dliteratum%253Aachs%26aulast%3DSanti%26aufirst%3DD.%2BV.%26aulast%3DSchneider%26aufirst%3DE.%2BL.%26aulast%3DReid%26aufirst%3DR.%26aulast%3DRobinson%26aufirst%3DL.%26aulast%3DAshley%26aufirst%3DG.%2BW.%26atitle%3DPredictable%2520and%2520tunable%2520half-life%2520extension%2520of%2520therapeutic%2520agents%2520by%2520controlled%2520chemical%2520release%2520from%2520macromolecular%2520conjugates%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2012%26volume%3D109%26spage%3D6211%26epage%3D6216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group">Strop, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorywalska, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaria, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dushin, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farias, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casas, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abdiche, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandrasekaran, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samain, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rickert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krimm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dilley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaparro-Riggers, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filzen, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pons, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shelton, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajpal, A.</span><span> </span><span class="NLM_article-title">Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">167</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1016%2Fj.chembiol.2013.01.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=23438745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtFWht74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=161-167&author=P.+Stropauthor=S.+H.+Liuauthor=M.+Dorywalskaauthor=K.+Delariaauthor=R.+G.+Dushinauthor=T.+T.+Tranauthor=W.+H.+Hoauthor=S.+Fariasauthor=M.+G.+Casasauthor=Y.+Abdicheauthor=D.+Zhouauthor=R.+Chandrasekaranauthor=C.+Samainauthor=C.+Looauthor=A.+Rossiauthor=M.+Rickertauthor=S.+Krimmauthor=T.+Wongauthor=S.+M.+Chinauthor=J.+Yuauthor=J.+Dilleyauthor=J.+Chaparro-Riggersauthor=G.+F.+Filzenauthor=C.+J.+O%E2%80%99Donnellauthor=F.+Wangauthor=J.+S.+Myersauthor=J.+Ponsauthor=D.+L.+Sheltonauthor=A.+Rajpal&title=Location+matters%3A+site+of+conjugation+modulates+stability+and+pharmacokinetics+of+antibody+drug+conjugates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Location Matters: Site of Conjugation Modulates Stability and Pharmacokinetics of Antibody Drug Conjugates</span></div><div class="casAuthors">Strop, Pavel; Liu, Shu-Hui; Dorywalska, Magdalena; Delaria, Kathy; Dushin, Russell G.; Tran, Thomas-Toan; Ho, Wei-Hsien; Farias, Santiago; Casas, Meritxell Galindo; Abdiche, Yasmina; Zhou, Dahui; Chandrasekaran, Ramalakshmi; Samain, Caroline; Loo, Carole; Rossi, Andrea; Rickert, Mathias; Krimm, Stellanie; Wong, Teresa; Chin, Sherman Michael; Yu, Jessica; Dilley, Jeanette; Chaparro-Riggers, Javier; Filzen, Gary F.; O'Donnell, Christopher J.; Wang, Fang; Myers, Jeremy S.; Pons, Jaume; Shelton, David L.; Rajpal, Arvind</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">161-167</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Antibody drug conjugates (ADCs) are a therapeutic class offering promise for cancer therapy.  The attachment of cytotoxic drugs to antibodies can result in an effective therapy with better safety potential than nontargeted cytotoxics.  To understand the role of conjugation site, we developed an enzymic method for site-specific antibody drug conjugation using microbial transglutaminase.  This allowed us to attach diverse compds. at multiple positions and investigate how the site influences stability, toxicity, and efficacy.  We show that the conjugation site has significant impact on ADC stability and pharmacokinetics in a species-dependent manner.  These differences can be directly attributed to the position of the linkage rather than the chem. instability, as was obsd. with a maleimide linkage.  With this method, it is possible to produce homogeneous ADCs and tune their properties to maximize the therapeutic window.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIo4ZEVMFX2LVg90H21EOLACvtfcHk0lhPKNLk3Y8ebQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtFWht74%253D&md5=0b419848b5fd4dfa4863a29de0555cf4</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2013.01.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2013.01.010%26sid%3Dliteratum%253Aachs%26aulast%3DStrop%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DS.%2BH.%26aulast%3DDorywalska%26aufirst%3DM.%26aulast%3DDelaria%26aufirst%3DK.%26aulast%3DDushin%26aufirst%3DR.%2BG.%26aulast%3DTran%26aufirst%3DT.%2BT.%26aulast%3DHo%26aufirst%3DW.%2BH.%26aulast%3DFarias%26aufirst%3DS.%26aulast%3DCasas%26aufirst%3DM.%2BG.%26aulast%3DAbdiche%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DChandrasekaran%26aufirst%3DR.%26aulast%3DSamain%26aufirst%3DC.%26aulast%3DLoo%26aufirst%3DC.%26aulast%3DRossi%26aufirst%3DA.%26aulast%3DRickert%26aufirst%3DM.%26aulast%3DKrimm%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DT.%26aulast%3DChin%26aufirst%3DS.%2BM.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DDilley%26aufirst%3DJ.%26aulast%3DChaparro-Riggers%26aufirst%3DJ.%26aulast%3DFilzen%26aufirst%3DG.%2BF.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DMyers%26aufirst%3DJ.%2BS.%26aulast%3DPons%26aufirst%3DJ.%26aulast%3DShelton%26aufirst%3DD.%2BL.%26aulast%3DRajpal%26aufirst%3DA.%26atitle%3DLocation%2520matters%253A%2520site%2520of%2520conjugation%2520modulates%2520stability%2520and%2520pharmacokinetics%2520of%2520antibody%2520drug%2520conjugates%26jtitle%3DChem.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D161%26epage%3D167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group">Muller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schibli, R.</span><span> </span><span class="NLM_article-title">Prospects in folate receptor-targeted radionuclide therapy</span> <span class="citation_source-journal">Front. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">249</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.3389%2Ffonc.2013.00249" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=24069581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFOrsb%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=249&author=C.+Mullerauthor=R.+Schibli&title=Prospects+in+folate+receptor-targeted+radionuclide+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="#"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=&md5=9874b665cc7a056b8e2f928dd3112440</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2013.00249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2013.00249%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DC.%26aulast%3DSchibli%26aufirst%3DR.%26atitle%3DProspects%2520in%2520folate%2520receptor-targeted%2520radionuclide%2520therapy%26jtitle%3DFront.%2520Oncol.%26date%3D2013%26volume%3D3%26spage%3D249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group">Gutbrodt, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, D.</span><span> </span><span class="NLM_article-title">Antibody-based delivery of IL2 and cytotoxics eradicates tumors in immunocompetent mice</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1772</span><span class="NLM_x">–</span> <span class="NLM_lpage">1776</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1158%2F1535-7163.MCT-14-0105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=24759429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFSmsbfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=1772-1776&author=K.+L.+Gutbrodtauthor=G.+Casiauthor=D.+Neri&title=Antibody-based+delivery+of+IL2+and+cytotoxics+eradicates+tumors+in+immunocompetent+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-Based Delivery of IL2 and Cytotoxics Eradicates Tumors in Immunocompetent Mice</span></div><div class="casAuthors">Gutbrodt, Katrin L.; Casi, Giulio; Neri, Dario</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1772-1776</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Antibody-drug conjugates are increasingly being used for cancer therapy, but little is known about their ability to promote anticancer immunity, which may lead to long-lasting remissions.  We investigated the therapeutic effect of antibody-based pharmacodelivery of cemadotin, a cytotoxic drug, and IL2, a strong proinflammatory cytokine.  Using the F8 antibody, which selectively localizes to the tumor neovasculature, combination treatment led to tumor eradication, in a process dependent on CD8+ T cells and natural killer cells in the C1498 syngeneic mouse model of acute myelogenous leukemia.  The clin. combination of antibody-drug conjugates and antibody-cytokine proteins should be facilitated by their orthogonal toxicity profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYKqzwv7dNPbVg90H21EOLACvtfcHk0lirz0xen7SF5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFSmsbfF&md5=e2eceece6e4067596cee2d56aeee028d</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0105%26sid%3Dliteratum%253Aachs%26aulast%3DGutbrodt%26aufirst%3DK.%2BL.%26aulast%3DCasi%26aufirst%3DG.%26aulast%3DNeri%26aufirst%3DD.%26atitle%3DAntibody-based%2520delivery%2520of%2520IL2%2520and%2520cytotoxics%2520eradicates%2520tumors%2520in%2520immunocompetent%2520mice%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D1772%26epage%3D1776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group">List, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, D.</span><span> </span><span class="NLM_article-title">A chemically defined trifunctional antibody–cytokine–drug conjugate with potent antitumor activity</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2641</span><span class="NLM_x">–</span> <span class="NLM_lpage">2652</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1158%2F1535-7163.MCT-14-0599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=25205656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGju7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=2641-2652&author=T.+Listauthor=G.+Casiauthor=D.+Neri&title=A+chemically+defined+trifunctional+antibody%E2%80%93cytokine%E2%80%93drug+conjugate+with+potent+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">A Chemically Defined Trifunctional Antibody-Cytokine-Drug Conjugate with Potent Antitumor Activity</span></div><div class="casAuthors">List, Thomas; Casi, Giulio; Neri, Dario</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2641-2652</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The combination of immunostimulatory agents with cytotoxic drugs is emerging as a promising approach for potentially curative tumor therapy, but advances in this field are hindered by the requirement of testing individual combination partners as single agents in dedicated clin. studies, often with suboptimal efficacy.  Here, we describe for the first time a novel multipayload class of targeted drugs, the immunocytokine-drug conjugates (IDC), which combine a tumor-homing antibody, a cytotoxic drug, and a proinflammatory cytokine in the same mol. entity.  In particular, the IL2 cytokine and the disulfide-linked maytansinoid DM1 microtubular inhibitor could be coupled to the F8 antibody, directed against the alternatively spliced EDA domain of fibronectin, in a site-specific manner, yielding a chem. defined product with selective tumor-homing performance and potent anticancer activity in vivo, as tested in two different immunocompetent mouse models.  Mol Cancer Ther; 13(11); 2641-52. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYZvMHK0YJXLVg90H21EOLACvtfcHk0lirz0xen7SF5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGju7jN&md5=7659283abd808fe2115d06dfe6ca3c28</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0599%26sid%3Dliteratum%253Aachs%26aulast%3DList%26aufirst%3DT.%26aulast%3DCasi%26aufirst%3DG.%26aulast%3DNeri%26aufirst%3DD.%26atitle%3DA%2520chemically%2520defined%2520trifunctional%2520antibody%25E2%2580%2593cytokine%25E2%2580%2593drug%2520conjugate%2520with%2520potent%2520antitumor%2520activity%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D2641%26epage%3D2652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group">Wittrup, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thurber, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhoden, J. J.</span><span> </span><span class="NLM_article-title">Practical theoretic guidance for the design of tumor-targeting agents</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">503</span><span class="NLM_x">, </span> <span class="NLM_fpage">255</span><span class="NLM_x">–</span> <span class="NLM_lpage">268</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=10.1016%2FB978-0-12-396962-0.00010-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=22230572" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;key=1%3ACAS%3A528%3ADC%252BC38Xkt1CjsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=503&publication_year=2012&pages=255-268&author=K.+D.+Wittrupauthor=G.+M.+Thurberauthor=M.+M.+Schmidtauthor=J.+J.+Rhoden&title=Practical+theoretic+guidance+for+the+design+of+tumor-targeting+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Practical theoretic guidance for the design of tumor-targeting agents</span></div><div class="casAuthors">Wittrup, K. Dane; Thurber, Greg M.; Schmidt, Michael M.; Rhoden, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">503</span>
        (<span class="NLM_cas:issue">Protein Engineering for Therapeutics, Part B</span>),
    <span class="NLM_cas:pages">255-268</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Theor. analyses of targeting agent pharmacokinetics provides specific guidance with respect to desirable design objectives such as agent size, affinity, and target antigen.  These analyses suggest that IgG-sized macromol. constructs exhibit the most favorable balance between systemic clearance and vascular extravasation, resulting in maximal tumor uptake.  Quant. predictions of the effects of dose and binding affinity on tumor uptake and penetration are also provided.  The single bolus dose required for satn. of xenografted tumors in mice can be predicted from knowledge of antigen expression level and metabolic half-life.  The role of high binding affinity in tumor uptake can be summarized as: essential for small peptides, less important for antibodies, and negligible for nanoparticles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsTAqo0Zxr9LVg90H21EOLACvtfcHk0lirz0xen7SF5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xkt1CjsLg%253D&md5=7ae4e26c99bb6b7246c8c2fe417410be</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-396962-0.00010-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-396962-0.00010-0%26sid%3Dliteratum%253Aachs%26aulast%3DWittrup%26aufirst%3DK.%2BD.%26aulast%3DThurber%26aufirst%3DG.%2BM.%26aulast%3DSchmidt%26aufirst%3DM.%2BM.%26aulast%3DRhoden%26aufirst%3DJ.%2BJ.%26atitle%3DPractical%2520theoretic%2520guidance%2520for%2520the%2520design%2520of%2520tumor-targeting%2520agents%26jtitle%3DMethods%2520Enzymol.%26date%3D2012%26volume%3D503%26spage%3D255%26epage%3D268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group">Tzeng, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwan, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Opel, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navaratna, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittrup, K. D.</span><span> </span><span class="NLM_article-title">Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">3320</span><span class="NLM_x">–</span> <span class="NLM_lpage">3325</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=3320-3325&author=A.+Tzengauthor=B.+H.+Kwanauthor=C.+F.+Opelauthor=T.+Navaratnaauthor=K.+D.+Wittrup&title=Antigen+specificity+can+be+irrelevant+to+immunocytokine+efficacy+and+biodistribution"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTzeng%26aufirst%3DA.%26aulast%3DKwan%26aufirst%3DB.%2BH.%26aulast%3DOpel%26aufirst%3DC.%2BF.%26aulast%3DNavaratna%26aufirst%3DT.%26aulast%3DWittrup%26aufirst%3DK.%2BD.%26atitle%3DAntigen%2520specificity%2520can%2520be%2520irrelevant%2520to%2520immunocytokine%2520efficacy%2520and%2520biodistribution%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2015%26volume%3D112%26spage%3D3320%26epage%3D3325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2015.58.issue-22%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.5b00457" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.5b00457" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679908993e523dc4","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
